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Insulin	  is	  known	  to	  act	  as	  an	  anti-­‐inflammatory	  agent	  and	  protect	  vascular	  endothelial	  cells	  
during	   ischaemic	  damage	   in	  vivo.	  Although	  it	   is	  known	  that	   insulin	  signals	   in	  part	  through	  
phosphatidylinositol	  3-­‐kinases	  (PI3Ks)	  and	  Akt,	  its	  effects	  on	  endothelial	  junctions	  and	  actin	  
cytoskeleton	   are	   unknown.	   This	   study	   aimed	   to	   characterise	   endothelial	   responses	   to	  
insulin,	   identify	   endothelial	   insulin-­‐induced	   changes	   in	   protein	   phosphorylation	   and	  
determine	  the	  roles	  of	  these	  changes	  in	  regulating	  endothelial	  functions.	  	  
Insulin	   stimulation	   induced	   dose-­‐dependent	   Akt	   activation	   in	   both	   primary	   human	  
umbilical	  vein	  endothelial	  cells	  (HUVECs)	  and	  an	  endothelial	  cell	  line,	  human	  bone-­‐marrow	  
endothelial	   cells	   (HBMECs).	   Insulin	   decreased	   basal	   HUVEC	   permeability,	   increased	  
angiogenic	  loop	  formation	  in	  vitro	  and	  increased	  cell	  migration	  in	  a	  wound-­‐healing	  model,	  
compared	  to	  untreated	  cells.	  	  
Insulin-­‐stimulated	   changes	   in	   protein	   phosphorylation	   were	   identified	   using	   a	   14-­‐3-­‐3	  
affinity	   purification	   proteomic	   screen,	   as	   14-­‐3-­‐3	   proteins	   interact	   specifically	   with	  
phosphorylated	   Ser/Thr	   residues	   within	   14-­‐3-­‐3-­‐binding	   motifs.	   A	   total	   of	   390	   14-­‐3-­‐3-­‐
binding	  proteins	  were	   identified	  from	  insulin-­‐stimulated	  HBMECs,	   from	  which	  12	  proteins	  
were	   selected	  based	  on	  predicted	   roles	   in	  endothelial	   cytoskeleton	   regulation.	  Validation	  
of	  these	  hits,	  performed	  by	  Far-­‐Western	  overlay	  analysis,	  identified	  4	  IGF-­‐I-­‐regulated	  14-­‐3-­‐
3-­‐binding	  proteins:	  Parg1	  (ARHGAP29),	  RICH-­‐1	  (ARHGAP17),	  LMO7	  and	  Epsin2.	  	  
Parg1	   depletion	   in	   HUVECs	   induced	   stress	   fibre	   formation,	   increased	   endothelial	  
permeability,	  severely	  decreased	  angiogenic	   loop	  formation	  and	  decreased	  cell	  migration,	  
compared	   to	   siRNA	   control-­‐treated	   cells.	   This	   suggests	   that	   Parg1	   regulates	   contractility	  
and	   hence	   could	   affect	   endothelial	   cell-­‐cell	   junctional	   stability.	   Depletion	   of	   RICH-­‐1	   and	  
LMO7	   in	  HUVECs	   resulted	   in	  mislocalisation	  of	   the	   tight	   junction	  protein	   ZO-­‐1.	  However,	  
this	  did	  not	  affect	  endothelial	  permeability,	   suggesting	   that	   these	  proteins	  are	   important	  
for	   maintaining	   tight	   junction	   integrity.	   LMO7	   and	   Epsin2	   depletion	   each	   resulted	   in	   an	  
increase	  in	  angiogenic	   loop	  formation,	  but	  did	  not	  detectably	  affect	  cell	  migration.	   Insulin	  
stimulation	  of	  Epsin2	  might	  increase	  lamellipodium	  formation,	  although	  further	  studies	  are	  
required	  to	  establish	  the	  mechanisms	  involved.	  
In	   conclusion,	   this	   thesis	  describes	  a	  14-­‐3-­‐3-­‐based	  proteomic	   screen	   that	   identified	  novel	  
regulators	   of	   endothelial	   function.	   These	   proteins	   could	   contribute	   to	   the	   anti-­‐
inflammatory	  roles	  of	  insulin.	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1 Introduction	  
1.1 Cardiovascular	  disease	  
Cardiovascular	   disease	   (CVD)	   is	   the	   number	   one	   cause	   of	   death	   globally	   (Alwan,	  
2011;	   Murray	   et	   al.,	   2012).	   A	   better	   understanding	   of	   the	   disease	   has	   led	   to	  
improved	   prevention	   and	   therapy	   resulting	   in	   the	   decline	   of	   CVD.	   However,	   an	  
estimated	  17.3	  million	  people	  still	  die	  from	  CVD	  every	  year,	  which	  is	  equivalent	  to	  
approximately	   30%	   of	   all	   deaths	   worldwide.	   Although	   many	   diseases	   affect	   the	  
cardiovascular	   system,	   the	   greatest	   numbers	   of	   deaths	   are	   due	   to	   myocardial	  
infarction	  (MI)	  and	  ischaemic	  stroke	  caused	  by	  atherosclerosis	  (Libby	  et	  al.,	  2013).	  
Hypertension,	   high	   levels	   of	   low-­‐density	   lipoprotein	   cholesterol	   (LDL),	   and	   low	  
levels	   of	   high-­‐density	   lipoprotein	   (HDL)	   have	   all	   been	   identified	   as	   risk	   factors	  
associated	  with	  an	  increased	  incidence	  of	  cardiovascular	  disease	  (Ferri,	  2013).	  	  	  
Atherosclerosis	  is	  a	  progressive	  disease	  characterised	  by	  the	  accumulation	  of	  lipids	  
and	  fibrous	  elements	  in	  the	  large	  and	  medium-­‐sized	  arteries	  resulting	  in	  blot	  clots	  
(thrombosis)	   or	   severe	   narrowing	   of	   the	   vessels	   (stenosis)	   (Libby,	   2012).	  
Accelerated	  atherosclerosis	  is	  observed	  in	  diabetics,	  resulting	  in	  CVD	  developing	  on	  
average	   15	   years	   earlier	   (Booth	   et	   al.,	   2006)	   and	   having	   more	   than	   a	   two-­‐fold	  
increase	   in	   the	   risk	   of	   dying	   from	  CVD	   than	   non-­‐diabetics	   (Seshasai	   et	   al.,	   2011).	  
Previously,	   it	  was	  believed	  that	  atherosclerosis	  resulted	  from	  a	  passive	  build	  up	  of	  
cholesterol	  in	  the	  artery	  wall.	  However,	  new	  evidence	  implicates	  inﬂammation	  and	  
immune	   effector	   mechanisms	   in	   the	   pathogenesis	   of	   this	   disease	   (reviewed	   in	  
(Libby,	   2012).	   Atherogenesis	   develops	   when	   oxidative,	   haemodynamic,	   and/or	  
biochemical	   stimuli	   and	   inflammatory	   factors	   change	   the	   permeability	   of	   the	  
endothelium	  (see	  section	  1.2)	  and	  promote	  the	  entry	  and	  retention	  of	  monocytes	  
and	  cholesterol-­‐containing	  LDL	  particles	  from	  the	  blood.	  This	  triggers	  a	  cascade	  of	  
inflammatory	   and	   biochemical	   modifications	   that	   results	   in	   endothelial	   and	  
smooth-­‐muscle	   cell	   proliferation,	   producing	   extracellular	   matrix	   molecules.	   A	  
fibrous	  cap	   is	   formed	  over	   the	  developing	  atheromatous	  plaque	  and	   this	   leads	   to	  
clinical	  symptoms	  by	  producing	  flow-­‐limiting	  stenosis	  (causing	  stable	  angina),	  or	  the	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formation	  of	  thrombi	  that	  interrupt	  blood	  flow	  resulting	  in	  myocardial	  ischaemia	  on	  
either	   a	   temporary	   basis	   (causing	   unstable	   angina)	   or	   a	   permanent	   one	   (causing	  
myocardial	   infarction	   or	   stroke).	   If	   the	   plaque	   ruptures,	   it	   exposes	   procoagulant	  
material	  within	  the	  core	  of	  the	  plaque	  to	  coagulation	  proteins	  and	  platelets	  in	  the	  
blood,	  which	  triggers	  thrombosis	  (Nabel	  and	  Braunwald,	  2012).	  Identifying	  the	  key	  
events	   that	   trigger	   inflammation	   and	   understanding	   the	   regulation	   of	   these	  
signalling	   pathways	   could	   provide	   potential	   new	   preventative	   and	   treatment	  
strategies,	  specifically	  targeting	  CVD.	  The	  mechanisms	  involved	  in	  inflammation	  will	  
be	  discussed	  in	  section	  1.2.5.	  
	  
1.2 The	  vascular	  endothelium	  
The	   endothelium	   is	   a	   single	   layer	   of	   endothelial	   cells	   (ECs)	   that	   form	   the	   inner	  
cellular	   lining	   of	   the	   entire	   vascular	   system.	   Blood	   vessels	   (arteries,	   veins	   and	  
capillaries)	  and	  lymphatic	  vessels	  are	  lined	  by	  ECs,	  however	  for	  the	  purpose	  of	  this	  
thesis,	  focus	  will	  be	  placed	  on	  vascular	  ECs.	  This	  monolayer	  is	  in	  direct	  contact	  with	  
the	  blood	  and	  acts	  as	  a	  physical	  barrier	  separating	  blood	  and	  circulating	  cells	  from	  
the	  surrounding	  tissue.	  The	  ECs	  attach	  to	  a	  basal	  lamina	  that	  provides	  the	  scaffold	  
of	   all	   blood	   vessels,	  with	   the	   ECs	   lining	   the	   inside	  of	   scaffold	   and	   the	  outer	   layer	  
covered	   with	   smooth	   muscle	   cells	   or	   pericytes,	   depending	   on	   the	   site	   in	   the	  
vasculature.	   ECs	   can	  produce	   almost	   all	   the	  proteins	   comprising	   the	  basal	   lamina	  
and	  enzymes	   involved	   in	   its	   remodelling	   (Félétou,	  2011).	   Endothelial	   shape	  varies	  
across	  the	  vasculature,	  but	  these	  cells	  are	  generally	  approximately	  50–70	  μm	  long,	  
10–30	   μm	   wide	   and	   0.1–10	   μm	   thick,	   and	   slightly	   elongated	   in	   the	   direction	   of	  
blood	   flow,	  due	   to	   the	   shear	   stress	   forces	   exerted	  by	   the	   flowing	  blood.	  	   ECs	   are	  
highly	   sensitive	   to	   their	   surroundings,	   as	   they	  need	   to	  be	  able	   to	   respond	   to	  and	  
resist	   haemodynamic	   forces.	   Perturbations	   of	   endothelial	   structure	   and	   function	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1.2.1 Endothelial	  cell	  function	  
EC	  structure	  and	  functional	  integrity	  are	  necessary	  to	  maintain	  the	  vessel	  wall	  and	  
provide	  a	  semi-­‐selective	  permeable	  barrier	  between	  the	  blood	  and	  the	  tissues.	  This	  
versatile	   and	   multifunctional	   monolayer	   not	   only	   controls	   oxygen	   and	   nutrient	  
exchange	   but	   also	   has	  many	   other	   physiological	   roles.	   ECs	   control	   blood	   fluidity,	  
platelet	   aggregation	   and	   vascular	   tone,	   as	   well	   as	   regulate	   immune	   and	  
inflammatory	   responses	   and	   angiogenesis	   (Sumpio	   et	   al.,	   2002).	   When	   the	  
endothelium	  is	  at	  rest,	  under	  normal	  unstimulated	  conditions,	  blood	  flow	  is	  laminar	  
and	   platelets	   and	   leucocytes	   do	   not	   adhere	   to	   ECs	   due	   to	   the	   anticoagulant	   and	  
non-­‐thrombogenic	  properties	  of	  the	   luminal	  surface	  of	  quiescent	  ECs	  (reviewed	  in	  
(Pober	  and	  Sessa,	  2007).	  ECs	  sense	  mechanical	  stimuli,	  such	  as	  pressure	  and	  shear	  
stress,	   hormonal	   and	   chemical	   stimuli,	   such	   as	   thrombin,	   histamine	   and	   tissue	  
necrosis	   factor	   α	   (TNF-­‐α)	   (Ehringer	   et	   al.,	   1996;	   Endemann	   and	   Schiffrin,	   2004;	  
McKenzie	   and	   Ridley,	   2007).	   These	   stimuli	   alter	   EC	   adhesion	   molecules,	   cell-­‐cell	  
junctions	  and	  the	  cytoskeleton,	  as	  well	  as	  influence	  the	  smooth	  muscle	  cells	  of	  the	  
vessels	   resulting	   in	   the	   EC	   regulation	   of	   vasomotor	   function,	   inflammatory	  
processes,	  and	  controlling	  haemostasis	   (Endemann	  and	  Schiffrin,	  2004).	  Failure	  of	  
ECs	   to	   adequately	   perform	   any	   of	   these	   physiological	   functions	   constitutes	  
‘endothelial	  cell	  dysfunction’.	  	  
	  
1.2.2 Cell-­‐cell	  junctions	  
ECs	  tightly	  regulate	  the	  infiltration	  of	  solutes,	  plasma	  proteins	  and	  circulating	  cells	  
from	   the	   blood	   into	   the	   vessel	   wall	   and	   underlying	   tissue	   (Wojciak-­‐Stothard	   and	  
Ridley,	   2002).	   This	   vascular	   permeability	   is	   achieved	   by	   specialised	   transcellular	  
systems	  of	  transport	  vesicles	  and	  by	  the	  regulated	  opening	  and	  closing	  of	  cell-­‐cell	  
junctions	   (Dejana,	   2004).	   ECs	   are	   in	   constant,	   dynamic	   interaction	   with	   their	  
neighbouring	   cells	   and	   are	   attached	   via	   transmembrane	   homophilic	   adhesion	  
proteins	   localised	   at	   cell-­‐cell	   junctions	   (Bazzoni	   and	   Dejana,	   2004).	   The	   cell-­‐cell	  
junctions	   are	   stabilised	   by	   specific	   intracellular	   partners	   that	   anchor	   the	  
transmembrane	   adhesion	   proteins	   to	   the	   actin	   cytoskeleton.	   These	   complex	  
structures	   serve	  many	  purposes,	  and	  are	  not	   just	  necessary	   to	  maintain	  adhesion	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between	  cells.	  Cell-­‐cell	  junctions	  mediate	  intracellular	  signals	  that	  communicate	  cell	  
position,	   and	   contact-­‐dependent	   inhibition	   of	   growth,	   maintain	   cell	   shape	   and	  
establish	  cell	  polarity.	  Furthermore,	  junction	  signalling	  is	  implicated	  in	  angiogenesis,	  
shear	   stress	   responses	   and	   leucocyte	   extravasation	   and	   infiltration	   into	   inflamed	  
areas	  (Bazzoni	  and	  Dejana,	  2004).	  Junctional	  signalling	  can	  either	  occur	  directly	  by	  
engaging	   signalling	   proteins	   or	   growth-­‐factor	   receptors,	   or	   indirectly	   by	   binding	  
transcription	  factors	  at	  the	  cell	  membrane,	  preventing	  them	  from	  translocating	  to	  
the	  nucleus	  (Dejana,	  2004).	  An	  example	  of	  indirect	  intracellular	  signalling	  regulation	  
is	  the	  junctional	  protein	  β-­‐catenin,	  which	  can	  translocate	  to	  the	  nucleus	  and	  act	  as	  a	  
transcription	   factor.	   Furthermore,	   binding	   of	   β-­‐catenin	   to	   the	   cell-­‐cell	   junctions	  
prevents	  it	  from	  being	  degraded	  (Sadot	  et	  al.,	  1998).	  Adhesion	  proteins	  are	  always	  
in	  a	  dynamic	  equilibrium,	  even	  after	  contacts	  have	  been	  stably	  formed,	  and	  recycle	  
continuously	  between	  plasma	  membrane	  and	  intracellular	  compartments	  (Bazzoni	  
and	  Dejana,	  2004).	  Usually,	  changes	  in	  endothelial	  permeability	  are	  reversible	  and	  
the	  gaps	  close	  quite	  rapidly,	  unless	  episodes	  of	  chronic	  inflammation	  occur	  (Dejana	  
and	  Orsenigo,	  2013).	  	  
The	   endothelial	   adhesive	   complexes	   comprise	   three	   types	   of	   junctions:	   the	   tight	  
junctions	   (TJs),	   adherens	   junctions	   (AJs)	   and	   gap	   junctions	   (Bazzoni	   and	   Dejana,	  
2004)	   (Figure	  1.1).	  Moreover,	  adjacent	  quiescent	  ECs	  may	  overlap	  resulting	   in	  the	  
formation	   of	   contact	   regions	   where	   AJ	   components	   arrange	   in	   a	   reticular	  
distribution	   and	   are	   termed	   reticular	   AJs	   (Fernandez-­‐Martin	   et	   al.,	   2012).	   In	  
addition	  to	  the	  defined	  junctional	  complexes,	  other	  adhesion	  proteins	  contribute	  to	  
cell-­‐cell	  adhesion,	  such	  as	  platelet	  endothelial	  adhesion	  molecule-­‐1	  (PECAM-­‐1),	  and	  
intercellular	  adhesion	  molecule	  2	   (ICAM-­‐2)	   (Dejana	  and	  Giampietro,	  2012;	  Dejana	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Figure	  1.1	  Schematic	  representation	  of	  junctions	  between	  endothelial	  cells	  
Junctions	  in	  endothelial	  cells	  include	  tight	  junctions,	  adherens	  junctions,	  gap	  junctions	  and	  
PECAM-­‐1	  and	  the	  nectin-­‐afadin	  system.	  TJs	  are	  comprised	  of	  claudins	  and	  occludin,	  as	  well	  
as	   members	   of	   the	   JAM	   family	   and	   ESAM.	   The	   ZO	   family	   of	   proteins	   are	   cytoplasmic	  
components	   of	   the	   TJs.	   The	   AJs	   consist	   of	   a	   transmembrane	   VE-­‐cadherin	   that	   binds	   to	  
p120-­‐catenin,	   β-­‐catenin	   and	   plakogloblin.	   The	   adherens	   junctions	   are	   connected	   to	   the	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AJs	   are	   formed	   at	   early	   stages	   of	   intercellular	   contact	   and	   are	   followed	   by	   TJ	  
organization	   (Dejana	   et	   al.,	   2009).	   TJs	   act	   as	   a	   primary	  barrier	   to	   the	  diffusion	  of	  
solutes	  through	  the	  intercellular	  space,	  they	  create	  a	  boundary	  between	  the	  apical	  
and	  the	  basolateral	  plasma	  membrane	  domains,	  and	  they	  maintain	  cell	  polarity	  by	  
recruiting	   various	   cytoskeletal	   as	  well	   as	   signalling	  molecules	   at	   their	   cytoplasmic	  
surface	   (Tsukita	   et	   al.,	   2001).	   In	   epithelia,	   TJs	   occupy	   the	   most	   apical	   position	  
between	  the	  neighbouring	  cells,	  sealing	  the	  cleft	  edges	  towards	  the	  luminal	  surface	  
and	  limiting	  the	  free	  movement	  of	   lipids	  and	  proteins	  between	  the	  apical	  and	  the	  
basolateral	  cell	   surfaces	   (Dejana	  et	  al.,	  2009;	  Lampugnani,	  2012).	  However,	   in	   the	  
endothelium,	   TJs	   are	   frequently	   intermingled	   with	   AJs	   throughout	   the	   cell-­‐cell	  
boundaries	   (Dejana,	   2004).	   AJs	   promote	   TJ	   maturation	   and	   maintenance.	   In	  
addition	   to	   controlling	   cell	   permeability,	   AJs	   are	   required	   for	   the	   correct	  
organisation	   of	   new	   vessels	   in	   angiogenesis	   (Bazzoni	   and	   Dejana,	   2004).	   	   Gap	  
junctions	   serve	   as	   communication	   structures	   between	   adjacent	   cells	   allowing	   the	  
passage	   of	   small	  molecular	  weight	   solutes,	   however	   they	   are	   not	   involved	   in	   the	  
control	  of	  endothelial	  barrier	  function	  (Dejana	  et	  al.,	  2009).	  	  
Junctions	  between	  ECs	  have	  a	  variable	  organisation	   throughout	   the	  vascular	   tree,	  
depending	  on	  the	  organ-­‐specific	  requirements	  (Simionescu,	  2000).	  For	  example,	  the	  
endothelium	  in	  the	  brain	   is	  rich	   in	  TJs,	  as	  strict	  control	  of	  permeability	   is	  required	  
for	   the	   blood-­‐brain	   barrier;	   whereas	   areas	   that	   have	   dynamic	   trafficking	   of	  
circulating	  cells	  and	  plasma	  proteins,	  such	  as	  postcapillary	  venules,	  display	  fewer	  TJ	  
(Engelhardt,	   2003;	   Wolburg	   and	   Lippoldt,	   2002).	   Although	   endothelial	   junctions	  
share	  several	  morphological	  and	  molecular	  similarities	  with	   junctions	  of	  other	  cell	  
types,	  they	  also	  have	  important	  cell-­‐specific	  features	  (Dejana	  and	  Orsenigo,	  2013).	  
	  
1.2.2.1 Molecular	  organisation	  of	  adherens	  junctions	  
Transmembrane	  adhesion	  proteins	  of	  the	  cadherin	  family	  form	  adherens	  junctions.	  
Cadherins	   are	   Ca2+-­‐dependent	   cell	   adhesion	   molecules	   (CAMs)	   mediating	  
homophilic	  adhesion	  and	  are	  organized	  in	  multimeric	  complexes	  at	  the	  cell	  borders	  
(reviewed	  in	  (Bazzoni	  and	  Dejana,	  2004).	  In	  ECs,	  a	  specific	  cadherin	  called	  vascular	  
endothelial	  cadherin	  (VE-­‐cadherin)	  is	  the	  key	  component	  of	  endothelial	  AJs	  (Dejana	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et	  al.,	  1999).	  VE-­‐cadherin	   is	  present	   in	  all	  ECs,	   in	  all	   types	  of	  vessels,	  and	   forms	  a	  
zipper-­‐like	  structure	  along	  cell-­‐cell	  borders	  by	  dimerising	   laterally	   in	  cis	  with	  trans	  
VE-­‐cadherin	   on	   the	   adjacent	   cell	   (Bazzoni	   and	   Dejana,	   2004;	   Dejana	   and	  
Giampietro,	  2012).	  VE-­‐cadherin	  is	  anchored	  to	  the	  actin	  cytoskeleton	  by	  linking	  to	  a	  
large	  number	  of	  intracellular	  proteins	  through	  its	  cytoplasmic	  tail.	  This	  interaction	  is	  
vital	   for	   junctional	   stability	   and	   also	   for	   the	   dynamic	   opening	   and	   closing	   of	  
junctions	   (see	   section	   1.2.3).	   The	   carboxy-­‐terminal	   region	   of	   VE-­‐cadherin	   directly	  
binds	  to	  β-­‐catenin,	  plakoglobin	  (also	  known	  as	  γ-­‐catenin)	  and	  p120-­‐catenin	  (Dejana	  
and	  Giampietro,	  2012)	  (Figure	  1.1).	  
Both	   β-­‐catenin	   and	   plakoglobin	   bind	   to	   the	   actin	   binding	   protein	   α–catenin.	   The	  
cadherin–catenin	   complex	   interacts	   with	   the	   actomyosin	   cytoskeleton,	   which	   is	  
vital	   for	   cell	   adhesion	   stability	   (Pokutta	   and	   Weis,	   2007;	   Vestweber,	   2008).	  
However,	   the	   role	   of	   α-­‐catenin	   in	   AJs	   has	   not	   been	   fully	   elucidated.	   Although	   it	  
might	   serve	   as	   a	   linker	   that	   directly	   connects	   the	   cadherin–β-­‐catenin	   complex	   to	  
filamentous	   actin	   (F-­‐actin),	  the	   binding	   of	   α-­‐catenin	   to	   β-­‐catenin	   or	   F-­‐actin	   is	  
believed	  to	  be	  mutually	  exclusive	  (Yamada	  et	  al.,	  2005).	  Several	  other	  actin	  binding	  
proteins	   that	   are	   located	   at	   AJs	   have	   been	   shown	   to	   bind	   to	   α-­‐catenin	   and	   to	  
localize	   to	   cell–cell	   contacts	   including:	   afadin	   (Pokutta	   et	   al.,	   2002),	   zonula	  
occludens	   protein	   1	   (ZO-­‐1)	   (Itoh	   et	   al.,	   1997),	   eplin	   (Abe	   and	   Takeichi,	   2008),	   α-­‐
actinin	  (Nieset	  et	  al.,	  1997)	  and	  vinculin	  (Huveneers	  et	  al.,	  2012;	  Weiss	  et	  al.,	  1998).	  
The	   roles	   of	   these	   proteins	   and	   the	   exact	   molecular	   organisation	   in	   cell–cell	  
junctions	  are	  partially	  defined,	  but	  they	  may	  provide	  additional	  linkages	  to	  F-­‐actin.	  
Interestingly,	   ZO-­‐1	   is	   commonly	   considered	   a	   cytoplasmic	   component	   of	   TJs	   (see	  
section	  1.2.2.2),	   but	   is	   found	   in	  AJs	   at	   early	   stages	  of	   their	   organisation	   and	  only	  
localises	  in	  TJs	  once	  when	  junctions	  are	  stabilized	  (Dejana,	  2004;	  Itoh	  et	  al.,	  1997).	  
ECs	  express	  other	  cadherins	  such	  as	  neural	  (N)	  -­‐cadherin,	  T-­‐cadherin	  and	  P-­‐cadherin	  
(Dejana	  et	  al.,	  2008).	  T-­‐cadherin	  and	  P-­‐cadherin	  are	  non-­‐cell	  type	  specific	  cadherins	  
and	   are	   variably	   expressed	   in	   different	   types	   of	   ECs	   (Ivanov	   et	   al.,	   2001).	   While	  
abundant	  in	  the	  endothelium,	  N-­‐cadherin	  does	  not	  localise	  at	  the	  cell-­‐cell	  junctions	  
and	  it	  has	  been	  suggested	  that	  N-­‐cadherin	  may	  be	  responsible	  for	  the	  anchorage	  of	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the	   endothelium	   to	   the	   surrounding	  mesenchymal	   cells,	   such	   as	   vascular	   smooth	  
muscle	  cells	  or	  pericytes	  (mesenchymal	  cells	  that	  associate	  with	  the	  walls	  of	  small	  
blood	  vessels)	  (Navarro	  et	  al.,	  1998). 
Recent	   findings	   have	   elucidated	   the	   establishment	   of	   AJs	   in	   ECs	   (Hoelzle	   and	  
Svitkina,	  2012).	  Migrating	  human	  umbilical	  vein	  endothelial	  cells	   (HUVECs)	   initiate	  
interaction	  with	  each	  other	  by	  protruding	   lamellipodia	  (thin	  sheet-­‐like	  protrusions	  
that	   are	   filled	   with	   a	   branched	   network	   of	   F-­‐actin	   with	   barbed	   ends	   facing	   the	  
leading	   edge	   (Mattila	   and	   Lappalainen,	   2008)).	   The	   subsequent	   retraction	   of	   the	  
lamellipodia	   results	   in	   the	   formation	   of	   filopodium-­‐like	   bridges	   (finger-­‐like	  
structures	   that	   are	   filled	  with	   tight	   parallel	   bundles	  of	   F-­‐actin).	   These	  bridges	   are	  
bundled	   by	   fascin,	   VE-­‐cadherin	   accumulates	   at	   points	   of	   contact,	   and	   the	  
recruitment	   of	   non-­‐muscle	   myosin	   II	   matures	   these	   bridges	   into	   stress-­‐fibre	   like	  
structures.	   These	   bridges	   link	   adjacent	   cells	   that	   lead	   to	   subsequent	   junction	  
expansion	   (Hoelzle	   and	   Svitkina,	   2012).	   Discontinuous	   AJs	   in	   ECs	   have	   a	   similar	  
structure	   where	   adjacent	   cells	   are	   linked	   by	   stress-­‐fibres	   and	   VE-­‐cadherin	   is	  
localised	  in	  short	  linear	  structures	  that	  are	  orthogonal	  to	  cell-­‐cell	  borders	  (Millan	  et	  
al.,	   2010).	   In	   contrast,	   continuous	   AJs	   have	   a	   linear	   morphology	   along	   cell	  
boundaries.	  The	  regulation	  of	  vascular	  permeability	  and	  the	  switch	  from	  continuous	  
to	  discontinuous	  AJs	  will	  be	  discussed	  in	  section	  1.2.3.	  
	  
1.2.2.2 Molecular	  organisation	  of	  tight	  junctions	  
Tight	   junctions	   comprise	   three	   distinct	   types	   of	   integral	   membrane	   proteins,	  
claudin,	   occludin,	   and	   an	   additional,	   structurally	   different	   protein,	   junction	  
adhesion	   molecule	   (JAM)	   (Figure	   1.1).	   TJs	   have	   been	   extensively	   studied	   in	  
epithelial	  cells,	  however	  relatively	   little	   is	  known	  about	  cell-­‐specific	  characteristics	  
of	  TJs	  in	  ECs.	  There	  are	  over	  20	  members	  in	  the	  claudin	  family,	  however	  only	  a	  few	  
are	  expressed	  in	  the	  endothelium	  with	  claudin5	  expressed	  primarily	  in	  ECs	  of	  blood	  
vessels	  (Dejana	  et	  al.,	  2009).	  Another	  transmembrane	  component	  of	  TJs	  is	  occludin.	  
Although	   not	   necessary	   for	   TJ	   formation,	   it	   contributes	   to	   TJ	   stabilization	   and	  
optimal	  barrier	  function	  (reviewed	  in	  (Cummins,	  2012)).	  Claudins	  and	  occludin	  are	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linked	  to	  a	  variety	  of	  intracellular	  signalling	  and	  structural	  mediators.	  These	  include	  
actin	  binding	  ZO	  proteins	   (ZO-­‐1,	   -­‐2	   and	   -­‐3)	   and	  AF-­‐6/afadin,	  which	   link	  TJs	   to	   the	  
actin	   cytoskeleton;	   as	   well	   as	   PAR-­‐3,	   cingulin	   and	   7H6	   antigen,	   also	   present	   in	  
epithelial	  TJs	  (Bazzoni	  and	  Dejana,	  2004)	  (Figure	  1.1).	  
JAMs	   are	   localized	   at	   intercellular	   contacts	   and	   participate	   in	   the	   assembly	   and	  
maintenance	   of	   junctions,	   signalling	   to	   cytoskeleton-­‐associated	   proteins	   and	  
recruiting	  cell-­‐polarity	  proteins	  to	  the	  junctions	  via	  their	  PDZ-­‐domain-­‐binding	  motif	  
(Weber	  et	  al.,	  2007).	  ECs	  express	  JAM-­‐A,	  JAM-­‐B	  and	  JAM-­‐C.	  JAM-­‐A	  co-­‐localises	  with	  
occludin,	   claudins,	   ZOs	  and	  cingulin	  at	   the	   level	  of	  TJs,	   and	   JAM-­‐B	  and	   JAM-­‐C	  are	  
specifically	  enriched	  in	  certain	  vessels,	  such	  as	  high	  endothelial	  venules	  (Weber	  et	  
al.,	   2007).	   The	   intracellular	   proteins	   of	   all	   the	   endothelial	   junctions	   are	   able	   to	  
interact	  with	  each	  other.	  ZO-­‐1	  can	  bind	  to	  JAMs,	  the	  AJ	  protein	  α-­‐catenin,	  as	  well	  as	  
the	  gap	  junction	  connexion-­‐43	  (Harhaj	  and	  Antonetti,	  2004).	  Interestingly,	  occludin	  
also	  interacts	  with	  a	  gap	  junction	  protein,	  connexin-­‐32,	  co-­‐localizing	  at	  TJs	  (Kojima	  
et	  al.,	  1999).	  ESAM	  (endothelial	  cell	  selective	  adhesion	  molecule)	  is	  an	  endothelial-­‐
specific	   transmembrane	   Ig	   protein	   related	   to	   JAMs	   that	   mediates	   homophilic	  
binding,	   and	   its	   only	   known	   cytoplasmic	   binding	   partner	   is	   MAGI-­‐I	   (Wallez	   and	  
Huber,	   2008).	   It	   is	   probable	   that	   the	   different	   junction	   systems	   interact	   and	  
cooperate	  with	  each	  other	  to	  regulate	  barrier	  integrity.	  	  
	  
1.2.2.3 Other	  adhesive	  complexes	  
In	   addition	   to	   AJs	   and	   TJs,	   ECs	   express	   other	   adhesive	   proteins	   that	   are	  
concentrated	  at	  the	  intercellular	  cleft	  but	  are	  not	  specifically	  confined	  to	  AJs	  or	  TJs.	  
Nectins	  participate	  in	  the	  initial	  step	  of	  junction	  formation	  and	  play	  a	  fundamental	  
role	  in	  the	  establishment	  of	  polarity	  (Takai	  et	  al.,	  2003).	  They	  are	  Ca2+-­‐independent	  
immunoglobulin-­‐like	  CAMs	  and	  the	  nectin	  family	  comprises	  four	  members,	  nectin-­‐
1,	   nectin-­‐2,	   nectin-­‐3	   and	  nectin-­‐4	   (reviewed	   in	   (Rikitake	   et	   al.,	   2012).	  Nectins	   are	  
connected	  to	  the	  actin	  cytoskeleton	  through	  the	  binding	  of	  their	  cytoplasmic	  tails	  to	  
the	   PDZ-­‐containing	   protein	   afadin,	   which	   also	   binds	   to	   ponsin	   (Reymond	   et	   al.,	  
2000;	  Takahashi	  et	  al.,	  1999).	  Ponsin	  binds	  afadin,	  vinculin,	  and	  α-­‐catenin	  (Bazzoni	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and	  Dejana,	  2004)	  (Figure	  1.1).	  Both	  vinculin	  and	  α-­‐catenin	  are	  part	  of	  the	  AJs,	  and	  
therefore	   provide	   the	   link	   between	   the	   cadherin	   and	   nectin	   systems	   (Wallez	   and	  
Huber,	   2008).	   Nectins	   can	   also	   interact	   with	   TJs	   through	   ZO-­‐1,	   and	   through	   the	  
interaction	  of	  afadin	  and	  JAM-­‐A	  (Ebnet	  et	  al.,	  2000).	  These	  interactions	  may	  depend	  
on	  the	  specific	  localization	  of	  these	  proteins	  and	  the	  on	  the	  cell	  type	  in	  relation	  to	  
the	  junctional	  complex	  arrangement.	  
PECAM-­‐1/CD31	   is	   another	   endothelial	   adhesive	   protein	   that	   does	   not	   co-­‐localise	  
with	  AJs	   or	   TJs.	   It	   is	   a	   transmembrane	   immunoglobulin-­‐like	  CAM	  concentrated	   at	  
intercellular	   contacts	   in	   the	  endothelium	   (Bazzoni	   and	  Dejana,	   2004).	   PECAM-­‐1	   is	  
also	   expressed	   by	   leucocytes	   and	   platelets	   and	   is	   required	   for	   leucocyte	  
transendothelial	  migration	   (TEM)	   (Mamdouh	  et	  al.,	  2003).	  A	   recent	  study	  showed	  
that	   PECAM-­‐1	   coordinates	   with	   AJs	   to	   maintain	   endothelial	   barrier	   function	  
(Fernandez-­‐Martin	  et	  al.,	  2012).	  
	  
1.2.3 	  Mechanisms	  regulating	  endothelial	  permeability	  
There	  are	  two	  main	  types	  of	  endothelial	  permeability:	   i)	  basal	  permeability,	  which	  
occurs	  at	  the	  level	  of	  capillaries,	  the	  major	  site	  of	  exchange	  in	  the	  vascular	  bed,	  and	  
ii)	   induced	   permeability	   that	   is	   associated	   with	   inflammation,	   predominantly	  
involving	   post-­‐capillary	   venules	   (Félétou,	   2011).	   In	   a	   state	   of	   acute	   or	   chronic	  
inflammation,	   ischaemia–reperfusion	   and	   atherosclerosis,	   mediators	   (such	   as	  
histamine	   and	   thrombin),	   cytokines,	   growth	   factors	   (such	   as	   vascular	   endothelial	  
growth	   factor	   (VEGF))	   and	   reactive	   oxygen	   species	   induce	   EC	   retraction,	   which	  
increases	  the	  intercellular	  space	  and	  subsequently	  the	  permeability	  to	  solutes	  and	  
plasma	  proteins	  (Félétou,	  2011).	  In	  normal	  conditions,	  endothelial	  cells	  control	  the	  
passage	   of	   plasma	   proteins	   and	   circulating	   cells	   from	   blood	   to	   tissues	   by	   two	  
different	  routes:	  the	  transcellular	  or	  paracellular	  pathways	  (reviewed	  in	  (Komarova	  
and	   Malik,	   2010)).	   The	   transcellular	   pathway	   involves	   the	   passage	   of	   plasma	  
components	  through	  the	  endothelial	  cytoplasm	  by	  the	  action	  of	  vesicular	  transport	  
systems,	   specialized	   pore-­‐like	   structures	   called	   fenestrae,	   and	   biochemical	  
transporters.	  Molecules	  are	  transported	  inside	  the	  vesicles	  either	  in	  solid	  phase	  (i.e.	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bound	   to	   membrane	   receptors)	   or	   in	   fluid	   phase	   (i.e.	   diluted	   in	   the	   vesicular	  
content)	   (Bazzoni	   and	   Dejana,	   2001).	   Leucocytes	   can	   transmigrate	   through	   the	  
endothelial	   barrier	   via	   both	   the	   transcellular	   and	   paracellular	   routes.	   With	   the	  
assistance	   of	   intracellular	   vesicular	   structures,	   indentation	   of	   the	   apical	   plasma	  
membrane	   of	   an	   endothelial	   cell	   would	   lead	   to	   fusion	   with	   the	   basal	   plasma	  
membrane	  that	  could	  serve	  to	  bridge	  the	  gap	  between	  the	  two	  sides,	  providing	  a	  
channel	  that	  allows	  a	  leucocyte	  to	  traverse	  through	  the	  thin	  cell	  body	  (Feng	  et	  al.,	  
2002).	   It	  was	   observed	   that	   7	   to	   11%	  of	   neutrophils,	  monocytes,	   or	   lymphocytes	  
migrate	   via	   a	   transcellular	   route	   through	   the	   monolayer	   of	   HUVECs	   (Vestweber,	  
2012b).	  	  
The	   paracellular	   route	   of	   endothelial	   permeability	   regulation	   is	   mediated	   by	   the	  
rearrangement	   of	   endothelial	   cell-­‐cell	   junction	   complexes	   (Bazzoni	   and	   Dejana,	  
2004).	   Endothelial	   cell	   contacts	   need	   to	   be	   opened	   to	   allow	   leucocytes	   to	   pass	  
through	   the	   junctions	   of	   the	   endothelial	   barrier	   (Vestweber,	   2008)	   and	   ECs	  
dynamically	   regulate	   this	   paracellular	   permeability	   in	   response	   to	   diverse	   stimuli,	  
such	  as	  histamine,	  thrombin	  or	  VEGF	  (Bogatcheva	  and	  Verin,	  2008).	  	  
	  
1.2.3.1 Adherens	  junctions	  and	  regulation	  of	  vascular	  permeability	  
VE-­‐cadherin	   plays	   a	   central	   role	   in	   regulating	   endothelial	   permeability.	   There	   are	  
four	  interconnected	  biochemical	  routes	  whereby	  permeability-­‐increasing	  agents	  or	  
inflammatory	   stimuli	   lead	   to	   the	   loss	   of	   VE-­‐cadherin	   function,	   and	   ultimately	   an	  
increase	   of	   vascular	   permeability:	   (1)	   phosphorylation-­‐driven	   VE-­‐cadherin/catenin	  
complex	   destabilization,	   (2)	   reduction	   of	   VE-­‐cadherin	   cell	   surface	   levels,	   (3)	  
crosstalk	  with	  tight	  junctions,	  and	  (4)	  tension	  and	  mechanical	  forces	  (Gavard,	  2009).	  
For	  example,	  VEGF	  induces	  VE-­‐cadherin	  tyrosine	  phosphorylation	  and	  disrupts	  VE-­‐
cadherin/catenin	   binding	   (Esser	   et	   al.,	   1998).	   Tyrosine	   phosphorylation	   of	   VE-­‐
Cadherin	   causes	   subtle	   changes	   in	   the	   organisation	   of	   AJs	   and	   is	   associated	  with	  
destabilizing	   junctions	   and	   impaired	   barrier	   control.	   Interestingly,	   it	   has	   recently	  
been	  shown	  that	  hemodynamic	  forces	  can	  also	  result	  in	  tyrosine	  phosphorylation	  of	  
VE-­‐cadherin	  in	  vivo	  via	  Src	  kinase	  in	  veins,	  but	  not	  in	  arteries	  (Orsenigo	  et	  al.,	  2012).	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Phosphorylation	   of	   VE-­‐cadherin	   by	   the	   non-­‐receptor	   tyrosine	   kinase	   Src	   is	   not	  
sufﬁcient	   to	   decrease	   endothelial	   barrier	   function	   (Adam	   et	   al.,	   2010),	   but	   it	   is	  
thought	   to	   serve	  as	  a	  priming	  mechanism	  to	   sensitise	  veins	   to	  other	  permeability	  
inducing	   agents	   such	   as	   inflammatory	   cytokines	   (Orsenigo	   et	   al.,	   2012).	   Full	  
understanding	  of	   the	  direct	  and	   indirect	   interactions	  of	  VE-­‐cadherin	   that	   regulate	  
paracellular	   permeability	   are	   still	   unknown.	   However,	   it	   has	   been	   suggested	   that	  
VE-­‐cadherin	   forms	   different	   complexes	   in	   response	   to	   different	   needs	   of	   the	  
vasculature,	   such	   as	   low	   or	   tight	   control	   of	   permeability,	   growing	   or	   resting	   of	  
vessels,	  and	  in	  response	  to	  inflammation	  (Dejana	  and	  Giampietro,	  2012).	  	  
The	  VE-­‐cadherin–catenin	  complex	  is	  a	  central	  target	  for	  the	  opening	  of	  endothelial	  
junctions	  during	  leucocyte	  extravasation.	  This	  complex	  is	  focally	  lost	  at	  endothelial	  
contacts	  where	  monocytes	  transmigrate	  under	  flow	  conditions	  (Allport	  et	  al.,	  2000)	  
and	   mice	   with	   strongly	   stabilised	   endothelial	   junctions	   (modified	   with	   a	   VE-­‐
cadherin-­‐α-­‐catenin	   fusion	   protein)	   exhibited	   impaired	   leucocyte	   extravasation	   in	  
vivo	  under	  various	  inflammatory	  situations	  (Schulte	  et	  al.,	  2011).	  	  
AJs	   are	   also	   destabilized	   by	   the	   internalization	   of	   VE-­‐cadherin.	   Tyrosine	  
phosphorylation	  of	  VE-­‐cadherin	  by	  permeability-­‐increasing	  agents	  or	  inflammatory	  
stimuli	  promotes	  the	  internalization	  of	  VE-­‐cadherin	  through	  clathrin-­‐coated	  vesicles	  
(Dejana	  and	  Orsenigo,	  2013;	  Gavard	  and	  Gutkind,	  2006).	  However,	   the	  binding	  of	  
p120-­‐catenin	   to	  VE-­‐cadherin	  maintains	  VE-­‐cadherin	   localization	   at	   the	  membrane	  
and	  p120-­‐catenin	  selectively	  prevents	  the	  clathrin-­‐dependent	  endocytic	  machinery	  
from	  targeting	  VE-­‐cadherin	  for	  endocytosis	  (Xiao	  et	  al.,	  2005).	  Internalization	  of	  VE-­‐
cadherin	  requires	  p120-­‐catenin	  dissociation.	  
Several	   protein	   tyrosine	  phosphatases	   (PTPs)	   associate	  with	   and	  dephosphorylate	  
VE-­‐cadherin.	  Vascular	  endothelial	  protein	  tyrosine	  phosphatase	  (VE-­‐PTP)	  is	  the	  only	  
known	   endothelial	   specific	   receptor-­‐type	   tyrosine	   phosphatase	   and	   its	   activity	  
enhances	  VE-­‐cadherin	  mediated	   cell–cell	   adhesion,	   decreasing	   endothelial	   barrier	  
permeability	   (Nawroth	   et	   al.,	   2002).	   VEGF	   is	   able	   to	   dissociate	   VE-­‐PTP	   from	   VE-­‐
cadherin,	  resulting	  in	  AJ	  destabilisation	  (Vestweber,	  2012b).	  Interestingly,	  VE-­‐PTP	  is	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thought	   to	   participate	   in	   leucocyte	   transmigration	   as	   leucocytes	   also	   trigger	   the	  
dissociation	  of	  VE-­‐PTP	   from	  VE-­‐cadherin	   (Nottebaum	  et	  al.,	  2008),	   supporting	   the	  
idea	  that	  leucocytes	  induce	  changes	  in	  the	  phosphorylation	  state	  of	  VE-­‐cadherin	  to	  
enhance	  their	  transmigration	  (Harris	  and	  Nelson,	  2010).	  
Not	  only	  is	  VE-­‐cadherin	  relocated	  and	  phosphorylated	  upon	  stimulation	  by	  diverse	  
permeability	   inducing	   agents,	   but	   it	   has	   also	   been	   shown	   to	   influence	   tight	  
junctional	   assembly.	   VE-­‐cadherin	   can	   directly	   enhance	   the	   expression	   level	   of	  
claudin-­‐5	  by	   tethering	   repressive	   transcription	   factors	  away	   from	  the	  nucleus	  and	  
claudin-­‐5	  promoter	  (Taddei	  et	  al.,	  2008).	  
The	   shape	  of	   the	  endothelial	   cell	   also	  determines	   the	   integrity	  of	   the	  endothelial	  
barrier.	  The	  tension	  exerted	  by	  actomyosin	  contraction	  can	  disrupt	  AJs.	  This	  will	  be	  
discussed	  further	   in	  section	  1.4.4,	  when	  the	  regulators	  of	  actomyosin	  contractility	  
are	  described.	  
	  
1.2.3.2 Tight	  junctions	  and	  the	  regulation	  of	  vascular	  permeability	  
In	  comparison	  to	  AJs,	  the	  regulation	  of	  TJs	   in	  the	  endothelial	  barrier	   is	  not	  as	  well	  
understood.	   Expression	   levels	   of	   occludin	   and	   its	   localization	   at	   TJs	   in	   the	  
endothelium	  correlate	  with	  the	  permeability	  of	  different	  segments	   in	  the	  vascular	  
tree.	  Occludin	  is	  expressed	  at	  high	  levels	  in	  brain	  endothelial	  cells	  with	  a	  continuous	  
distribution,	   and	   at	   much	   lower	   levels	   in	   ECs	   of	   non-­‐neural	   tissues,	   exhibiting	   a	  
discontinuous	   distribution	   (Harhaj	   et	   al.,	   2006).	   Like	   VE-­‐cadherin,	   endothelial	  
specific	  Claudin	  5	   levels	  and	  cellular	   localization	  are	   regulated	  by	  phosphorylation	  
(reviewed	   in	   (Gonzalez-­‐Mariscal	   et	   al.,	   2008)).	   Protein	   kinase	   C	   (PKC)	   is	   an	  
important	   TJ	   mediator.	   PKC	   activation	   supports	   assembly	   of	   growing	   TJs,	   but	  
impairs	   the	   integrity	   of	   established	   TJs	   (Bazzoni,	   2006).	   This	   suggests	   that	  
phosphorylation	  of	  TJ	  proteins	  has	  a	  different	  effect	  on	  the	  endothelium	  depending	  
on	  whether	  the	  TJ	  are	  in	  an	  assembled	  or	  disassembled	  state.	  VEGF	  activates	  PKC	  in	  
primary	   retinal	   ECs,	   stimulating	   the	   phosphorylation	   of	   occludin	   resulting	   in	   an	  
increase	   in	   endothelial	   permeability	   (Harhaj	   et	   al.,	   2006).	   It	   is	   unclear	   whether	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occludin	  is	  a	  direct	  target	  of	  PKC	  activity,	  or	   if	  VEGF	  induces	  a	  cascade	  of	  occludin	  
phosphorylation	  that	  requires	  more	  than	  PKC	  activation	  alone.	  
JAM	  expression	  is	  upregulated	  in	  response	  to	  inflammation	  and	  ischaemia	  (Weber	  
et	  al.,	  2007).	  Although	  the	  role	  of	  JAMs	  in	  the	  mechanism	  of	  increased	  permeability	  
is	   not	   yet	   determined,	   JAM-­‐A	   responds	   to	   permeability-­‐increasing	   cytokines	   by	  
dissociating	  from	  the	  actin	  cytoskeleton	  and	  destabilising	  TJs	  (Vandenbroucke	  et	  al.,	  
2008).	   Long-­‐term	   stimulation	   of	   ECs	   with	   TNF-­‐α	   leads	   to	   reduced	   localisation	   of	  
occludin	   and	   JAM-­‐A	   at	   TJs	   (McKenzie	   and	   Ridley,	   2007).	   JAM-­‐B	   is	   unregulated	   in	  
chronic	   inflammation	   (Aurrand-­‐Lions	  et	  al.,	   2001)	  and	  both	   JAM-­‐A	  and	   JAM-­‐C	  are	  
upregulated	   in	   ECs	   obtained	   from	   atherosclerotic	   vessels	   (Keiper	   et	   al.,	   2005;	  
Ostermann	  et	  al.,	  2005).	  	  
In	   summary,	   the	   loss	   of	   function	   and/or	   mislocalisation	   of	   most	   of	   the	   key	  
components	  of	  TJs	  result	  in	  increased	  paracellular	  permeability.	  
 
1.2.4 The	  actin	  cytoskeleton	  
ECs	  require	  a	  strong	  and	  dynamic	  structure	  that	  is	  able	  to	  maintain	  cell-­‐cell	  and	  cell-­‐
matrix	  tethering,	  as	  well	  as	  provide	  mechanical	  support	  to	  facilitate	  cell	  migration.	  
The	   cytoskeleton	   provides	   these	   essential	   functions	   by	   forming	   an	   intracellular	  
scaffold	   that	   links	   integral	   membrane	   proteins	   to	   the	   interior	   of	   the	   cell,	   and	  
responds	   to	  environmental	   signals	  by	   coordinating	  changes	   in	   cell	   shape	   required	  
for	   cell	  motility	   and	  membrane	  protrusion.	   The	   cytoskeleton	   is	  made	  up	  of	   three	  
types	  of	  polymers:	  actin	   filaments,	  microtubules	  and	   intermediate	   filaments.	  Each	  
component	  has	  a	  specific	  role	  to	  play	  in	  the	  cell;	  actin	  filaments	  provide	  mechanical	  
structure	   and	  motility,	  microtubules	   are	   responsible	   for	   separating	   chromosomes	  
and	  transport	  of	  large	  particles,	  and	  intermediate	  filaments	  function	  as	  intracellular	  
ligaments	   and	   tendons	   to	   resist	   mechanical	   forces	   (Pollard	   and	   Cooper,	   2009).	  
Reinforcement	   of	   the	   cytoskeleton	   occurs	   through	   the	   interaction	   of	   these	   three	  
components.	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Soluble	  globular	  monomers	  of	   actin	   (G-­‐actin)	   assemble	   into	   insoluble	   filamentous	  
polymers	  (F-­‐actin),	  depending	  on	  cellular	  demand.	  In	  general	  the	  amount	  of	  G-­‐actin	  
and	   F-­‐actin	   is	   always	   in	   equilibrium	   in	   the	   cell	   (Stossel	   et	   al.,	   1985).	   The	  
polymerisation	  process	  begins	  slowly,	  as	  small	  oligomers	  of	  actin	  are	  very	  unstable,	  
but	   once	   filaments	   have	   been	   created,	   actin	   polymerizes	   rapidly	   (Pollard	   and	  
Cooper,	  2009).	  Actin	   filaments	  are	  polarised,	   they	  possess	  a	   ‘fast	  growing’	  barbed	  
end	  and	  a	  slow	  growing	  pointed	  end	  with	  all	  the	  subunits	  in	  the	  filament	  oriented	  in	  
the	   same	   direction	   (reviewed	   in	   (Pollard	   and	   Borisy,	   2003)).	   Adenosine	  
triphosphate	  (ATP)	   is	   bound	   to	   magnesium	   ions	   in	   a	   deep	   cleft	   in	   actin	   that	  
stabilises	  the	  molecule	  but	  is	  not	  required	  for	  polymerisation	  (Asakura,	  1961).	  Once	  
incorporated	  at	  the	  barbed	  end,	  ATP-­‐actin	  hydrolyses	  its	  bound	  ATP.	  The	  ADP-­‐actin	  
molecules	   are	   left	   on	   the	   filament	   and	   eventually	   dissociate	   at	   the	   pointed	   end.	  
ADP-­‐actin	  monomers	  are	  subsequently	  reloaded	  with	  ATP	  and	  shuttle	  back	  to	  the	  
barbed	   ends	   for	   a	   new	   round	   of	   polymerisation	   (Lambrechts	   et	   al.,	   2004).	   This	  
simple	  steady	  state	  polymerization/depolymerisation	  mechanism	  is	  known	  as	  actin	  
filament	  treadmilling	   (Dominguez,	  2009).	  However,	   this	  simple	  mechanism	  cannot	  
account	   for	   the	   vast	   variety	   of	   actin-­‐dependent	   processes	   and	   actin	   networks	  
observed	  in	  cells.	  Actin	  polymerisation	  in	  eukaryotic	  cells	  is	  a	  dynamic	  process	  that	  
depends	   on	   interactions	   of	   actin	   monomers	   and	   filaments	   with	   numerous	   other	  
proteins	   to	   initiate	   polymerization,	   restrict	   the	   length	   of	   actin	   filaments,	   regulate	  
the	  assembly	  and	  turnover	  of	  actin	  filaments,	  and	  cross-­‐link	  filaments	  into	  networks	  
or	   bundles	   (Pollard	   and	   Cooper,	   2009).	   New	   actin	   filaments	   are	   formed	   in	   three	  
ways:	   i)	   by	   growing	   a	   branch	   on	   the	   side	   of	   an	   existing	   filament,	   ii)	   severing	   a	  
filament	   to	   create	   two	   new	   ends,	   or	   iii)	   starting	   up	   a	   filament	   from	  monomers.	  
Several	   actin-­‐binding	   proteins	   have	   been	   identified	   that	   are	   responsible	   for	  
modulating	   the	   organisation	   and	   function	   of	   the	   actin	   cytoskeleton	   (Pollard	   and	  
Borisy,	  2003).	  For	  example,	  capping	  proteins,	  like	  Gelsolin	  or	  Eps8,	  terminate	  active	  
polymerisation	   by	   capping	   barbed	   ends	   of	   the	   actin	   filament.	   The	   regulation	   of	  
cytoskeleton	  dynamics	  will	  be	  discussed	  in	  more	  detail	  in	  section	  1.4.2.	  
Similar	  to	  the	  endothelial	  cell-­‐cell	   junctions	  (see	  section	  1.2.2),	  the	  organisation	  of	  
actin	  and	  the	  signal	  transduction	  events	  that	  control	  it	  vary	  across	  the	  vascular	  tree	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and	  contribute	  greatly	   to	  differences	   in	  barrier	   function.	  The	  actin	  cytoskeleton	   is	  
organized	  principally	  into	  3	  distinct	  structures	  in	  ECs:	  i)	  the	  membrane	  skeleton,	  ii)	  
the	  actin	  cortex	  and	  iii)	  actomyosin-­‐based	  stress	  fibres	  (Prasain	  and	  Stevens,	  2009).	  	  
	  
1.2.4.1 The	  membrane	  skeleton	  
The	   membrane	   skeleton	   (also	   known	   as	   the	   cortical	   web	   or	   spectrin-­‐based	  
membrane	  skeleton)	  is	  immediately	  adjacent	  to	  the	  plasma	  membrane	  and	  plays	  an	  
important	   role	   in	   determining	   the	   organisation,	   stability	   and	   shape	   of	   the	  
membrane	   (De	  Matteis	   and	  Morrow,	   2000).	   	   It	   is	   composed	   of	   an	   evolutionarily	  
conserved	   rod-­‐shaped	  protein	  called	  spectrin,	  originally	   identified	   in	  erythrocytes,	  
which	   associates	  with	   actin	   filaments	   to	   form	   a	   2D	  meshwork	   at	   the	   cytoplasmic	  
border	   of	   the	   plasma	   membrane	   (Heltianu	   et	   al.,	   1986).	   Spectrins	   bind	  
transmembrane	  adhesion	  proteins	  within	  the	  plasma	  membrane	  either	  directly,	  or	  
through	  adapter	  proteins	  such	  as	  ankyrin	  and	  protein	  4.1	  (Pradhan	  et	  al.,	  2001).	  α-­‐
catenin	  tethers	  the	  membrane	  skeleton	  to	  the	  plasma	  membrane	  through	  AJs	  (see	  
section	  1.2.2.1).	  
	  
1.2.4.2 The	  actin	  cortex	  
A	  dense	   ring	   of	   actin	   fibres	   is	   organised	   and	   stabilised	   just	   beneath	   the	   spectrin-­‐
based	  membrane	   skeleton	   and	   serves	   to	   support	   the	   cell	   periphery	   (Bogatcheva	  
and	   Verin,	   2008).	   The	   attachment	   of	   the	   actin	   cortex	   to	   the	   membrane	   and	   its	  
dynamic	   rearrangement	   is	   modulated	   by	   the	   array	   of	   actin	   and/or	   membrane-­‐
binding	  proteins.	  These	  include	  endothelial	   junction	  proteins	  such	  as	  ZO-­‐1	  (Itoh	  et	  
al.,	   1997),	  α-­‐catenin	   (Muller	  et	  al.,	   2005)	   connexin-­‐43	   (Toyofuku	  et	  al.,	   1998)	  and	  
members	   of	   the	   Enabled/vasodilator-­‐stimulated	   phosphoprotein	   (Ena/VASP)	  
protein	  family	  (Benz	  et	  al.,	  2008;	  Comerford	  et	  al.,	  2002).	  The	  ezrin/radixin/moesin	  
(ERM)	   family	   are	   also	   actin-­‐binding	   proteins	  that	   integrate	   cell	   surface	   receptors	  
and	  proteins	  with	  the	  actin	  cortex	  (Ivetic	  and	  Ridley,	  2004).	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Stabilisation	   of	   the	   actin	   cortex	   is	   regulated	   via	   phosphorylation	   of	   actin-­‐binding	  
proteins	  such	  as	  filamin.	  Constitutively	  phosphorylated	  filamin	  cross-­‐links	  F-­‐actin	  to	  
membrane	  glycoproteins,	   stabilising	   the	  actin	   cortex	  at	   the	  membrane	   (Stossel	  et	  
al.,	  2001).	  
	  	  
1.2.4.3 Structure	  and	  function	  of	  stress	  fibres	  
The	   actin	   cytoskeleton	   responds	   dynamically	   to	   changes	   in	   the	   environment.	  
Quiescent	  ECs	  are	   characterised	  by	  a	   thick	  actin	   cortex	  and	   the	  absence	  of	   stress	  
fibres,	  however	  when	   the	   cells	   are	  activated	  by	   stimuli	   such	  as	   thrombin,	   a	   rapid	  
reorganization	   of	   actin	   structures	   results	   in	   a	   reduction	   of	   cortical	   actin	   and	   an	  
increase	   in	   stress	   fibres	   (Bogatcheva	   and	   Verin,	   2008).	   Stress	   fibres	   are	   thick	  
contractile	  bundles	  of	  actin	  and	  myosin	  II	  filaments	  with	  alternating	  polarity	  in	  non-­‐
muscle	   cells	   (reviewed	   in	   (Naumanen	   et	   al.,	   2008;	   Pellegrin	   and	   Mellor,	   2007;	  
Tojkander	  et	  al.,	  2012).	  These	  bundles	  are	  cross-­‐linked	  by	  α-­‐actinin	  with	  the	  double-­‐
headed	   myosin	   II	   motor	   protein	   between	   consecutive	   α-­‐actinin-­‐foci,	   forming	  
bipolar	  filaments	  (Langanger	  et	  al.,	  1986).	  Interestingly,	  stress	  fibres	  do	  not	  contract	  
uniformly	  along	  their	  lengths	  due	  to	  the	  widths	  of	  myosin–α-­‐actinin	  bands	  varying	  
in	  different	  regions	  (Peterson	  et	  al.,	  2004).	  While	  the	  membrane	  skeleton	  and	  actin	  
cortex	  are	  situated	  close	  to	  the	  cell	  membrane,	  stress	  fibres	  extend	  throughout	  the	  
cell	   cytoplasm	   generating	   a	   centripetal	   (inward)	   tension	   that	   counteracts	   the	  
centrifugal	  (outward)	  tension	  established	  by	  the	  cortical	  actin	  (Prasain	  and	  Stevens,	  
2009).	  This	  maintains	  straight	  non-­‐adherent	  cell	  borders	  (Thery	  et	  al.,	  2006).	  	  
At	   least	   three	   different	   categories	   of	   stress	   fibres	   are	   present	   in	   cultured	  
mammalian	   cells	   in	   vitro,	   based	   on	   their	   sub-­‐cellular	   localization	   and	   interactions	  
with	   integrin-­‐rich	   focal	   adhesions	   (molecular	   complexes	   that	   connect	   the	   actin	  
cytoskeleton	   with	   the	   extracellular	   matrix).	   These	   include:	   ventral	   stress	   fibres,	  
dorsal	  stress	  fibres	  and	  transverse	  arcs	  (Small	  et	  al.,	  1998)	  (Figure	  1.2).	  Stress	  fibre	  
bundles	  on	   the	  ventral	   cell	   surface	   lie	  along	   the	  base	  of	   the	  cell	   and	  are	   typically	  
associated	  with	  focal	  adhesions	  at	  both	  ends.	  Ventral	  stress	  fibres	  are	  responsible	  
for	  the	  tail	  retraction	  by	  occasional	  contraction	  cycles	  that	  facilitate	  cell	  movement	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(Chen,	  1981),	  and	  also	  work	  against	  membrane	  tension	  at	  cell	  borders	  (Thery	  et	  al.,	  
2006).	  Dorsal	   stress	   fibres	   are	   attached	   to	   a	   focal	   adhesion	   at	   their	   distal	   ends,	  
tethering	  them	  to	  the	  base	  of	  the	  cell,	  with	  their	  other	  end	  rising	  towards	  the	  dorsal	  
surface	   and	   terminating	   in	   a	   loose	  matrix	   of	   actin	   filaments.	   Dorsal	   stress	   fibres	  
cannot	  contract,	  as	  they	  do	  not	  typically	  contain	  myosin	  II	  (Tojkander	  et	  al.,	  2011),	  
and	  thus	  are	  not	  true	  stress	  fibres	  by	  definition.	  However	  they	  do	  provide	  a	  scaffold	  
for	  the	  assembly	  of	  other	  types	  of	  stress	  fibres	  that	  tether	  them	  to	  focal	  adhesions	  
(Hotulainen	   and	   Lappalainen,	   2006).	   Transverse	   arcs	   are	   bundles	   of	   F-­‐actin	   that	  
form	   beneath	   the	   dorsal	   surface	   of	   migrating	   cells,	   just	   behind	   the	   protrusive	  
lamella.	  These	  structures	  are	  typically	  not	  directly	  attached	  to	  focal	  adhesions,	  but	  
they	  are	  connected	  to	  the	  substrate	  via	  dorsal	  stress	  fibres.	  In	  migrating	  cells,	  they	  
sweep	   backwards	   from	   the	   leading	   edge	   towards	   the	   nucleus,	   where	   they	  
disassemble	  (Heath,	  1983).	  This	  process,	  known	  as	  retrograde	  flow,	  is	  driven	  by	  the	  
continuous	  contraction	  of	  transverse	  arcs	  (Zhang	  et	  al.,	  2003).	  
	  
	  
Figure	  1.2	  Actin	  stress	  fibres	  
Schematic	   illustration	  of	  the	  different	  stress	  fibre	  networks	   in	  migrating	  mammalian	  cells.	  
Dorsal	   stress	   fibres	   arise	   from	   focal	   adhesions	   at	   the	   cell	   periphery	   and	   elongate	   up	  
through	   the	   cell	   to	   join	   transverse	  arcs	   at	   the	   cell	   surface.	  Ventral	   stress	   fibres	   attach	   to	  
focal	  adhesions	  at	  both	  ends	  along	  the	  base	  of	  the	  cell.	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The	  activity	  of	  myosin	  and	  its	  interaction	  with	  actin	  filaments	  in	  non-­‐muscle	  cells	  is	  
regulated	   by	   phosphorylation	   of	   the	   myosin	   regulatory	   light	   chain	   (MLC).	   MLC-­‐
phosphorylation-­‐mediated	  contractility	  of	  stress	  fibres	  is	  controlled	  by	  at	  least	  two	  
distinct	  pathways:	   i)	  MLC	  kinase	  (MLCK)	   in	  a	  Ca2+/calmodulin-­‐dependent	  pathway,	  
and	  ii)	  Rho	  kinase/ROCK	  in	  a	  Rho-­‐dependent	  pathway	  (Katoh	  et	  al.,	  2001).	  This	  will	  
be	  discussed	  in	  section	  1.4.2	  Rho	  GTPases	  as	  regulators	  of	  cytoskeleton	  dynamics	  in	  
endothelial	  cells.	   
The	  function	  of	  stress	  fibres	  that	  is	  particularly	  relevant	  to	  this	  thesis	  is	  their	  role	  in	  
the	  vasculature.	  Stress	  fibres	  are	  found	  in	  both	  motile	  and	  non-­‐motile	  ECs.	  	  In	  non-­‐
motile	   cells	   such	   as	   confluent	   vascular	   ECs,	   stress	   fibres	   elongate	   both	   over	   and	  
under	  the	  nucleus	  and	  orient	  in	  a	  speciﬁc	  direction	  in	  response	  to	  ﬂuid	  shear	  stress	  
(Wojciak-­‐Stothard	   and	   Ridley,	   2003).	   They	   are	   thought	   to	   be	   required	   for	  
endothelial	   cells	   to	   remain	   flat	   under	   flow	   conditions,	   reducing	   shear	   stress	   and	  
providing	   rigidity	   to	   the	   cell	   to	   resist	   these	   forces	   (Pellegrin	   and	   Mellor,	   2007).	  
Interestingly,	   there	   are	   few	   focal	   adhesions	   in	   confluent	   endothelial	  monolayers,	  
however	  adherens	  junctional	  complexes	  can	  act	  as	  substitutes	  to	  anchor	  these	  cells	  
(Millan	  et	  al.,	  2010).	  
	  
1.2.5 Inflammation	  and	  the	  endothelium	  
Acute	   inflammation	  occurs	   in	   the	  endothelium	   in	   response	   to	   infectious	  microbes	  
or	   injured	   tissue.	   The	   innate	   immune	   response	   recruits	   and	   activates	   neutrophils	  
locally	  to	  eliminate	  the	  stimulus	  by	  killing	  microbes	  or	  removing	  cellular	  debris,	  and	  
if	   this	   fails	   the	   inflammatory	   process	   will	   persist	   and	   evolve	   (Pober	   and	   Sessa,	  
2007).	  However,	  while	  serving	  their	  protective	  role,	   inﬂammatory	  responses	  could	  
contribute	   to	   tissue	   damage.	   Many	   diseases	   are	   caused	   by	   dysregulated	  
inﬂammatory	   responses	   that	   are	   initiated	   in	   the	   absence	   of	   a	   stimulus	   or	   persist	  
even	  after	  resolution	  of	  the	  inciting	  infection	  or	  injury	  (Taqueti	  et	  al.,	  2006).	  During	  
tissue	  damage,	  such	  as	  ischaemia,	  proinflammatory	  cytokines	  are	  released	  that	  lead	  
to	   the	   induction	   of	   endothelial	   adhesion	   molecules	   and	   the	   presentation	   of	  
chemokines	   and	   other	   chemotactic	   factors	   on	   the	   luminal	   endothelial	   surface	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(Vestweber,	   2012a).	   This	   initiates	   the	   inflammatory	   process	   by	   activating	   the	  
leucocyte	   adhesion	   cascade,	   which	   involves	   rolling	   of	   the	   leucocyte,	   followed	   by	  
adhesion	   strengthening	   and	   arrest,	   intraluminal	   crawling,	   paracellular	   and/or	  
transcellular	   migration	   and	   finally	   results	   in	   TEM	   (also	   known	   as	   diapedesis)	  
(reviewed	  in	  (Muller,	  2011)).	  	  
The	   capture	   and	   rolling	   of	   leucocytes	   are	   mediated	   by	   transmembrane	  
glycoproteins	   known	   as	   selectins.	   L-­‐selectins	   are	   expressed	   on	   leucocytes,	   and	   E-­‐	  
and	   P-­‐selectins	   are	   expressed	   on	   endothelial	   cells	   that	   interact	   with	   P-­‐selectin	  
glycoprotein	   ligand1	  (PSGL1)	  and	  other	  glycosylated	   ligands.	  Leucocytes	  adhere	  to	  
inflamed	   endothelium	   under	   conditions	   of	   blood	   flow	   because	   L-­‐selectin	   and	   P-­‐
selectin	  actually	  require	  shear	  stress	  to	  strengthen	  the	  bonds	  and	  support	  adhesion	  
(Ley	  et	  al.,	  2007).	  Resting	  ECs	  do	  not	  interact	  with	  leucocytes	  as	  basal	  production	  of	  
nitric	  oxide	  (NO)	  sequesters	  E-­‐	  and	  P-­‐selectin,	  as	  well	  as	  other	  adhesion	  molecules	  
such	   as	   vascular	   cell-­‐adhesion	   molecule	   1	   (VCAM1)	   and	   intracellular	   adhesion	  
molecule	   I	   (ICAM-­‐1)	   (De	   Caterina	   et	   al.,	   1995).	   The	   expression	   of	   endothelial	  
adhesion	  molecules	  P-­‐selectin,	  E-­‐selectin	  and	  VCAM-­‐1	  has	  also	  been	   implicated	   in	  
atherosclerosis	   (Dong	   and	  Wagner,	   1998).	   These	   are	   induced	   by	  multiple	   factors	  
including	  oxidized	  LDL,	  inflammatory	  cytokines	  such	  as	  interleukin-­‐1	  (IL-­‐1)	  or	  TNF-­‐α,	  
as	  well	  as	  biomechanical	  forces	  such	  as	  shear	  stress	  (reviewed	  in	  (Libby,	  2012)).	  The	  
rolling	  of	  leucocytes	  on	  the	  blood	  wall	  allows	  the	  cells	  to	  slow	  down	  and	  to	  detect	  
chemokines	   on	   the	   endothelium	   surface.	   Chemokines	   activate	   leucocyte	   integrin	  
receptors	  promoting	  adhesion	  to	  ICAM-­‐1	  (Yang	  et	  al.,	  2005)	  and	  VCAM-­‐1,	  stabilising	  
leucocyte	  adhesion	  and	  migration	  on	  the	  activated	  endothelial	  cell	  surface	  (Ley	  et	  
al.,	   2007).	   As	   the	   leucocyte	   crawls	   to	   the	   EC	  border,	   ICAM-­‐1	   and	  VCAM-­‐1	   cluster	  
underneath	  it	  and	  transmit	  a	  number	  of	  signals	  into	  the	  EC.	  These	  signals	  stimulate	  
an	   increase	   of	   cytosolic	   free	   Ca2+	   (Huang	   et	   al.,	   1993)	   which	   activates	   MLCK	  
(Hixenbaugh	   et	   al.,	   1997),	   and	   results	   in	   stress	   fibre	   contraction	   that	   induces	  
junctional	  disruption	  (see	  sections	  1.2.4.3	  and	  1.4.2).	  Inflamed	  ECs	  can	  redistribute	  
junctional	   molecules	   that	   favour	   TEM.	   Stimulation	   of	   ICAM-­‐1	   also	   leads	   to	   the	  
phosphorylation	  of	  VE-­‐cadherin	  by	  the	  kinases	  Src	  and	  Pyk2	  (Turowski	  et	  al.,	  2008).	  
Phosphorylation	   of	   VE-­‐cadherin	   on	   the	   p120-­‐	   and	   β-­‐catenin-­‐binding	   sites	   inhibits	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their	  binding	  and	  destabilises	  the	  AJs	  (Allingham	  et	  al.,	  2007)	  (see	  section	  1.2.3.1).	  
The	  cross-­‐linking	  of	  VCAM-­‐1	  also	  leads	  to	  AJ	  disassembly	  by	  the	  activation	  of	  Rac1	  
(see	  section	  1.4)	  as	  a	  result	  of	  an	  increase	  in	  reactive	  oxygen	  species	  in	  ECs	  (Cook-­‐
Mills	   et	   al.,	   2004;	   van	   Wetering	   et	   al.,	   2002).	   PECAM-­‐1	   is	   an	   interesting	   cell	  
adhesion	   and	   signalling	   molecule	   in	   terms	   of	   TEM,	   as	   it	   is	   concentrated	   at	   the	  
borders	   of	   endothelial	   cells	   and	   expressed	   diffusely	   on	   platelets	   and	   leucocytes	  
(Muller,	  2011).	  Homophilic	  interaction	  between	  the	  PECAM	  molecules	  of	  both	  cells	  
is	   required	   for	   TEM	   (Mamdouh	  et	   al.,	   2003;	  Muller	   et	   al.,	   1993).	   It	   is	   vital	   to	   the	  
regulation	  of	  inflammatory	  responses,	  and	  interestingly	  it	  has	  been	  shown	  to	  serve	  
a	   variety	   of	   both	   pro-­‐inflammatory	   and	   anti-­‐inflammatory	   functions	   (reviewed	   in	  
(Privratsky	  et	  al.,	  2010)).	  	  
	  
1.3 Insulin	  
The	  discovery	  of	  insulin	  in	  1921	  by	  Frederick	  Banting,	  Charles	  Best,	  James	  Bertram	  
Collip	  and	  John	  James	  Rickard	  Macleod	  (Banting	  et	  al.,	  1922),	  is	  considered	  one	  of	  
the	  great	  biological	  and	  medical	  advances	  of	  the	  twentieth	  century	  (Cohen,	  2006).	  
Insulin	  was	   the	   first	   protein	   to	  have	   its	   amino	  acid	   sequence	  determined	   (Sanger	  
and	  Tuppy,	  1951),	   	   the	   first	  protein	   to	  be	  synthesized	  chemically	   (Du	  et	  al.,	  1961;	  
Katsoyannis,	  1967),	  first	  to	  be	  measured	  by	  radioimmunoassay	  (Yalow	  and	  Berson,	  
1961)	  and	  first	  to	  have	  its	  three-­‐dimensional	  structure	  solved	  (Blundell	  et	  al.,	  1971).	  
Insulin	   is	   a	   peptide	   hormone	   produced	   from	   pro-­‐insulin	   in	   the	   β-­‐cells	   of	   the	  
pancreas	   in	  response	  to	  high	  blood	  glucose	  after	  a	  meal	  (Steiner	  and	  Oyer,	  1967).	  
Insulin	   is	   the	   primary	   hormone	   involved	   in	   controlling	   blood	   glucose	   levels	   in	  
humans	  and	  most	  vertebrates.	  As	  well	  as	  maintaining	  glucose	  homeostasis,	  insulin	  
is	   also	   responsible	   for	   promoting	   a	   number	   of	   other	   cellular	   events	   including	  
regulation	   of	   ion	   and	   amino	   acid	   transport,	   lipid	  metabolism,	   glycogen	   synthesis,	  
gene	   transcription	   and	   mRNA	   turnover,	   protein	   synthesis	   and	   degradation,	   and	  
DNA	   synthesis	   (Kahn	   and	   White,	   1988).	   It	   regulates	   glucose	   uptake,	  
gluconeogenesis	   and	   glycogenesis	   in	   skeletal	   muscle,	   adipocytes,	   and	   liver	   by	  
modifying	  the	  activity	  of	  a	  variety	  of	  enzymes	  and	  transport	  processes	  (Chaudhuri	  
Chapter	  1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Introduction	  
	  
	   	   38	  
et	   al.,	   2012).	   However,	   as	   molecular	   pathways	   of	   insulin	   signalling	   are	   being	  
elucidated,	  more	  evidence	  is	  developing	  on	  many	  non-­‐metabolic	  actions	  of	  insulin.	  	  
	  
1.3.1 Insulin	  and	  insulin-­‐like	  growth	  factor-­‐1	  (IGF-­‐I)	  receptors	  
Insulin	  mediates	   its	  actions	  at	  the	  cellular	   level	  by	  binding	  to	  a	  plasma	  membrane	  
receptor.	  The	  insulin	  receptor	  (IR)	  and	  the	  insulin-­‐like	  growth	  factor	  I	  receptor	  (IGF-­‐
IR)	   are	   homologues,	   sharing	   >50%	   of	   their	   amino	   acid	   sequence	   (Ullrich	   et	   al.,	  
1986).	   Insulin-­‐like	  growth	  factor	   I	   (IGF-­‐I)	   is	  a	  member	  of	  the	   insulin	  superfamily	  of	  
polypeptide	   hormones	   that	   all	   share	   the	   distinctive	   insulin	   structural	   motif	  
(Shabanpoor	  et	  al.,	  2009).	  The	  major	  source	  of	   IGF-­‐I	   is	   the	   liver,	  but	  synthesis	  has	  
been	  shown	  to	   take	  place	   in	  numerous	   tissues	  and	   it	   is	  an	   important	  mediator	  of	  
cell	  and	  tissue	  growth	  and	  differentiation,	  in	  response	  to	  pituitary	  growth	  hormone	  
(GH),	  which	   in	   turn	  regulates	   the	  production	  and	  release	  of	   IGF-­‐I	   (Daughaday	  and	  
Rotwein,	   1989).	   IR	   and	   IGF-­‐IR	   are	   cell-­‐surface	   glycoproteins,	   belonging	   to	   the	  
tyrosine	   kinase	   family.	   They	   consist	   of	   an	   extracellular	   α-­‐subunit	   and	   a	  
transmembrane	   β-­‐subunit	   linked	   by	   disulphide	   bonds	   to	   form	   an	   α2β2-­‐
heterotetramer	   (Cheatham	   and	   Kahn,	   1995;	   Kasuga	   et	   al.,	   1982a).	   The	   α-­‐subunit	  
contains	  the	  ligand-­‐binding	  site	  and	  the	  β-­‐subunit	  has	  the	  ligand-­‐sensitive	  tyrosine	  
kinase	   site	   that	   undergoes	   a	   conformational	   change	   leading	   to	   ATP	   binding	   and	  
autophosphorylation	  upon	   ligand	  binding	  (Frattali	  et	  al.,	  1992).	   IR	  and	  IGF-­‐IR	  have	  
84%	  homology	  in	  the	  β-­‐subunit	  tyrosine	  kinase	  domains	  (Ullrich	  et	  al.,	  1986).	  Both	  
insulin	  and	   IGF-­‐I	  bind	   to	  either	   receptor	  at	  high	  concentrations	  but	  have	  a	  100	  to	  
1000	  times	  higher	  affinity	  for	  their	  respective	  receptor	  (Werner	  et	  al.,	  2008).	  Hybrid	  
insulin/IGF-­‐I	   receptors	   have	   been	   found	   in	   tissues	   that	   co-­‐express	   both	   receptors	  
and	   are	   composed	   of	   half	   an	   αβ	   IR	   disulphide-­‐linked	   to	   an	   αβ	   half	   of	   the	   IGF-­‐IR	  
(Moxham	  et	  al.,	  1989).	  Endothelial	  cells	  express	  insulin	  and	  IGF-­‐I	  receptors	  as	  well	  
as	   hybrid	   receptors,	   with	   HUVECs	   expressing	   more	   IGF-­‐IR	   than	   IR.	   Low	  
concentrations	   of	   IGF-­‐I	   can	   activate	   IR	   and	   the	   insulin/IGF-­‐I	   hybrid	   receptors;	  
however	   insulin	   cannot	   activate	   IGF-­‐IR	   or	   the	   hybrid	   receptors	   at	   normal	   plasma	  
insulin	  levels	  (10-­‐9	  to	  10-­‐8	  M)	  (Nitert	  et	  al.,	  2005).	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1.3.2 Insulin	  signalling	  pathways	  in	  endothelial	  cells	  
The	   insulin	   receptor	   serves	   two	   purposes:	   i)	   to	   recognise	   insulin	   among	   all	   other	  
circulating	  molecules	  in	  the	  blood	  by	  binding	  it	  with	  a	  high	  degree	  of	  specificity	  and	  
affinity,	   and	   ii)	   to	   induce	   a	   transmembrane	   signal	   that	  mediates	   the	   intracellular	  
action	  of	  insulin	  (Kahn	  and	  White,	  1988).	  When	  insulin	  binds	  to	  the	  α-­‐subunit	  of	  its	  
cognate	   receptor,	   a	   rapid	   conformational	   change	   in	   the	   β-­‐subunit	   results	   in	  
dimerization	  and	  activation	  of	  the	  tyrosine	  kinase	  domain	  (Lee	  et	  al.,	  1997).	  This	  in	  
turn,	   enhances	   the	   kinase	   activity	   of	   the	   receptor	   enabling	   it	   to	   phosphorylate	   a	  
series	   of	   cytoplasmic	   substrates	   (Kasuga	   et	   al.,	   1982b).	   In	   addition	   to	   tyrosine	  
autophosphorylation,	   the	   insulin	   receptor	   is	   also	   subject	   to	   β-­‐subunit	  
serine/threonine	  phosphorylation	  (Pessin	  and	  Saltiel,	  2000).	  The	  three-­‐dimensional	  
structure	  of	  the	  insulin–IR	  complex,	  demonstrating	  how	  insulin	  engages	  the	  IR,	  has	  
only	   recently	  been	  elucidated	   (Menting	  et	  al.,	  2013),	  and	   this	   interaction	   initiates	  
the	  activation	  of	  many	   signal	   transduction	  networks	   that	   regulate	  diverse	   cellular	  
functions	   (Nystrom	   and	   Quon,	   1999).	   Two	   major	   pathways	   are	   known	   to	   be	  
activated	   by	   insulin	   in	   endothelial	   cells:	   the	   phosphatidylinositol	   3-­‐kinase	   (PI3K)-­‐
Akt/protein	  kinase	  B	   (PKB)	  pathway	  and	   the	  Ras-­‐mitogen-­‐activated	  protein	  kinase	  
(MAPK)	  pathway	  (Taniguchi	  et	  al.,	  2006)	   (Figure	  1.3).	  The	   IR	  engages	  directly	  with	  
intracellular	   signalling	  molecules	  via	   interactions	  between	  phosphotyrosine	  motifs	  
in	   the	   receptor	   and	   downstream	  molecules	   containing	   src	   homology-­‐2	   (SH2)	   and	  
phosphotyrosine-­‐binding	   (PTB)	  domains.	  At	   least	  11	   intracellular	  substrates	  of	   the	  
IR	   kinase	   have	   been	   identified	   including	   6	   members	   of	   the	   insulin	   receptor	  
substrate	   (IRS)	   family	   (IRS-­‐1,	   2,	   3,	   4,	   5,	   and	   6),	   the	   Shc	   adaptor	   protein	   isoforms,	  
SIRP	   (signal-­‐regulatory	   protein)	   family	   members,	   Gab-­‐1	   (GRB2-­‐associated-­‐binding	  
protein	  1),	  Cbl,	  and	  APS	   (adaptor	  protein	  with	  a	  PH	  and	  SH2	  domain)	   (Pessin	  and	  
Saltiel,	  2000).	  	  
	  
Chapter	  1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Introduction	  
	  
	   	   40	  
	  
	  
Figure	  1.3	  Major	  signalling	  pathways	  activated	  by	  insulin	  
Insulin	   binds	   to	   the	   insulin	   receptor	   (IR)	   inducing	   tyrosine	   autophosphorylation	   and	  
activating	   two	   signalling	   pathways:	   Ras-­‐mitogen	   activated	   protein	   kinase	   (MAPK),	   which	  
results	   in	  cell	  proliferation	  and	  differentiation	  and	  vasoconstriction	  by	  endothelin-­‐1	  (ET-­‐1)	  
via	   ETA	   receptors	   on	   smooth	   muscle	   cells;	   and	   phosphatidylinositol	   3-­‐kinase	   (PI3K)-­‐Akt,	  
which	   mediates	   the	   metabolic	   actions	   of	   insulin	   and	   vasodilation	   via	   nitric	   oxide	   (NO).	  
Insulin	  receptor	  substrate	  (IRS)	  is	  phosphorylated	  by	  the	  IR,	  creating	  Src	  homology	  2	  (SH2)-­‐
domain	   binding	   motifs	   for	   the	   SH2	   domain	   of	   the	   regulatory	   p85	   subunit	   of	   PI3K.	   This	  
interaction	   allosterically	   activates	   the	   PI3K	   p110	   catalytic	   subunit	   to	   convert	  
phosphatidylinositol	   4,5-­‐diphosphate	   (PIP2)	   to	   phosphatidylinositol	   3,4,5-­‐trisphosphate	  
(PIP3).	   PIP3	   binds	   Akt	   and	   induces	   a	   conformational	   change	   that	   promotes	   Akt-­‐Thr308	  
phosphorylation	   by	   constitutively	   active	   3-­‐phosphoinositide-­‐dependent	   protein	   kinase	   1	  
(PDK1).	   This	   enables	   Mammalian	   target	   of	   rapamycin	   complex	   2	   (mTORC2)	   or	   DNA-­‐
dependent	   protein	   kinase	   (DNA-­‐PK)	   to	   phosphorylate	   Akt	   Ser473	   and	   fully	   activate	   it	  
resulting	   in	   a	   cascade	   of	   phosphorylation	   to	   its	  many	   substrates.	   Darker	   arrows	   indicate	  
phosphorylation	  and	  regulation	  of	  target	  proteins.	  In	  the	  endothelium,	  Akt	  phosphorylates	  
and	   activates	   endothelial	   nitric	   oxide	   synthase	   (eNOS)	   to	   produce	   more	   NO	   resulting	   in	  
vasodilation.	  Shc	  and	  Grb2-­‐associated-­‐binding	  protein	  1	  (Gab-­‐1)	  bind	  to	  the	  IR	  and	  recruit	  
Son-­‐of-­‐sevenless	  (SOS)	  that	  activates	  Ras	  resulting	  in	  a	  serine	  kinase	  cascade	  activating	  Raf,	  
MEK	  (MAPK	  and	  ERK	  kinase)	  and	  MAPK	  (also	  known	  as	  ERK).	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1.3.2.1 The	  phosphatidylinositol	  3-­‐kinase	  (PI3K)	  –	  Akt	  /	  protein	  kinase	  B	  (PKB)	  
pathway	  
The	   PI3K-­‐Akt	   pathway	   is	   a	   highly	   conserved,	   tightly	   regulated	   multistep	   process	  
(Hemmings	   and	   Restuccia,	   2012).	   Although	   IR	   phosphorylates	   many	   proteins	  
(Schmelzle	  et	  al.,	  2006),	  IRS-­‐1	  and	  IRS-­‐2	  are	  particularly	  important	  players	  in	  insulin	  
signalling	   in	  endothelial	   cells	   (Hanke	  and	  Mann,	  2009).	  The	   IRS	  proteins	  contain	  a	  
pleckstrin-­‐homology	   (PH)	   domain,	   required	   to	   anchor	   IRS	   proteins	   to	   the	   plasma	  
membrane	   and	   a	   PTB	   domain,	   able	   to	   bind	   IR	   and	   IGF-­‐IR.	   The	   C-­‐terminal	   region	  
contains	  more	   than	  twenty	  potential	   sites	   for	  phosphorylation	  by	   the	   IR.	  Class	  1A	  
PI3Ks	  are	  one	  of	  the	  best-­‐characterised	  downstream	  effectors	  of	  IRS	  proteins,	  and	  
are	   responsible	   for	   regulating	   growth	   and	  metabolism	   (Cantley,	   2002).	   PI3Ks	   are	  
heterodimers	   consisting	  of	  a	  p85	   regulatory	   subunit	  and	  a	  p110	  catalytic	   subunit,	  
and	  several	  isoforms	  of	  each	  subunit	  exist	  in	  mammals	  (Engelman	  et	  al.,	  2006).	  The	  
interaction	   of	   the	   SH2	  domain	   of	   the	   p85	   subunit	   allosterically	   activates	   the	   pre-­‐
associated	  p110	  catalytic	  subunit	  to	  generate	  the	  lipid	  product	  phosphatidylinositol	  
3,4,5-­‐trisphosphate	   [PI(3,4,5)P3	   or	   PIP3]	   from	   the	   substrate	   phosphatidylinositol	  
4,5-­‐bisphosphate	   [PI(4,5)P2	  or	  PIP2]	   (Hemmings	  and	  Restuccia,	  2012)	   (Figure	  1.3).	  
PIP3	  transmits	  multiple	  signals	  by	  binding	  to	  proteins	  with	  PIP3-­‐binding	  PH	  domains,	  
localizing	  them	  to	  the	  same	  region	  of	  the	  plasma	  membrane.	  Several	  members	  of	  
the	   AGC	   superfamily	   of	   serine/threonine	   protein	   kinases,	   guanine-­‐nucleotide	  
exchange	   proteins	   of	   the	   Rho	   family	   and	   the	   TEC	   family	   of	   tyrosine	   kinases	   are	  
among	  these	  proteins	  (Saltiel	  and	  Kahn,	  2001).	  	  
Akt/PKB	  binds	  to	  PIP3	  at	  the	  plasma	  membrane	  via	  its	  PH	  domain,	  which	  induces	  a	  
conformational	  change	  in	  Akt,	  enabling	  co-­‐recruited	  3-­‐phosphoinositide-­‐dependent	  
protein	   kinase	   1	   (PDK1)	   to	   access	   the	   activation	   loop	   and	   phosphorylate	   Akt-­‐
Thr308	  (Alessi	   et	   al.,	   1997).	   Phosphorylation	   of	   Thr308	   increases	   Akt	   activity	   by	  
approximately	   100-­‐fold,	   however	   maximal	   Akt	   activity	   also	   requires	  
phosphorylation	   of	   Ser473	   in	   the	   hydrophobic	   motif	  (Alessi	   et	   al.,	   1996a).	   The	  
kinase	   responsible	   for	   Ser473	   phosphorylation	   has	   been	   elusive	   and	   was	  
provisionally	   called	   PDK2.	   Current	   evidence	   suggests	   that	   different	   kinases	  
phosphorylate	   Ser473	   depending	   on	   the	   cellular	   conditions	   and	   could	   be	   cell	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type/tissue-­‐speciﬁc	   and	   stimulus-­‐speciﬁc	   Akt.	   Two	   potential	   candidates	   for	   PDK2	  
have	   been	   reported:	   mammalian	   target	   of	   rapamycin	   complex	   2	   (mTORC2)	  
phosphorylates	   Ser473	   under	   conditions	   of	   growth	   and	   mitogen	   stimulation	  
(Sarbassov	  et	  al.,	  2005),	  and	  DNA-­‐dependent	  protein	  kinase	  (DNA-­‐PK)	  is	  the	  kinase	  
activated	  in	  stress	  situations,	  such	  as	  after	  DNA	  damage	  (Feng	  et	  al.,	  2004)	  (Figure	  
1.3).	  Akt	  is	  a	  serine/threonine	  kinase	  belonging	  to	  the	  AGC	  protein	  kinase	  family.	  It	  
facilitates	   most	   of	   the	   PI3K-­‐mediated	   metabolic	   actions	   of	   insulin	   as	   well	   as	  
regulates	  many	  cellular	  processes	   including	  proliferation,	  cell	   survival,	  growth	  and	  
angiogenesis.	   These	   processes	   are	   mediated	   through	   serine	   and/or	   threonine	  
phosphorylation	  of	  a	  wide	  range	  of	  downstream	  substrates	  including	  other	  kinases,	  
signalling	  proteins	  and	  transcription	  factors	  (Taniguchi	  et	  al.,	  2006).	  The	  Akt	  family	  
has	  three	  closely	  related	  mammalian	  isoforms	  PKB-­‐α,	  PKB-­‐β	  and	  PKB-­‐γ	  (referred	  to	  
as	  Akt1,	  Akt2	  and	  Akt3	  respectively),	  which	  are	  encoded	  by	  distinct	  genes,	  and	  have	  
diverse	   functions	   (Hanada	   et	   al.,	   2004). The	   activation	   of	   Akt	   leads	   to	   the	  
phosphorylation	   of	   a	   number	   of	   targets	   that	   contain	   sequences	   with	   a	   specific	  
recognition	   motif	   of	   Akt,	   defined	   as	   RxRxx(S/T)B	   (Alessi	   et	   al.,	   1996b),	   where	   x	  
represents	  any	  amino	  acid,	  B	   represents	  bulky	  hydrophobic	   residues	   	  and	  S/T	   the	  
phosphorylation	  site.	  The	  critical	  requirement	  for	  R	  residues	  at	  both	  the	  −5	  and	  −3	  
positions	   on	   substrates	   efficiently	   phosphorylated	   by	   Akt,	   distinguishes	   the	  
substrate	   specificity	   of	   Akt	   from	   that	   of	   other	   mitogen-­‐stimulated	   AGC	   kinases	  
(Manning	   and	  Cantley,	   2007).	  Over	   100	   non-­‐redundant	  Akt	   substrates	   have	   been	  
reported	   (Manning	   and	   Cantley,	   2007).	   In	   the	   endothelium,	   Akt	   directly	  
phosphorylates	  and	  activates	  endothelial	  nitric	  oxide	  synthase	   (eNOS)	  at	  Ser1179,	  
leading	  to	  an	  increased	  production	  of	  nitric	  oxide	  (NO)	  and	  subsequent	  vasodilation	  
(Dimmeler	  et	  al.,	  1999;	  Zeng	  and	  Quon,	  1996)	  (Figure	  1.3).	  The	  Akt	  phosphorylation	  
site	   on	   eNOS	   is	   essential	   for	   its	   activation,	   as	   cells	   expressing	   a	   mutant	   eNOS	  
S1179A	  did	  not	  produce	  detectable	  NO	   in	   response	   to	   insulin	   (Montagnani	  et	   al.,	  
2001).	   The	   consequences	   of	   insulin	   regulation	   of	   eNOS	   on	   cardiovascular	   disease	  
are	  discussed	  in	  section	  1.3.3.	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1.3.2.2 The	  Ras-­‐mitogen	  activated	  kinase	  (MAPK)	  pathway	  	  
 
In	   addition	   to	   PI3K-­‐Akt	   signalling,	   insulin	   also	   stimulates	   the	  MAPK/ERK	   pathway.	  	  
This	  pathway	  does	  not	  mediate	  the	  metabolic	  actions	  of	  insulin,	  but	  is	  responsible	  
for	  mitogenic	  effects	  leading	  to	  differentiation	  and	  proliferation,	  as	  well	  as	  exerting	  
feedback	   regulatory	   functions	   by	  modulating	   the	   secretion	   of	   the	   vasoconstrictor	  
endothelin-­‐1	   from	   the	   endothelium	   (Muniyappa	   et	   al.,	   2007).	   The	   MAPK/ERK	  
pathway	  is	  activated	  by	  the	  binding	  of	  Shc	  and	  Gab1	  to	  the	  activated	  IR,	  which	  once	  
phosphorylated	  binds	  the	  adaptor	  protein	  growth	  factor	  receptor-­‐bound	  protein	  2	  
(Grb2)	   (Figure	   1.3).	   Grb2	   constitutively	   associates	   with	   the	   guanyl	   nucleotide	  
exchange	   factor	  Son-­‐of-­‐sevenless	   (SOS)	   that	  mediates	   the	  activation	  of	  Ras	  at	   the	  
membrane	  (Skolnik	  et	  al.,	  1993).	  Ras	   is	  activated	  by	  the	  exchange	  of	  GDP	  to	  GTP,	  
and	  subsequently	  operates	  as	  a	  molecular	  switch.	  GTP-­‐bound	  active	  Ras	  initiates	  a	  
kinase	  cascade,	  involving	  sequential	  activation	  of	  Raf,	  MEK	  (MAPK	  and	  ERK	  kinase)	  
and	  ERK	  (extracellular	  signal-­‐regulated	  kinase)	  (Taniguchi	  et	  al.,	  2006)	  (Figure	  1.3).	  	  
Activated	  ERKs	  phosphorylate	  and	   regulate	   the	  activity	  of	  a	  number	  of	   substrates	  
such	  as	  protein	  kinase	  p90	  ribosomal	  S6	  kinase	  (p90RSK),	  and	  can	  also	  translocate	  
into	   the	  nucleus	  and	  phosphorylate	   transcription	   factors	   such	  as	   ternary	   complex	  
factors	  (TCFs)	   and	   others	   (Pouyssegur	   and	   Lenormand,	   2003).	   Activated	   ERK	   also	  
induces	  the	  secretion	  of	  endothelin-­‐1	   (ET-­‐1).	  ET-­‐1	   is	  a	  vasoconstrictor	  secreted	  by	  
endothelial	  cells	  that	  activates	  PKC	   in	  vascular	  smooth	  muscle	  cells	   (Marasciulo	  et	  
al.,	  2006).	  	  
A	   critical	   balance	   between	   the	   endothelium-­‐derived	   relaxing	   and	   constricting	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1.3.3 Insulin	  and	  cardiovascular	  disease	  
In	   addition	   to	   its	   metabolic	   actions,	   insulin	   elicits	   metabolism-­‐independent,	   anti-­‐
inflammatory	   protection	   against	   atherosclerosis	   and	   injury	   caused	   by	  myocardial	  
ischaemia	   (Yu	   et	   al.,	   2011).	   It	   is	   well	   recognised	   that	   diabetic	   patients	   have	   an	  
increased	   risk	   of	   cardiovascular	   disease	   (Seshasai	   et	   al.,	   2011).	   Insulin	   is	  
fundamental	  for	  normal	  cardiovascular	  function,	  as	  a	  loss	  of	  insulin	  signalling	  in	  the	  
endothelium,	  as	  well	  as	  endothelium	  specific	  insulin	  resistance,	  leads	  to	  accelerated	  
atherosclerosis	   (Gage	   et	   al.,	   2013;	   Rask-­‐Madsen	   et	   al.,	   2010)	   and	   endothelial	  
dysfunction	  (Muniyappa	  and	  Sowers,	  2013).	  Insulin	  also	  inhibits	  the	  development	  of	  
atherosclerosis	   in	   apolipoprotein	   E–knockout	  mice,	  which	  develop	   atherosclerosis	  
spontaneously	  (Shamir	  et	  al.,	  2003).	  Intensive	  insulin	  therapy	  in	  critically	  ill	  patients	  
protected	   the	   endothelium	   by	   lowering	   levels	   of	   ICAM-­‐1	   and	   E-­‐selectin,	   thus	  
reducing	  the	  activation	  of	  the	  endothelium,	  which	  contributed	  to	  the	  prevention	  of	  
organ	   failure	   and	   death	   (Langouche	   et	   al.,	   2005).	   Insulin	   exerts	   significant	  
cardiovascular	   protection	   from	   ischaemia	   and	   reperfusion	   injury.	   A	   “metabolic	  
cocktail”	  comprising	  glucose,	  insulin	  and	  potassium	  (GIK)	  has	  been	  shown	  to	  reduce	  
mortality	  in	  patients	  with	  acute	  myocardial	  infarction	  undergoing	  reperfusion	  (Diaz	  
et	  al.,	  1998).	  Moreover,	  the	  early	  administration	  of	  GIK	  at	  the	  onset	  of	  reperfusion	  
significantly	  reduced	  infarct	  size	  and	  insulin-­‐mediated	  cardioprotection	  was	  shown	  
to	   be	   independent	   of	   the	   presence	   of	   glucose	   (Jonassen	   et	   al.,	   2001).	   Several	  
mechanisms	   have	   been	   proposed	   to	   explain	   how	   GIK	   may	   be	   cardioprotective.	  
Insulin	  induces	  anti-­‐inflammatory	  (Li	  et	  al.,	  2009),	  anti-­‐apoptotic	  (Gao	  et	  al.,	  2002),	  
and	   antioxidant	   effects	   (Suranadi	   et	   al.,	   2012),	   as	   well	   as	   a	   vasodilatory	   effect	  
through	   the	   increased	   expression	   of	   endothelial	   nitric	   oxide	   synthase	   and	  
subsequent	   release	   of	   NO	   (Zeng	   and	  Quon,	   1996).	   Insulin	   also	   appears	   to	   inhibit	  
leucocyte-­‐endothelium	   adherence.	   GIK	   administration	   in	   a	   rabbit	   myocardial	  
ischaemia-­‐reperfusion	   model	   significantly	   decreased	   coronary	   endothelial	  
expression	   of	   P-­‐selectin	   and	   ICAM-­‐1	   via	   Akt-­‐NO	   signalling,	   inhibiting	  
polymorphonuclear	   leucocyte	   adherence	   to	   the	   endothelium	   (Li	   et	   al.,	   2009).	  
Insulin-­‐NO	  signalling	  and	  its	   importance	  in	  cardioprotection	  are	  reviewed	  in	  (Yu	  et	  
al.,	  2011).	  	  
Chapter	  1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Introduction	  
	  
	   	   45	  
1.4 Rho	  GTPases	  
The	   Ras	   homologous	   (Rho)	   family	   guanosine	   triphosphate	   (GTP)	   binding	   proteins	  
(Rho	  GTPases)	  are	  small	  molecular	  switches	  that	  regulate	  many	  signal	  transduction	  
pathways	   in	   eukaryotic	   cells	   (Hall,	   2012).	   They	   are	   principally	   known	   for	   their	  
essential	  role	  in	  regulating	  actin	  cytoskeletal	  dynamics,	  but	  are	  also	  key	  regulators	  
of	   adhesion	   organisation,	   cell	   polarity,	   cell	   migration,	   cell	   division	   and	   vesicle	  
trafficking	   (Heasman	   and	   Ridley,	   2008).	   These	   proteins	   are	   highly	   conserved	   in	  
evolution	  and	  are	  present	   in	  all	  eukaryotic	  genomes	  sequenced	   thus	   far	   including	  
animals,	  plants	  and	  yeast	  (Boureux	  et	  al.,	  2007).	  The	  Rho	  GTPases	  belong	  to	  the	  Ras	  
GTPase	  superfamily	  and	  comprise	  20	  family	  members	  organised	  into	  8	  subfamilies:	  
i)	  the	  RhoA,	  B	  and	  C	  subfamily,	   ii)	  the	  RhoD	  and	  RhoF	  subfamily,	   iii)	  the	  Rac1,	  2,	  3	  
and	  RhoG	  subfamily,	  iv)	  the	  Cdc42,	  RhoJ	  and	  RhoQ	  subfamily,	  v)	  the	  RhoV	  and	  RhoU	  
subfamily,	  vi)	   the	  RhoH	  subfamily,	  vii)	   the	  RhoBTB	  1	  and	  2	  subfamily,	  and	  viii)	   the	  
Rnd1,	  2	  and	  3	  subfamily	  (Figure	  1.4).	  The	  best-­‐characterized	  members	  of	  the	  family	  
are	  RhoA,	  Rac	  and	  Cdc42	  (reviewed	  in	  (Heasman	  and	  Ridley,	  2008)).	  
	  
Figure	  1.4	  The	  Rho	  GTPase	  family	  tree	  
The	  20	  members	  of	  the	  Rho	  GTPase	  family	  are	  divided	  into	  8	  subfamilies,	  designated	  by	  the	  
different	   coloured	   boxes.	   These	   families	   can	   be	   classified	   as	   typical	   (in	   bold)	   or	   atypical,	  
depending	  on	  their	  type	  of	  regulation.	  
	  
Chapter	  1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Introduction	  
	  
	   	   46	  
1.4.1 Regulation	  of	  Rho	  GTPase	  activity	  
For	   the	   Rho	   GTPases	   to	   act	   as	  molecular	   switches	   they	   cycle	   between	   an	   active	  
GTP-­‐bound	  and	  an	  inactive	  GDP-­‐bound	  state.	  These	  transitions	  are	  tightly	  regulated	  
by	   3	   sets	   of	   proteins:	   i)	   guanine	   nucleotide	   exchange	   factors	   (GEFs),	   ii)	   GTPase-­‐
activating	  proteins	  (GAPs),	  and	  iii)	  guanine	  nucleotide	  dissociation	  inhibitors	  (GDIs).	  
The	   GTP-­‐bound	   form	   activates	   downstream	   pathways	   by	   binding	   to	   effectors	  
(Figure	  1.5).	  
GDP	  is	  tightly	  bound	  to	  typical	  Rho	  GTPases	  and	  therefore	  require	  GEFs	  to	  facilitate	  
the	   release	   of	   the	   GDP	   molecule.	   This	   causes	   the	   formation	   of	   an	   unstable	  
nucleotide-­‐free	   intermediate	   that	   is	   then	   loaded	   with	   GTP	   due	   to	   the	   higher	  
cytosolic	   GTP	   levels	   present	   in	   the	   cell	   (reviewed	   in	   (Cook	   et	   al.,	   2013)	   and	  
(Rossman	  et	  al.,	  2005)).	  The	  RhoGEFs	  are	  divided	   into	   two	  major	  classes.	  The	  Dbl	  
family	  GEFs	  contain	  a	  Dbl	  homology	  (DH)–pleckstrin	  homology	  (PH;	  DH-­‐PH)	  tandem	  
domain	  and	  mediates	  the	  GDP–GTP	  exchange	  through	  the	  DH	  domain.	  The	  second	  
class	  of	  GEFs	  for	  Rho	  GTPases	  is	  the	  DOCK	  family	  GEFs	  that	  have	  no	  DH-­‐PH	  tandem	  
domain,	   but	   contain	   a	   conserved	   DHR2	   domain	   that	   directly	   interacts	   with	   Rho	  
GTPases	  and	  mediates	  GDP–GTP	  exchange	  (Bos	  et	  al.,	  2007;	  Rossman	  et	  al.,	  2005).	  	  
Rho	   GTPases	   have	   low	   intrinsic	   GTPase	   activity,	   which	   is	   usually	   slower	   than	   the	  
cellular	   functions	   they	   are	   required	   to	   regulate.	   In	   order	   to	   terminate	   the	   signal	  
generated	  by	  activated	  Rho	  GTPases,	  GAPs	  are	   required	   to	   stimulate	   the	   intrinsic	  
enzymatic	   activity	   leading	   to	   hydrolysis	   of	   the	   GTP	   and	   consequently	   to	   their	  
functional	  inactivation	  (Tcherkezian	  and	  Lamarche-­‐Vane,	  2007).	  Most	  Rho	  GAPs	  are	  
therefore	  negative	  modulators	  of	  Rho	  GTPase	  function.	  	  
Many	  Rho	  GTPases	  exert	  their	  functions	  at	  the	  plasma	  membrane.	  To	  ensure	  they	  
are	   properly	   localised	   in	   the	   cell	   they	   are	   post-­‐translationally	   modified	   at	   the	   C-­‐
terminus	   by	   the	   addition	   of	   a	   lipid	   group,	   which	   increases	   the	   protein	  
hydrophobicity	  and	  facilitates	  membrane	  association.	  The	  majority	  of	  Rho	  GTPases	  
have	   a	   CAAX	  tetrapeptide	   motif	   (where	   C	   represents	   cysteine,	   A	   is	   an	   aliphatic	  
amino	  acid,	  and	  X	  is	  any	  amino	  acid,	  which	  determines	  the	  type	  of	  isoprenyl	  group)	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at	   the	  C-­‐terminus	   that	   is	   required	   for	  prenylation	   (Roberts	  et	   al.,	   2008).	   The	   lipid	  
can	   either	   be	   a	   geranylgeranyl	   or	   farnesyl	   group.	   A	   lack	   of	   prenylation	   causes	  
mislocalisation	   of	   the	   Rho	   GTPase	   to	   the	   cytoplasm,	   resulting	   in	   them	   being	  
functionally	   inactive.	  GDIs	   sequester	   some	  GTPases	   in	   the	   cytosol	  by	  masking	   the	  
prenyl	  lipid	  groups,	  preventing	  the	  association	  of	  Rho	  GTPases	  with	  the	  membranes	  
and	   blocking	   the	   dissociation	   of	   GDP,	   thus	   inhibiting	   their	   interaction	   with	  
downstream	   effectors	   (reviewed	   in	   (Garcia-­‐Mata	   et	   al.,	   2011).	   Despite	   the	   wide	  
diversity	  in	  the	  Rho	  GTPase	  family,	  only	  three	  genes	  encode	  GDIs	  in	  mammals:	  GDI-­‐
1	  or	  –α,	  GDI-­‐2	  or	  β	  and	  GDI-­‐3	  or	  –γ.	  GDIs	  ensure	  a	  stable	  soluble	  pool	  of	   inactive	  
Rho	   GTPases	   is	   available	   in	   the	   cytosol,	   acting	   as	   a	   reservoir	   that	   can	   be	   rapidly	  
translocated	  to	  any	  membrane	  in	  the	  cell	  in	  response	  to	  specific	  signals.	  	  
In	   addition	   to	   prenylation,	   Rho	   proteins	   can	   be	   regulated	   by	   other	   post-­‐
translational	   modifications.	   Rho	   GTPases	   can	   be	   regulated	   through	   direct	  
phosphorylation	  (Lang	  et	  al.,	  1996;	  Riento	  et	  al.,	  2005b)	  ubiquitylation	  (Wei	  et	  al.,	  
2013)	   and	   palmitoylation	  (Navarro-­‐Lerida	   et	   al.,	   2012).	   RhoA	   was	   the	   first	   Rho	  
protein	   shown	   to	  be	   subject	   to	  phosphorylation.	   cAMP-­‐dependent	  protein	   kinase	  
(PKA)	   and	   cGMP-­‐dependent	   protein	   kinase	   (PKG)	   phosphorylate	   RhoA	   at	   Ser188	  
(Lang	   et	   al.,	   1996;	   Sauzeau	  et	   al.,	   2000).	  However,	   this	   phosphorylation	  does	  not	  
modify	   its	  GTPase	   activity	   or	   its	   interaction	  with	  GEFs	   and	  GAPs,	   but	   significantly	  
increases	   its	   interaction	   with	   GDI	   independently	   of	   the	   nucleotide	   (GDP	   or	   GTP)	  
loaded	   on	   the	   protein,	   and	   enhances	   the	   ability	   of	   GDI	   to	   extract	   RhoA	   from	  
membranes	   (Ellerbroek	   et	   al.,	   2003;	   Forget	   et	   al.,	   2002).	   Subsequently,	   other	  
members	  of	  the	  Rho	  family	  have	  been	  shown	  to	  be	  regulated	  by	  serine	  or	  tyrosine	  
phosphorylation.	   Cdc42	   is	   phosphorylated	   at	   Tyr64	   by	   Src	   also	   resulting	   in	   its	  
increased	  interaction	  with	  GDI	  (Tu	  et	  al.,	  2003).	  Rnd3	  is	  phosphorylated	  on	  multiple	  
sites	  by	  Rho-­‐associated	  kinase	  1	  (ROCK1)	  (Riento	  et	  al.,	  2005a)	  and	  protein	  kinase	  C	  
(PKC)α	  (Madigan	  et	  al.,	  2009),	  which	  causes	  the	  cytosolic	  relocation	  and	  increased	  
stability	   of	   Rnd3.	   Rac1	   is	   reported	   to	   be	   phosphorylated	   at	   Ser71	   by	   Akt,	   which	  
inhibits	  its	  GTP	  binding	  activity	  without	  any	  significant	  change	  in	  GTPase	  activity.	  A	  
mutant	  Rac1	  S71A	  inhibited	  GTP-­‐binding	  and	  GTPase	  activity	  (Kwon	  et	  al.,	  2000).	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GEFs,	  GAPs	  and	  GDIs	  therefore	  play	  crucial	  roles	  in	  regulating	  typical	  Rho	  GTPases.	  
The	   typical	   members	   include	   the	   Rho,	   Rac,	   Cdc42,	   RhoF	   and	   RhoD	   subfamilies.	  
However,	   the	   atypical	   members	   of	   the	   GTPase	   family,	   which	   include	   the	   Rnd	  
subfamily	  members,	  RhoBTBs	  and	  RhoH,	  do	  not	  act	  as	  molecular	  switches	  and	  do	  
not	  cycle	  between	  an	  active/inactive	  bound	   form.	   Instead	   they	  stay	  constitutively	  
bound	  to	  GTP	  as	  a	  result	  of	  amino	  acid	  substitutions	  in	  key	  residues	  involved	  in	  GTP	  
hydrolysis,	  and	  have	  a	  very	   low	  affinity	   for	  GDP	   (Chardin,	  2003).	  The	  atypical	  Rho	  
GTPases	   RhoU	   and	   RhoV	   have	   a	   high	   intrinsic	   GDP/GTP	   exchange	   rate	   and	   are	  
therefore	  mainly	   in	   an	   active	   form	   (Shutes	   et	   al.,	   2004).	   	   Thus,	   atypical	   GTPases	  
have	  to	  be	  regulated	  by	  alternative	  methods	  and	  are	  often	  positively	  regulated	  at	  
the	   level	   of	   expression	   and	   negatively	   regulated	   by	   targeted	   destruction,	   for	  
example	  by	  proteasomal	  degradation	  (Aspenstrom	  et	  al.,	  2007).	  Their	  function	  can	  
also	  be	  regulated	  by	  protein-­‐protein	  interactions	  induced	  by	  phosphorylation,	  such	  
as	   14-­‐3-­‐3	   proteins	   (see	   section	   1.6).	   For	   example,	   Rnd3	   is	   inactivated	   by	   protein	  




Figure	  1.5	  Regulation	  of	  Rho	  GTPase	  activity	  
Typical	  members	  of	  the	  Rho	  GTPase	  family	  cycle	  between	  an	  inactive	  GDP-­‐bound	  form	  and	  
an	   active	   GTP-­‐bound	   form.	   GEFs	   facilitate	   the	   exchange	   of	   GDP	   for	   GTP	   promoting	   the	  
active	  state,	  whereas	  GAPs	  stimulate	  the	  hydrolysis	  of	  GTP	  to	  GDP	  and	  down-­‐regulate	  the	  
Rho	  GTPase	  activity.	  GDIs	  sequester	  several	  Rho	  proteins	  in	  the	  cytoplasm,	  preventing	  their	  
association	  with	  membranes	  where	  they	  mediate	  their	  actions.	  Protein	  phosphorylation	  by	  
various	  kinases,	  such	  as	  the	  AGC	  kinases	  and	  ROCK1,	  can	  also	  regulate	  Rho	  GTPase	  activity.	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1.4.2 Rho	  GTPases	  as	  regulators	  of	  cytoskeleton	  dynamics	  in	  endothelial	  cells	  
Cells	  remodel	  their	  cytoskeletons	  by	  responding	  to	  diverse	  stimuli	  from	  the	  external	  
environment.	  As	  key	  regulators	  of	  cytoskeletal	  dynamics	  the	  GTP-­‐bound	  active	  Rho	  
GTPases	  perform	  their	  regulatory	  function	  by	  integrating	  information	  from	  a	  broad	  
spectrum	   of	   upstream	   signals,	   such	   as	   growth	   factors,	   chemokines	   and	   cell	  
adhesion	  receptors	  and	  interacting	  with	  an	  array	  of	  down-­‐stream	  target	  (effector)	  
proteins.	  These	  effector	  proteins	  include	  serine/threonine	  kinases,	  tyrosine	  kinases,	  
lipid	  kinases,	  lipases,	  oxidases	  and	  scaffold	  proteins	  (Jaffe	  and	  Hall,	  2005).	  	  
As	   discussed	   in	   section	   1.2.4.3,	   stress	   fibre	   contractility	   is	   regulated	   by	  
phosphorylation	   of	   the	   regulatory	   subunit	   of	   the	   myosin	   II,	   MLC.	   Reversible	  
phosphorylation	  of	  MLC	  stimulates	  the	  ATPase	  activity	  of	  myosin	  II	  resulting	  in	  the	  
assembly	  of	  actomyosin	  filaments	  (Vicente-­‐Manzanares	  et	  al.,	  2009).	  The	  activation	  
of	   Rho	   proteins	   contribute	   to	   the	   formation	   of	   contractile	   actomyosin	   filaments	  
(see	   section	  1.2.4),	  and	  RhoA	   in	  particular	   induces	   stress-­‐fibre	  and	   focal	  adhesion	  
formation	   (Ridley	  and	  Hall,	   1992).	  RhoA	   is	  able	   to	  phosphorylate	  MLC	   through	   its	  
downstream	   effectors	   ROCK1	   and	   ROCK2	   (Naumanen	   et	   al.,	   2008).	   ROCKs	  
phosphorylate	  MLC	   (Amano	   et	   al.,	   1996)	   and	   also	   indirectly	   increase	   the	   pool	   of	  
phosphorylated	   MLC	   (p-­‐MLC)	   by	   inactivating	   the	   enzyme	   that	   dephosphorylates	  
MLC,	  myosin	   light	  chain	  phosphatase	   (MLCP)	   (Kimura	  et	  al.,	  1996).	  ROCKs	  play	  an	  
important	  role	  in	  stress	  fibre	  turnover,	  as	  they	  activate	  the	  LIM	  kinase	  pathway.	  LIM	  
kinase	  (LIMK)	  regulates	  actin	  dynamics	  and	  increases	  the	  stability	  of	  stress	  fibres	  by	  
inactivating	   actin-­‐dissociating	   protein	   (ADF)/cofilin	   (Ohashi	   et	   al.,	   2000).	   Cofilins	  
catalyse	   depolymerisation	   of	   actin	   filaments	   by	   promoting	   actin	   monomer	  
dissociation	   from	   the	   pointed	   end,	   increasing	   the	   rate	   of	   actin	   turnover	   by	  
providing	  new	  actin	  monomers	  for	  polymerization	  (Carlier	  et	  al.,	  1997).	  Cofilin	  can	  
also	   sever	   actin	   filaments,	   increasing	   the	   number	   of	   uncapped	   barbed	   ends	   that	  
serve	  as	  sites	  for	  actin	  polymerization	  and	  filament	  elongation	  (Ghosh	  et	  al.,	  2004)	  
(see	  section	  1.2.4).	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RhoA	   can	   also	   stimulate	   actin	   polymerization	   in	   mammalian	   cells	   through	   its	  
effector	  the	  diaphanous-­‐related	  formin	  1(DRF1)/	  mammalian	  diaphanous	  1	  (mDia1)	  
(Watanabe	  et	  al.,	  1997).	  mDia1	  facilitates	  the	  polymerization	  of	   long	  parallel	  actin	  
filaments	  and	  is	  important	  for	  the	  formation	  of	  dorsal	  stress	  fibres	  (Hotulainen	  and	  
Lappalainen,	   2006).	   Furthermore,	   RhoA	   can	   control	   the	   composition	   of	   the	   actin	  
cytoskeleton	   by	   regulating	   the	   transcription	   of	   several	   genes	   that	   encode	  
cytoskeletal	  proteins,	  through	  the	  myocardin-­‐related	  transcription	  factor	  MAL	  (also	  
known	   as	   MRTF-­‐A)	   and	   serum	   response	   factor	   (SRF)	   pathway	   (Hill	   et	   al.,	   1995;	  
Miralles	   et	   al.,	   2003).	   Rho	   activation	   induces	   a	   reduction	   in	   cytoplasmic	   G-­‐actin	  
triggering	   the	   dissociation	   of	   G-­‐actin	   from	  MAL,	   resulting	   in	   the	   translocation	   of	  
MAL	  into	  the	  nucleus	  where	  it	  acts	  as	  a	  co-­‐activator	  of	  SRF	  (Miralles	  et	  al.,	  2003).	  
Rac	  and	  Cdc42	  are	  primarily	  known	  for	  their	  essential	  roles	  in	  cell	  migration	  as	  they	  
regulate	   actin-­‐rich	   protrusive	   lamellipodia	   and	   filopodia,	   respectively	   (Nobes	   and	  
Hall,	   1995;	   Ridley	   et	   al.,	   1992).	   This	   is	   described	   in	   section	   1.4.3.	   They	   stimulate	  
actin	   polymerisation	   via	   the	   actin-­‐related	   protein	   2/3	   (Arp2/3)	   complex.	   The	  
heptameric	   Arp2/3	   complex	   nucleates	   new	   actin	   filaments	   by	   branching	   off	   pre-­‐
existing	   filaments,	   when	   activated	   by	   nucleation	   promoting	   factors	   (NPFs)	  
(reviewed	   in	   (Rotty	   et	   al.,	   2013)).	   Cdc42	   directly	   binds	   and	   activates	   the	   NPFs	  
Wiskott–Aldrich	   syndrome	   protein	   (WASP)	   and	   neuronal	   WASP	   (N-­‐WASP).	   Rac	  
activates	   the	   Arp2/3	   complex	   via	   WASP	   family	   verprolin-­‐homologous	   protein	  
(WAVE,	   also	   known	  as	   SCAR).	  Cdc42	  and	  Rac	  are	   also	   involved	   in	   stabilizing	   actin	  
filaments	  as	  they	  can	  also	  activate	  LIMK	  via	  the	  p21	  activated	  kinase	  (PAK)	  family,	  
which	  phosphorylates	  and	  inhibits	  cofilin	  (Jaffe	  and	  Hall,	  2005).	  	  
	  
1.4.3 Rho	  GTPases	  as	  regulators	  of	  cell	  migration	  in	  endothelial	  cells	  
An	   important	   feature	   of	   many	   cells	   is	   their	   ability	   to	   migrate	   in	   response	   to	  
particular	   chemical	   or	   mechanical	   stimuli.	   Many	   physiological	   processes	   require	  
cells	   to	   be	  motile,	   including	   angiogenesis,	   tissue	   repair	   and	   immune	   surveillance,	  
however	   cell	  migration	  also	   contributes	   to	  pathological	   conditions	   such	  as	   cancer	  
metastasis,	   chronic	   inflammation	   and	   vascular	   disease	   (Ridley	   et	   al.,	   2003).	   Cell	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migration	  involves	  many	  coordinated	  signalling	  events	  that	  regulate	  changes	  to	  the	  
cytoskeleton	   and	   cell	   adhesion.	   It	   requires	   the	   cell	   to	   polarise	   in	   response	   to	  
extracellular	  stimuli,	  extend	  lamellipodia	  or	  blebs	  at	  the	  leading	  edge,	  followed	  by	  
the	  formation	  and	  turnover	  of	  new	  cell-­‐substrate	  adhesions,	  and	  finally	  contraction	  
of	  the	  cell	  body	  and	  tail	  detachment	  (reviewed	  in	  (Ridley,	  2011)).	  Endothelial	  cells	  
can	   directionally	   migrate	   toward	   a	   gradient	   of	   soluble	   chemoattractants	  
(chemotaxis),	   immobilized	   ligands	   (haptotaxis),	   or	   by	   mechanical	   forces	  
(mechanotaxis)	   (Lamalice	   et	   al.,	   2007).	   The	   specific	   mechanisms	   involved	   in	  
endothelial	  cell	  migration	  will	  be	  discussed	  in	  the	  context	  of	  angiogenesis	  in	  section	  
1.5.	  
The	   presence	   of	   Rho	   GTPases	   and	   their	   effector	   proteins	   at	   specific	   loci	   on	   the	  
membrane	  dictates	  the	  directionality	  of	  cell	  migration.	  The	  major	  driving	  force	  for	  
migration	   to	   occur	   requires	   actin	   polymerisation	   and	   filament	   elongation	   at	   the	  
front,	   and	   actomyosin	   contraction	   at	   the	   back.	   The	   establishment	   of	   this	   cell	  
polarity	   is	  tightly	  regulated,	  mediated	  by	  several	  positive	  feedback	   loops	   involving	  
Rho	  GTPases,	  PI3Ks,	   integrins,	  microtubules,	  and	  vesicular	   transport	   (Ridley	  et	  al.,	  
2003).	   Cdc42	   is	   active	   at	   the	   front	   of	   migrating	   cells	   and	   is	   a	   key	   regulator	   of	  
directional	   sensing	   and	   migration.	   Cdc42	   induces	   filopodia	   by	   activating	   actin	  
polymerization	  via	  three	  of	  its	  targets:	  i)	  WASP/N-­‐WASP,	  which	  activates	  the	  Arp2/3	  
complex	  previously	  discussed;	   ii)	   formins,	  such	  as	  mDia2	  (Firat-­‐Karalar	  and	  Welch,	  
2011)	  and	   iii)	   insulin-­‐receptor	  substrate	  p53	  (IRSp53),	  a	  membrane	  deforming	  and	  
curvature	  sensing	  protein	  (Ridley,	  2011).	  Filopodia	  act	  as	  sensors	  that	  navigate	  cell	  
migration,	   however	   the	   exact	   molecular	   mechanisms,	   by	   which	   ﬁlopodia	   are	  
initiated	  and	  spatially	  restricted	  to	  speciﬁc	  sites	  on	  the	  plasma	  membrane,	  are	  still	  
unknown	   (Disanza	  et	  al.,	  2013).	  Cdc42	   is	  also	  able	   to	  control	   cell	  directionality	  by	  
restricting	   where	   lamellipodia	   form	   through	   regulating	   spatial	   Rac	   activation	   and	  
consequently	  actin	  polymerization	  (Cau	  and	  Hall,	  2005).	  	  
Polarity	   proteins	   react	   to	   extrinsic	   or	   intrinsic	   polarity	   cues	   such	   as	   extracellular	  
matrix	   ligands,	   growth	   factor	   or	   chemoattractant	   gradients	   and	   assemble	   into	  
multiprotein	   complexes,	   inducing	   downstream	   signalling	   that	   triggers	   the	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establishment	   of	   cellular	   asymmetry.	   Cdc42	   acts	   through	   a	   polarity	   protein,	  
partitioning-­‐defective-­‐6	   (PAR6),	   and	   forms	   a	   polarity	   complex	   with	   PAR3	   and	  
atypical	  protein	  kinase	  C	  (aPKC)	  (Joberty	  et	  al.,	  2000;	  Lin	  et	  al.,	  2000).	  For	  example,	  
active	  Cdc42	  at	  the	  leading	  edge	  binds	  PAR6,	  which	  stimulates	  PAR3	  in	  the	  complex	  
to	  bind	  Tiam1,	  a	  GEF	  for	  Rac,	  resulting	  in	  Rac	  activation	  (Nishimura	  et	  al.,	  2005).	  In	  
endothelial	   cells,	   Rho,	   Rac,	   and	   Cdc42	   differentially	   facilitate	   cell	   migration	  
depending	  on	  the	  stimulus.	  ECs	  polarise	  in	  response	  to	  shear	  stress	  whereby	  RhoA	  
is	   initially	  activated,	   inducing	  stress-­‐fibres	   that	  cause	  cell	   contraction,	   followed	  by	  
Rac1	   and	   Cdc42	   activation	   resulting	   in	   cells	   respreading	   and	   elongation	   in	   the	  
direction	   of	   flow.	   Interestingly,	   unlike	   other	   cell	   types,	   endothelial	   cells	   do	   not	  
require	   Cdc42	   to	   polarise,	   as	   Rho	   and	   Rac	   maintain	   polarized	   migration	   in	   the	  
direction	  of	  shear	  stress	  (Wojciak-­‐Stothard	  and	  Ridley,	  2003).	  	  
Polarised	  migrating	   cells	   have	   a	   stable	   fan-­‐shaped	   front	   called	   the	   lamella,	   from	  
which	  the	  highly	  dynamic	  lamellipodia	  protrude,	  composed	  of	  orthogonal	  arrays	  of	  
actin	   filaments	   with	   branched	   actin	   filaments	   near	   the	   leading	   edge	   plasma	  
membrane	  (Suraneni	  et	  al.,	  2012).	  The	  primary	  mediator	  of	  actin	  polymerization	  in	  
lamellipodia	   is	   Rac	   activation	   of	   the	   Arp2/3	   complex	   via	   the	   WAVE	   complex,	   as	  
previously	   discussed.	   Other	   potential	   actin	   filament	   nucleators	   have	   also	   been	  
shown	   to	   contribute	   to	   lamellipodium	   extension,	   such	   as	   the	   members	   of	   the	  
formin	   (Firat-­‐Karalar	   and	   Welch,	   2011)	   and	   Spire	   families	   (Ito	   et	   al.,	   2011).	   The	  
exact	   molecular	   mechanisms	   are	   still	   not	   fully	   understood,	   however	   evidence	  
suggests	  that	  the	  Arp2/3	  complex	  and/or	  Spires	  initiate	  nucleation	  in	  lamellipodia,	  
whereas	  formins	  promote	  elongation	  (Ridley,	  2011).	  
	  
1.4.4 Rho	  GTPases	  as	  regulators	  of	  endothelial	  cell-­‐cell	  junctions	  
Direct	  association	  of	  the	  actin	  cytoskeleton	  with	  cell	  adhesion	  proteins	  is	  essential	  
for	  barrier	  function.	  The	  molecular	  mechanisms	  involved	  are	  not	  fully	  understood,	  
as	   the	   endothelial	   barrier	   is	   rapidly	   regulated	   in	   vivo.	   Thus,	   in	   vitro	   models	   are	  
required	   to	   elucidate	   these	   dynamic	   changes.	   Pro-­‐inflammatory	   stimuli,	   such	   as	  
TNF-­‐α,	   induce	  changes	   in	   cell-­‐cell	   junctions,	   actin	   stress	   fibre	  organisation	  and	  an	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increase	   in	  permeability	   in	  vitro	   (McKenzie	  and	  Ridley,	  2007).	  As	  key	  regulators	  of	  
the	   actin	   cytoskeleton,	   small	   Rho	   GTPases	   regulate	   the	   stability	   of	   endothelial	  
intercellular	  junctions	  (reviewed	  in	  (Wojciak-­‐Stothard	  and	  Ridley,	  2002)).	  In	  addition	  
to	   the	  mechanisms	   that	   regulate	  endothelial	   barrier	   function	  discussed	   in	   section	  
1.2.3,	   increased	  centripetal	   tension	  as	  a	  result	  of	  actomyosin-­‐induced	  contractility	  
can	   open	   intercellular	   gaps	   (Dejana	   and	   Orsenigo,	   2013).	   Rho-­‐induced	  
phosphorylation	   of	   MLC	   via	   ROCK	   results	   in	   the	   formation	   of	   stress	   fibres	   (see	  
section	   1.2.4.3)	   that	   have	   been	   shown	   to	   be	   associated	   with	   AJs	   (Millan	   et	   al.,	  
2010).	  Depending	  on	  the	  strength	  of	  cell-­‐cell	  junctions,	  this	  actomyosin	  contractility	  
results	  in	  reduced	  endothelial	  barrier	  function.	  ROCK	  also	  phosphorylates	  occludin,	  
which	  promotes	  the	  disassembly	  of	  TJs	  (Hirase	  et	  al.,	  2001).	  Therefore,	  Rho	  plays	  a	  
dual	  role	  in	  regulating	  endothelial	  permeability	  through	  stress	  fibre	  formation	  and	  
destabilizing	  intercellular	  junctions	  (Beckers	  et	  al.,	  2010).	  However,	  RhoA	  is	  not	  just	  
responsible	   for	   junctional	   destabilisation	   as	   a	   certain	   amount	   of	   contraction	   is	  
necessary	  for	  tension	  and	  remodelling	  of	  circumferential	  actin	  filaments	  (Gomez	  et	  
al.,	  2011),	  thus	  a	  very	  fine	  balance	  of	  RhoA	  is	  required.	  
Rac1	  and	  Cdc42	  are	  only	  activated	  after	  RhoA	  activity	  subsides	  (Wildenberg	  et	  al.,	  
2006),	   and	   function	   to	   re-­‐establish	   cell-­‐cell	   contact	   by	   inducing	   lamellipodia	   or	  
filopodia.	  Rac	  is	  activated	  in	  response	  to	  cadherin	  contact	  assembly	  (Kovacs	  et	  al.,	  
2002),	   whereas	   Rho	   is	   inhibited	   through	   a	   process	   that	   involves	   p190RhoGAP	  
(Noren	  et	  al.,	  2003).	  Interestingly,	  Rac1	  appears	  to	  have	  a	  dual	  role	  on	  endothelial	  
intercellular	   junction	   maintenance	   and	   stabilization,	   depending	   on	   signalling	  
conditions.	   Rac	   activity	   is	   associated	   with	   endothelial	   junction	   strengthening,	   as	  
dominant	  negative	  Rac	  (Wojciak-­‐Stothard	  et	  al.,	  2001)	  and	  Rac	  inhibition	  (Waschke	  
et	   al.,	   2004)	   increased	   endothelial	   permeability,	   in	   the	   absence	   of	   vasoactive	  
stimuli.	   Rac1	   and	   Cdc42	   are	   able	   to	   stabilise	   endothelial	   cell-­‐cell	   junctions	   by	  
regulating	   the	   interactions	   between	   α-­‐catenin	   and	   cadherins,	   by	   two	   different	  
mechanisms.	   Rac1	   and	   Cdc42	   bind	   to	   and	   negatively	   regulate	   IQGAP1,	   which	  
directly	   interacts	   with	   β-­‐catenin	   and	   dissociates	   α-­‐catenin	   from	   the	   cadherin-­‐
catenin	   complex	   resulting	   in	   junctional	   destabilization	   (Fukata	   et	   al.,	   1999).	   They	  
have	   also	   been	   reported	   to	   inhibit	   cadherin	   endocytosis	   through	   the	   interaction	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with	   IQGAP	  and	  actin	  cytoskeleton	  reorganization	  (Izumi	  et	  al.,	  2004).	  Conversely,	  
Rac1	   can	   weaken	   junctions	   by	   inducing	   VE-­‐cadherin	   internalisation	   after	   VEGF	  
stimulation,	  via	  phosphorylation	  by	  the	  Rac1	  downstream	  target	  PAK	  (Gavard	  and	  
Gutkind,	   2006).	   PAK	   has	   also	   been	   shown	   to	   enhance	  MLC	   phosphorylation	   and	  
increase	   actomyosin	   contractility	   (Stockton	   et	   al.,	   2004).	   Rac1	   activation	   could	  
possibly	   destabilise	   barrier	   function	   through	   the	   generation	   of	   reaction	   oxygen	  
species	   (ROS)	   (van	   Wetering	   et	   al.,	   2002).	   Although	   the	   same	   GTPase	   can	  
participate	   in	   junction	   assembly	   and	   destabilisation,	   the	   regulators,	   effectors	   and	  
cellular	  processes	  involved	  might	  differ	  in	  each	  case.	  
	  
1.4.5 Rho	  GTPases	  in	  cardiovascular	  disease	  
Statins	   (3-­‐hydroxy-­‐3-­‐methylglutaryl-­‐coenzyme	   A	   reductase	   inhibitors)	   are	   one	   of	  
the	   most	   widely	   used	   therapies	   to	   prevent	   and	   regulate	   the	   risk	   factors	   of	  
cardiovascular	   disease	   (Taylor	   et	   al.,	   2013).	   However,	   their	   anti-­‐atherosclerotic	  
effects	  may	  not	  only	  be	  as	  a	   result	  of	   their	   lipid-­‐lowering	  properties,	  but	  possibly	  
through	  other	  pleiotropic	  consequences	  mediated	  by	  the	  inhibition	  of	  Rho	  GTPases	  
(Tanaka	   et	   al.,	   2013).	   Statins	   block	   the	   synthesis	   of	   important	   isoprenoid	  
intermediates	   in	   the	   cholesterol	   biosynthetic	   pathway,	   required	   for	   the	   post-­‐
translational	   lipid	  modification	  of	  Rho	  GTPases	   (see	   section	  1.4.1)	   (Takemoto	  and	  
Liao,	  2001).	  Consequently,	  statins	  inhibit	  Ras	  and	  Rho	  isoprenylation,	  leading	  to	  the	  
accumulation	  of	  Ras	  and	  Rho	  in	  the	  cytoplasm	  and	  preventing	  their	  signalling.	  RhoA	  
is	  particularly	  important	  in	  the	  pathophysiology	  of	  cardiovascular	  disease,	  as	  it	  has	  
been	   shown	   to	   negatively	   regulate	   eNOS	   expression,	   a	   hallmark	   of	   endothelial	  
dysfunction	   (Laufs	   and	   Liao,	   1998).	   Moreover,	   the	   RhoA	  gene	   was	   implicated	   in	  
contributing	   to	   the	   variation	   observed	   in	   LDL-­‐cholesterol	   response	   to	   statins	  
(Medina	  et	  al.,	  2012).	  These	  findings	  have	  initiated	  a	  new	  era	  of	  drug	  development,	  
using	   selective	   small	   GTPase	   inhibitors	   as	   potential	   anti-­‐atherosclerotic	   and	  
cardioprotective	  therapies.	  One	  of	  the	  most	  extensively	  studied	  therapeutic	  targets	  
in	   cardiovascular	   disease	   is	   ROCK,	   the	   major	   downstream	   effector	   of	   RhoA	  
(reviewed	   in	   (Shi	   and	  Wei,	   2013;	   Surma	   et	   al.,	   2011).	   ROCK	   inhibitors	   have	   been	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shown	   to	   reduce	   endothelial	   dysfunction,	   inflammatory	   cell	   recruitment,	  
hypercontraction	  of	   vascular	   smooth	  muscle	   cells,	   as	  well	   as	   vascular	   and	   cardiac	  
remodelling,	   however	   the	   mechanisms	   involved	   are	   yet	   to	   be	   fully	   elucidated	  
(Noma	  et	  al.,	  2012).	  
	  
1.5 Angiogenesis	  
Angiogenesis	  is	  the	  development	  of	  new	  blood	  vessels	  from	  pre-­‐existing	  structures	  
and	   is	   essential	   in	   physiological	   and	   pathological	   conditions,	   including	   embryonic	  
development,	  wound	  healing,	  tissue	  regeneration	  and	  tumour	  growth	  (Lamalice	  et	  
al.,	   2007).	   Angiogenesis	   involves	   endothelial	   cell	   activation,	   degradation	   of	   the	  
basement	   membrane,	   invasion,	   proliferation,	   lumen	   formation	   and	   stabilization	  
and	   is	   regulated	  by	   a	  balance	  of	   pro-­‐	   and	   anti-­‐angiogenic	  molecules	   (Bayless	   and	  
Johnson,	  2011).	   The	  various	   steps	  of	   angiogenesis	   are	   coordinated	  by	   several	   key	  
factors,	   such	   as	   growth	   factors,	   bioactive	   lipids,	   integrins,	   junctional	   proteins	   and	  
transmembrane	   proteinases	   to	   ultimately	   transduce	   intracellular	   signals	   to	   the	  
cytoskeleton	  (Bayless	  and	  Johnson,	  2011).	  The	  scientiﬁc	  literature	  on	  angiogenesis	  
is	   vast,	   and	   therefore	   this	   section	   will	   focus	   on	   the	   links	   between	   angiogenesis,	  
endothelial	  cell-­‐cell	  junctions	  and	  the	  cytoskeleton,	  relevant	  for	  this	  thesis.	  
When	  the	  usually	  quiescent	  endothelium	  receives	  an	  angiogenic	  stimulus,	  such	  as	  
VEGF	   induced	   by	   wounding	   and	   ischaemia,	   the	   vascular	   basement	   membrane	   is	  
degraded	   by	   matrix	   metalloproteinases	   (MMPs)	   (Carmeliet	   and	   Jain,	   2011).	   This	  
relieves	   pericyte-­‐endothelial	   contacts	   and	   releases	   extracellular	   matrix	   (ECM)-­‐
sequestered	  growth	  factors	  (Senger	  and	  Davis,	  2011).	  In	  addition,	  VEGF	  destabilises	  
junctions	  by	  promoting	  VE-­‐cadherin	  internalisation	  (Gavard	  and	  Gutkind,	  2006)	  (as	  
described	   above	   in	   section	   1.4.4).	   Integrin	   signals,	   as	   well	   as	   chemoattractants,	  
initiate	   the	   next	   stage	   of	   angiogenesis,	   which	   is	   known	   as	   sprouting.	   One	  
endothelial	   cell,	   known	   as	   the	   tip	   cell,	   becomes	   selected	   to	   lead	   and	   guide	   the	  
emerging	  vessel	  sprout	  towards	  the	  angiogenic	  signal,	  whilst	  the	  neighbouring	  cells,	  
called	  stalk	  cells,	  proliferate	  and	  elongate	  to	  form	  the	  lumen	  of	  the	  new	  vessel.	  This	  
differentiation	   is	   determined	   by	   the	  Notch	   signalling	   pathway,	   a	   key	   regulator	   of	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cell	   fate,	  differentiation	  and	  patterning	  processes	   in	  a	   large	  variety	  of	   tissues	  and	  
organisms	  (reviewed	  in	  (Thomas	  et	  al.,	  2013).	  	  
VEGF	   exerts	   its	   effects	   by	   binding	   to	   its	   tyrosine	   kinase	   receptors,	   and	   VEGF	  
regulated	  endothelial	  migration	  mainly	  occurs	   through	  signalling	   induced	  by	  VEGF	  
receptor	   2	   (VEGFR-­‐2)	   (Lamalice	   et	   al.,	   2007).	   VEGF	   activates	   N-­‐WASP,	   promoting	  
actin	  nucleation,	  and	  also	  leads	  to	  the	  rapid	  phosphorylation	  and	  inactivation	  of	  the	  
actin	  depolymerisation	  factor	  cofilin,	  via	  its	  upstream	  regulator	  LIM-­‐kinase	  (Gong	  et	  
al.,	  2004).	  Therefore,	  VEGF	  stimulates	   the	   formation	  of	   filopodia	  and	   lamellipodia	  
via	  Cdc42	  and	  Rac1	  at	  the	  leading	  edge	  of	  the	  tip	  cell,	  which	  then	  migrates	  by	  the	  
general	   mechanisms	   described	   in	   section	   1.4.3.	   Interestingly,	   endothelial	   cells	  
migrate	  in	  a	  coordinated	  group	  where	  the	  polarized	  rear	  of	  the	  migrating	  tip	  cell	  is	  
associated	   with	   an	   endothelial	   stalk	   cell	   via	   VE-­‐cadherin	   adhesion,	   causing	   a	  
‘stretch’	  response	  that	  induces	  proliferation	  via	  Rac1	  activation	  (Liu	  et	  al.,	  2007).	  	  
After	  the	  initial	  sprouting	  phase,	  endothelial	  cells	  undergo	  complex	  morphogenesis	  
to	  assemble	  as	  coalesced	  lumen-­‐bearing	  cords	  with	  a	  branching	  structure	  (reviewed	  
in	   (Iruela-­‐Arispe	   and	   Davis,	   2009)).	   The	   leading	   tip	   cells	   do	   not	   form	   lumens,	  
however	  the	  trailing	  stalk	  cells	  rapidly	  lumenize	  by	  two	  possible	  mechanisms.	  Cord	  
hollowing	  forms	  a	  lumen	  by	  altering	  cell	  shape	  and	  cell-­‐cell	  junctions	  of	  endothelial	  
trunk	  cells,	  flattening	  along	  the	  wall	  of	  matrix	  space	  created	  by	  the	  leading	  cell.	  The	  
second	   method,	   known	   as	   cell	   hollowing	   or	   intracellular	   vacuolation,	   forms	  
endothelial	   luminal	   structures	   by	   coalescing	   and	   fusing	   individual	   vacuoles	   with	  
those	  in	  neighbouring	  cells	  (Davis	  et	  al.,	  2000).	  Tip	  cells	  eventually	  anastomose	  with	  
other	   tip	   cells	   from	   neighbouring	   sprouts	   to	   build	   new	   blood	   vessel	   circuits.	   In	  
addition	   to	   their	   roles	   in	   sprouting,	   Rac1	   and	   Cdc42	   are	   essential	   for	   regulating	  
these	   morphological	   changes,	   mediated	   by	   their	   various	   downstream	   effectors,	  
including	  Pak2,	  Pak4,	  Par3	  and	  Par6.	  In	  vitro	  depletion	  of	  Rac1	  and	  Cdc42,	  or	  their	  
effectors,	   impairs	   endothelial	   cell	   tube	   and	   lumen	   formation	   (Bayless	   and	   Davis,	  
2002;	  Koh	  et	  al.,	  2008).	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VE-­‐cadherin	  is	  not	  only	  fundamental	  for	  maintaining	  quiescent	  endothelium	  barrier	  
integrity,	  but	  also	  plays	  an	  important	  role	  in	  angiogenesis	  signalling.	  Although	  a	  loss	  
of	   VE-­‐cadherin	   does	   not	   prevent	   vessel	   development,	   defects	   in	   vascular	  
remodelling	   and	   integrity	   are	   observed.	   VE-­‐cadherin	   is	   reduced	   between	   cells	  
during	  sprouting	  by	  endocytosis	  as	  a	  result	  of	  VEGF	  stimulation,	  allowing	  the	  cells	  to	  
move	  more	  freely	  (Carmeliet	  and	  Jain,	  2011).	  However,	  VE-­‐cadherin	  is	  required	  for	  
the	   cessation	   of	   sprouting.	   Localisation	   of	   VE-­‐cadherin	   at	   the	   tip	   cell	   filopodium	  
allows	   for	   the	   establishment	   of	   new	   contacts	   with	   other	   tip	   cells	   and	   this	  
engagement	   of	   junctions	   leads	   to	   increased	   actomyosin	   contractility	   via	   ROCK,	  
antagonizing	  VEGF	  signalling	  and	  terminating	  sprouting	  (Abraham	  et	  al.,	  2009).	  The	  
establishment	  of	  a	   functional	   vasculature	   then	  occurs	  by	   subsequent	  pruning	  and	  
remodelling	  of	  the	  branches,	  while	  the	  endothelial	  cells	  become	  quiescent	  and	  cell-­‐
cell	  junctions	  strengthen,	  reducing	  VEGF	  signalling.	  	  
	  	  
1.6 14-­‐3-­‐3	  Proteins	  
The	  14-­‐3-­‐3	  protein	  family	  are	  a	  group	  of	  highly	  conserved	  28-­‐33	  kDa	  acidic	  proteins	  
found	   in	  all	   eukaryotes	   from	   fungi	   to	  animals	  and	  plants.	   Their	  unique	  name	  was	  
derived	  from	  their	  initial	  discovery,	  when	  they	  were	  eluted	  in	  the	  fourteenth	  DEAE-­‐
cellulose	   chromatography	   fraction	   and	   migrated	   as	   spot	   cluster	   3.3	   by	   two-­‐
dimensional	   starch	   gel	   electrophoresis	   during	   fractionation	   of	   extracts	   of	   bovine	  
brain	  (Moore	  and	  Perez,	  1967).	  There	  are	  seven	  14-­‐3-­‐3	  isoforms	  found	  in	  mammals	  
(14-­‐3-­‐3	  β,	  ε,	  η,	  γ,	   τ,	   ζ	  and	  σ)	   that	  are	  expressed	   from	  different	  genes,	  and	  vary	   in	  
expression	   between	   cell	   types	   and	   tissues	   (Kleppe	   et	   al.,	   2011).	   However,	   the	  
functional	   distinctions	   among	   isoforms	   is	   not	   fully	   understood.	   In	  Arabidopsis,	   15	  
isoforms	  have	  been	   identified,	  whereas	  only	  two	  14-­‐3-­‐3	  proteins	  are	   found	   in	  the	  
yeast	  Saccharomyces	  cerevisiae,	  named	  BMH1	  (brain	  neuromodulin	  homologue	  1)	  
and	   BMH2.	   14-­‐3-­‐3	   proteins	   exhibit	   a	   remarkable	   degree	   of	   amino	   acid	   sequence	  
conservation	   both	  within	   and	   across	   species	   (Wang	   and	   Shakes,	   1996).	   This	   high	  
degree	  of	  conservation	  and	  ubiquity	  reflects	  their	  fundamental	  importance	  in	  many	  
biological	  processes.	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1.6.1 Structure	  of	  14-­‐3-­‐3	  dimers	  	  
Crystal	  structural	  studies	  show	  that	  14-­‐3-­‐3	  proteins	  are	  highly	  helical	  proteins	  that	  
are	   able	   to	   self	   assemble	   into	   homo-­‐	   and	   hetero-­‐dimers	   (Aitken,	   2006).	   Each	   L-­‐
shaped	  monomer	   consists	   of	   a	   bundle	   of	   nine	   antiparallel	   α-­‐helices	   (H1-­‐H9)	   that	  
interact	  at	  the	  N-­‐termini,	  forming	  a	  cup-­‐shape	  with	  a	  central	  groove	  approximately	  
35	  Å	  broad,	  35	  Å	  wide	  and	  20	  Å	  deep	  (Obsil	  and	  Obsilova,	  2011)	  (Figure	  1.6).	  Certain	  
family	  members	  prefer	  to	  homodimerise,	  such	  as	  γ	  and	  σ,	  whereas	  other	  members	  
such	   as	   ε	   have	   a	   higher	   affinity	   for	   subunits	   other	   than	   itself	   and	   hence	  
preferentially	  heterodimerise	   (Morrison,	  2009).	  Homodimers	  have	  one	   salt	  bridge	  
at	  the	  interface,	  while	  heterodimers	  are	  stabilized	  by	  up	  to	  three	  (Yang	  et	  al.,	  2006).	  
The	  conserved	  sequences	  between	  the	  different	   isoforms	  of	  the	  14-­‐3-­‐3	  family	  are	  
mainly	   found	   in	   the	   concave	   surface	   that	   contains	   an	   amphipathic	   ligand-­‐binding	  
groove,	   while	   variable	   residues	   are	  more	   likely	   to	   be	   found	   at	   the	   outer	   convex	  
surface,	  particularly	  in	  the	  N-­‐	  and	  C-­‐termini.	  The	  ligand-­‐binding	  groove	  is	  formed	  by	  
α-­‐helices	   H3,	   H5,	   H7	   and	   H9	   and	   each	   subunit	   of	   the	   dimer	   is	   able	   to	   bind	   one	  
discrete	  phosphoserine	  or	  phosphothreonine	  containing	   ligand	   independently	  at	  a	  
distance	  of	  34	  Å	  between	   (Figure	  1.6).	   These	  binding	   sites	  are	  either	   in	   the	   same	  
protein	  or	  in	  two	  independent	  proteins	  that	  are	  linked	  by	  their	  interaction	  with	  14-­‐
3-­‐3	  (Xiao	  et	  al.,	  1995).	  The	  structure	  of	  the	  14-­‐3-­‐3	  dimer	  is	  relatively	  rigid	  and	  little	  
structural	  change	  is	  observed	  upon	  binding	  to	  its	  ligands.	  This	  rigidity	  facilitates	  one	  
of	   the	   roles	   of	   14-­‐3-­‐3	   proteins	   to	   induce	   conformational	   changes	   to	   their	   bound	  
target	  proteins	  (Obsil	  and	  Obsilova,	  2011)	  (see	  section	  1.6.3).	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Figure	  1.6	  The	  crystal	  structure	  of	  dimeric	  14-­‐3-­‐3	  proteins	  
The	  ribbon	  representation	  (A)	  and	  the	  surface	  representation	  (B)	  of	  human	  14-­‐3-­‐3ζ.	  Dimers	  
are	  formed	  by	  9	  helices	  (H1-­‐H9)	  and	  each	  L-­‐shaped	  monomer	  contains	  a	  conserved	  ligand-­‐
binding	   groove	   formed	   by	   α-­‐helices	   H3,	   H5,	   H7	   and	   H9.	   Residues	   depicted	   in	   red	   are	  
conserved	   among	   all	   seven	   human	   isoforms.	   Image	   adapted	   from	   (Obsil	   and	   Obsilova,	  
2011).	  
	  
1.6.2 14-­‐3-­‐3	  interactions	  with	  phosphopeptides	  	  
14-­‐3-­‐3	   dimers	   interact	   with	   a	   diverse	   array	   of	   cellular	   proteins,	   including	  
transcription	   factors,	   biosynthetic	   enzymes,	   cytoskeletal	   proteins,	   signalling	  
molecules,	   apoptosis	   factors,	   tumour	   suppressors	   and	   small	   GTPases	   (Morrison,	  
2009).	  These	   interactions	  are	  primarily	  regulated	  by	  phosphorylation	  of	  the	  target	  
proteins	   (Muslin	   et	   al.,	   1996).	   	   Oriented	   peptide	   library	   screening	   identified	   two	  
canonical	  motifs	   found	  to	  bind	  optimally	  to	  14-­‐3-­‐3s,	  namely	  RSX(pS/T)XP	  (mode	  I)	  
and	   RXXX(pS/T)XP	   (mode	   II)	   where	   pS/T	   represents	   the	   phosphoserine	   or	  
phosphothreonine,	  and	  X	  can	  be	  any	  amino	  acid	  (Yaffe	  et	  al.,	  1997).	  Further	  analysis	  
of	  over	  200	  phosphorylated	  14-­‐3-­‐3-­‐binding	  sites	  in	  the	  literature	  identified	  that	  the	  
proline	   (P)	   located	   at	   position	   +2	   of	   the	   phosphorylation	   site	   only	   occurs	   in	  
approximately	   50%	   of	   14-­‐3-­‐3	   binding	  motifs	   (Johnson	   et	   al.,	   2010).	   Interestingly,	  
many	   target	   proteins	   do	   not	   contain	   sequences	   that	   conform	   precisely	   to	   these	  
motifs.	  Binding	  partners	  that	  contain	  more	  than	  one	  14-­‐3-­‐3	  binding	  site	  have	  a	  30-­‐
fold	   higher	   affinity	   for	   the	   14-­‐3-­‐3	   dimer	   than	   a	   peptide	   containing	   a	   single	  
phosphorylated	  motif	  (Yaffe	  et	  al.,	  1997).	  This	  means	  that	  two	  imperfect	  sites	  could	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be	  sufficient	  to	  allow	  14-­‐3-­‐3-­‐binding,	  if	  they	  are	  in	  antiparallel	  orientation	  and	  able	  
to	  achieve	  the	  correct	  spacing	  (Bridges	  and	  Moorhead,	  2005).	  In	  addition	  to	  the	  two	  
canonical	   binding	   motifs,	   14-­‐3-­‐3	   proteins	   can	   bind	   to	   the	   C-­‐terminus	   of	   several	  
proteins,	  and	  the	  motif	  R-­‐X-­‐X-­‐pS/pT-­‐X-­‐COOH	  has	  been	  defined	  as	  a	  mode	  III	  binding	  
site	  (Coblitz	  et	  al.,	  2005).	  The	  importance	  of	  14-­‐3-­‐3	  binding	  to	  the	  C-­‐terminus	  was	  
recently	   demonstrated	   in	   the	   Rnd	   family	   of	   Rho	   GTPases.	   14-­‐3-­‐3	   simultaneously	  
engages	   the	   C-­‐terminal	   farnesyl	   group	   and	   the	   adjacent	   phosphorylated	   serine	  
residues	   of	   Rnd3,	   inhibiting	   its	   translocation	   from	   the	   plasma	   membrane	   to	   the	  
cytosol,	   which	   provides	   a	   novel	   mechanism	   of	   regulation	   for	   this	   atypical	   Rho	  
GTPase	  (Riou	  et	  al.,	  2013).	  
	  
1.6.3 Functional	  effects	  of	  14-­‐3-­‐3	  binding	  to	  target	  proteins	  
14-­‐3-­‐3	  proteins	  have	  no	  intrinsic	  enzymatic	  activity	  of	  their	  own,	  however	  they	  are	  
involved	   in	   many	   cellular	   processes	   through	   their	   interaction	   with	   their	   many	  
binding	   proteins.	   There	   are	   three	   proposed	  mechanisms	   to	   describe	   how	   14-­‐3-­‐3	  
proteins	  modify	  the	  properties	  and	  function	  of	  their	  binding	  partners.	  These	  modes	  
of	   action	   are:	   (i)	   direct	   conformational	   changes	  of	   the	   target	   protein,	   (ii)	   physical	  
occlusion	   of	   sequence-­‐specific	   or	   structural	   features,	   and	   (iii)	   scaffolding	   (Bridges	  
and	  Moorhead,	  2005;	  Mackintosh,	  2004).	  
Due	  to	  their	  rigid	  α-­‐helical	  structure,	  14-­‐3-­‐3	  proteins	  can	  act	  as	  a	  stable	  support	  on	  
which	  target	  proteins	  can	  be	  reshaped.	  Many	  14-­‐3-­‐3	  ligands	  have	  two	  or	  more	  14-­‐
3-­‐3-­‐binding	  motifs	  that	  simultaneously	  engage	  both	  subunits	  in	  the	  14-­‐3-­‐3	  dimer.	  It	  
has	  been	  proposed	  that	  one	  site	  on	  the	  target	  protein	  acts	  as	  a	  dominant	  site	  and	  
once	  phosphorylated	  and	  binding	  to	  one	  monomer	  occurs,	  subsequent	  binding	  of	  a	  
weaker	  secondary	  site	   in	   the	   ligand	  protein	   to	   the	  other	  14-­‐3-­‐3	  monomer	   follows	  
due	  to	  its	  proximity	  and	  conformational	  changes	  (Yaffe,	  2002).	  The	  ability	  of	  14-­‐3-­‐3	  
proteins	   to	   act	   as	   conformational	   clamps	   can	   also	   result	   in	   substantial	  
rearrangement	   of	   an	   active	   site	   in	   target	   enzymes.	   In	   addition	   to	   inducing	   these	  
conformational	  changes,	  14-­‐3-­‐3s	  provide	  the	  structural	  support	  needed	  to	  stabilise	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enzyme	   targets	   in	   a	   specific	   conformation,	   thus	   directly	   increasing	   or	   decreasing	  
their	  catalytic	  activity	  (Mackintosh,	  2004).	  	  
Binding	  to	  14-­‐3-­‐3	  proteins	  can	  change	  the	  subcellular	  localisation	  of	  a	  protein,	  but	  
does	  not	  target	  proteins	  to	  one	  specific	  location.	  The	  effect	  of	  14-­‐3-­‐3	  binding	  on	  the	  
subcellular	  localisation	  of	  a	  partner	  protein	  depends	  solely	  on	  information	  encoded	  
within	  the	  partner	  protein	  and	  the	  proximity	  of	  that	  information	  to	  a	  14-­‐3-­‐3	  binding	  
motif.	  In	  several	  cases,	  if	  a	  binding	  partner	  contains	  a	  nuclear	  localisation	  sequence	  
(NLS)	  or	  a	  nuclear	  export	  sequence	  (NES)	  within	  close	  proximity	  of	  a	  14-­‐3-­‐3–binding	  
site,	   then	   the	   14-­‐3-­‐3	   dimer	   can	   interfere	   with	   their	   function	   by	   masking	   or	  
obscuring	  these	  sites.	  This	  could	  alter	  the	  kinetics	  of	  nuclear-­‐cytoplasmic	  shuttling,	  
and	  result	  in	  a	  change	  or	  protein	  localisation	  (Muslin	  and	  Xing,	  2000).	  For	  example,	  
the	   junctional	   protein	   and	   transcription	   factor	   β-­‐catenin	   is	   exported	   out	   of	   the	  
nucleus	  upon	  binding	  to	  14-­‐3-­‐3	  with	   its	  antagonist	  Chibby,	  thereby	  suppressing	  β-­‐
catenin	   signalling	   activity	   (Takemaru	   et	   al.,	   2009).	   Cytoplasmic-­‐endoplasmic	  
reticulum	   (ER)	   localisation	   can	   also	   be	   regulated	   by	   14-­‐3-­‐3	   binding.	   Proteins	  
synthesized	  in	  the	  ER	  are	  retained	  there	  by	  a	  dibasic	  ER	  retention	  motif	  that	  could	  
be	  obscured	  upon	  14-­‐3-­‐3	  binding	  (Bridges	  and	  Moorhead,	  2005).	  Binding	  to	  14-­‐3-­‐3	  
dimers	  can	  mask	  protein-­‐protein	  sites,	  protein-­‐DNA	  sites	  as	  well	  as	  protect	   target	  
proteins	   against	   dephosphorylation	   and	   proteolytic	   degradation	   (Obsil	   and	  
Obsilova,	  2011).	  
The	  dimeric	  nature	  of	  14-­‐3-­‐3	  proteins	  with	  two	  adjacent	  phospho-­‐peptide	  binding	  
sites	   provides	   a	   phosphorylation-­‐dependent	   scaffold	   to	   anchor	   proteins	   within	  
close	   proximity	   of	   one	   another	   and	   function	   as	   an	   adaptor	   (Obsil	   and	   Obsilova,	  
2011).	  This	  allows	   for	   two	  phosphorylated	  residues	   to	  dock	   into	   the	  dimer,	  which	  
may	  be	  phosphorylated	  by	  different	  kinases.	  The	  14-­‐3-­‐3	  dimer	  can	  therefore	  act	  as	  
a	  logic	  gate	  that	  integrates	  two	  inputs	  to	  generate	  an	  action	  (Johnson	  et	  al.,	  2010).	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1.7 Aims	  of	  the	  study	  
	  
The	   aim	   of	   this	   research	   was	   to	   identify	   protein	   phosphorylation	   changes	   in	  
response	  to	  insulin	  treatment	  of	  endothelial	  cells	  and	  determine	  the	  roles	  of	  these	  
changes	   in	   regulating	   endothelial	   functions.	   The	   hypothesis	   of	   the	   study	   is	   that	  
insulin	   protects	   endothelial	   cells	   from	   damage	   by	   phosphorylating	   proteins	   that	  
may	  be	  involved	  in	  stabilising	  endothelial	  cell-­‐cell	  junctions.	  	  
	  
The	  study	  was	  divided	  into	  three	  main	  objectives:	  
	  
1. The	   first	   aim	   was	   to	   establish	   the	   cellular	   model	   for	   the	   study	   by	  
investigating	  the	  effects	  of	   insulin	  on	  human	  umbilical	  vein	  endothelial	  cell	  
(HUVEC)	  barrier	  function,	  endothelial	  migration	  and	  angiogenesis.	  	  
	  
2. The	   second	   objective	   of	   the	   project	   was	   to	   identify	   new	   targets,	   whose	  
phosphorylation	   and	   binding	   to	   14-­‐3-­‐3	   proteins	   is	   stimulated	   by	   insulin	   in	  
endothelial	  cells.	  Proteins	  of	  interest	  were	  validated	  and	  selected	  based	  on	  
predicted	   roles	   in	  endothelial	   function	   specifically	   in	  Rho	  GTPase	  and	  PI3K	  
signalling	  pathways.	  
	  
3. The	  third	  aim	  of	  the	  study	  was	  to	  investigate	  how	  these	  proteins	  contribute	  
to	  endothelial	   functions.	  The	  objective	  was	  approached	  by	  over-­‐expression	  
and	  protein	  silencing	  analysis	  to	  identify	  their	  roles	  in	  ECs.	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2 Materials	  and	  Methods	  	  
Chemicals	   and	   salts	   for	   solutions	   were	   purchased	   from	   Sigma-­‐Aldrich,	   unless	  
otherwise	  stated.	  
2.1 Materials	  	  
2.1.1 Reagents	  and	  Kits	  	  
	  
Table	  2.1	  Reagents	  and	  Kits	  
Reagents/Kits	   Source	  
Amaxa	  TM	  HUVEC	  Nucleofector	  TM	  Kit	  	   Lonza	  
Cell	  Tracker	  TM	  Orange,	  CMRA	   Invitrogen	  
Complete,	  mini	  EDTA-­‐free	  protease	  inhibitor	  cocktail	   Roche	  Applied	  Science	  
Colloidal	  Coomassie	  Brilliant	  Blue-­‐G	   Sigma-­‐Aldrich	  
Coverslips	  (13	  mm)	   VWR	  
Dulbecco’s	   modified	   eagle	   medium	   (DMEM)(+	   4500	   mg/L	  
glucose,	   +	   L-­‐Glutamine,	   +	   25	   mM	   HEPES,	   +	   110	   mg/L	  
sodium	  pyruvate)	  
Gibco®,	  Life	  Technologies	  
Dried,	  skimmed	  milk	   Marvel	  
Endothelial	  cell	  basal	  medium-­‐2	  (EBM-­‐2),	  
supplemented	  with	  ascorbic	  acid,	  R3-­‐IGF-­‐1,	  heparin,	  rhFGF-­‐
B,	  hydrocortisone,	  GA-­‐1000,	  rhEGF,	  VEGF,	  2%	  foetal	  bovine	  
serum.	   Supplements	   provided	   as	   part	   of	   a	   bullet	   kit,	  
SingleQuots®,	  purchased	  with	  the	  basal	  medium.	  
Clonetics®,	  Lonza	  
Enhanced	  chemiluminescence	  (ECL)	  reagent	   GE	  Healthcare	  
Foetal	  calf	  serum	   Invitrogen	  
Fibronectin	   Calbiochem	  
FITC-­‐dextran	  (molecular	  weight	  42,000)	   Sigma-­‐Aldrich	  
Fluorescent	  mounting	  medium	   	   DAKO	  
Gelatin	   Sigma-­‐Aldrich	  
Glutathione	  sepharose	  beads	   GE	  Healthcare	  
Insulin	  from	  bovine	  pancreas	   Sigma-­‐Aldrich	  	  
(cat.	  no.	  I1882) 
Recombinant	  human	  insulin	  like	  growth	  factor-­‐1	   Millipore	  
L-­‐broth	   Sigma-­‐Aldrich	  
BDMatrigel	  TM	  basement	  membrane	  matrix	   BD	  Biosciences	  
Nitrocellulose	  membranes	   Millipore	  
Nu	  PAGE®	  4-­‐12	  %	  Bis-­‐Tris	  Gels	   Invitrogen	  
Nu	  PAGE®	  MES	  Running	  buffer	   Invitrogen	  
Nu	  PAGE®	  LDS	  Sample	  buffer	  (4x)	   Invitrogen	  
Chapter	  2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Materials	  and	  Methods	  
	  
	   	   64	  
Novex®	  Colloidal	  Coomassie	  Blue	  Staining	  Kit	   Invitrogen	  
Oligofectamine	  TM	   Invitrogen	  
Opti-­‐MEM	  +	  GlutaMax	  TM	   Gibco®,	  Life	  Technologies	  
ORISTM	  assay	  stoppers	   Platypus	  Technologies	  
HiSpeed	  Maxiprep	  kit	   Qiagen	  
Penicillin	  /	  Streptomycin	  (10,000	  U/ml/10,000	  mg/l)	   Gibco®,	  Life	  Technologies	  
Phosphate	  buffered	  saline	  (PBS)	  	  
(-­‐)	  CaCl2	  /	  MgCl2	  or	  (+)	  100	  mg/L	  CaCl2	  /	  MgCl2	  
Gibco®,	  Life	  Technologies	  
Pierce®	  BCA	  Protein	  Assay	  Kit	   Thermo	  Scientific	  
PI-­‐103	   Millipore	  
Polyethylenimine	  (PEI),	  linear,	  MW	  ~	  25,000	  	   Polysciences,	  Inc	  
(cat.	  no.	  23966)	  
Precision	  PlusProtein	  TM	  standards	   Bio-­‐Rad	  
Transwell	  Permeable	  Supports,	  0.4	  µm	  pore	  size,	  12	  mm	   Costar	  
Trypsin	  /	  EDTA	  0.05%	   Gibco®,	  Life	  Technologies	  
Vivaspin	  concentrators	  (5	  000	  and	  10	  000	  MWCO)	   Vivascience	  
Whatman	  3MM	  chromatography	  paper	  	   Whatman	  
X-­‐ray	  film	   Fujifilm	  
	  
2.1.2 Buffers	  and	  solutions	  	  
	  
Table	  2.2	  Buffers	  and	  solutions	  
	  
Buffer	   Composition	  
Lysis	  buffer	   50	  mM	  Tris-­‐HCl	  pH	  7.5	  
150	  mM	  NaCl	  
1	  mM	  EDTA	  
1	  mM	  EGTA	  
270	  mM	  Sucrose	  
1	  mM	  Benzamidine	  
0.1%	  β-­‐mercaptoethanol	  
1%	  Triton	  X-­‐100	  
50	  mM	  NaF	  
1	  mM	  Na3VO4	  
1	  mM	  PMSF	  
20	  nM	  Calyculin	  A	  
Complete	   mini	   EDTA-­‐free	   protease	  
inhibitor	  
NuPAGE®	  MES	  SDS	  running	  buffer	   50	  mM	  MES	  
50	  mM	  Tris	  base	  
0.1%	  SDS	  
1	  mM	  EDTA	  
pH	  7.3	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NuPAGE®	  MOPS	  SDS	  running	  buffer	   50	  mM	  MOPS	  
50	  mM	  Tris	  base	  
0.1%	  SDS	  
1	  mM	  EDTA	  
pH	  7.7	  
Transfer	  buffer	   25	  mM	  Tris	  
192	  mM	  Glycine	  
20%	  Methanol	  
pH	  8.3	  
Tris-­‐buffered	  saline	  with	  Tween	  (TBST)	   20	  mM	  Tris-­‐HCl	  pH	  7.6	  
140	  mM	  NaCl	  
0.1%	  Tween-­‐20	  
Stripping	  buffer	   70	  mM	  Tris	  
20	  mM	  NaCl	  
pH	  2.3	  
14-­‐3-­‐3	  Affinity	  Purification	  
Peptide	  coupling	  buffer	   0.1	  M	  NaHCO3	  pH	  8.0	  
0.5	  M	  NaCl	  
Blocking	  buffer	   0.1	  M	  Tris-­‐HCl	  pH	  8.0	  
High	  pH	  Buffer	   50	  mM	  Tris-­‐HCl	  pH	  8.0	  
0.5	  M	  NaCl	  
Low	  pH	  Buffer	   50	  mM	  NaAcetate	  pH	  4.0	  
0.5	  M	  NaCl	  
Buffer	  A	   25	  mM	  Tris-­‐HCl	  pH	  7.5	  (4°C)	  
100	  mM	  NaCl	  
25	  mM	  NaF	  
Buffer	  B	   25	  mM	  Tris-­‐HCl	  pH	  7.5	  (4°C)	  
500	  mM	  NaCl	  
25	  mM	  NaF	  











50	  mM	  Tris-­‐HCl	  pH	  7.5	  
120	  mM	  NaCl	  
1	  mM	  EDTA	  
1	  mM	  EGTA	  
270	  mM	  Sucrose	  
1	  mM	  Benzamidine	  
0.1%	  β-­‐mercaptoethanol	  
1%	  Triton	  X-­‐100	  
5	  mM	  sodium	  pyrophosphate	  
10	  mM	  Na-­‐	  β-­‐Glycerolphosphate	  
1	  μM	  microcystin-­‐LR	  
1	  mM	  Na3VO4	  
50	  mM	  NaF	  
1	  mM	  PMSF	  
Complete	   mini	   EDTA-­‐free	   protease	  
inhibitor	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GFP-­‐Trap	  pull	  down	  
High	  salt	  buffer	   50	  mM	  Tris-­‐HCl	  pH	  7.5	  
250	  mM	  NaCl	  
	  
2.1.3 Antibodies	  	  
Table	  2.3	  Primary	  Antibodies	  
Western	  Blot	  (WB);	  Immunofluorescence	  (IF)	  
Antibody	  (clone)	   Species	   Dilution	  
Supplier	  and	  Catalogue	  
number	  
Akt	   Rabbit	   WB	  1/1000	   Sigma-­‐Aldrich	  
#HPA019657	  
Phospho-­‐Akt	  (Ser473)	   Rabbit	   WB	  1/1000	   Cell	  Signaling	  
#4060	  
ARHGAP17	   Rabbit	   WB	  1/500	  
Abcam	  
#74454	  
β-­‐Catenin	   Rabbit	   IF	  1/100	   Sigma-­‐Aldrich	  
#C2206	  
Epsin2	   Rabbit	   WB	  1/500	   Abcam	  
#ab74942	  
GAPDH	   Mouse	   WB	  1/5000	   Millipore	  
#MAB374	  
GFP	   Rabbit	   WB	  1/1000	   Santa	  Cruz	  Biotechnology	  
LMO	  (C-­‐5)	   Mouse	   WB	  1/200	   Santa	  Cruz	  Biotechnology	  
#sc-­‐365515	  
PARG1	  (ARHGAP29)	   Mouse	   WB	  1/2000	   Bethyl	  Laboratories	  
#A301-­‐924A	  
pan	  14-­‐3-­‐3	  (K-­‐19)	   Rabbit	   WB	  1/1000	  
Santa	  Cruz	  Biotechnology	  
#sc-­‐629	  
PECAM1/CD31	  (cloneJC70A)	   Mouse	   IF	  1/200	   Dako	  Cytomation	  
VE-­‐cadherin	   Mouse	   IF	  1/100	   BD	  Biosciences	  
#555289	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Table	  2.4	  Secondary	  Antibodies	  and	  reagents	  
	  
Antigen	   Species	   Conjugate	   Dilution	   Supplier	  
Anti-­‐Digoxigenin	  
(Fab	  fragments)	  
Sheep	   HRP	   1/5000	  
Roche	  Diagnostics	  
#11	  207	  733	  910	  
Mouse	  IgG	   Sheep	   HRP	   1/5000	  
GE	  Healthcare	  
#NA931V	  
Rabbit	  IgG	   Donkey	   HRP	   1/5000	  
GE	  Healthcare	  
#NA934V	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2.1.4 siRNA	  oligonucleotides	  
	  
Table	  2.5	  siRNA	  oligonucleotides	  
All	   siRNAs	   were	   purchased	   from	   Dharmacon.	   Oligo	   numbers	   assigned	   by	  
Dharmacon.	  
Gene	  name	   Oligo	  number	   Sequence	  
ARHGAP17	   #1	   GCAGACAUGUACAACUUUA	  
#2	   AAACAGAAGUCCUUAGUGA	  
#4	   CUGAAGAGGUGGAAUUUAA	  
#17	   GUAAGAAGCAGUGCGUUAA	  
ARHGAP29	   #1	   GCAAAGACCUUCUAAGACA	  
#2	   GAAGUUCUCCCACAUGUUA	  
#3	   GGAAUGCACUUGGUAGAUA	  
#4	   GAACUAACAUUGGAAUUCA	  
EPN2	   #1	   AGACUACGCUGUUGGAUUU	  
#3	   CCACUGGGCCCUGCAAUGA	  
#4	   CCACCAAGCCCGUGUCUGU	  
#17	   AUUAAAAUCCACUAGAGCGA	  
LMO7	   #1	   CUACUGAACUGGAUGAUUA	  
#2	   GAAGUAUAAUGGAGAUGUU	  
#3	   UAGCAGGAUUGGAUAAUAU	  
#4	   GGACUAUUCUCAUUAAGGC	  
	  
2.1.5 Software	  	  
Table	  2.6	  Software	  
Software	   Supplier	  
Illustrator	  CS4	   Adobe	  
Photoshop	  CS4	   Adobe	  
Metamorph	   Molecular	  Devices	  
Volocity	  	   Volocity	  Perkin	  Elmer,	  Improvision	  
LSM	  +	  ZEN	   Zeiss	  
ImageJ	   National	  Institutes	  of	  Health	  
VisANT	   National	  Institutes	  of	  Health	  
Jalview	   University	  of	  Dundee	  
SigmaPlot	  Version	  12.5	   Systat	  Software,	  San	  Jose,	  CA	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2.2 Methods:	  General	  molecular	  biology	  	  
2.2.1 Plasmid	  transformation	  of	  Escherichia	  coli	  (E.	  coli)	  
Plasmid	  DNA	   (100	  ng)	  was	   added	   to	   100	  µl	   of	   competent	  DH5α	   cells	   (Invitrogen)	  
and	  incubated	  on	  ice	  for	  15	  min.	  The	  suspension	  was	  heat-­‐shocked	  at	  42°C	  for	  45	  
sec	  and	  then	  placed	  on	  ice	  for	  5	  min.	  After	  addition	  of	  500	  µl	  of	  antibiotic-­‐free	  LB	  
(Luria	  broth)	  the	  cells	  were	  allowed	  to	  grow	  at	  37°C	  for	  1	  h.	  Transformed	  plasmid	  
DNA	   suspensions	   (100	   µl)	   were	   streaked	   onto	   LB	   agar	   plates	   containing	   the	  
appropriate	  antibiotic	  for	  selection	  (100	  µg/ml	  ampicillin).	  
	  
2.2.2 Plasmid	  and	  construct	  preparation	  	  
All	  expression	  plasmids	  used	  in	  this	  thesis	  were	  kindly	  generated	  by	  Dr	  Rachel	  Toth	  
at	  the	  Division	  of	  Signal	  Transduction	  Therapy	  (DSTT)	  of	  the	  University	  of	  Dundee.	  	  
Table	  2.7	  List	  of	  plasmids	  
Plasmid	  name	   DSTT	  number	  
EGFP-­‐C1	  VASP	   DU1556	  
EGFP-­‐C1	  HA	  RhoGef16	   DU1595	  
pcDNA5	  FRT/TO	  GFP	  RhoA	   DU11862	  
pcDNA5	  FRT/TO	  GFP	  PANK2	   DU31932	  
pcDNA5	  FRT/TO	  GFP	  LMO7	   DU31944	  
pcDNA5	  FRT/TO	  GFP	  Rac3	   DU40610	  
pcDNA5	  FRT/TO	  GFP	  ARHGD1A	   DU40632	  
pcDNA5	  FRT/TO	  GFP	  ARHGD1B	   DU40633	  
pcDNA5	  FRT/TO	  GFP	  CDC42	   DU40634	  
pcDNA5	  FRT/TO	  GFP	  ARHGAP17	   DU40635	  
pcDNA5	  FRT/TO	  GFP	  ARHGAP29	   DU40636	  
pcDNA5	  FRT/TO	  GFP	  EPN2	   DU40672	  
pcDNA5	  FRT/TO	  GFP	  SCFD1	   DU40684	  
pcDNA5	  FRT/TO	  GFP	  DOCK10	   DU45027	  
pcDNA5	  FRT/TO	  GFP	  DOCK10	  T1440A	   DU45089	  
	  	  
A	   starter	   culture	   of	   transformed	   E.	   coli	   was	   prepared	   by	   inoculating	   15	   ml	   LB	  
containing	   antibiotic	   for	   selection	   (ampicillin	   or	   kanamycin)	   with	   a	   single	   colony	  
from	  an	  LB	  agar	  plate	  and	  incubated	  for	  6	  h	  at	  37°C.	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From	   the	   starter	   culture,	   10	   ml	   was	   used	   to	   inoculate	   200	   ml	   of	   LB	   containing	  
antibiotic	   for	  selection,	  and	   incubated	   for	  up	  to	  16	  h	  at	  37°C.	  Bacterial	  cells	  were	  
pelleted	  at	  5500	  g	  in	  a	  Sorvall	  RC5C	  centrifuge	  (Rotor	  SLA-­‐1500)	  for	  15	  min	  and	  the	  
bacterial	  pellets	  were	  either	  stored	  at	  -­‐20°C	  or	  purified	  immediately.	  
	  
2.2.3 Purification	  of	  plasmid	  DNA	  	  
The	  bacterial	  pellet	  was	  purified	  using	  the	  Qiagen	  HiSpeed	  Maxiprep	  kit,	  according	  
to	   the	  manufacturer’s	   instructions,	  at	   room	  temperature.	  The	  bacterial	  pellet	  was	  
resuspended	  in	  10	  ml	  of	  cold	  Buffer	  P1	  (50	  mM	  Tris-­‐HCl,	  pH	  8.0,	  10	  mM	  EDTA,	  100	  
µg/ml	  RNase	  A).	  After	  complete	  resuspension,	  10	  ml	  lysis	  buffer	  P2	  (200	  mM	  NaOH,	  
1%	  SDS)	  was	  added	  and	  the	  suspension	  mixed	  gently.	  The	  solution	  was	  neutralised	  
after	  5	  min	  with	  10	  ml	  of	  cold	  neutralisation	  buffer	  P3	  (3.0	  M	  potassium	  acetate,	  pH	  
5.5),	   mixed	   thoroughly	   and	   poured	   into	   the	   QIAfilter	   Cartridge.	   During	   a	   10	  min	  
incubation,	   the	  HiSpeed	  Maxi	   Tip	  was	   equilibrated	   by	   applying	   10	  ml	   Buffer	  QBT	  
(750	  mM	  NaCl,	  50	  mM	  MOPS,	  pH	  7.0,	  15%	   isopropanol,	  0.15%	  Triton	  X-­‐100).	  Cell	  
debris	   was	   separated	   from	   the	   soluble	   lysate	   by	   filtering	   through	   a	   QIAfilter	  
Cartridge	  into	  a	  HiSpeed	  Maxi	  Tip.	  The	  cleared	  lysate	  was	  left	  to	  filter	  through	  the	  
tip	  by	  gravity,	  and	  the	  bound	  DNA	  was	  washed	  by	  the	  addition	  of	  60	  ml	  QC	  wash	  
buffer	  (1.0	  M	  NaCl,	  50	  mM	  MOPS,	  pH	  7.0,	  15%	  isopropanol)	  to	  the	  tip.	  The	  DNA	  was	  
eluted	   with	   15	   ml	   Buffer	   QF	   (1.25	   M	   NaCl,	   50	   mM	   Tris-­‐HCl,	   pH	   8.5,	   15%	  
isopropanol),	  and	  precipitated	  by	  the	  addition	  of	  10.5	  ml	  isopropanol.	  Following	  a	  5	  
min	   incubation,	   the	   DNA	   was	   concentrated	   by	   filtering	   the	   solution	   through	   the	  
QIAprecipitator	  Maxi	  Module,	  and	  washed	  by	  passing	  2	  ml	  of	  70%	  ethanol	  through	  
the	  Module.	  After	  air-­‐drying	  the	  QIAprecipitator	  membrane	  by	  pressing	  air	  through	  
it	  with	  a	  dry	  syringe,	  the	  DNA	  was	  eluted	  by	  filtering	  1	  ml	  Tris-­‐EDTA	  (TE)	  buffer	  (10	  
mM	  Tris-­‐HCl,	  pH	  8.0,	  1	  mM	  EDTA)	   through	   the	  Module.	  To	  ensure	  a	  high	  yield	  of	  
DNA,	   the	   elution	   step	   was	   repeated	   using	   the	   eluted	   1	   ml	   TE	   buffer.	   The	   DNA	  
concentration	  was	  then	  measured,	  and	  samples	  were	  stored	  at	  -­‐20°C.	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2.2.4 Measurement	  of	  DNA	  concentration	  	  
DNA	   concentration	   was	   determined	   spectrophotometrically	   using	   a	   Nano-­‐Drop	  
system	   (ND-­‐1000,	  www.nanodrop.com).	   The	   sample	   (1	  µl)	  was	   pipetted	  onto	   the	  
end	  of	  a	   fibre	  optic	  cable,	  and	  the	  optical	  density	   (OD)	  was	  measured	  at	  260	  nm.	  
The	  DNA	  concentration	  was	  automatically	  determined	  using	  the	  following	  formula:	  
concentration	  of	  DNA	  =	  OD260	  x	  50	  μg/ml.	  
	  
2.3 Methods:	  Cell	  biology	  
2.3.1 Cell	  culture	  	  
Pooled	   primary	   human	   umbilical	   vein	   endothelial	   cells	   (HUVECs)	   (Lonza	   or	  
PromoCell)	  were	  grown	  on	  flasks,	  plates	  and	  glass	  coverslips	  coated	  with	  10	  µg/ml	  
fibronectin	  (FN).	  FN	  was	  diluted	  in	  PBS	  (+Ca2+,	  +Mg2+),	  plastic-­‐ware	  was	  coated	  for	  
at	  least	  1	  h	  and	  glass	  coverslips	  were	  coated	  overnight	  in	  a	  humidified	  incubator	  at	  
37°C	  with	  5%	  CO2.	  	  HUVECs	  were	  grown	  in	  Endothelial	  Cell	  Basal	  Medium-­‐2	  (EBM-­‐
2),	  supplemented	  with	  endothelial	  cell	  growth	  supplement	  (EGM-­‐2)	  containing	  2%	  
heat-­‐inactivated	   foetal	   bovine	   serum	   (FBS),	   growth	   factors	   and	   antibiotics	   (see	  
Table	   2.1).	   Cells	   reached	   80%	   confluence	   between	   3	   to	   4	   days	   after	   thawing,	  
medium	  was	  changed	  every	  2	  days	  and	  cells	  sub-­‐cultured	  1:3	  or	  1:4	  depending	  on	  
their	  growth.	  Cells	  were	  only	  used	  up	  to	  passage	  4,	  as	  cell	  growth	  slowed,	  cell	  area	  
increased	  and	  cell	  morphology	  became	  irregular	  beyond	  this.	  	  
The	  human	  bone	  marrow	  endothelial	  cell	   line	  (HBMECs)	  was	  kindly	  obtained	  from	  
Babette	  Weksler	  of	  Cornell	  University	  (Schweitzer	  et	  al.,	  1997).	  Cells	  were	  grown	  on	  
flasks	   and	   plates	   coated	   with	   0.2%	   (w/v)	   gelatin	   in	   Dulbecco’s	   Modiﬁed	   Eagle’s	  
Medium	  (DMEM;	  Gibco),	  supplemented	  with	  10%	  (v/v)	  heat-­‐inactivated	  FBS,	  2	  mM	  
glutamine,	   10	   mM	   HEPES,	   10	   000	   U/ml	   penicillin,	   10	   000	   µg/ml	   streptomycin	  
(pen/strep)	  and	  RPMI	  vitamin	  mix.	  Cells	  were	  passaged	  at	  least	  twice	  after	  thawing	  
before	  being	  used	  for	  experiments	  and	  used	  until	  passage	  25.	  Medium	  was	  changed	  
every	  2	  days	  and	  cells	  were	  sub-­‐cultured	  1:5.	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Adherent	   human	   embryonic	   kidney	   293	   cells	   (HEK293)	   were	   cultured	   in	   DMEM	  
supplemented	  with	  10%	  (v/v)	  heat-­‐inactivated	  FBS,	  2	  mM	  glutamine,	  10	  mM	  HEPES,	  
10	  000	  U/ml	  penicillin,	  10	  000	  µg/ml	  streptomycin.	  Medium	  was	  changed	  every	  2	  
days	  and	  cells	  were	  sub-­‐cultured	  1:5.	  	  
All	  cells	  were	  maintained	  at	  37°C	  with	  5%	  CO2.	  	  
	  
2.3.2 Thawing	  and	  freezing	  of	  cells	  
Frozen	   cryovials	   in	   liquid	   nitrogen	  were	   thawed	   rapidly	   in	   a	   37°C	  waterbath,	   and	  
cells	  were	  slowly	  diluted	  up	  to	  10	  ml	  with	  their	  respective	  medium,	  in	  a	  drop-­‐wise	  
manner.	  Cells	  were	  centrifuged	  at	  200	  g	  for	  4	  min,	  supernatant	  aspirated	  and	  10	  ml	  
complete	  medium	  added.	  The	  cells	  were	  then	  transferred	  to	  a	  75	  cm2	  tissue	  culture	  
flask,	   incubated	  overnight	  at	  37°C	  with	  5%	  CO2	  and	  the	  medium	  was	  changed	  the	  
next	  day.	  
To	   freeze	   cell	   lines,	   cells	   were	   washed	   with	   PBS	   (-­‐Ca2+,	   -­‐Mg2+),	   detached	   using	  
trypsin	  and	  pelleted	  at	  200	  g	  for	  4	  min.	  Cells	  were	  resuspended	  in	  freezing	  solution	  
(90%	  FBS,	  10%	  dimethyl	  sulphoxide	  (DMSO))	  and	  aliquoted	  into	  cryovials	  containing	  
1	  ml	  each.	  Cryovials	  were	  inserted	  into	  a	  cryo	  freezing	  container	  and	  stored	  at	  -­‐80°C	  
to	   allow	   slow	   freezing	   of	   1°C	   per	   hour,	   overnight.	   The	   cells	   were	   transferred	   to	  
liquid	  nitrogen	  for	  long-­‐term	  storage.	  	  
	  
2.3.3 Treatment	  of	  cells	  with	  insulin,	  insulin	  like	  growth	  factor-­‐I,	  and	  inhibitors	  	  
Prior	   to	   any	   stimulation,	   cells	   were	   serum	   starved.	   Due	   to	   their	   sensitivity	   as	  
primary	  cells,	  HUVECs	  were	  serum	  starved	  in	  EBM-­‐2	  medium	  containing	  1%	  FBS	  and	  
pen/strep	  for	  either	  4	  h,	  for	  short-­‐term	  experiments	  (less	  than	  8	  h);	  or	  for	  2	  h,	  for	  
long-­‐term	  experiments	  (16	  to	  24	  h).	  HBMEC	  and	  HEK293	  cells	  were	  starved	  for	  16	  h	  
in	   serum	   free	   DMEM	   containing	   pen/strep.	   Cells	   were	   maintained	   in	   starving	  
medium	  throughout	   the	  experiments,	   to	  which	   insulin,	   insulin	   like	  growth	   factor-­‐I	  
(IGF-­‐I)	  and/or	  the	  inhibitors	  were	  added.	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Insulin	  was	  prepared	  as	  a	  10	  mg/ml	  stock	  solution	  and	  stored	  at	  4°C.	  The	  optimal	  
concentration	  of	  insulin	  required	  to	  activate	  the	  cells	  was	  first	  determined	  in	  initial	  
experiments,	   testing	   final	   concentrations	   of	   0,	   12.5,	   25,	   50,	   100	   and	   200	   nM.	   An	  
optimal	   concentration	   of	   100	   nM	   was	   used	   in	   subsequent	   experiments.	   A	   time	  
course	   analysis	   of	   0,	   5,	   10,	   15,	   30	   and	   60	  min	  was	   initially	   performed	   to	   identify	  
optimal	  insulin	  stimulation	  times.	  Cells	  were	  stimulated	  for	  10	  min	  for	  subsequent	  
biochemical	  analysis.	  
IGF-­‐I	   was	   prepared	   as	   a	   50	   µg/ml	   stock	   solution	   in	   sterile	   water,	   aliquoted	   and	  
stored	  a	  -­‐20°C.	  HEK293	  cells	  were	  treated	  at	  a	  final	  concentration	  of	  50	  ng/ml	  for	  20	  
min.	  
The	   PI3K	   inhibitor,	   PI-­‐103,	   was	   prepared	   as	   a	   10	   mM	   stock	   solution	   in	   DMSO,	  
aliquoted	  and	  stored	  at	  -­‐20°C.	  HEK293	  cells	  were	  treated	  at	  a	  final	  concentration	  of	  
10	  µM	  for	  30	  min,	  and	  then	  treated	  with	  IGF-­‐I	  as	  described	  above.	  
	  
2.3.4 DNA	  transfection	  of	  HUVECs	  using	  Amaxa	  nucleofection	  	  
HUVECs	  were	  transfected	  with	  plasmid	  DNA	  using	  the	  Amaxa	  HUVEC	  nucleofection	  
kit.	   HUVECs	   were	   trypsinised	   and	   washed	   once	   with	   PBS	   (+Ca2+,	   +Mg2+)	   and	  
resuspended	   in	   HUVEC	   electroporation	   buffer	   (Amaxa)	   (1	   x	   106	   cells	   in	   100	   µl	   of	  
buffer	  per	  condition).	  Plasmid	  DNA	  (4	  µg)	  was	  mixed	  with	  the	  cell	  suspension	  and	  
transferred	   to	   an	   electroporation	   cuvette.	   Nucleofection	  was	   carried	   out	  with	   an	  
Amaxa	  NucleofectorTM	   (Amaxa,	  Cologne,	  Germany)	  using	  program	  A-­‐34	  according	  
to	  the	  manufacturer’s	  instructions.	  After	  nucleofection,	  the	  cells	  were	  immediately	  
diluted	  with	  1	  ml	  EGM-­‐2	  medium	  and	  transferred	  to	  two	  FN-­‐coated	  glass	  coverslips	  
(for	   confluent	   monolayers)	   or	   four	   coverslips	   (for	   sub-­‐confluent	   monolayers).	  
Following	  a	  24	  h	  incubation	  at	  37°C	  with	  5%	  CO2,	  cells	  were	  fixed	  in	  4%	  PFA	  at	  room	  
temperature	  for	  20	  min	  and	  stained	  for	   immunofluorescence	  (see	  section	  2.3.10).	  
Transfection	  efficiencies	  of	  ≈20	  –	  30%	  were	  achieved.	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2.3.5 Transfection	  of	  mammalian	  cells	  using	  PEI	  
HEK293	  cells	  were	  grown	  in	  complete	  DMEM	  medium.	  An	  80%	  confluent	  T75	  flask	  
was	  split	  into	  six	  10	  cm-­‐diameter	  dishes	  containing	  10	  ml	  media,	  and	  incubated	  for	  
24	  h.	  For	  each	  dish,	  a	  DNA/PEI	  solution	  of	  10	  μg	  of	  plasmid	  DNA	  and	  40	  μl	  of	  PEI	  
(polyethylenimine)	   was	   mixed	   into	   1	   ml	   of	   serum-­‐free	   DMEM	   and	   incubated	   at	  
room	  temperature	  for	  20	  min.	  The	  cells	  were	  then	  transfected	  by	  slowly	  adding	  1	  
ml	   DNA/PEI	   solution	   in	   a	   drop-­‐wise	   manner,	   and	   incubated	   at	   37°C	   for	   24	   h.	  
Transfection	  efficiencies	  of	  ≈75	  -­‐	  90%	  were	  achieved.	  	  
	  
2.3.6 	  siRNA	  transfection	  of	  HUVECs	  using	  Oligofectamine	  	  
HUVECs	  were	  seeded	  for	  siRNA	  transfection	  in	  a	  6-­‐well	  plate	  at	  a	  density	  of	  1	  x	  105	  
cells	  per	  well,	  24	  h	  before	  transfection.	  On	  the	  day	  of	  transfection,	  growth	  medium	  
in	  each	  well	  was	  replaced	  with	  800	  µl	  of	  Opti-­‐MEM.	  Individual	  siRNAs	  (20	  µM	  stock)	  
were	  diluted	  in	  Opti-­‐MEM	  (2.5	  µl	  siRNA	  in	  182.5	  µl	  Opti-­‐MEM	  per	  condition)	  so	  as	  
to	  reach	  a	  concentration	  of	  50	  nM	  in	  the	  final	  transfection	  mix.	  Oligofectamine	  was	  
diluted	  in	  Opti-­‐MEM	  (4	  µl	  in	  15	  µl)	  and	  the	  two	  prepared	  solutions	  were	  incubated	  
at	  room	  temperature	  for	  5	  min.	  The	  two	  solutions	  were	  then	  mixed	  and	  lipid-­‐siRNA	  
complexes	  allowed	  to	  form	  for	  20	  min	  at	  room	  temperature.	  This	  mixture	  (200	  µl)	  
was	   then	   added	   drop-­‐wise	   to	   the	   cells	   in	   each	   well	   (in	   800	   µl	   of	   medium)	   and	  
incubated	  at	  37°C	  with	  5%	  CO2.	  After	  5	  to	  6	  h,	  500	  µl	  of	  EGM-­‐2	  medium	  containing	  
12%	  FBS	  was	  added	  to	  each	  well	  (for	  a	  final	  FBS	  concentration	  of	  4%).	  The	  following	  
day,	   medium	   was	   changed	   to	   EGM-­‐2	   containing	   2%	   FBS	   and	   the	   cells	   used	   for	  
subsequent	  experiments.	  Mock	  transfections	  in	  all	  experiments	  were	  performed	  by	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2.3.7 ORISTM	  cell	  migration	  assay	  
The	  ORISTM	  cell	  migration	  assay	  (Platypus	  Technologies)	   (Figure	  2.1)	   is	  a	  migration	  
assay	   in	  which	   stoppers	   are	   introduced	   into	   a	  well	   of	   a	   96-­‐well	   plate	   preventing	  
cells	   from	   seeding	  onto	  a	   central	   ‘wound’.	   Stoppers	   are	   removed	  after	   cells	   have	  
adhered	  following	  which	  migration	  is	  monitored.	  The	  percentage	  area	  of	  the	  central	  




Figure	  2.1	  Schematic	  of	  the	  ORISTM	  Migration	  assay	  	  
A	  central	  stopper	  creates	  a	  wound	  in	  the	  HUVEC	  monolayer.	  The	  migration	  capacity	  of	  the	  
cells	   is	   analysed	   when	   the	   stopper	   is	   removed	   and	   imaged	   before	   and	   after	   incubation,	  
with	  or	  without	  the	  presence	  of	  insulin.	  	  
	  
HUVECs	   were	   stained	   with	   Cell-­‐Tracker	   Orange	   fluorescent	   dye,	   seeded	   (5	   x	   104	  
cells/well,	   4	  wells	   per	   condition)	   on	   FN-­‐coated	  wells	   containing	   a	   central	   stopper	  
and	   incubated	  overnight	  at	  37°C	   in	  EGM-­‐2	  (Figure	  2.1).	  siRNA-­‐transfected	  HUVECs	  
were	  seeded	  48	  h	  after	  transfection	  and	  maintained	  in	  growth	  medium	  throughout	  
the	  experiment.	  For	  the	  insulin	  studies,	  cells	  were	  washed	  with	  PBS	  and	  starved	  in	  
EBM-­‐2	  medium	  containing	  1%	  FBS	  for	  4	  h.	  The	  stopper	  was	  then	  removed	  to	  create	  
a	   central	   ‘wound’	   in	   the	  monolayer.	   Images	   were	   acquired	   in	   the	   TRITC	   channel	  
(excitation	  548	  nm,	  emission	  576	  nm),	  using	  a	  Nikon	  TE2000-­‐E	  microscope	  with	  a	  
Plan	   Fluor	   4x	   objective	   (Nikon)	   and	   a	   Hamamatsu	   Orca-­‐ER	   digital	   camera.	   Stage	  
positions	  were	  saved	  using	  Velocity	  or	  Metamorph	  software	  and	   following	  a	  24	  h	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incubation	  at	  37°C,	  the	  stage	  file	  was	  reloaded	  and	  wells	  were	  imaged	  again	  at	  the	  
identical	  position.	  
Cell	   migration	   was	   quantified	   by	   thresholding	   images	   using	   the	   auto	   thresholder	  
applet	   in	   the	   ImageJ	   software	   and	   subtracting	   the	   percentage	   area	   of	   the	   24	   h	  
wound	  from	  the	  initial	  wound	  (Figure	  2.2).	  The	  mean	  of	  quadruplicate	  readings	  was	  
expressed	  as	  a	  ratio	  of	  control	  versus	  untreated	  wells	  in	  insulin	  studies	  or	  siControl	  
in	  knockdown	  analyses.	  
	  
	  
Figure	  2.2	  Cell	  migration	  quantification	  method	  
Images	  of	  monolayer	  wounds	  were	   thresholded	  using	   the	   auto	   thresholder	   applet	   in	   the	  
ImageJ	  software.	  Cell	  migration	  was	  quantified	  by	  subtracting	  the	  percentage	  area	  of	  cells	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2.3.8 Permeability	  assay	  
In	  order	  to	  quantify	  junctional	  strength	  and	  permeability,	  FITC-­‐dextran	  permeability	  
assays	   were	   performed	   (Figure	   2.3)	   (Monaghan-­‐Benson	   and	   Wittchen,	   2011;	  
Siflinger-­‐Birnboim	   et	   al.,	   1987).	   HUVECs	   were	   plated	   at	   confluency	   (1.2	   x	   105	  
cells/well)	  on	  FN-­‐coated	  0.4	  µm	  Transwell™	  filters	  (Thermo	  Fisher	  Scientific).	  siRNA-­‐
transfected	  HUVECs	  were	  seeded	  48	  h	  after	  transfection	  and	  maintained	  in	  EGM-­‐2	  
throughout	  the	  experiment.	  For	  insulin	  studies,	  monolayers	  were	  starved	  in	  EBM-­‐2	  
containing	  1%	  FBS	  for	  4	  h	  and	  then	  treated	  with	  various	  concentrations	  of	  insulin	  (0	  
to	  200	  nM)	  for	  30	  min.	  For	  the	  analysis	  of	  HUVEC	  junctional	  permeability	  over	  time,	  
cells	  were	  serum	  starved	  for	  2	  h	  and	  then	  treated	  with	  100	  nM	  insulin	  for	  0,	  10,	  30,	  
60,	  90	  min	  and	  4,	  8	  and	  24	  h.	  
FITC-­‐dextran	   (0.1	   mg/ml,	   molecular	   weight,	   42	   kDa)	   was	   added	   to	   the	   upper	  
chamber	  and	  incubated	  at	  37°C	  for	  60	  min.	  Therefore,	   in	   insulin	  studies	  with	  time	  
points	   longer	   than	   60	   min,	   FITC-­‐dextran	   was	   added	   in	   the	   final	   60	   min	   of	  
incubation;	  and	  for	  shorter	  time-­‐points,	  FITC-­‐dextran	  was	  added	  to	  all	  wells	  prior	  to	  
insulin	   stimulation	   to	   allow	   for	   equilibration	   before	   stimulation.	   A	   sample	   of	  
medium	  (200	  μl)	  was	  removed	  from	  the	  lower	  chamber	  to	  measure	  permeability	  to	  
FITC-­‐dextran	  and	  added	  to	  wells	  in	  a	  black	  96	  well	  plate	  with	  clear	  bottom	  (NuncTM).	  
Fluorescence	  was	  measured	   using	   a	  microplate	   analyser	   (Fusion-­‐FA;	   PerkinElmer;	  
excitation,	  492	  nm;	  detection,	  520	  nm).	  	  
	  
Figure	  2.3	  Schematic	  of	  the	  Transwell®	  permeability	  assay	  with	  FITC-­‐dextran	  
HUVEC	  barrier	  function	  was	  analysed	  by	  permeability	  to	  FITC-­‐dextran	  in	  a	  transwell	  assay.	  
Fluorescence	  of	  the	  medium	  in	  lower	  chamber	  was	  used	  as	  a	  measure	  of	  permeability.	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2.3.9 Loop-­‐formation	  angiogenesis	  assay	  
When	   ECs	   are	   seeded	   onto	   the	   surface	   of	   a	   three-­‐dimensional	   gel	   of	   Matrigel	  
matrix	   they	  undergo	  morphogenic	   changes	  and	   form	   tube-­‐like	   structures.	  The	  gel	  
layer	  was	  prepared	  by	  thawing	  growth	  factor	  reduced	  Matrigel	  overnight	  at	  4°C	  and	  
diluted	  to	  a	  concentration	  of	  4.5	  mg/ml	  with	  cold	  PBS	  (+Ca2+,	  +Mg2+).	  This	  mixture	  
(300	  µl)	  was	  spread	  out	  onto	  each	  well	  of	  a	  6-­‐well	  dish	  and	  allowed	  to	  polymerise	  at	  
room	   temperature	   for	   1.5	   h.	   For	   the	   insulin	   studies,	   HUVECs	   were	   incubated	   in	  
EBM2	   containing	   1%	   FBS	   for	   2	   h,	   harvested	   with	   trypsin	   and	   seeded	   onto	   the	  
Matrigel	  layer	  at	  a	  density	  of	  2	  x	  105	  cells	  per	  well	  in	  low	  serum	  medium.	  The	  cells	  
were	   then	   treated	   with	   various	   concentrations	   of	   insulin.	   For	   the	   protein	  
knockdown	   studies,	   HUVECs	   were	   transfected	   with	   siRNAs	   and	   seeded	   onto	   the	  
Matrigel	   after	   48	   h,	   at	   a	   density	   of	   2	   x	   105	   cells	   per	   well	   in	   EGM-­‐2.	   Loops	  were	  
allowed	  to	   form	  for	  24	  h	  and	  monitored	  by	  phase-­‐contrast	   time-­‐lapse	  microscopy	  
using	   a	   Nikon	   TE2000-­‐E	   microscope	   with	   a	   Plan	   Fluor	   4X	   objective	   and	   a	  
Hamamatsu	   Orca-­‐ER	   digital	   camera,	   at	   37°C	   and	   5%	   CO2.	   Images	   were	   captured	  
using	  Metamorph	  software.	  A	  frame	  rate	  of	  1	  frame/20	  min	  was	  used	  for	  24	  h	  and	  
movies	   were	   initiated	   1	   h	   after	   seeding	   cells	   onto	  Matrigel.	   Loop	   formation	   was	  
quantified	  by	  counting	  the	  number	  of	  loops	  formed	  per	  field	  of	  the	  final	  frame	  (24	  
h,	  Figure	  2.4).	  The	  mean	  value	  for	  at	   least	  5	   fields	  of	  each	  condition	  was	  used	  for	  
statistical	  analysis.	  
	  
Figure	  2.4	  Quantification	  of	  the	  number	  of	  loops	  formed	  in	  the	  angiogenesis	  assay	  
The	  final	  image	  from	  time-­‐lapse	  movies	  of	  angiogenic	  loops	  formed	  by	  HUVECs	  after	  24	  h	  is	  
shown	  on	  the	  left;	   loops	  were	  quantified	  by	  counting	  the	  total	  number	  of	  complete	  loops	  
as	  shown	  in	  pink	  on	  the	  right.	  Scale	  bar	  is	  200	  µm.	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2.3.10 Immunofluorescence	  
Sterile	   glass	   coverslips	   (13	   mm	   in	   diameter)	   were	   placed	   in	   a	   24-­‐well	   plate	   and	  
coated	   with	   10	   µg/ml	   FN	   overnight	   at	   37°C.	   For	   insulin	   studies,	   1.5	   x	   105	  
HUVECs/well	   were	   seeded	   onto	   the	   coverslips	   and	   incubated	   overnight	   at	   37°C.	  
Cells	   were	   starved	   for	   4	   h	   in	   EBM-­‐2	   containing	   1%	   FBS	   and	   then	   treated	   with	  
various	  concentrations	  of	  insulin	  (0	  –	  200	  nM)	  for	  1	  h	  or	  100	  nM	  insulin	  for	  1,	  4,	  16	  
and	  24	  h.	  	  
In	  over-­‐expression	  studies,	  1	  x	  106	  HUVECs	  were	  transfected	  with	  4	  µg	  DNA	  coding	  
for	   GFP-­‐fusion	   proteins	   of	   interest	   (RICH-­‐1,	   Parg1,	   Epsin2	   and	   LMO7)	   by	  
nucleofection	  (see	  section	  2.3.4).	  These	  cells	  were	  then	  seeded	  onto	  two	  coverslips	  
and	   incubated	   for	   24	   h	   at	   37°C.	   Cells	   transfected	   with	   siRNA	   targeting	   RICH-­‐1,	  
Parg1,	  Epsin2	  and	  LMO7	  were	   seeded	  onto	  coverslips	  48	  h	  after	   transfection	  and	  
incubated	  for	  24	  h	  at	  37°C.	  
Cells	  were	  fixed	  in	  4%	  paraformaldehyde	  (PFA)	  at	  RT,	  washed	  twice	  with	  PBS	  (+Ca2+,	  
+Mg2+),	  and	  stored	  overnight	  at	  4°C	  in	  PBS	  (+Ca2+,	  +Mg2+).	  Cells	  were	  permeabilised	  
with	  0.2%	  Triton-­‐X	  100	   (v/v)	   in	  PBS,	  at	  4°C	   for	  5	  min	  and	  blocked	  with	  3%	  bovine	  
serum	   albumin	   (BSA)	   in	   PBS	   at	   RT	   for	   30	  min,	   to	   reduce	   non-­‐specific	   binding	   of	  
antibodies.	  Coverslips	  were	  stained	  with	  primary	  antibodies	  diluted	  in	  3%	  BSA/PBS	  
for	   2	   h	   at	   RT	   or	   overnight	   at	   4°C.	   Coverslips	  were	  washed	   3	   times	  with	   PBS	   and	  
incubated	  with	  fluorophore-­‐conjugated	  secondary	  antibodies	  and	  phalloidin	  (1:400,	  
to	   label	  F-­‐actin)	   for	  60	  min	  at	  RT.	  Cells	  were	   then	  washed	  once	   in	  PBS	  containing	  
DAPI	   (1:10	  000)	   (for	  DNA	   staining),	   followed	  by	  3	  washes	  with	  PBS	  and	  2	  washes	  
with	  H2O.	  Coverslips	  were	  mounted	  onto	  glass	  slides	  using	  an	  anti-­‐fade	  fluorescent	  
mounting	   medium.	   Slides	   were	   stored	   in	   the	   dark	   at	   RT	   overnight	   for	   mounting	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2.3.11 Confocal	  microscopy	  
A	   Zeiss	   LSM510	   confocal	   laser-­‐scanning	   microscope	   with	   an	   EC	   Plan-­‐Neofluar	  
40x/1.30	  Oil	  DIC	  M27	  or	   a	  Plan-­‐Apochromat	  63x/1.40	  Oil	  DIC	  M27	  objective,	   and	  
ZEN	  software	  was	  used	  to	  take	   images	  of	   fluorescently	  stained	  cells.	   Images	  were	  
taken	   at	   a	   resolution	   of	   512	   x	   512	   pixels	   using	   an	   average	   of	   2	   or	   4	   frames.	  
Maximum	   intensity	   projections	   of	  HUVEC	  monolayers	  were	   generated	   from	  10	   z-­‐
stacks,	  spanning	  4	  μm	  with	  0.4	  μm	  intervals	  between	  each	  image.	  
The	   range	   finder	   function	   in	   the	   ZEN	   software	   was	   used	   to	   adjust	   the	   gain	   and	  
offset	   to	   avoid	   saturation	   and	   high	   background	   in	   images.	   Images	   in	   each	  
experiment	  were	   acquired	   using	   the	   same	   gain	   and	   offset	   settings	   if	   comparison	  
between	  images	  was	  required.	  Lasers	  and	  filters	  used	  are	  shown	  in	  Table	  2.8.	  
	  
Table	  2.8	  Lasers	  and	  filters	  used	  for	  confocal	  microscopy	  
	  
Fluorophore	   Laser	   Excitation	  (nm)	   Emission	  (nm)	   Filter	  (nm)	  
Alexa	  488	   Argon	   488/494	   520/517	   Bandpass	  
505-­‐530	  
Alexa	  546	   Helium/Neon	   556	   573	   Bandpass	  
560-­‐615	  
Alexa	  647	   Helium/Neon	   650	   668	   Longpass	  
650	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2.4 Methods:	  Biochemistry	  	  
2.4.1 Preparation	  of	  cell	  lysates	  	  
Cells	  in	  6-­‐well	  plates	  or	  10-­‐cm	  dishes	  were	  placed	  on	  ice	  and	  washed	  with	  ice-­‐cold	  
PBS	  (+Ca2+,	  +Mg2+).	  Cells	  were	  lysed	  in	  120	  µl	  lysis	  buffer	  per	  well	  for	  6-­‐well	  plates,	  
or	  350	  µl	  lysis	  buffer	  for	  each	  10-­‐cm	  dish.	  Cells	  were	  scraped	  into	  microfuge	  tubes,	  
and	  incubated	  on	  ice	  for	  10	  min.	  Samples	  were	  cleared	  by	  centrifugation	  at	  13	  000	  
g	  at	  4°C	  for	  20	  min,	  and	  the	  supernatant	  transferred	  to	  new	  tubes.	  	  
An	  appropriate	  volume	  of	  4x	  sample	  buffer	  was	  added	  to	  the	  lysates	  to	  be	  analysed	  
by	  Western	  blotting,	  samples	  were	  boiled	  at	  72°C	  for	  10	  min	  and	  stored	  at	  -­‐20°C.	  
For	   14-­‐3-­‐3	   overlay	   samples,	   a	   bicinchoninic	   acid	   (BCA)	   protein	   determination	  
(Thermo	   Scientific)	   was	   performed	   according	   to	   the	   manufacturer’s	   instructions,	  
and	   equal	   quantities	   of	   protein	   were	   added	   to	   pre-­‐clearing	   beads	   	   (see	   section	  
2.5.5).	  
	  
2.4.2 SDS-­‐PAGE	  and	  Western	  blotting	  
Prepared	   cell	   lysates	   were	   loaded	   into	   NuPAGE	   4-­‐12%	   Bis-­‐Tris	   gels	   and	   resolved	  
using	  an	  initial	  voltage	  of	  75	  V	  for	  30	  min,	  followed	  by	  a	  voltage	  of	  150	  V	  for	  60	  min	  
in	  either	  NuPAGE	  MES	  buffer	   (for	   low	  molecular	  weight	  proteins	  10	  to	  50	  kDa)	  or	  
MOPS	   buffer	   (for	   high	   molecular	   weight	   proteins	   50	   to	   250	   kDa).	   After	   gel	  
electrophoresis,	   proteins	   were	   transferred	   onto	   a	   nitrocellulose	  membrane	   (0.45	  
µm)	  (Millipore)	  by	  Western	  blotting.	  The	  gel	  and	  membrane	  were	  equilibrated	  in	  1X	  
transfer	   buffer	   and	   sandwiched	   between	   2	   layers	   of	  Whatman	   paper,	   2	   sponges	  
and	   inserted	   into	   a	   transfer	   cassette.	   The	   cassette	   was	   placed	   in	   a	  Mini-­‐Protean	  
transfer	  system	  (Bio-­‐Rad)	  filled	  with	  1X	  transfer	  buffer.	  Electrophoretic	  transfer	  of	  
proteins	  onto	  the	  membrane	  was	  achieved	  at	  a	  constant	  voltage	  of	  100	  V	  for	  1	  h,	  
for	   smaller	   proteins,	   or	   90	  min	   for	   high	  molecular	   weight	   proteins,	   at	   4°C.	   After	  
electrophoresis,	   membranes	   were	   blocked	   in	   blocking	   buffer	   (5%	   skimmed	   milk	  
powder	  in	  TBST	  or	  5%	  BSA	  in	  TBST)	  for	  1	  h	  at	  room	  temperature.	  Membranes	  were	  
then	  incubated	  with	  primary	  antibodies	  (in	  BSA	  blocking	  buffer	  at	  the	  appropriate	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dilution,	   see	   Table	   2.3)	   overnight	   at	   4°C.	  Membranes	  were	  washed	   3	   times	  with	  
TBST	  for	  10	  min	  each	  and	  incubated	  with	  the	  secondary	  antibody	  (in	  BSA	  blocking	  
buffer)	  at	  room	  temperature	  for	  1	  h.	  Unbound	  antibody	  was	  removed	  by	  washing	  3	  
times	   with	   TBST	   and	   the	   HRP	   signal	   determined	   using	   an	   enhanced	  
chemiluminescence	   (ECL)	   detection	   kit	   (GE	   Healthcare)	   according	   to	   the	  
manufacturer’s	   instructions	   and	   X-­‐ray	   film	   (Fujifilm).	   Bands	   on	   X-­‐ray	   films	   of	  
immunoblots	  were	  quantified	  by	  densitometric	  analysis	  of	  the	  scanned	  films	  using	  
ImageJ	  software.	  
	  
2.4.3 Stripping	  of	  Western	  blots	  	  
To	   allow	   reprobing,	   nitrocellulose	   membranes	   were	   stripped	   by	   incubating	   in	  
stripping	  buffer	  (70	  mM	  Tris,	  20	  mM	  NaCl,	  pH	  2.3),	  twice	  for	  20	  min	  each	  at	  65°C.	  
Membranes	   were	   subsequently	   washed	   3	   times	   with	   TBST	   and	   re-­‐blocked	   in	   5%	  
skimmed	  milk	   powder	   in	   TBST	   or	   5%	   BSA	   in	   TBST	   for	   1	   h	   at	   room	   temperature.	  
Membranes	   were	   then	   reprobed	   with	   primary	   and	   secondary	   antibodies	   and	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2.5 Methods:	  14-­‐3-­‐3	  chromatography	  and	  14-­‐3-­‐3	  overlays	  	  
2.5.1 Expression	  and	  purification	  of	  the	  S.	  cerevisiae	  14-­‐3-­‐3	  isoforms	  BMH1	  and	  
BMH2	  	  
 
The	   6-­‐His	   tagged	   BMH1	   and	   BMH2	   14-­‐3-­‐3	   isoforms	   from	  Saccharomyces	  
cerevisiae	  were	   produced	   by	   staff	   at	   the	   Division	   of	   Signal	   Transduction	   Therapy	  
(DSTT)	  of	  the	  University	  of	  Dundee.	  The	  methods	  have	  been	  previously	  described	  in	  
(Moorhead	  et	  al.,	  1996).	  Briefly,	  plasmids	  expressing	  N-­‐terminal	  6-­‐His	  tagged	  BMH1	  
and	  BMH2	  were	  generated	   from	  the	  trc	  promoter	   in	  plasmid	  pTrcHisA	  as	   follows:	  
polymerase	  chain	  reaction	  (PCR)	  mixes	  (0.1	  ml)	  contained	  10	  mM	  Tris	  (pH	  8.5),	  50	  
mM	   KCl,	   2	   mM	   MgCl2,	   0.1	   mg/ml	  gelatin,	   0.2	   mM	   each	   dNTP,	   100	   pmol	   each	  
primer,	   100	   ng	   DNA	   and	   1.25	   units	   Taq	   polymerase	   which	   was	   added	   when	   the	  
reaction	   mix	   was	   at	   94°C.	   Conditions	   for	   each	   cycle	   were	   94°C	   for	   1	   min	   to	  
denature	  the	  DNA;	  55°C	  for	  1	  min	  to	  anneal	  the	  primers;	  and	  72°C	  for	  1	  min	  of	  DNA	  
chain	   extension.	   The	   primers	   (synthesized	   by	   the	  NIMR	   sequencing	   service)	  were	  
for	   BMH1,	   5ʹ′CGCGGATCCATGGTCAACCAGTCGTGAAGATTC	   (which	   carries	   a	  BamH1	  
site)	   and	   5ʹ′CCCAAGCTTTTACTTTGGTGCTTCACCTTCGGCGGCAGC	   (which	   carries	  
a	  HindIII	   site);	   and	   for	   BMH2	   5'CGCGGATCCATGTCCCAAACTCGTGAAGATTC	   and	  
5'CCCAAGCTTTTATTTGGTTGGTTCACCTTGAG.	   Products	   were	   electrophoresed	   on	   a	  
1%	  (w/w)	  TAE	  agarose	  gel	  and	  DNA	  fragments	  were	  purified	  using	  a	  Gene-­‐clean	  kit	  
from	  Bio101.	  After	  ligation	  into	  the	  plasmid,	  the	  PCR	  products	  were	  sequenced	  by	  
the	  dideoxy	  chain	  termination	  method	  using	  the	  Sequenase	  kit	  (USB).	  	  
LB	   containing	   50	  μg	   ampicillin/ml	   was	   inoculated	   with	   E.	   coli	   DH5α	   cells	  
overexpressing	   6-­‐His	   tagged	   BMH1	   or	   BMH2,	   and	   grown	   at	   37°C	   until	   the	  
absorbance	  at	  600	  nm	   reached	  0.6.	   Expression	  was	   induced	   for	  3	  h	  with	  0.5	  mM	  
isopropyl-­‐thio-­‐β-­‐D-­‐galactopyranoside	   and	   cells	   were	   harvested	   by	   centrifugation.	  
The	   bacterial	   pellet	   was	   resuspended	   in	   buffer	   B	   (1.5	   mM	   Na2HPO4,	   5	   mM	  
KH2PO4	  (pH	  7.2),	  137	  mM	  NaCl,	  5	  mM	  KCl,	  1	  mM	  dithiothreitol	  (DTT),	  1	  mM	  EDTA,	  
5%	  glycerol	   and	  1	  mM	  PMSF)	   and	   sonicated	   at	   12	  microns	   for	   7	   cycles	   of	   30	   sec	  
sonication	   and	   30	   sec	   cooling.	   The	   sonicate	   was	   clarified	   by	   centrifugation,	   and	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applied	   to	   a	   Ni2+-­‐nitrilotriacetic	   acid–agarose	   column	   equilibrated	   and	  washed	   in	  
buffer	   B.	   Fusion	   proteins	   (6-­‐His	   BMH1	   and	   6-­‐His	   BMH2)	   were	   eluted	   in	   buffer	   B	  
containing	   100	  mM	   imidazole,	   concentrated	   in	   a	   Centricon-­‐10	   (Amicon),	   dialysed	  
into	  storage	  buffer	   (25	  mM	  Tris-­‐HCl	   (pH	  8),	  90	  mM	  NaCl,	  1	  mM	  EDTA,	  1	  mM	  DTT	  
and	  50%	  (v/v)	  glycerol)	  and	  stored	  at	  -­‐20°C.	  
	  
2.5.2 Coupling	  BMH1	  and	  BMH2	  to	  activated	  CH-­‐Sepharose	  4B	  
The	   recombinant	   14-­‐3-­‐3	   proteins	   were	   coupled	   to	   NHS-­‐activated	   Sepharose	   (CH	  
Sepharose	  4B),	  which	  forms	  covalent	  bonds	  with	  lysine	  residues	  and	  other	  primary	  
amine	  groups.	  Dry	  matrix	  (5	  g)	  was	  poured	  onto	  the	  glass	  sinter	  of	  a	  filtering	  system	  
and	  swelled	  to	  15	  ml	  in	  500	  ml	  of	  cold	  1	  mM	  HCl	  for	  30	  min	  with	  occasional	  stirring.	  
The	   solution	   was	   removed	   under	   vacuum,	   insuring	   that	   the	   Sepharose	   always	  
remained	  moist.	  The	  matrix	  was	  washed	  twice	  with	  200	  ml	  coupling	  buffer	  (0.1	  M	  
NaHCO3,	   0.5	  M	  NaCl	   pH	   8.0).	   Purified	   BMH1	   and	   BMH2	   (15	  mg	   each,	   for	   a	   final	  
concentration	  of	  2	  mg/ml)	  were	  added	  to	  the	  matrix,	  the	  volume	  was	  made	  up	  to	  
40	   ml	   with	   coupling	   buffer	   and	   left	   to	   crosslink	   for	   4	   h	   at	   4°C.	   The	   matrix	   was	  
centrifuged	   at	   400	   g	   at	   4°C	   for	   5	  min	   and	   the	   supernatant	  was	   removed.	   A	   5	   μl	  
sample	   of	   the	   supernatant	   was	   used	   for	   a	   Bradford	   assay	   (A595)	   to	   assess	   the	  
efficiency	  of	  protein	  coupling	   to	   the	  matrix.	  Any	   remaining	   reactive	  groups	  of	   the	  
matrix	  were	  blocked	  in	  40	  ml	  0.1	  M	  Tris-­‐HCl	  pH	  8.0	  at	  4°C	  for	  1	  h,	  mixing	  end-­‐over-­‐
end.	   The	   matrix	   was	   washed	   by	   pouring	   onto	   a	   glass	   sinter	   under	   vacuum	   and	  
washed	  alternately	  with	  50	  ml	  high	  pH	  buffer	  (50	  mM	  Tris-­‐HCl,	  0.5	  M	  NaCl,	  pH	  8.0)	  
followed	  by	  50	  ml	  low	  pH	  buffer	  (50	  mM	  sodium	  acetate,	  0.5	  M	  NaCl,	  pH	  4.0)	  for	  a	  
total	  of	  5	  washes	  for	  each	  buffer.	  The	  14-­‐3-­‐3-­‐Sepharose	  was	  stored	  in	  50	  mM	  Tris-­‐
HCl,	  pH	  7.5	  and	  0.05%	  sodium	  azide	  at	  4°C	  until	  use.	  Before	  using,	  14-­‐3-­‐3	  Sepharose	  
was	  washed	  twice	  with	  20	  ml	  Buffer	  A	  (25	  mM	  Tris-­‐HCl	  pH	  7.5	  (4°C),	  100	  mM	  NaCl,	  
25	  mM	  NaF).	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2.5.3 14-­‐3-­‐3-­‐affinity	  chromatography	  of	  human	  cell	  extracts	  
Confluent	  HBMECs	  were	  incubated	  in	  low	  serum	  conditions	  (DMEM	  containing	  1%	  
FBS,	  2	  mM	  glutamine,	  10	  000	  U/ml	  penicillin,	  10	  000	  µg/ml	  streptomycin)	  for	  16	  h.	  
Fifty	  15-­‐cm	  dishes	  were	  stimulated	  with	  100	  nM	  insulin	  for	  10	  min	  and	  fifty	  15-­‐cm	  
dishes	  were	   left	   untreated	   as	   control	   cells.	   Cells	  were	  washed	  with	   cold	   PBS	   and	  
lysed	  in	  500	  μl	  lysis	  buffer	  per	  dish,	  on	  ice	  and	  centrifuged	  at	  15000	  g	  for	  30	  min	  at	  
4°C.	   Samples	   of	   the	   supernatants	   were	   collected	   for	   biochemical	   and	   protein	  
analysis.	  The	  remaining	  clarified	  supernatants	  (control	  and	  insulin-­‐stimulated)	  were	  
mixed	   end-­‐over-­‐end	   with	   5	   ml	   14-­‐3-­‐3-­‐Sepharose	   each,	   overnight	   at	   4°C.	   The	  
mixture	  was	  poured	  into	  two	  Econo-­‐columns,	  the	  flow	  throughs	  collected,	  and	  the	  
columns	  washed	  with	  500	  ml	  Buffer	  B	   (25	  mM	  Tris-­‐HCl	  pH	  7.5,	  500	  mM	  NaCl,	  25	  
mM	   NaF).	   Proteins	   that	   bound	   to	   the	   phosphopeptide	   binding	   site	   of	   14-­‐3-­‐3	  
proteins	   were	   eluted	   by	   the	   competitive	   phosphopeptide	   ARAApSAPA.	   The	  
protein/Sepharose	  mixture	  was	  incubated	  with	  12	  ml	  of	  2	  mM	  ARAApSAPA	  peptide	  
in	  Buffer	  A	  for	  2	  h	  at	  4°C.	  A	  second	  elution	  was	  performed	  with	  a	  further	  12	  ml	  of	  2	  
mM	  phosphopeptide	  for	  1	  h	  at	  4°C.	  The	  eluates	  were	  combined	  with	  a	  final	  wash	  of	  
12	  ml	  Buffer	  A	  and	  concentrated	  to	  40	  μl	  and	  desalted	  in	  Vivaspin	  concentrators	  (10	  
000	   MWcut-­‐off).	   Samples	   were	   then	   alkylated	   and	   separated	   by	   SDS-­‐PAGE	  
electrophoresis	  (see	  section	  2.6.1).	  This	  protocol	  is	  summarised	  in	  Figure	  2.5.	  
	  
Figure	  2.5	  14-­‐3-­‐3-­‐affinity	  capture	  and	  identification	  of	  proteins	  whose	  
phosphorylation	  and	  binding	  to	  14-­‐3-­‐3s	  is	  stimulated	  by	  insulin	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2.5.4 Preparation	  of	  DIG-­‐labelled	  14-­‐3-­‐3	  probe	  for	  14-­‐3-­‐3	  overlays	  
The	   DIG-­‐labelled	   14-­‐3-­‐3	   probe	   was	   prepared	   by	   Dr	   Catherine	   Johnson	   in	   the	  
MacKintosh	  laboratory	  (University	  of	  Dundee).	  14-­‐3-­‐3	  protein	  (usually	  50	  μg	  each	  of	  
the	   6-­‐His-­‐tagged	   BMH1	   and	   BMH2	   isoforms)	   was	   incubated	   for	   2	   h	   at	   room	  
temperature	   with	   8	   μg	   digoxygenin-­‐Omethylcarbonyl-­‐ε-­‐aminocaproic	   acid-­‐N-­‐
hydroxysuccinimide	   (DIG-­‐NHS)	   ester,	   added	   from	   a	   2	   mg/ml	   stock	   solution	   in	  
DMSO,	  and	  400	  μl	  PBS,	  pH	  8.5,	  with	  occasional	  mixing.	   The	  mixture	  was	  dialysed	  
extensively	   in	  PBS	  pH	  7.2	  at	  4°C	   to	   remove	  unreacted	  DIG	  ester,	  and	  diluted	   to	  a	  
final	  protein	  concentration	  of	  1	  μg/ml	   in	  25	  mM	  Tris-­‐HCl	  pH	  7.5,	  500	  mM	  NaCl,	  2	  
mg/ml	  BSA.	  The	   resulting	  DIG-­‐14-­‐3-­‐3	  probe	  was	  stored	  at	  4°C	  with	  0.05%	  sodium	  
azide.	  	  
2.5.5 GFP-­‐Trap	  pull-­‐downs	  
GFP-­‐fusion	  proteins	  of	  the	  candidate	  insulin-­‐regulated	  protein	  hits	  identified	  in	  the	  
14-­‐3-­‐3-­‐affinity	   purification	   were	   overexpressed	   in	   HEK293	   cells	   (as	   described	   in	  
section	   2.3.5).	   These	   proteins	   were	   enriched	   by	   GFP-­‐Trap	   pull	   downs	   for	   14-­‐3-­‐3	  
overlay	   analysis	   (described	   in	   the	   section	   2.5.6).	   GFP-­‐Trap	   (DSTT,	   University	   of	  
Dundee)	   is	   a	   GFP-­‐binding	   protein	   coupled	   to	   Sepharose	   beads	   for	   biochemical	  
analysis	   of	   GFP	   fusion	   proteins	   and	   their	   interacting	   partners	   (Rothbauer	   et	   al.,	  
2008).	  All	  procedures	  were	  carried	  out	  at	  4°C.	  Cell	   lysates	  with	  equal	  quantities	  of	  
total	   protein	   (between	   1	   and	   3	   mg)	   were	   pre-­‐cleared	   to	   remove	   proteins	   that	  
bound	   specifically	   or	   non-­‐specifically	   to	   Protein	   G	   Sepharose.	   Cell	   lysates	   were	  
incubated	  with	  20	  μl	  of	  washed	  Protein	  G-­‐Sepharose	  beads	  on	  a	  rotating	  wheel	  for	  
30	  min,	  followed	  by	  centrifugation	  at	  5500	  g	  at	  2	  min.	  The	  pre-­‐cleared	  lysates	  were	  
added	  to	  GFP-­‐Trap	  coupled	  to	  Sepharose	  beads	  (produced	  by	  DSTT)	  and	  incubated	  
on	   a	   rotating	   wheel	   for	   2	   h.	   Following	   centrifugation	   at	   5500	   g	   for	   2	   min,	   the	  
supernatant	  was	   removed	   and	   the	   beads	  washed	   twice	  with	   high	   salt	   buffer	   (50	  
mM	  Tris-­‐HCl	  pH	  7.5,	  250	  mM	  NaCl)	  and	  a	  further	  two	  times	  with	  no	  salt	  buffer	  (50	  
mM	  Tris-­‐HCl	  pH	  7.5).	  Sample	  buffer	  containing	  500	  mM	  DTT	  was	  then	  added	  to	  the	  
beads,	  and	  the	  proteins	  were	  dissociated	  and	  denatured	  by	  boiling	  the	  samples	  at	  
72°C	  for	  10	  min.	  Samples	  were	  stored	  at	  -­‐20°C.	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2.5.6 DIG-­‐14-­‐3-­‐3	  overlays	  	  
Proteins	  enriched	  by	  GFP-­‐Trap	  pull	  downs	  were	  separated	  by	  SDS-­‐PAGE,	  transferred	  
to	   nitrocellulose,	   and	   the	   membrane	   was	   blocked	   with	   5%	   (w/v)	   non-­‐fat	   milk	  
powder	   as	   previously	   described	   for	   Western	   blotting	   (see	   section	   2.4.2).	   The	  
membrane	  was	  washed	   in	   TBST,	   and	   incubated	  with	   1	   ng/ml	  DIG-­‐labelled	   14-­‐3-­‐3	  
protein	   in	   5%	   BSA	   blocking	   buffer,	   overnight	   at	   4°C.	   The	  membrane	  was	  washed	  
three	   times	   for	   10	   min	   in	   TBST,	   and	   incubated	   with	   HRP-­‐conjugated	   anti-­‐DIG	  
antibody	   diluted	   1:5000	   in	   TBST	   containing	   5%	   BSA	   for	   1	   h.	   Following	   another	  
washing	  step	  to	  remove	  any	  unbound	  probe,	  the	  overlay	  was	  developed	  with	  ECL	  
reagent	  as	  described	  in	  the	  manufacturer’s	  instructions	  and	  X-­‐ray	  film.	  
	  
2.6 Methods:	  Protein	  chemistry	  	  
2.6.1 Proteolytic	  digestion	  of	  proteins	  ‘in	  gel’	  
Concentrated	   proteins	   eluted	   from	   the	   14-­‐3-­‐3-­‐affinity	   column	  were	   prepared	   for	  
SDS-­‐PAGE	   by	   adding	   4X	   LDS	   sample	   buffer	   containing	   DTT	   (10	   mM	   final	  
concentration),	   and	   boiled	   at	   72°C	   for	   10	  min.	   After	   cooling,	   iodoacetamide	  was	  
added	   to	   a	   concentration	   of	   50	   mM,	   and	   the	   samples	   incubated	   at	   room	  
temperature	   for	   30	   min	   on	   a	   shaking	   platform	   in	   the	   dark	   to	   alkylate	   cysteine	  
residues.	   Samples	   were	   then	   subjected	   to	   electrophoresis	   with	   a	   NuPAGE	   4-­‐12%	  
Bis-­‐Tris	  gel	  and	  resolved	  at	  a	  constant	  voltage	  of	  150	  V	  for	  90	  min	  in	  NuPAGE	  MES	  
buffer.	   The	   gels	   were	   stained	   overnight	   with	   Colloidal	   Coomassie	   blue	   using	   the	  
Novex®	   Colloidal	   Coomassie	   Blue	   Staining	   Kit	   (Invitrogen).	   Stained	   protein	   bands	  
were	   excised,	   and	   the	   proteins	   digested	   ‘in	   gel’	  with	   trypsin.	   The	   proteins	   in	   the	  
elution	   lanes	   were	   excised	   with	   a	   razor	   blade;	   cut	   into	   6	   small	   pieces	   each	   and	  
placed	   in	   microfuge	   tubes.	   The	   gel	   pieces	   were	   destained	   for	   15	   min	   at	   room	  
temperature	  on	  a	  vibrating	  platform	  in	  a	  solution	  of	  200	  μl	  methanol	  (MeOH)	  and	  
100	   mM	   ammonium	   bicarbonate	   (AmBic),	   50%	   (v/v).	   Gel	   pieces	   were	   then	  
alternately	  incubated	  three	  times	  in	  100%	  MeOH	  for	  15	  min,	  followed	  by	  100	  mM	  
triethylammonium	   bicarbonate	   (TEAB).	   A	   final	   wash	   in	  MeOH	   was	   performed	   to	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completely	  dehydrate	  the	  gel,	  the	  MeOH	  was	  removed	  and	  samples	  were	  left	  to	  air	  
dry.	  Trypsin	  was	  diluted	  to	  a	  final	  concentration	  of	  5	  ng/μl	  in	  TEAB,	  pH	  7.8,	  and	  30	  
μl	  was	  added	  to	  each	  gel	  piece	  (150	  ng	  trypsin	  each).	  Samples	  were	  placed	  on	  ice	  
for	  10	  min,	  followed	  by	  the	  addition	  of	  30	  μl	  TEAB	  to	  cover	  gel	  pieces	  and	  incubated	  
overnight	   on	   a	   vibrating	   platform	   at	   30°C.	   After	   16	   h,	   the	   supernatant	   was	  
transferred	  to	  new	  tubes,	  60	  μl	  MeOH/TEAB/formic	  acid	  (50%,	  45%,	  5%,	  v/v/v)	  was	  
added	   to	   the	   gel	   pieces	   and	   incubated	   for	   15	   min	   at	   room	   temperature.	   The	  
supernatant	  was	   then	   added	   to	   the	   previous	   extraction,	   evaporated	   to	   complete	  
dryness	  and	  stored	  at	  -­‐20°C.	  
	  
2.6.2 Protein	  mass	  fingerprinting	  analysis	  for	  protein	  identification	  	  
All	   the	   mass	   spectrometry	   (MS)	   analyses	   were	   performed	   by	   staff	   at	   the	   MRC	  
Protein	  Phosphorylation	  Unit	  (College	  of	  Life	  Sciences,	  University	  of	  Dundee).	  Mass	  
fingerprinting	   for	  protein	   identification	  was	  performed	  on	   the	   tryptic	   peptides	  by	  
LC-­‐MS-­‐MS	   (liquid	   chromatography	   mass	   spectrometry	   mass	   spectrometry)	   on	   a	  
Thermo	   LTQ-­‐Orbitrap	   system	   (Thermo	   Fisher	   Scientific,	   Schwerte,	   Germany)	  
coupled	  to	  a	  Proxeon	  Easy-­‐LC	  HPLC	  system.	  The	  peptide	  mixtures	  were	  loaded	  onto	  
a	   nanoseparations	   C18	   guard	   column	   (0.1	   x	   20	   mm)	   equilibrated	   in	   0.1%	   formic	  
acid/water	   at	   5	   ml/min	   and	   then	   separated	   on	   a	   0.075	   x	   150	   mm	   PepMap	   C18	  
column,	   equilibrated	   in	   0.1%	   formic	   acid/water	   (LC	   Packings,	   Amsterdam,	  
Netherlands).	   RAW	   files	   from	   Excalibur	   (Thermo)	   were	   processed	   by	   Raw2msm	  
(Olsen	   et	   al.,	   2005)	   to	   generate	   peak	   lists	   that	   were	   analysed	   using	   the	   Mascot	  
search	   engine	   (www.matrixscience.com)	   against	   the	   UniProt	   database	   (release	  
2012	   03	   (consisting	   of	   535	   248	   sequences	   and	   189	   901	   164	   residues)).	   For	   each	  
protein	  match,	  Mascot	  calculates	  an	  overall	  Protein	  Score.	  This	  number	  reflects	  the	  
combined	  scores	  of	  all	  observed	  mass	  spectra	  that	  can	  be	  matched	  to	  amino	  acid	  
sequences	  within	   that	   protein.	   A	   higher	   score	   indicates	   a	  more	   confident	  match.	  
The	  significance	  threshold	  was	  p	  <	  0.05;	  only	  peptides	  with	  ion	  scores	  over	  20	  were	  
considered	  and	  only	  proteins	  with	  at	  least	  one	  unique	  peptide	  (red	  bold	  in	  Mascot)	  
were	  considered.	  
Chapter	  2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Materials	  and	  Methods	  
	  
	   	   89	  
2.7 Statistical	  analysis	  
Statistical	  analysis	  was	  carried	  out	  where	  indicated	  using	  data	  from	  three	  or	  more	  
independent	   experiments.	   Statistical	   significance	   was	   calculated	   with	   SigmaPlot	  
Version	  12.0	   (http://www.sigmaplot.com)	  using	   statistical	   tests	   chosen	  as	  a	   result	  
of	   data	   meeting	   specific	   criteria	   using	   Normality	   (Shaprio-­‐Wilk)	   and	   Equal	   of	  
Variance	   tests.	   	   Statistical	   significance	   was	   determined	   by	   using	   an	   unpaired	  
Student’s	   t-­‐test,	   or	   where	   specified	   using	   the	   Mann-­‐Whitney	  U	   test	   or	   one-­‐way	  
ANOVA	  (analysis	  of	  variance)	  (Holm-­‐Sidak	  method).	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3 Effects	  of	  insulin	  on	  endothelial	  cells	  
3.1 Introduction	  
Endothelial	  cells	  (ECs)	  are	  the	  first	  cells	  to	  come	  into	  contact	  with	  chemical	  stimuli,	  
such	   as	   cytokines	   and	   hormones	   that	   pass	   through	   the	   systemic	   circulation.	   The	  
endothelium	   rapidly	   responds	   to	   these	   stimuli,	   activating	   many	   physiological	  
processes	   and	   thus	   acts	   as	   a	   key	   regulator	   of	   haemostasis,	   vascular	   tone,	   and	  
immune	   and	   inflammatory	   responses	   (Sumpio	   et	   al.,	   2002)	   (see	   section	   1.2).	   The	  
endothelium	   is	   an	   important	   insulin	   target.	   Previous	   studies	   have	   shown	   that	  
besides	   its	   metabolic	   effects,	   insulin	   acts	   as	   an	   anti-­‐inflammatory	   agent	   that	  
suppresses	  leucocyte	  adhesion	  molecules	  and	  NF-­‐κB	  (Dandona	  et	  al.,	  2009).	  	  
The	   balance	   between	   the	   two	   main	   signalling	   pathways	   in	   ECs	   determines	   the	  
vascular	   response	   to	   insulin	   (see	   section	   1.3.2).	   The	   PI3K/Akt	   pathway	   results	   in	  
vasodilation	   via	   nitric	   oxide	   production,	   whereas	   endothelin-­‐1	   dependent	  
vasoconstriction	  occurs	  through	  MAPK/ERK-­‐dependent	  signalling.	  The	  regulation	  of	  
insulin	   signalling	   in	   ECs	   is	   essential	   since	   impaired	  PI3K/Akt	   signalling	  observed	   in	  
obese	   and	   type	   2	   diabetic	   animal	   models	   attenuates	   insulin-­‐induced	   capillary	  
recruitment	  and	  insulin	  delivery,	  resulting	  in	  reduced	  glucose	  uptake	  by	  the	  skeletal	  
muscle	   (Kubota	   et	   al.,	   2013).	   Moreover,	   the	   impaired	   PI3K-­‐dependent	   signalling	  
causes	  an	  imbalance	  between	  the	  production	  of	  nitric	  oxide	  and	  endothelin-­‐1	  and	  
leads	  to	  a	  proflammatory	  and	  prothrombic	  state	  with	  defective	  vasodilation,	  known	  
as	   endothelial	   dysfunction	   (Endemann	   and	   Schiffrin,	   2004).	   Insulin	   resistance,	   a	  
decrease	  in	  insulin	  sensitivity,	  is	  frequently	  associated	  with	  endothelial	  dysfunction	  
that	  results	  in	  cardiovascular	  disease	  (Muniyappa	  and	  Sowers,	  2013).	  	  
A	   loss	   of	   endothelial	   barrier	   function	   is	   one	   of	   the	   earliest	   indications	   of	  
inflammation	   and	   atherosclerosis	   (Libby,	   2012).	   The	   integrity	   of	   the	   endothelial	  
barrier	  is	  highly	  dependent	  on	  actomyosin-­‐based	  contractility	  and	  cell-­‐cell	  junctions	  
(see	   section	   1.2.3),	   however	   the	   role	   of	   insulin	   in	   the	   regulation	   of	   endothelial	  
barrier	  function	  is	  not	  well	  described.	  This	  chapter	  focuses	  on	  identifying	  the	  effect	  
of	  insulin	  on	  endothelial	  junctions	  and	  the	  cytoskeleton.	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3.2 Insulin	  activates	  Akt	  in	  endothelial	  cells	  
Insulin	   signalling	   is	   mediated	   by	   a	   complex	   network	   of	   signalling	   pathways	   that	  
regulate	  diverse	   cellular	   functions	   and	   include	  multiple	   feedback	   loops,	   cross-­‐talk	  
between	   major	   signalling	   branches,	   and	   intersect	   signalling	   pathways	   of	  
heterologous	   receptors	   (Muniyappa	   et	   al.,	   2007;	   Nystrom	   and	   Quon,	   1999;	  
Taniguchi	   et	   al.,	   2006).	   Of	   the	   two	  main	   insulin	   signalling	   pathways	   the	   PI3K/Akt	  
pathway	   is	  responsible	  for	  most	  of	  the	  metabolic	  actions	  of	   insulin	  and	  regulating	  
cardiovascular	  homeostasis	  (Muniyappa	  et	  al.,	  2007)	  (see	  section	  1.3.2).	  
Experimentally,	  the	  optimal	  conditions	  required	  to	  stimulate	  ECs	  with	  insulin	  were	  
firstly	   determined.	   Insulin	   activates	   the	   PI3K	   pathway	   inducing	   a	   conformational	  
change	   in	   Akt	   that	  makes	   it	   accessible	   to	   phosphorylation	   at	   threonine	   308.	   Full	  
activation	   occurs	   by	   the	   subsequent	   phosphorylation	   of	   serine	   473	   (Alessi	   et	   al.,	  
1996a).	   In	   this	  study,	  Ser473	  phosphorylation	  of	  Akt	  was	  analysed	  to	  quantify	   the	  
degree	   of	   insulin-­‐stimulated	   endothelial	   activation.	   Initially,	   cells	  were	   stimulated	  
with	   physiological	   concentrations	   of	   insulin	   (100	   –	   500	   pmol/L),	   however,	   no	  
changes	   in	  Akt	  phosphorylation	  were	  observed	   (data	  not	   shown).	  The	  majority	  of	  
studies	  of	  insulin	  action	  on	  ECs	  have	  used	  unphysiologically	  high	  concentrations	  of	  
insulin	   to	   stimulate	   phosphorylation	   of	   Akt,	   eNOS	   and	   other	   insulin-­‐activated	  
pathways	  (Hermann	  et	  al.,	  2000;	  Zeng	  et	  al.,	  2000).	  As	  per	  previous	  studies,	  HUVECs	  
were	  stimulated	  with	   insulin	  at	  concentrations	  of	  0	  –	  200	  nM	  (Figure	  3.1)	  and	  for	  
different	  stimulation	  times	  (0	  –	  60	  min)	  with	  100	  nM	  insulin	  (Figure	  3.2).	  
Initially,	   primary	   human	   umbilical	   vein	   endothelial	   cells	   (HUVECs)	   and	   a	   human	  
bone	   marrow	   endothelial	   cell	   line	   (HBMECs)	   were	   incubated	   in	   low	   serum	  
conditions	  (growth	  factor	  free	  EBM2	  containing	  1%	  FCS)	  for	  4	  h	  followed	  by	  insulin	  
stimulation.	   However,	   basal	   levels	   of	   Akt	   phosphorylation	   levels	   were	   high	   and	  
increases	  could	  not	  be	  observed	  when	  compared	  to	  untreated	  control	  cells.	  When	  
these	   same	   conditions	   were	   used	   to	   treat	   HeLa	   cells,	   a	   four-­‐fold	   increase	   in	   Akt	  
phosphorylation	  was	   observed	   in	   response	   to	   insulin	   (data	   not	   shown).	   ECs	  were	  
too	   sensitive	   for	   complete	   serum	   starvation,	   as	   a	   high	   level	   of	   cell	   death	   was	  
observed.	   It	  was	  also	  noted	  that	   the	  PI3K/Akt	  pathway	  could	  also	  be	  activated	  by	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shear	   stress	   during	   the	   washing	   steps	   in	   the	   cell	   lysate	   preparation.	   Thus,	   basal	  
levels	  of	  pAkt	  were	  reduced	  by	  incubating	  the	  cells	  in	  low	  serum	  conditions	  for	  16	  h	  
and	   handled	   gently	   to	   ensure	   that	   cell	   activation	   was	   as	   a	   result	   of	   insulin	  
stimulation.	  	  
Insulin	   induced	   a	   strong	   dose-­‐dependent	   Akt	   activation	   in	   both	   HUVECs	   (Figure	  
3.1A)	   and	   HBMECs	   (Figure	   3.1B).	   Maximal	   increases	   of	   1.55-­‐	   and	   2.9-­‐fold	   were	  
observed	   in	   the	  HUVECs	  and	  HBMECs,	   respectively,	  after	   incubation	  with	  200	  nM	  
insulin	  for	  10	  min	  (Figure	  3.1).	  An	  optimal	  concentration	  of	  100	  nM	  was	  chosen	  for	  
subsequent	   experiments,	   as	   this	   concentration	   produced	   the	   most	   reproducible	  
response	  in	  the	  ECs.	  	  
Insulin	  activated	  Akt	  within	  the	  first	  5	  min	  of	  stimulation	  and	  phosphorylation	  was	  
maintained	   for	   30	   min	   in	   HUVECs	   (Figure	   3.2A)	   and	   for	   the	   whole	   period	   of	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Figure	  3.1	  Insulin	  stimulates	  the	  phosphorylation	  of	  Akt	  in	  endothelial	  cells	  
HUVECs	  (A)	  and	  HBMECs	  (B)	  were	  stimulated	  with	  increasing	  concentrations	  of	  insulin	  (0	  –	  
200	  nM)	  for	  10	  min,	  following	  low	  serum	  conditions	  (EBM2	  +	  1%	  FCS)	  for	  16	  h.	  Top	  panels	  
show	  representative	  Western	  blots.	  Graphs	   in	  the	   lower	  panel	  were	  generated	  from	  data	  
analysed	  by	  densitometric	  scanning	  of	  Western	  blots,	  normalised	  to	  total	  Akt	  and	  GAPDH	  
levels,	   relative	   to	  control.	  Data	   shown	  are	   the	  mean	  of	   five	   (A)	  and	   four	   (B)	   independent	  
experiments	   ±	   SEM.	   *p<0.05,	   **p<0.005,	   ***p<0.001;	   One-­‐way	   ANOVA	   (Holm-­‐Sidak	  
method).	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Figure	  3.2	  Insulin	  stimulates	  the	  phosphorylation	  of	  Akt	  within	  5	  minutes	  
HUVECs	  (A)	  and	  HBMEC	  s	  (B)	  were	  stimulated	  with	  insulin	  (100	  nM)	  at	  various	  time	  points	  
(0	  –	  60	  min),	   following	   low	  serum	  conditions	  (EBM2	  +	  1%	  FCS)	   for	  16	  h.	  Top	  panels	  show	  
representative	   Western	   blots.	   Graphs	   in	   the	   lower	   panel	   were	   generated	   from	   data	  
analysed	  by	  densitometric	  scanning	  of	  Western	  blots,	  normalised	  to	  total	  Akt	  and	  GAPDH	  
levels,	  relative	  to	  control.	  Data	  shown	  are	  the	  mean	  of	  five	  (A)	  and	  three	  (B)	  independent	  
experiments	   ±	   SEM.	   *p<0.05,	   **p<0.005,	   ***p<0.001;	   One-­‐way	   ANOVA	   (Holm-­‐Sidak	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3.3 Effect	  of	  insulin	  on	  endothelial	  cell-­‐cell	  junctions	  
	  
3.3.1 Insulin	  decreases	  basal	  endothelial	  cell	  permeability	  
ECs	   provide	   a	   semi-­‐selective	   permeable	   barrier	   between	   the	   blood	   and	   the	  
interstitial	  space.	  The	  degree	  of	  permeability	  depends	  on	  the	  structural	  integrity	  of	  
inter-­‐endothelial	   junctions,	  as	  well	   as	  actomyosin-­‐based	  cell	   contractility,	   and	  can	  
be	   modified	   by	   a	   variety	   of	   circulating	   vasoactive	   inflammatory	   stimuli	   and	  
hormones	  such	  as	  insulin,	  derived	  from	  blood	  or	  surrounding	  tissues	  (Gunduz	  et	  al.,	  
2010;	  Vandenbroucke	  et	  al.,	  2008).	  The	  effect	  of	  insulin	  on	  endothelial	  permeability	  
was	   investigated	   in	  a	  permeability	  assay	  using	  a	   tracer	   flux	  assay,	  quantifying	   the	  
movement	   of	   a	   40	   kDa	   fluorescent	   marker	   fluorescein	   isothiocyanate	  (FITC)	   –	  
dextran	   in	  a	  Transwell™	  system	  (Monaghan-­‐Benson	  and	  Wittchen,	  2011;	  Siflinger-­‐
Birnboim	   et	   al.,	   1987).	   Confluent	   HUVEC	   monolayers	   on	   FN-­‐coated	   Transwell™	  
filters	  were	  treated	  with	  insulin	  (0	  –	  200	  nM)	  for	  30	  min,	  following	  incubation	  in	  low	  
serum	  conditions	  	  (EBM2	  containing	  1%	  FCS)	  for	  4	  h.	  FITC-­‐Dextran	  was	  added	  to	  the	  
upper	  chamber	  for	  60	  min,	  and	  the	  fluorescence	  was	  measured	  from	  samples	  taken	  
from	  the	  lower	  chamber.	  
Insulin	  induced	  a	  small	  but	  significant	  decrease	  of	  approximately	  20%	  in	  endothelial	  
permeability	  that	  was	  not	  concentration	  dependent	  (Figure	  3.3).	  This	  reduction	  was	  
observed	  after	  60	  min	  of	  insulin	  stimulation	  (Figure	  3.4),	  following	  an	  initial	  variable	  
increase	   in	  permeability	   seen	  at	   earlier	   time-­‐points	   (10	   and	  30	  min).	  A	  maximum	  
reduction	   of	   40%	   in	   permeability	   to	   FITC-­‐dextran	  was	   observed	   after	   stimulating	  
HUVECs	  with	  insulin	  for	  4	  h.	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Figure	  3.3	  Insulin	  decreases	  basal	  endothelial	  cell	  permeability	  to	  FITC-­‐dextran	  
HUVECs	  were	  seeded	  on	  Transwell™	  filters	   (0.4	  µm	  pore	  size)	  and	   incubated	  overnight	  at	  
37	   °C.	   Cells	  were	   incubated	   in	  medium	   containing	   1%	   FCS	   for	   4	   h	   and	   then	   treated	  with	  
various	  insulin	  concentrations	  (0	  –	  200	  nM)	  for	  30	  min.	  FITC-­‐dextran	  (0.1	  mg/ml)	  was	  added	  
to	   the	   upper	   chamber	   and	   the	   lower	   chamber	   fluorescence	  was	  measured	   after	   60	  min.	  
Fluorescence	  was	  measured	  for	   triplicate	  wells	  and	  quantified	  as	  a	  percentage	  relative	  to	  
control.	  Data	  shown	  are	  the	  mean	  of	  four	  independent	  experiments	  ±	  SEM.	  *	  p<0.05;	  One-­‐





Figure	  3.4	  Effect	  of	  insulin	  on	  endothelial	  cell	  permeability	  over	  24	  hours	  
HUVECs	  were	  seeded	  on	  Transwell™	  filters	   (0.4	  µm	  pore	  size)	  and	   incubated	  overnight	  at	  
37	  °C.	  Cells	  were	  incubated	  in	  medium	  containing	  1%	  FCS	  for	  2	  h	  prior	  to	  being	  treated	  with	  
insulin	  (100	  nM)	  for	  the	  various	  time-­‐points.	  For	  early	  time-­‐points	  (0,	  10,	  30,	  60	  min)	  FITC-­‐
dextran	   (0.1	   mg/ml)	   was	   added	   to	   the	   upper	   chamber	   60	   min	   before	   measuring	  
fluorescence	  in	  the	  lower	  chamber.	  For	  time-­‐points	  up	  to	  90	  min,	  and	  from	  4	  to	  24	  h;	  FITC-­‐
dextran	  was	  added	  to	  the	  upper	  chamber	  in	  the	  final	  60	  min.	  Fluorescence	  was	  measured	  
for	  triplicate	  wells	  and	  quantified	  as	  a	  percentage	  relative	  to	  control.	  Data	  shown	  are	  the	  
mean	  of	  four	  independent	  experiments	  ±	  SEM.	  *	  p<0.05,	  ***p<0.001;	  2-­‐way-­‐paired	  t-­‐test.	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3.3.2 Effect	  of	  insulin	  on	  HUVEC	  morphology	  
The	  distribution	  of	  F-­‐actin	  within	  ECs	  as	  well	  as	  the	  cell-­‐cell	  junctions	  can	  be	  altered	  
by	   a	   number	   of	   inflammatory	   mediators	   resulting	   in	   changes	   in	   endothelial	  
morphology	  (Dejana	  and	  Giampietro,	  2012;	  Esser	  et	  al.,	  1998;	  McKenzie	  and	  Ridley,	  
2007).	  After	  observing	  insulin-­‐induced	  permeability	  changes	  in	  ECs	  (Figure	  3.3	  and	  
Figure	  3.4),	  the	  effects	  of	  insulin	  stimulation	  on	  cell	  morphology	  were	  investigated	  
by	   immunofluorescent	   staining.	   Confluent	   HUVEC	  monolayers	   were	   incubated	   in	  
EBM2	   medium	   containing	   1%	   FCS	   for	   4	   h	   and	   stimulated	   with	   various	  
concentrations	  (0	  to	  200	  nM)	  of	   insulin	  for	  10	  min	  (Figure	  3.5).	  HUVECs	  were	  also	  
stimulated	  with	  insulin	  (100	  nM)	  over	  a	  period	  of	  time	  (0,	  1,	  4,	  16	  and	  24	  h)	  (Figure	  
3.6).	  Unstimulated	  control	  HUVECs	  displayed	  a	  round	  cobblestone-­‐like	  morphology	  
with	   bundles	   of	   actin	   filaments	   enriched	   along	   the	   cell-­‐cell	   boundaries	   (yellow	  
asterisk,	   Figure	   3.6).	   VE-­‐cadherin	   staining	   was	   localized	   linearly	   along	   cell–cell	  
borders	   and	   with	   a	   wider	   reticular	   distribution	   where	   adjacent	   cells	   overlapped	  
(white	   arrows,	   Figure	   3.5).	   No	   noticeable	   changes	   were	   observed	   in	   HUVEC	  
morphology	   after	   10	   min	   of	   insulin	   stimulation	   at	   various	   insulin	   concentrations	  
(Figure	   3.5).	   This	   time-­‐point	   was	   optimal	   for	   Akt	   phosphorylation	   (Figure	   3.2),	  
however	  may	   not	   have	   been	   long	   enough	   to	   induce	   cytoskeletal	   changes.	  When	  
cells	   were	   stimulated	   for	   longer	   periods	   of	   time	   (1	   to	   24	   h),	   insulin	   induced	   an	  
increase	   in	   peripheral	   F-­‐actin	   bundles	   (red	   boxes,	   Figure	   3.6),	   with	   the	   greatest	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Figure	  3.5	  Insulin	  does	  not	  induce	  any	  major	  changes	  in	  HUVEC	  morphology	  at	  
early	  time-­‐points	  
Immunofluorescence	  micrographs	  of	  confluent	  HUVECs	  treated	  with	  insulin	  (0	  to	  200	  nM)	  
for	  10	  min	  after	   incubation	  in	  low	  serum	  conditions	  (EBM-­‐2	  containing	  1%	  FBS,	  4	  h).	  Cells	  
were	   stained	  with	  VE-­‐cadherin	   for	   adherens	   junctions	   (green	   in	  merge),	   Alexa	   Fluor	  546-­‐
conjugated	  phalloidin	  for	  F-­‐actin	  (red	  in	  merge),	  and	  DAPI	  for	  nuclei	  (blue	  in	  merge).	  White	  
arrows	   indicate	   reticular	   junctions.	   Images	  were	   acquired	   by	   confocal	  microscopy	  with	   a	  
63x	   oil	   immersion	   objective	   and	   are	   representative	   of	   random	   fields	   from	   three	  
independent	  experiments.	  Scale	  bars	  are	  20	  μm.	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Figure	  3.6	  Insulin	  increases	  peripheral	  F-­‐actin	  in	  HUVECs	  
Immunofluorescence	  micrographs	   of	   confluent	   HUVECs	   treated	   with	   insulin	   (100	   nM)	   at	  
various	   time	   points	   (0	   to	   24	   h),	   following	   incubation	   in	   low	   serum	   conditions	   (EBM2	  
containing	   1%	   FCS)	   for	   4	   h.	   Cells	   were	   stained	   with	   VE-­‐cadherin	   for	   adherens	   junctions	  
(green	  in	  merge),	  Alexa	  Fluor	  546-­‐conjugated	  phalloidin	  for	  F-­‐actin	  (red	  in	  merge),	  and	  DAPI	  
for	  nuclei	  (blue	  in	  merge).	  Yellow	  asterisk	  shows	  regular	  F-­‐actin	  arrangement	  in	  untreated	  
control	   cells,	   with	   actin	   filaments	   enriched	   along	   the	   cell-­‐cell	   boundaries.	   Red	   boxes	  
indicate	   increased	   peripheral	   F-­‐actin	   in	   insulin-­‐treated	   cells.	   Images	   were	   acquired	   by	  
confocal	   microscopy	   with	   a	   63x	   oil	   immersion	   objective	   and	   are	   maximum	   intensity	  
projections	   of	   10	   confocal	   z-­‐stacks,	   spanning	   4	   μm	  with	   0.4	   μm	   intervals	   between	   each	  
image.	   Images	   are	   representative	  of	   random	   fields	   from	   three	   independent	  experiments.	  
Scale	  bars	  are	  20	  μm.	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3.4 Insulin	  increases	  cell	  migration	  in	  a	  wound	  healing	  assay	  	  
Cell	  migration	  is	  essential	  for	  a	  variety	  of	  physiologic	  processes	  such	  as	  tissue	  repair	  
and	  regeneration.	  Wound	  healing	  is	  a	  dynamic,	  interactive	  process	  that	  consists	  of	  
three	  phases:	   inflammation,	   tissue	   formation	   and	   tissue	   remodelling	   (Chen	  et	   al.,	  
2012).	   The	   inflammatory	   phase	   is	   composed	   of	   a	   series	   of	   events	   including	  
coagulation,	   release	  of	  vasoactive	  substances,	  chemokines,	  and	  cytokines	  that	  are	  
important	  for	  regulating	  the	  consequential	  phases	  of	  proliferation	  and	  remodelling	  
(Schreml	  et	   al.,	   2010).	   PI3K/Akt	   signalling	   is	   activated	  during	   these	  phases,	   and	   is	  
also	  required	  for	  cell	  migration	  and	  survival.	  	  
A	   commonly	   used	   method	   to	   assess	   cell	   migration	   in	   vitro	   is	   the	   scratch	   assay,	  
which	  measures	   the	  movement	  of	   cells	   into	   a	  wound	  made	  by	   a	  physical	   scratch	  
through	   the	   confluent	   endothelial	   monolayer.	   However,	   results	   can	   be	   highly	  
variable	   due	   to	   the	   inconsistency	   of	   the	   wounds	   created	   and	   the	   scratch	   could	  
damage	  the	  underlying	  extracellular	  matrix	  affecting	  cell	  migration.	  The	  Oris™	  Cell	  
Migration	  Assay	  creates	  a	  reproducible	  cell-­‐free	  area	  with	  uniform	  dimensions	  with	  
the	  use	   silicone	   stoppers	   that	   act	   as	  barriers	  when	   cells	   are	   seeded	   into	   the	  well	  
(Gough	  et	   al.,	   2011).	   It	   is	   a	  particularly	  useful	   assay	   for	   studying	  EC	  migration,	   as	  
these	   cells	   tend	   to	   migrate	   collectively	   rather	   than	   as	   individual	   cells,	   for	   which	  
random	  migration	   assays	   are	   primarily	   used.	   The	  ORIS™	   cell	  migration	   assay	  was	  
performed	   in	   order	   to	   investigate	   whether	   insulin	   would	   have	   an	   effect	   on	   EC	  
migration.	  HUVECs	  were	  seeded	  onto	  wells	  in	  a	  FN-­‐coated	  96-­‐well	  plate	  containing	  
the	   central	   stoppers.	   After	   the	   cells	   attached	   and	   formed	   confluent	  monolayers,	  
they	  were	  incubated	  in	  EBM2	  medium	  containing	  1%	  FCS	  for	  4	  h	  and	  treated	  with	  
various	   concentrations	   of	   insulin	   (0	   to	   200	   nM).	   The	   stoppers	   were	   removed	   to	  
create	  a	  central	  cell-­‐free	  area,	  the	  wells	  were	  imaged	  and	  the	  cells	  were	  incubated	  
for	  24	  h	  and	  imaged	  again.	  More	  insulin-­‐treated	  HUVECs	  migrated	  into	  the	  cell-­‐free	  
area	   than	   untreated	   control	   cells.	   Both	   the	   50	   nM	   and	   100	   nM	   insulin	  
concentrations	  resulted	  in	  a	  46%	  increase	  in	  cell	  migration,	  compared	  to	  untreated	  
cells.	   These	   results	   suggest	   that	   insulin	   increases	   HUVEC	   migration	   in	   a	   dose-­‐
dependent	  manner	  (Figure	  3.7).	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Figure	  3.7	  Insulin	  increases	  cell	  migration	  in	  a	  wound-­‐healing	  assay	  
HUVECs	  were	  stained	  with	  Cell-­‐Tracker	  Orange	  fluorescent	  dye,	  seeded	  in	  wells	  containing	  
a	  central	  insert,	  and	  incubated	  for	  16	  to	  18	  h	  at	  37°C.	  The	  cells	  were	  washed	  and	  incubated	  
in	   low	  serum	  medium,	  EBM2	  containing	  1%	  FCS	   for	  4	  h.	  The	   insert	  was	   then	   removed	   to	  
create	  a	  central	  wound	  in	  the	  monolayer,	  and	  imaged	  at	  4x	  magnification	  (0	  h).	  Insulin	  was	  
added	  (0	  to	  200	  nM)	  and	  cells	  incubated	  for	  24	  hours	  at	  37°C.	  	  The	  wells	  were	  imaged	  again	  
(24	  h)	  using	  the	  saved	   locations	  of	  0	  h	  and	  the	  area	  of	   the	  wound	  closure	  was	  calculated	  
using	  ImageJ	  software,	  as	  a	  percentage	  relative	  to	  unstimulated	  control	  cells.	  Data	  shown	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3.5 Insulin	  stimulates	  angiogenic	  tube	  formation	  
Angiogenesis	   is	   the	   development	   of	   new	   blood	   vessels	   from	   pre-­‐existing	   vessels	  
that	   requires	   the	  proliferation,	  migration	   and	   remodelling	   of	   ECs	   (Lamalice	   et	   al.,	  
2007).	   Neoangiogenesis	   is	   an	   essential	   process	   in	   wound	   healing	   (Schreml	   et	   al.,	  
2010)	   and	   agents	   that	   stimulate	   angiogenesis	   can	   improve	  blood	   flow	   in	  patients	  
with	   ischaemic	   diseases	   (Goodwin,	   2007).	   When	   ECs	   are	   plated	   on	   a	   three-­‐
dimensional	   scaffold	   of	   extracellular	   matrix,	   they	   self-­‐organise	   and	   differentiate	  
into	   capillary-­‐like	   networks	   (Ingber	   and	   Folkman,	   1989;	   Risau,	   1997).	   In	   order	   to	  
study	   the	  effects	   of	   insulin	   on	   angiogenesis,	   an	   in	   vitro	  Matrigel-­‐based	   assay	  was	  
performed.	   HUVECs	  were	   incubated	   in	   EBM2	  medium	   containing	   1%	   FCS	   for	   2	   h	  
before	  insulin	  stimulation	  and	  plating	  on	  Matrigel.	  When	  the	  HUVECs	  attach	  to	  the	  
Matrigel	  they	  elongate	  and	  extend	  cellular	  processes	  to	  actively	  find	  other	  cells	  and	  
form	  a	  well-­‐organised	  network	  of	  loops.	  This	  requires	  many	  cytoskeletal	  changes	  as	  
well	  as	  migratory	  mechanisms	  and	   the	  HUVECs	  were	  not	  able	   to	  cope	  with	   these	  
demands	  for	  long	  periods	  of	  time	  in	  starving	  media.	  Therefore,	  a	  shorter	  starvation	  
period	  of	  2	  h	  was	  required	  for	  this	  assay	  compared	  to	  other	  assays	  that	  are	  usually	  
incubated	  in	  low	  serum	  conditions	  for	  4	  h.	  Insulin	  stimulation	  increased	  the	  number	  
of	  angiogenic	  loops	  formed	  by	  the	  HUVECs	  in	  a	  dose-­‐dependent	  manner,	  compared	  
to	  unstimulated	  control	  cells	  in	  24	  h	  (Figure	  3.8,	  Movies	  S1	  and	  S2).	  
Previous	   studies	   have	   shown	   that	   insulin	   does	   not	   stimulate	   endothelial	   cell	  
proliferation	  in	  24	  h	  (Liu	  et	  al.,	  2009),	  and	  therefore	  this	  increase	  is	  attributed	  to	  an	  
increase	   in	   cell	   migration,	   which	   is	   consistent	   with	   the	   findings	   from	   the	   ORIS™	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Figure	  3.8	  Insulin	  stimulates	  angiogenic	  loop	  formation	  
HUVECs	   were	   incubated	   in	   EBM2	  medium	   containing	   1%	   FCS	   for	   2	   h,	   and	   seeded	   onto	  
polymerised	   Matrigel	   (4.5	   mg/ml)	   in	   medium	   containing	   increasing	   concentrations	   of	  
insulin	   (0	  –	  200	  nM).	  Cells	  were	   incubated	   for	  1	  h	  and	   loop	   formation	  was	  monitored	  by	  
time-­‐lapse	   microscopy	   using	   a	   4x	   objective,	   acquiring	   images	   every	   20	   min	   for	   24	   h.	  
Representative	   images	   (A)	   are	   the	   final	   frames	   of	   angiogenic	   loops	   formed	   after	   24	   h.	  
Quantification	  was	  performed	  by	  counting	  the	  total	  number	  of	  complete	  loops	  in	  the	  final	  
frame	  of	  the	  movies,	  as	  a	  percentage	  relative	  to	  unstimulated	  control	  cells	  (B).	  Data	  shown	  
are	   the	   mean	   of	   three	   independent	   experiments	   ±	   SEM.	   *p<0.05,	   **p<0.005;	   One-­‐way	  
ANOVA	  (Holm-­‐Sidak	  method).	  Scale	  bar	  is	  200	  μm.	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3.6 Discussion	  
Results	  in	  this	  chapter	  indicate	  that	  insulin	  affects	  endothelium	  barrier	  function	  and	  
cell	  migration,	  which	  might	  be	  a	  consequence	  of	  changes	  to	  the	  actin	  cytoskeleton.	  
3.6.1 Insulin	  activates	  Akt	  in	  endothelial	  cells	  
Insulin	   mediates	   its	   effects	   by	   binding	   to	   its	   cell	   surface	   receptor,	   the	   insulin	  
receptor	   (IR)	   (Nitert	   et	   al.,	   2005).	   ECs	   from	   different	   vascular	   beds	   are	  
heterogeneous	   and	   differ	   in	   the	   surface	   receptor	   concentration	   and	   affinity	   for	  
insulin.	   For	   example,	   arterial	   ECs	   have	   2.5	   times	  more	   insulin	   receptors	   than	   ECs	  
isolated	  from	  veins	  (Bar	  et	  al.,	  1980).	  HUVECs	  are	  often	  used	  as	  a	  primary	  model	  for	  
studies	   of	   the	   human	   endothelium	   and	  were	   chosen	   for	   this	   study	   because	   they	  
were	   easily	   available	   and	   have	   been	   shown	   to	   specifically	   bind	   insulin	  (Bar	   et	   al.,	  
1978).	   Large	   quantities	   of	   cells	   were	   required	   for	   the	   subsequent	   protein	  
phosphorylation	  screen	  (see	  Chapter	  4),	  and	  these	  levels	  were	  not	  attainable	  using	  
primary	  cells.	  Therefore,	  HBMECs	  were	  used	  for	  the	  screen	  and	  included	  in	  the	  Akt	  
activation	  biochemical	  analyses.	  
It	  was	  firstly	  necessary	  to	  establish	  the	  optimal	  conditions	  required	  to	  stimulate	  ECs	  
with	  insulin.	  As	  most	  of	  the	  metabolic	  actions	  of	  insulin	  are	  mediated	  through	  the	  
PI3K/Akt	   pathway	   (Hermann	   et	   al.,	   2000;	   Zeng	   et	   al.,	   2000),	   phosphorylated	   Akt	  
(pAkt)	   was	   used	   as	   a	   read	   out.	   The	   limited	   insulin	   response	   detected	   in	   HUVECs	  
compared	   to	  HBMECs	   could	   be	   attributed	   to	   lower	   levels	   of	   IR,	   described	   above.	  
The	   variation	   between	   the	   response	   of	   the	   primary	   cells	   and	   the	   established	   cell	  
line	   is	   interesting,	   and	   further	   investigation	   into	   the	   IR	   gene	   expression,	   ligand	  
binding	   and	   receptor	   protein	   expression	   in	   HBMECs	   is	   required	   to	   determine	   if	  
these	   differences	   could	   be	   attributed	   to	   IR	   levels.	   In	   a	   study	   that	   compared	   the	  
expression	  of	   chemokine	   receptors	  and	  adhesion	  molecules	   in	  endothelia	  derived	  
from	  different	  human	  tissues,	  levels	  of	  chemokine	  receptors	  varied	  according	  to	  the	  
endothelial	   cell	   type	   with	   differences	   observed	   between	   HUVECs	   and	   HBMECs	  
(Hillyer	   et	   al.,	   2003).	   Therefore,	   differences	   in	   the	   IR	   levels	   between	   the	   two	   cell	  
types	   could	   also	   be	   possible,	   contributing	   to	   their	   variable	   response	   to	   insulin	  
stimulation.	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3.6.2 Insulin	  decreases	  endothelial	  permeability	  and	  induces	  cortical	  actin	  
filament	  remodelling	  
Cultured	  ECs	  are	  often	  used	  to	  model	  the	  endothelium	  and	  elucidate	  the	  molecular	  
mechanisms	   involved	   in	   regulating	   endothelial	   barrier	   function.	   Although	   these	  
models	   show	   limited	   resemblance	   to	   real	   physiological	   structures	   and	   functions,	  
they	   provide	   insight	   for	   testing	   mechanistic	   hypotheses	   related	   to	   cell	   signalling	  
that	   regulate	   barrier	   function.	   The	   addition	   of	   insulin	   to	   endothelial	   monolayers	  
demonstrates	  the	  ability	  of	  the	  endothelium	  to	  respond	  rapidly	  to	  chemical	  stimuli.	  
Insulin	   stimulation	   initially	   resulted	   in	   a	   variable	   response	   in	   permeability.	   This	  
increase	   in	  permeability	  might	  be	   attributable	   to	   the	  enhanced	   vesicle	   (caveolae)	  
transcellular	   transport	  of	   insulin	  across	  the	  endothelium	  (King	  and	  Johnson,	  1985;	  
Wang	   et	   al.,	   2006).	   Although	   the	   exact	   transit	   pathway	   that	   transports	   insulin	  
across	  ECs	  is	  not	  fully	  elucidated,	  it	  has	  been	  suggested	  that	  insulin	  remains	  within	  a	  
vesicular	  compartment,	  that	  buds	  off	  from	  the	  luminal	  plasma	  membrane	  of	  the	  EC	  
and	   moves	   to	   the	   abluminal	   side	   to	   subsequently	   fuse	   and	   release	   its	   content	  
(reviewed	   in	   (Tuma	  and	  Hubbard,	  2003).	  FITC-­‐dextran	  molecules	  could	  have	  been	  
incorporated	   in	   the	   vesicles	   and	   actively	   transported	   across	   the	   endothelial	  
monolayer,	   until	   insulin	   equilibrium	   was	   achieved.	   It	   would	   be	   interesting	   to	  
analyse	  endothelial	  permeability	  at	  these	  earlier	  time	  points	  using	  a	  more	  sensitive	  
technique,	   such	   as	   measuring	   transendothelial	   electrical	   resistance,	   to	   fully	  
investigate	   the	   initial	   permeability	   dynamics.	   Following	   this	   initial	   variability,	  
stimulation	  with	   insulin	   resulted	   in	  a	  small,	  but	  significant	  decrease	   in	  endothelial	  
permeability.	   The	   vasoprotective	   actions	   of	   insulin	   could	   be	   as	   a	   result	   of	  
decreasing	  endothelial	  permeability	   induced	  by	  pro-­‐inflammatory	  mediators,	   such	  
as	  TNF-­‐α	  (McKenzie	  and	  Ridley,	  2007).	  	  
The	  permeability	  effects	  of	   insulin	  on	  the	  endothelium	  are	  usually	  associated	  with	  
an	   increase	   in	   endothelial	   NO	   production	   through	   the	   PI3K	   pathway	   (Zeng	   and	  
Quon,	   1996).	   In	   smooth	   muscle	   cells,	   insulin	   inhibits	   Rho/ROCK-­‐mediated	   actin-­‐
myosin	  contraction	  via	  a	  mechanism	  dependent	  on	  the	  presence	  of	  NO	  (Begum	  et	  
al.,	   2002;	   Sandu	   et	   al.,	   2001).	   However,	   the	   role	   of	   NO	   in	   the	   regulation	   of	  
endothelial	  barrier	  function	  is	  controversial	  (reviewed	  in	  (Yuan,	  2006)).	  The	  debate	  
Chapter	  3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Effects	  of	  insulin	  on	  endothelial	  cells	  
	  
	   	   106	  
emerged	   from	   the	   observations	   that	   manipulation	   of	   endothelial	   NO	   production	  
has	   biphasic	   characteristics	   and	   could	   be	   either	   beneficial	   (cardioprotective	  
(Johnson	  et	  al.,	  1991;	  Ozaki	  et	  al.,	  2002;	  Rath	  et	  al.,	  2006))	  or	  detrimental	  (cytotoxic	  
(Bucci	   et	   al.,	   2005))	   to	   vascular	   barrier	   properties	   depending	   on	   the	   stimulus,	  
experimental	  conditions,	  vascular	  bed,	  time	  window	  and	  local	  concentration	  of	  NO	  
(Yuan,	  2006).	  Furthermore,	  eNOS	  activity	  is	  regulated	  by	  many	  other	  factors	  such	  as	  
its	  intracellular	  localisation	  (Shaul,	  2002),	  post-­‐translational	  modifications	  as	  well	  as	  
protein-­‐protein	   interactions	   with	   other	   effector	   molecules	   (Sessa,	   2005).	   These	  
differences	   illustrate	   that	   the	   effect	   of	   NO	   is	   context	   dependent	   and	   can	   be	  
influenced	   by	   other	   signalling	   pathways	   that	   are	   activated	   simultaneously	   by	  
growth	   factors	   or	   inflammatory	   mediators	   (Murohara	   et	   al.,	   1998).	   Thus,	   the	  
insulin-­‐mediated	  changes	   in	  endothelial	  permeability	  are	  unlikely	   to	  be	  due	  solely	  
to	  an	  increase	  in	  NO	  production.	  	  
A	   previous	   study	   has	   demonstrated	   that	   insulin	   increases	   endothelial	   barrier	  
function	   in	   rat	   coronary	   microvascular	   ECs	   (Gunduz	   et	   al.,	   2010).	   This	   study	  
observed	  that	  insulin	  induced	  an	  increase	  in	  the	  formation	  of	  the	  peripheral	  F-­‐actin	  
bundling	  along	  the	  edges	  of	  ECs	  and	  reduced	  stress	  fibre	  formation	  after	  5	  min	  of	  
exposure.	   No	   actin	   cytoskeletal	   changes	   were	   observed	   when	   HUVECs	   were	  
stimulated	  with	  insulin	  for	  10	  min,	  however	  increases	  in	  peripheral	  F-­‐actin	  bundles	  
was	   detected	   after	   1	   h.	   ECs	   are	  morphologically	   and	   functionally	   heterogeneous	  
with	  greatest	  differences	  between	  those	  from	  the	  macro-­‐	  and	  microcirculation	  in	  a	  
variety	  of	  tissues	  (reviewed	  in	  (Garlanda	  and	  Dejana,	  1997).	  These	  differences	  could	  
result	   in	   the	   different	   kinetics	   reported	   for	   the	  microvascular	   cells	   and	   observed	  
here	   with	   HUVECs,	   although	   both	   cell	   types	   would	   have	   to	   be	   simultaneously	  
compared	   to	   confirm	   this.	   A	   recent	   study	   has	   shown	   that	   cortical	   actin	   filament	  
remodelling	  occurs	  to	  facilitate	  the	  caveola-­‐mediated	  trans-­‐endothelial	  transport	  of	  
insulin	  (Wang	  et	  al.,	  2012).	  	  
The	  Rho	  GTPase	  Rac1	   is	  known	  to	  control	  F-­‐actin	  organisation	  (Aspenstrom	  et	  al.,	  
2004;	   Hall,	   1998).	   Moreover,	   Rac1	   is	   required	   for	   endothelial	   cell-­‐cell	   junctional	  
assembly	  and	  maturation	  (Lampugnani	  et	  al.,	  2002;	  Wojciak-­‐Stothard	  et	  al.,	  2001).	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Rac1	  appears	  to	  be	  a	  critical	  component	  in	  insulin	  signalling.	  Insulin	  induced	  a	  3-­‐fold	  
increase	   in	   Rac1	   activation	   in	   microvascular	   ECs,	   and	   insulin-­‐induced	   endothelial	  
barrier	  stabilization	  was	  abolished	  when	  Rac1	  was	   inhibited	  (Gunduz	  et	  al.,	  2010).	  
Furthermore,	  genetic	  deletion	  of	  Rac1	  in	  mouse	  lung	  ECs	  causes	  defective	  cell-­‐cell	  
contact	  organisation	  compared	  to	  control	  cells	   (Tan	  et	  al.,	  2008).	  Endothelia	   from	  
different	  tissues	  vary	  considerably	  in	  their	  permeability	  characteristics	  (Simionescu	  
et	  al.,	  2002).	  It	  would	  therefore	  be	  interesting	  to	  measure	  Rac1	  activity	  in	  HUVECs,	  
for	  example	  by	  pull	  downs	  using	  the	  region	  of	  Pak1	  that	  binds	  to	  activated	  Rac1,	  as	  
well	  as	  observing	  localised	  changes	  at	  the	  EC	  junctions	  using	  FRET	  analysis.	  	  
Stimulating	   microvascular	   ECs	   with	   insulin	   resulted	   a	   prominent	   increase	   in	   VE-­‐
cadherin	   staining	   at	   cell-­‐cell	   junctions	   (Gunduz	   et	   al.,	   2010).	   No	   observable	  
difference	   in	   the	  VE-­‐cadherin	   staining	  was	   detected	   in	   the	  HUVECs,	   although	  VE-­‐
cadherin	   staining	   was	   not	   quantitatively	   assessed	   and	   subtle	   changes	   could	   be	  
present.	  	  
In	  conclusion,	  insulin-­‐induced	  actin	  cytoskeleton	  reorganisation	  could	  be	  linked	  to	  a	  
decrease	   in	   basal	   endothelial	   permeability,	   however	   further	   experiments	   are	  
needed	   to	   further	   examine	   this	   association.	   These	   cytoskeletal	   rearrangements	  
could	  contribute	  to	  the	  anti-­‐inflammatory	  actions	  of	  insulin.	  	  
	  
3.6.3 Insulin	  increases	  EC	  migration	  in	  a	  wound	  healing	  assay	  and	  angiogenic	  
tube	  formation	  
One	  of	  the	  hallmarks	  of	  diabetes	  is	  impaired	  wound	  healing	  (Brem	  and	  Tomic-­‐Canic,	  
2007).	   Various	   animal	   models	   have	   demonstrated	   the	   importance	   of	   insulin	   for	  
healing,	   with	   systematic	   insulin	   treatment	   accelerating	   healing	   in	   fractures,	   skin	  
incision	  wounds	  and	   skin	  ulcers	   (Gregory,	  1965;	  Hanam	  et	  al.,	   1983;	  Pierre	  et	   al.,	  
1998;	   Rosenthal,	   1968).	   Moreover,	   severe	   impairment	   of	   insulin	   signalling	   is	  
observed	   in	   the	   wounds	   of	   diabetic	   mouse	   models	   (Goren	   et	   al.,	   2006).	   In	  
correspondence	   with	   these	   findings,	   insulin	   dose-­‐dependently	   increased	   HUVEC	  
migration	  in	  an	  in	  vitro	  ‘wound-­‐healing’	  assay.	  Wound	  healing	  in	  vivo	  requires	  three	  
phases:	   inflammation,	   tissue	   formation	   and	   tissue	   remodelling	   (Singer	   and	   Clark,	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1999).	   Insulin	   has	   been	   shown	   to	   improve	   healing	   by	   contributing	   to	   both	   the	  
inflammatory	  and	  tissue	  formation	  phases.	  Topical	  insulin	  application	  regulates	  the	  
wound	  inflammatory	  response	   in	  a	  mouse	  excision	  model	  by	   inducing	  accelerated	  
macrophage	  infiltration	  and	  inflammation	  resolution	  (Chen	  et	  al.,	  2012).	  However,	  
the	   in	  vitro	  experiments	  performed	   in	   this	   study	  utilised	  Transwell	  assays	  without	  
the	   presence	   of	   ECs.	   It	   would	   be	   interesting	   to	   investigate	   whether	   insulin	  
treatment	  of	  ECs	  affects	  leucocyte	  transendothelial	  migration.	  	  
Once	  the	   inflammatory	  phase	   is	  controlled,	  the	  healing	  proceeds	  with	  granulation	  
tissue	  development	  to	  generate	  new	  connective	  tissue	  and	  blood	  vessels	  within	  the	  
wound	   (Liu	   et	   al.,	   2009).	   Angiogenesis	   provides	   oxygen	   and	   nutrients	   to	   the	  
wounded	   area	   and	   is	   a	   critical	   process	   for	   optimal	   healing	   (Li	   et	   al.,	   2007).	   It	  
requires	  the	  proliferation	  and	  migration	  of	  ECs	  (Hoeben	  et	  al.,	  2004).	  In	  vitro	  insulin	  
stimulation	   of	   ECs	   on	   an	   extracellular	   matrix	   increased	   in	   angiogenic	   loop	  
formation,	  suggesting	  that	  insulin	  is	  a	  stimulator	  of	  angiogenesis.	  This	  was	  similarly	  
observed	   in	   a	   human	   microvascular	   endothelial	   cell	   line	   (HMEC-­‐1)	   with	   insulin	  
stimulating	   endothelial	   tube	   formation	   by	   increased	   cell	   migration	   and	   not	  
proliferation	  (Liu	  et	  al.,	  2009).	  The	   in	  vivo	  model	   in	  this	  study	  further	  showed	  that	  
the	   presence	   of	   insulin	   increased	   the	   vessel	   length	   as	   well	   as	   the	   number	   of	  
branches	  present,	  which	  indicates	  vessel	  maturation.	  The	  authors	  found	  that	  insulin	  
stimulated	  Rac1	  translocation	  from	  the	  cytosol	  to	  the	  membrane	  where	  it	  localised	  
to	  membrane	  ruffles	  in	  subconfluent	  cells.	  Furthermore,	  transfecting	  HMEC-­‐1	  with	  
a	   dominant-­‐negative	   form	   of	   Rac1	   (Rac1-­‐DN)	   abolished	   insulin-­‐induced	  
microvascular	  EC	  migration	  and	  angiogenesis	  (Liu	  et	  al.,	  2009).	  Interestingly,	  genetic	  
deletion	  of	  Rac1	  in	  mouse	  lung	  ECs	  causes	  reduced	  migration,	  tube	  formation	  and	  
adhesion,	   compared	   to	  control	   cells	   (Tan	  et	  al.,	  2008).	  The	   importance	  of	  Rac1	   in	  
the	  cardiovascular	  system	  including	  its	  critical	  role	  in	  ECs	  is	  reviewed	  in	  (Sawada	  et	  
al.,	   2010).	   Further	   analysis	   is	   required	   to	   establish	   if	   Rac1	   contributes	   to	   HUVEC	  
insulin-­‐induced	  migration	  and	  angiogenic	  loop	  formation.	  
In	   conclusion,	   insulin	   induces	   EC	   migration	   and	   increases	   angiogenic	   tube	  
formation.	  It	  would	  be	  interesting	  to	  test	  if	  these	  processes	  are	  dependent	  on	  the	  
activation	  of	  Rac1.	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4 Insulin	  stimulated	  binding	  of	  14-­‐3-­‐3s	  to	  proteins	  in	  endothelial	  
cells	  
4.1 Introduction	  
Protein	   kinase	   cascades	   provide	   the	   regulatory	   mechanisms	   for	   many	   essential	  
processes.	  Insulin	   signals	   through	   phosphorylation	   cascades	   with	   most	   of	   its	  
metabolic	   actions	   mediated	   via	   the	   highly	   conserved,	   tightly	   regulated	   PI3K/Akt	  
pathway	   (Muniyappa	   et	   al.,	   2007)	   (see	   Chapter	   1.3.2.1).	   The	   serine/threonine	  
protein	   kinase	   Akt	   acts	   as	   a	   central	   regulator	   in	   insulin	   signalling	   through	   the	  
phosphorylation	   of	   a	   wide	   variety	   of	   downstream	   substrates	   (Taniguchi	   et	   al.,	  
2006).	  Akt	  has	  been	  identified	  as	  a	  critical	  node	  in	  insulin	  signalling	  (Taniguchi	  et	  al.,	  
2006),	  and	  plays	  an	  important	  role	  in	  human	  physiology	  and	  disease	  (Manning	  and	  
Cantley,	  2007).	  Furthermore,	  the	  activation	  of	  PI3K	  and	  the	  subsequent	  generation	  
of	   PIP3	   also	   activates	   other	   AGC	   family	   protein	   kinases,	   including	   PKA,	   PKG,	   PKC,	  
ROCKs;	   serum	   and	   glucocorticoid-­‐regulated	   kinase	   (SGK),	   p90RSK,	   and	   AMP-­‐
activated	   protein	   kinase	   (AMPK)	   (Tinti	   et	   al.,	   2012;	   Yaffe	   et	   al.,	   1997).	   The	   AGC	  
kinases	  phosphorylate	  many	  downstream	  substrates	  at	  specific	  sites,	  which	  in	  some	  
cases	   can	   create	   binding	   motifs	   for	   the	   phosphoprotein-­‐binding	   14-­‐3-­‐3	   proteins	  
(see	   section	  1.6.2).	   Screening	  phosphopeptide	   libraries	   for	   sequences	   that	  display	  
optimal	  binding	  to	  14-­‐3-­‐3	  revealed	  two	  high-­‐affinity	  14-­‐3-­‐3	  binding	  motifs	  (Yaffe	  et	  
al.,	  1997)	  (see	  section	  1.6.2),	  with	  mode	  I	  motifs	  dominating	  in	  physiological	  14-­‐3-­‐3-­‐
binding	  proteins.	  These	  motifs	  overlap	  with	  the	  substrate	  specificity	  of	  AGC	  kinases	  
including	  Akt.	  This	  specificity	  means	  that	  the	  14-­‐3-­‐3	  proteins	  can	  be	  used	  to	  capture	  
and	  identify	  new	  substrates	  of	  these	  protein	  kinases	  in	  cellular	  responses	  to	  growth	  
factors	  and	  other	  stimuli	  (Dubois	  et	  al.,	  2009;	  Pozuelo	  Rubio	  et	  al.,	  2004).	  	  
Proteins	  that	  are	  phosphorylated	  in	  response	  to	  insulin	  can	  be	  purified	  using	  14-­‐3-­‐3	  
affinity	  capture	  (Pozuelo	  Rubio	  et	  al.,	  2004).	  Not	  only	  does	  this	  technique	   identify	  
new	  downstream	   targets	  of	   insulin	   signalling,	  but	   it	   also	  provides	   insight	   into	   the	  
biological	  effects	  of	  14-­‐3-­‐3s	  (Chen	  et	  al.,	  2011).	  	  Binding	  of	  14-­‐3-­‐3s	  to	  their	  targets	  
can	   trigger	   conformational	   changes,	   and	   can	   also	   alter	   how	   the	   binding	   proteins	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interact	  with	  other	  proteins	   (see	  section	  1.6.3).	  Therefore,	   identifying	  targets	  that	  
bind	   to	   14-­‐3-­‐3	   proteins	   provides	   a	   good	   starting	   point	   for	   determining	   the	  
mechanisms	  that	  are	  responsible	  for	  translating	  insulin-­‐stimulated	  phosphorylation	  
events	   into	  physiological	  actions	  and	   for	  mediating	  many	  of	   the	  actions	  of	   insulin	  
(Chen	  et	  al.,	  2011).	  
	  
4.2 Identification	  of	  insulin-­‐induced	  14-­‐3-­‐3	  binding	  proteins	  in	  
HBMECs	  
A	  large-­‐scale	  14-­‐3-­‐3	  affinity	  purification	  was	  performed	  to	  identify	  phosphorylated	  
targets	   of	   insulin	   signalling	   in	   ECs,	   using	   a	  method	   developed	   in	   the	  MacKintosh	  
laboratory	   (Pozuelo	   Rubio	   et	   al.,	   2004).	   HBMECs	   were	   incubated	   in	   low	   serum	  
conditions	   for	   16	   h	   (as	   previous	   described	   in	   sections	   2.5.3	   and	   3.2)	   and	   either	  
stimulated	  with	   insulin	   (100	  nM)	  for	  10	  min	  or	   left	  unstimulated.	  Cells	  were	   lysed	  
and	  extracts	  run	  through	  14-­‐3-­‐3-­‐Sepharose	  columns.	  Proteins	  that	  bound	  to	  14-­‐3-­‐3s	  
were	   eluted	   from	   the	   column	   by	   competition	   with	   a	   14-­‐3-­‐3-­‐binding	  
phosphopeptide	   ARAApSAPA	   (see	   Figure	   2.5).	   Figure	   4.1	   shows	   these	   eluted	  
proteins	   after	   concentration	   of	   approximately	   90	   fold,	   SDS-­‐PAGE	   separation	   and	  
visualisation	   with	   colloidal	   Coomassie	   blue.	   14-­‐3-­‐3-­‐capture	   chromatography	  
enriched	   several	   proteins	   compared	   to	   total	   cell	   extracts,	   however	   major	  
differences	  between	  insulin-­‐stimulated	  and	  control	  samples	  were	  not	  noticeable	  by	  
eye.	  This	  is	  not	  uncommon	  as	  the	  sensitivity	  required	  to	  detect	  these	  changes	  is	  not	  
achievable	  with	  Coomassie	  staining	  (Weiss	  et	  al.,	  2009).	  The	  lanes	  containing	  14-­‐3-­‐3	  
column	  eluates	  were	  each	  excised	  from	  the	  gel	  in	  six	  segments	  for	  tryptic	  digestion	  
and	   mass	   spectral	   analysis.	   Mass	   fingerprinting	   for	   protein	   identification	   was	  
performed	  on	  the	  tryptic	  peptides	  by	  LC-­‐MS-­‐MS	  on	  a	  Thermo	  LTQ-­‐Orbitrap	  system	  
by	   staff	   at	   the	   MRC	   Protein	   Phosphorylation	   Unit	   mass	   spectrometry	   service	  
(College	  of	  Life	  Sciences,	  University	  of	  Dundee).	  RAW	  files	  from	  Excalibur	  (Thermo)	  
were	  processed	  by	  Raw2msm	  (Olsen	  et	  al.,	  2005)	  to	  generate	  peak	  lists	  that	  were	  
analysed	   using	   the	   Mascot	   search	   engine	   (www.matrixscience.com)	   against	   the	  
UniProt	  database	   (release	  2012	  03	   (consisting	  of	  535	  248	  sequences	  and	  189	  901	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164	  residues).	  The	  significance	  threshold	  was	  p	  <	  0.05,	  only	  peptides	  with	  ion	  scores	  
over	  20	  were	  considered	  and	  only	  proteins	  with	  at	   least	  one	  unique	  peptide	   (red	  
bold	   in	  Mascot)	   were	   considered	   (see	   section	   2.6.2).	   In	   total,	   299	   proteins	   were	  
identified	  from	  the	  unstimulated	  control	  extract,	  and	  390	  proteins	   identified	  from	  
the	   insulin-­‐stimulated	   HBMEC	   extract.	   Supplementary	   Table	   1	   provides	   the	   full	  
dataset	  of	  proteins	  identified	  in	  the	  screen.	  14-­‐3-­‐3-­‐binding	  proteins	  for	  which	  14-­‐3-­‐
3-­‐binding	  sites	  have	  been	  established	  in	  the	  literature	  are	  known	  as	  ‘gold	  standard’	  
proteins.	  Seven	  ‘gold	  standard’	  proteins	  were	  identified	  in	  this	  study	  (highlighted	  in	  
red	   in	   Supplementary	   Table	   S1),	   as	   well	   as	   26	   established	   insulin	   mediators	  
(highlighted	  in	  blue	  in	  Supplementary	  Table	  S1),	  such	  as	  Mitogen-­‐activated	  protein	  
kinase	  1	  and	  Insulin-­‐degrading	  enzyme.	  
	  
Figure	  4.1	  Coomassie-­‐stained	  SDS-­‐polyacrylamide	  gel	  of	  HBMEC	  proteins	  eluted	  
from	  the	  14-­‐3-­‐3-­‐affinity	  chromatography	  columns	  
HBMECs	  were	   stimulated	  with	   insulin	   (100	  nM)	   for	  10	  min,	  or	   left	  unstimulated	   (control)	  
after	  incubation	  in	  DMEM	  containing	  1%	  FCS	  for	  16	  h.	  Small	  aliquots	  of	  the	  protein	  lysates	  
were	   stored	   for	   crude	   sample,	   and	   proteins	   in	   cell	   lysates	   were	   captured	   on	   14-­‐3-­‐3-­‐
Sepharose.	  After	  washing,	  parallel	  elutions	  with	  2	  mM	  of	  the	  competitive	  phosphopeptide	  
ARAApSAPA	  were	   performed.	   Following	   concentration	   in	   Vivaspin	   concentrators	   (10	   000	  
MW	  cut-­‐off),	   the	   eluted	   samples	  were	   separated	  on	   a	   4–12%	  Bis-­‐Tris	   SDS-­‐polyacryamide	  
gel	   and	   proteins	  were	   visualised	   using	   colloidal	   Coomassie	   blue.	   The	   two	   lanes	  were	   cut	  
into	  six	  horizontal	  fragments	  (labelled	  1-­‐12)	  for	  tryptic	  digestion	  and	  mass	  spectral	  analysis.	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In	  order	  to	  investigate	  how	  the	  14-­‐3-­‐3-­‐binding	  proteins	  isolated	  from	  ECs	  relate	  to	  
all	   the	   currently	   known	   14-­‐3-­‐3	   partners,	   the	   data	   were	   compared	   to	   the	   14-­‐3-­‐3	  
interactome	   of	   all	   known	   14-­‐3-­‐3-­‐binding	   partners	   to	   date	   (Figure	   4.2).	   This	  
interactome	   was	   created	   by	   Johnson	   et	   al.	   (2011),	   with	   data	   collated	   from	  
publications	   that	   described	   one-­‐interaction	   at	   a	   time,	   as	  well	   as	   high-­‐throughput	  
14-­‐3-­‐3-­‐affinity	   and	   mass	   spectrometry-­‐based	   studies.	   Proteins	   identified	   in	   the	  
present	  study	  were	  added	  to	  the	  database	  and	  transcribed	  into	  a	  VisANT	  graph	  (Hu	  
et	   al.,	   2009)	   to	   identify	   the	   commonalities	   and	   differences	   among	   experiments.	  
Each	   study	   was	   assigned	   a	   node	   (red),	   connected	   to	   all	   the	   proteins	   identified	  
(green)	   in	   that	   study	   by	   grey	   lines.	   If	   identical	   proteins	   were	   identified	   in	   other	  
studies,	  another	  grey	   line	  connects	  to	   it	   from	  that	  particular	  node,	  and	  orientates	  
the	  protein	  between	  the	  two	  studies.	  Using	  the	  ‘relaxed	  elegant’	  VisANT	  rule	  (Hu	  et	  
al.,	   2004)	   proteins	   that	   were	   identified	   in	   at	   least	   3	   studies	   were	   placed	   in	   the	  
centre	  of	  the	  figure,	  whereas	  proteins	  on	  the	  outer	  edges	  were	  unique	  to	  each	  of	  
the	   individual	   studies.	   All	   known	   gold	   standard	   proteins	   are	   depicted	   in	  magenta	  
(GD,	  Figure	  4.2).	  Of	  the	  433	  14-­‐3-­‐3-­‐binding	  proteins	   identified	   in	  this	  study	  (blue),	  
234	   proteins	   were	   previously	   identified	   in	   other	   studies,	   and	   199	   proteins	   were	  
unique	  (Figure	  4.2).	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Figure	  4.2	  HBMEC	  14-­‐3-­‐3-­‐Binding	  partners	  in	  the	  relation	  to	  14-­‐3-­‐3	  interactome	  	  
A	  VisANT	  graph	  showing	  overlap	  between	  14-­‐3-­‐3-­‐captured	  proteins	   identified	   in	  HBMECs	  
(Figure	   4.1)	   and	   proteins	   identified	   for	   their	   affinity	   for	   14-­‐3-­‐3s	   in	   proteomics	   screens	  
reported	   in	  the	   literature	  (Johnson	  et	  al.,	  2011).	  Each	  study	   is	  assigned	  a	  node	   in	  red	  and	  
grey	  lines	  connect	  the	  same	  proteins	  between	  studies,	  which	  are	  assigned	  as	  green	  nodes.	  
Gold	   standard	   proteins	   (GD),	   for	   which	   14-­‐3-­‐3-­‐binding	   sites	   have	   been	   established,	   are	  
depicted	   in	  magenta.	  Blue	  nodes	  are	  proteins	   identified	   in	  this	  HBMEC	  study.	  The	  14-­‐3-­‐3-­‐
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Changes	   in	   endothelial	   cell-­‐cell	   junctions	   and	   the	   endothelial	   cytoskeleton	   are	  
essential	   for	  vascular	  repair	  and	   inflammatory	  responses	  (see	  section	  1.2.5).	  Since	  
insulin	   stimulation	   decreased	   basal	   endothelial	   permeability,	   and	   increased	   EC	  
migration	  and	  angiogenic	  loop	  formation	  (see	  Chapter	  3),	  the	  next	  aim	  of	  the	  study	  
was	  to	  identify	  proteins	  that	  regulate	  the	  effects	  of	  insulin	  on	  cell-­‐cell	  junctions	  and	  
cell	   migration.	   Among	   the	   14-­‐3-­‐3-­‐binding	   proteins	   identified	   in	   HBMECs,	   those	  
involved	   in	  cytoskeletal	   regulation	  were	  therefore	  of	  particular	   interest,	  especially	  
Rho	   family	   signalling	   components,	   as	   these	   proteins	   regulate	   actin	   cytoskeletal	  
organization	  and	  intercellular	  junction	  integrity	  (Ridley,	  2006).	  Twelve	  of	  the	  14-­‐3-­‐3-­‐
binding	  proteins	  identified	  in	  HBMECs	  were	  shortlisted	  for	  further	  analysis	  based	  on	  
their	   predicted	   roles	   in	   endothelial	   cytoskeletal	   regulation	   (Table	   4.1).	   Proteins	  
highlighted	  in	  blue	  were	  isolated	  in	  both	  insulin-­‐stimulated	  and	  control	  lysates,	  and	  
proteins	  highlighted	   in	  yellow	  were	   isolated	   from	  the	   insulin-­‐stimulated	  cells	  only	  
(Table	   4.1).	   Transforming	   protein	   RhoA	   (RhoA),	   Ras-­‐related	   C3	   botulinum	   toxin	  
substrate	  3	  (Rac3)	  and	  Cell	  division	  control	  protein	  42	  (Cdc42)	  are	  Rho	  GTPases.	  Rho	  
guanine	   nucleotide	   exchange	   factor	   16	   (ARHGEF16)	   and	   Dedicator	   of	   cytokinesis	  
protein	   10	   (DOK10)	   are	   guanine	   nucleotide	   exchange	   factors	   (GEFs,	   GTPase	  
activators).	   RICH-­‐1	   and	   Parg1	   are	   GTPase-­‐activating	   proteins	   (GAPs,	   down	  
regulators	   of	   GTPases);	   and	   Rho	   GDP-­‐dissociation	   inhibitor	   1	   and	   2	   (GDIR1	   and	  
GDIR2)	  are	  Rho	  GDP	  dissociation	   inhibitors	  (RhoGDIs,	  sequestering	  GTPases	   in	  the	  
cytoplasm).	  See	  section	  1.4.1	   for	   regulation	  of	  Rho	  GTPase	  activity.	  Epsin2	   (EPN2)	  
and	   Sec1	   family	   domain-­‐containing	   protein	   1	   (SCFD1)	   are	   proteins	   involved	   in	  
clathrin-­‐mediated	   endocytosis,	   and	   EPN2	   has	   previously	   been	   shown	   to	   regulate	  
Cdc42	   signalling	   (Aguilar	   et	   al.,	   2006).	   LIM	   domain	   only	   protein	   7	   (LMO7)	   is	   a	  
regulator	  of	  the	  myocardin-­‐related	  transcription	  factors	  (MRTFs),	  and	  has	  recently	  
been	  shown	  to	  play	  an	  important	  role	  in	  cell	  migration,	  requiring	  Rho	  GTPases	  (Hu	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   Protein	  Name	   Abbreviation	   	  
1	   Transforming	  protein	  RhoA	  	   RHOA	  
RhoGTPase	  2	   Ras-­‐related	  C3	  botulinum	  toxin	  substrate	  3	   RAC3	  
3	   Cell	  division	  control	  protein	  42	   CDC42	  
4	   Rho	  guanine	  nucleotide	  exchange	  factor	  16	   ARHGEF16	  	  
RhoGEF	  
5	   Dedicator	  of	  cytokinesis	  protein	  10	   DOC10	  
6	   Rho	  GDP-­‐dissociation	  inhibitor	  1	   GDIR1	  
RhoGDI	  
7	   Rho	  GDP-­‐dissociation	  inhibitor	  2	   GDIR2	  
8	   Rho	  GTPase-­‐activating	  protein	  17	   RICH-­‐1	  
RhoGAP	  
9	   Rho	  GTPase-­‐activating	  protein	  29	   PARG1	  
10	   Epsin2	   EPN2	   	  	  
11	   Sec1	  family	  domain-­‐containing	  protein	  1	   SCFD1	   	  	  
12	   LIM	  domain	  only	  protein	  7	   LMO7	   	  
	  
	  
Table	  4.1	  HBMEC	  14-­‐3-­‐3-­‐binding	  proteins	  shortlisted	  for	  further	  analysis	  
Mass	  spectral	  analysis	  identified	  299	  proteins	  in	  the	  control	  sample,	  and	  390	  proteins	  in	  the	  
insulin-­‐stimulated	   sample	   from	   the	   phosphopeptide	   elution	   of	   the	   14-­‐3-­‐3-­‐affinity	  
chromatography.	  From	  these,	  12	  proteins	  were	  chosen	  for	  further	  analysis	  based	  on	  their	  
predicted	   roles	   in	   endothelial	   cytoskeletal	   regulation.	   Proteins	   highlighted	   in	   blue	   were	  
isolated	   in	  both	   insulin-­‐stimulated	  and	   control	   lysates,	   and	  proteins	  highlighted	   in	   yellow	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4.3 Validation	  of	  protein	  hits	  
Proteins	  isolated	  by	  14-­‐3-­‐3	  affinity	  capture	  include	  phosphoproteins	  that	  bind	  14-­‐3-­‐
3s	   directly,	   as	   well	   as	   proteins	   that	   bind	   14-­‐3-­‐3s	   indirectly	   as	   components	   of	  
multiprotein	  complexes.	  In	  order	  to	  test	  which	  of	  the	  twelve	  selected	  proteins	  bind	  
directly	   to	   14-­‐3-­‐3s	   and	   are	   regulated	   by	   insulin	   signalling,	   14-­‐3-­‐3	   far-­‐Western	  
overlay	   assays	   were	   performed	   (Moorhead	   et	   al.,	   1999).	   Validation	   analysis	   in	  
HBMECs	   with	   insulin	   stimulation	   would	   have	   been	   ideal,	   however	   this	   was	  
precluded	   by	   the	   low	   transfection	   rates	   and	   subtle	   insulin	   responses	   observed	   in	  
HBMECs	   (see	   section	   3.2).	   As	   the	   interaction	   between	   14-­‐3-­‐3	   proteins	   and	   their	  
possible	   binding	   partners	  was	   the	   focus	   of	   these	   experiments,	   human	   embryonic	  
kidney	  cells	   (HEK293)	  were	  chosen	   for	   their	  high	   transfection	  efficiency	   rates	  and	  
ability	   to	  generate	   functional,	  mature	  proteins	   from	  plasmid	  vectors	   (Thomas	  and	  
Smart,	  2005).	  HEK293	  cells	  express	  both	  IR	  and	  IGF-­‐IR,	  which	  share	  a	  high	  similarity	  
of	   structure	   and	   intracellular	   signalling	   events	   (Dupont	   and	   LeRoith,	   2001).	  
However,	  HEK293	  cells	  are	  more	  sensitive	  to	  IGF-­‐I	  stimulation	  (Beitner-­‐Johnson	  and	  
LeRoith,	   1995;	   El-­‐Shewy	   et	   al.,	   2007)	   and	   thus	   IGF-­‐I	   was	   used	   for	   14-­‐3-­‐3	   binding	  
validation	   analyses.	   A	   PI3K	   inhibitor	   (PI-­‐103)	   (Knight	   et	   al.,	   2006)	  was	   included	   in	  
these	  experiments	  to	  determine	  whether	  protein	  phosphorylation,	  and	  hence	  14-­‐3-­‐
3	  binding,	  was	  stimulated	  via	  the	  PI3K/Akt	  pathway.	  GFP-­‐fusion	  proteins	  for	  each	  of	  
the	  proteins	   in	  Table	  4.1	  were	  over-­‐expressed	   in	  HEK293	  cells,	  which	  were	  serum	  
starved	  for	  16	  to	  18	  h,	  and	  either	  treated	  with	  IGF-­‐I,	  or	  PI-­‐103	  and	  then	  with	  IGF-­‐I.	  
The	  cells	  were	  lysed	  and	  proteins	  isolated	  by	  GFP	  immunoprecipitation,	  separated	  
by	   SDS-­‐PAGE,	   and	   transferred	   onto	   nitrocellulose	   membranes.	   Compared	   with	  
conventional	  Western	  blots,	  Far-­‐Westerns	  use	  digoxigenin	  (DIG)-­‐labelled	  14-­‐3-­‐3s	  in	  
place	   of	   the	   primary	   antibody,	   followed	   by	   a	   horseradish	   peroxidase-­‐conjugated	  
anti-­‐DIG	  antibody	  (Moorhead	  et	  al.,	  1999).	  
Vasodilator-­‐stimulated	   phosphoprotein	   (VASP)	   was	   identified	   in	   this	   study	   (see	  
Supplementary	  Table	  S1)	  and	  was	  included	  as	  a	  negative	  control	  in	  the	  14-­‐3-­‐3	  far-­‐
Western	  overlays,	  as	  it	  has	  been	  previously	  reported	  that	  VASP	  binding	  to	  14-­‐3-­‐3	  is	  
not	   regulated	   by	   insulin	   (Dubois	   et	   al.,	   2009).	   Similarly,	   Pantothenate	   kinase	   2	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(PANK2)	  was	  included	  as	  a	  positive	  control	  (Figure	  4.4),	  as	  it	  is	  an	  insulin-­‐regulated	  
14-­‐3-­‐3-­‐binding	   protein	   (MacKintosh	   laboratory,	   unpublished	   data).	   Of	   the	   twelve	  
proteins	  selected	  from	  the	  14-­‐3-­‐3-­‐affinity	  purification,	  RhoA	  and	  ARHGEF16	  did	  not	  
bind	  to	  DIG-­‐14-­‐3-­‐3	  above	  background	   levels	   (Figure	  4.3)	  and	  therefore	  most	   likely	  
came	   down	   in	   multiprotein	   complexes	   or	   they	   bound	   non-­‐specifically	   to	   the	  
Sepharose.	   SCFD1,	   Rac3,	   GDIR1,	   GDIR2,	   Cdc42	   and	   Dok10	   were	   shown	   to	   bind	  
directly	   to	   14-­‐3-­‐3	   proteins,	   but	   these	   interactions	   were	   not	   regulated	   by	   IGF-­‐1	  
(Figure	  4.3).	  
RICH-­‐1,	  Parg1,	  EPN2	  and	  LMO7	  all	  bound	  directly	  to	  14-­‐3-­‐3s	  and	  these	  interactions	  
were	  increased	  by	  IGF-­‐I	  stimulation	  and	  decreased	  by	  PI-­‐103	  (Figure	  4.4).	   	  A	  small	  
increase	   in	   14-­‐3-­‐3	   binding	   to	   RICH-­‐1	   and	   Parg1	   in	   the	   Far-­‐Western	   assay	   was	  
observed	  when	  cells	  were	  stimulated	  with	  IGF-­‐I,	  and	  so	  too	  was	  an	  increase	  in	  the	  
co-­‐immunoprecipitation	   of	   endogenous	   14-­‐3-­‐3s	   with	   the	   test	   protein.	   14-­‐3-­‐3	  
binding	   to	  EPN2	  was	   increased	  when	  cells	  were	  stimulated	  by	   IGF-­‐I,	  however	   this	  
was	  not	  decreased	  when	  PI3K	  signalling	  was	  inhibited	  with	  PI-­‐103.	  There	  are	  fifteen	  
members	  of	  the	  PI3K	  family,	  and	  although	  PI-­‐103	  is	  a	  potent	  inhibitor	  of	  PI3K	  family	  
members,	   it	   has	   selectivity	   toward	   PI3K	   class	   I	   isoforms	   (particularly	   p110α)	   and	  
mTOR	   (Knight	   et	   al.,	   2006).	  Therefore	   it	   may	   be	   that	   the	   14-­‐3-­‐3-­‐binding	   sites	   of	  
EPN2	  are	  phosphorylated	  by	  PI3K-­‐independent	  kinases	   stimulated	  by	   IGF-­‐I.	   LMO7	  
binding	  to	  14-­‐3-­‐3	  was	   increased	  by	   IGF-­‐I	  stimulation,	  and	  this	  was	   inhibited	  by	  PI-­‐
103	  (Figure	  4.4).	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Figure	  4.3	  Proteins	  whose	  binding	  to	  14-­‐3-­‐3	  is	  not	  regulated	  by	  IGF-­‐I	  in	  HEK293	  
cells	  
HEK293	  cells	  were	  transfected	  to	  express	  GFP-­‐fusions	  of	  proteins	  identified	  in	  the	  HBMEC	  
14-­‐3-­‐3-­‐affinity	  capture	  experiment.	  After	  24	  h,	  cells	  were	  serum	  starved	  (ss)	  overnight	  and	  
then	  treated	  with	  IGF-­‐I	  for	  20	  min,	  or	  PI-­‐103	  and	  IGF-­‐I	  for	  30	  min	  and	  20	  min,	  respectively.	  
Cells	   were	   lysed	   and	   proteins	   enriched	   by	   anti-­‐GFP	   immunoprecipitation.	   Samples	   were	  
electrophoresed	  on	  4–12%	  Bis-­‐Tris	  SDS-­‐polyacryamide	  gels	  and	  14-­‐3-­‐3-­‐overlays	  performed	  
to	   observe	   direct	   binding	   of	   proteins	   to	   14-­‐3-­‐3	   in	   response	   to	   IGF-­‐I	   stimulation.	   In	   some	  
cases,	   immunoprecipitated	  proteins	  were	  also	  immunoblotted	  with	  a	  pan-­‐14-­‐3-­‐3	  antibody	  
(Santa	   Cruz	   K-­‐19)	   to	   detect	   endogenous	   14-­‐3-­‐3-­‐proteins	   that	  were	   pulled	   down	  with	   the	  
overexpressed	  proteins	  of	  interest.	  Cell	  stimulation	  was	  confirmed	  by	  immunobloting	  with	  
an	  antibody	  to	  pAkt.	  VASP	  was	  used	  as	  a	  negative	  control,	  as	  it	   is	  a	  known	  14-­‐3-­‐3	  binding	  
protein,	  whose	  interaction	  is	  not	  regulated	  by	  insulin.	  Images	  are	  representative	  blots	  from	  
three	  independent	  experiments.	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Figure	  4.4	  Proteins	  whose	  binding	  to	  14-­‐3-­‐3	  is	  stimulated	  by	  IGF-­‐I	  
HEK293	  cells	  were	  transfected	  to	  express	  GFP-­‐fusions	  of	  proteins	  identified	  in	  the	  HBMEC	  
14-­‐3-­‐3-­‐affinity	  capture.	  After	  24	  h,	  cells	  were	  serum	  starved	  (ss)	  overnight	  and	  then	  treated	  
with	  IGF-­‐1	  for	  20	  min,	  or	  PI-­‐103	  followed	  by	  IGF-­‐1	  for	  30	  min	  and	  20	  min,	  respectively.	  Cells	  
were	   lysed	  and	  proteins	  enriched	  by	  anti-­‐GFP	   immunoprecipitation.	  Samples	  were	  run	  on	  
SDS-­‐PAGE	  gels	  and	  14-­‐3-­‐3-­‐overlays	  were	  performed	  to	  observe	  protein	  binding	  to	  14-­‐3-­‐3	  in	  
response	  to	  IGF-­‐1	  stimulation.	  Immunoprecipitated	  proteins	  were	  also	  probed	  with	  a	  pan-­‐
14-­‐3-­‐3	  antibody	  (Santa	  Cruz	  K-­‐19)	  to	  detect	  endogenous	  14-­‐3-­‐3-­‐proteins	  that	  were	  pulled	  
down	   with	   the	   overexpressed	   proteins	   of	   interest.	   Cell	   stimulation	   was	   confirmed	   by	  
immunobloting	  with	  an	  antibody	  to	  pAkt.	  PANK2	  was	  used	  as	  a	  positive	  control,	  as	   it	   is	  a	  
known	   insulin-­‐regulated	   14-­‐3-­‐3	   binding	   protein.	   Graphs	   were	   generated	   from	   data	  
analysed	  by	  densitometric	  scanning	  of	  DIG-­‐14-­‐3-­‐3	   from	  each	  representative	  Western	  blot	  
above,	   normalised	   to	   GFP.	   Images	   and	   their	   respective	   quantitation	   are	   representative	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4.4 Bioinformatic	  prediction	  of	  14-­‐3-­‐3	  binding	  sites	  
Much	   is	  already	  known	  about	   the	  sequences	  of	  14-­‐3-­‐3-­‐binding	  motifs	   in	  proteins,	  
which	  can	  be	  translated	  into	  algorithms	  to	  predict	  potential	  phosphorylation	  sites.	  
Together	  with	   the	  high	  affinity	  binding	  motifs	   (see	   section	  1.6.2),	   there	  are	  other	  
structural	   restrictions	   that	   have	   been	   identified.	   Generally	   14-­‐3-­‐3-­‐binding	  
phosphosites	  must	  have	  at	  least	  one	  basic	  residue	  in	  the	  -­‐3	  to	  -­‐5	  positions	  relative	  
to	  the	  phosphorylated	  serine	  or	  threonine,	  and	  never	  a	  +1	  proline	  (Tinti	  et	  al.,	  2012;	  
Yaffe	  et	  al.,	  1997).	  Several	  in	  silico	  methods	  are	  available	  to	  predict	  phosphosites	  on	  
linear	  motifs	  ranging	  from	  simple	  consensus	  patterns	  and	  position-­‐specific	  scoring	  
matrix	   (PSSM)	   to	   more	   advanced	   machine-­‐learning	   algorithms	   such	   as	   artificial	  
neuronal	  networks	  (NetPhosK,	  (Hjerrild	  et	  al.,	  2004))	  (reviewed	  in	  (Miller	  and	  Blom,	  
2009)	   and	   (Krogh,	   2008)).	   PSSM	   is	   a	   sequence	   profile	   that	   represents	   the	  
preference	  of	  particular	  amino	  acids	  surrounding	  the	  residue	  of	  interest	  (Miller	  and	  
Blom,	  2009).	  	  
Recently,	   Tinti	   et	   al.	   (2012)	   demonstrated	   that	  most	  well-­‐defined	   human	   14-­‐3-­‐3-­‐
binding	  proteins	  are	  2R-­‐ohnologues,	  which	  are	  protein-­‐coding	  genes	  in	  families	  that	  
were	   produced	   by	   two	   rounds	   of	   whole	   genome	   duplication	   at	   the	   origin	   of	  
vertebrates,	  and	  usually	  consist	  of	  two	  to	  four	  members	  in	  a	  family.	  Aligning	  14-­‐3-­‐3-­‐
binding	   proteins	   with	   their	   pro-­‐orthologues	   from	   the	   invertebrate	   chordates	  
identified	   lynchpins:	   14-­‐3-­‐3-­‐binding	   phosphosites	   that	   are	   conserved	   across	  
members	   of	   a	   given	   family.	   Current	   experiments	   in	   the	   MacKintosh	   laboratory	  
indicate	  that	  aligning	  the	  sequences	  of	  14-­‐3-­‐3-­‐binding	  proteins	  with	  other	  members	  
of	  their	  2R-­‐ohnologue	  family	  and	  searching	  for	  potential	  lynchpins	  provides	  a	  better	  
method	   of	   predicting	   14-­‐3-­‐3-­‐binding	   sites,	   compared	   with	   motif-­‐based	   profile	  
scanning	   alone.	   	   The	   search	   for	   lynchpins	   also	   takes	   account	   of	   physiological	  
phosphorylation	   sites	   that	   are	   recorded	   in	   Phosphosite	   (www.phosphosite.org)	  
(Hornbeck	   et	   al.,	   2012).	   While	   these	   bioinformatics	   predictions	   are	   accelerating	  
experimental	   identification	  of	  regulatory	  sites,	  they	  are	  not	   intended	  to	  substitute	  
for	  experimental	  analyses.	  With	   this	   caution,	  Michele	  Tinti	   (University	  of	  Dundee)	  
performed	  this	  method	  of	  sequence	  alignment	  for	  RICH-­‐1,	  Parg1,	  Epsin2	  and	  LMO7	  
to	  predict	  their	  candidate	  14-­‐3-­‐3	  phosphosites	  (Table	  4.2).	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Protein	  	  
ID	   Description	   Abbreviation	   Candidate	  phosphorylation	  site(s)	  




Q52LW3	   ARHGAP29/Parg1	   RHG29_HUMAN	   S607	   S1019	  
S1144/
S1146	   	  	   	  	  
O95208	   Epsin2	   EPN2_HUMAN	   T272	   	  	   	  	  
	   	  Q8WWI1	   LIM	  domain	  only	  7	   LMO7_HUMAN	   S300	   T753	   T780	   S1493	   S1510	  
	  
Table	  4.2	  Summary	  of	  candidate	  14-­‐3-­‐3-­‐binding	  phosphosites	  for	  IGF-­‐I-­‐responsive	  
14-­‐3-­‐3-­‐binding	  proteins	  
	  
RICH-­‐1	   is	   predicted	   to	   have	   two	   potential	   14-­‐3-­‐3-­‐binding	   phosphosites,	   S595	   and	  
T808	   (Figure	   4.5).	   These	   were	   predicted	   by	   aligning	   sequences	   from	   ARHGAP44	  
(RICH-­‐2),	   SH3	   domain-­‐binding	   protein	   1,	   and	   from	   the	   genome	   sequence	   of	  
amphioxus	   (lancelet,	  Branchiostoma),	   the	   least-­‐derived	   living	   invertebrate	   relative	  
of	  the	  vertebrates	  within	  the	  phylum	  Chordata	  (Tinti	  et	  al.,	  2012).	  Neither	  of	  these	  
sites	  match	   the	   Akt	   consensus,	   and	   therefore	   could	   be	   phosphorylated	   by	   other	  
AGC	  kinases	  activated	  by	  insulin.	  
The	   putative	   14-­‐3-­‐3	   binding	   phosphosites	   for	   Parg1	   (S607;	   S1019;	   S1144/1146)	  
were	   identified	   by	   aligning	   sequences	   from	   GEM-­‐interacting	   protein,	   Minor	  
histocompatibility	  protein	  HA-­‐1	  and	  sequences	  from	  invertebrates	  Caenorhabditis,	  
Cintestinalis,	  Branchiostoma	  floridae,	  and	  Trichoplax	  adhaerens	  (Figure	  4.6).	  S1019	  
and	   S1146	   are	   identified	   to	   conform	   to	   Akt	   consensus	   sites	   when	   analysed	   on	  
ScanSite	   2.0	   (Obenauer	   et	   al.,	   2003)	   using	   a	  medium	   stringency	   threshold,	  which	  
indicates	   that	   the	  motif	   identified	   is	  within	   the	   top	  1%	  of	   all	  matching	   sequences	  
contained	  in	  the	  SwissProt	  vertebrate	  database.	  
Epsins	   are	   a	   conserved	   family	   of	   endocytic	   adapter	   proteins.	   When	   EPN2	   was	  
aligned	  with	  other	  members	  of	  the	  epsin	  family,	  as	  well	  as	  thirteen	  chordates,	  only	  
T272	  was	  identified	  as	  a	  potential	  14-­‐3-­‐3-­‐binding	  phosphosite	  (Figure	  4.7).	  This	  site	  
is	   highly	   conserved	   throughout	   the	   sequences,	   however	   is	   not	   a	   predicted	   Akt	  
consensus	  site.	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LMO7	  has	  been	   identified	   in	   five	  previous	  high-­‐throughput	  14-­‐3-­‐3-­‐binding	   studies	  
(Benzinger	   et	   al.,	   2005;	   Dubois	   et	   al.,	   2009;	   Johnson	   et	   al.,	   2010;	   Larance	   et	   al.,	  
2010;	   Meek	   et	   al.,	   2004).	   There	   are	   five	   putative	   14-­‐3-­‐3-­‐binding	   phosphosites	  
(S300;	   T753;	   T780;	   S1493	  and	  S1510),	   predicted	  by	   sequence	  alignment	  with	   LIM	  
and	  calponin	  homology	  domains-­‐containing	  protein	  1,	  and	  four	  different	  chordates	  
(Figure	   4.8).	   S1493	   is	   identified	   as	   an	   Akt	   consensus	   site	   using	   a	   high	   stringency	  
threshold,	   which	   indicates	   that	   the	   motif	   identified	   is	   within	   the	   top	  0.2%	  of	   all	  
matching	   sequences	   contained	   in	   the	   SwissProt	   vertebrate	   database.	   S1510	  
matches	  Akt	  consensus	  under	  medium	  stringency.	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Figure	  4.5	  Bioinformatic	  prediction	  of	  14-­‐3-­‐3	  phosphorylation	  sites	  for	  ARHGAP17	  (RICH-­‐1)	  
The	  sequence	  of	  ARHGAP17	  (RICH-­‐1;	  RHG17)	  was	  aligned	  with	  ARHGAP44	  (RICH-­‐2),	  SH3	  domain-­‐binding	  
protein	  1	  (3BP1),	  and	  amphioxus	  (lancelet,	  Branchiostoma,	  the	  last-­‐derived	  living	  invertebrate	  relative	  of	  
the	  vertebrates	  within	  the	  phylum	  Chordata)	  using	  Jalview	  (version	  2.8,	  http://www.jalview.org/).	  Figure	  
only	  depicts	  regions	  of	  the	  sequence	  that	  contain	  predicted	  14-­‐3-­‐3-­‐binding	  phosphosites	  (highlighted	  in	  
red	  boxes,	  predicted	  by	  both	  neural	  network	  and	  position	  specific	   scoring	  matrix),	  with	   the	  alignment	  
column	   number	   depicted	   above	   the	   sequences.	   	   Blue	   lines	   and	   arrows	   indicate	  where	   regions	   in	   the	  
sequences	   were	   condensed.	   Full	   sequence	   alignments	   are	   provided	   on	   the	   compact	   disc	   (CD)	   in	   the	  
supplementary.	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Figure	  4.6	  Bioinformatic	  prediction	  of	  14-­‐3-­‐3	  phosphorylation	  sites	  for	  ARHGAP29	  (Parg1)	  
The	  sequence	  of	  ARHGAP29	  (Parg1,	  RHG29)	  was	  aligned	  with	  GEM-­‐interacting	  protein	  (GMIP),	  Minor	  histocompatibility	  protein	  HA-­‐1	  (HMHA1)	  
and	  homologous	   sequences	   from	   invertebrates	  Caenorhabditis,	   Cintestinalis,	   Branchiostoma	   floridae,	   and	  Trichoplax	   adhaerens	  using	   Jalview	  
(version	  2.8,	  http://www.jalview.org/).	  14-­‐3-­‐3-­‐binding	  phosphosites	  (red	  boxes)	  highlighted	  in	  light	  blue	  are	  predicted	  by	  either	  neural	  network	  
or	  position	  specific	  scoring	  matrix;	  residues	  highlighted	  in	  red	  are	  predicted	  by	  both.	  Figure	  only	  depicts	  regions	  of	  the	  sequence	  that	  contain	  
predicted	  14-­‐3-­‐3-­‐binding	  phosphosites,	  with	  the	  alignment	  column	  number	  depicted	  above	  the	  sequences.	  Blue	  lines	  and	  arrows	  indicate	  where	  
regions	  in	  the	  sequences	  were	  condensed.	  Full	  sequence	  alignments	  are	  provided	  on	  the	  CD	  in	  the	  supplementary.	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Figure	  4.7	  Bioinformatic	  prediction	  of	  14-­‐3-­‐3	  phosphorylation	  sites	  for	  Epsin2	  (EPN2)	  
The	   sequence	   of	   EPN2	   was	   aligned	   with	   other	   members	   of	   the	   human	   Epsin	   family	   as	   well	   as	  
homologous	  sequences	  from	  13	  chordates	  using	  Jalview	  (version	  2.8,	  http://www.jalview.org/).	  T272	  is	  
the	   putative	   14-­‐3-­‐3-­‐binding	   phosphosite	   highlighted	   in	   red,	   based	   on	   predictions	   from	   both	   neural	  
network	   and	   position	   specific	   scoring	   matrix.	   The	   alignment	   column	   number	   is	   depicted	   above	   the	  
sequences.	  Full	  sequence	  alignment	  is	  provided	  on	  the	  CD	  in	  the	  supplementary.	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Figure	  4.8	  Bioinformatic	  prediction	  of	  14-­‐3-­‐3	  phosphorylation	  sites	  for	  LIM	  domain	  only	  7	  (LMO7)	  
The	   sequence	   of	   LMO7	   was	   aligned	   with	   LIM	   and	   calponin	   homology	   domains-­‐containing	   protein	   1,	   and	   homologous	   sequences	   from	   four	  
different	  chordates	  using	  Jalview	  (version	  2.8,	  http://www.jalview.org/).	  The	  putative	  14-­‐3-­‐3-­‐binding	  phosphosites	  are	  highlighted	  in	  red	  boxes;	  
blue	  residues	  are	  predicted	  by	  neural	  network	  or	  position	  specific	  scoring	  matrix	  and	  red	  residues	  predicted	  by	  both.	  Figure	  only	  depicts	  regions	  
of	   the	  sequence	  that	  contain	  predicted	  14-­‐3-­‐3-­‐binding	  phosphosites,	  with	  the	  alignment	  column	  number	  depicted	  above	  the	  sequences.	  Blue	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4.5 Discussion	  
Insulin	   exerts	   most	   of	   its	   metabolic	   actions	   by	   protein	   phosphorylation	   cascades	  
through	   the	   PI3K/Akt	   pathway,	   which	   plays	   an	   essential	   role	   in	   regulating	   many	  
biological	   processes.	   Most	   metabolic	   pathways	   are	   mapped	   using	   a	   reverse	  
discovery	  method,	  whereby	  the	  metabolic	  action	  is	  identified	  and	  used	  as	  the	  end	  
point	   to	   determine	   the	   upstream	   signalling.	   However,	   a	   forward	   method	   of	  
discovery	   is	   possible	   by	   using	   14-­‐3-­‐3	   proteins	   as	   bait	   to	   identify	   novel	   insulin-­‐
responsive	   proteins	   (Larance	   et	   al.,	   2010).	   The	   phosphorylation	   of	   many	   AGC	  
protein	  kinase	  substrates	  creates	  a	  docking	  site	  for	  14-­‐3-­‐3	  protein	  family	  members	  
(Johnson	  et	  al.,	  2010)	  and	  this	  high	  affinity	  binding	  specificity	  was	  used	  to	  identify	  
insulin-­‐stimulated	   protein	   phosphorylation	   changes	   in	   ECs.	   Although	   14-­‐3-­‐3	  
proteins	  do	  not	  bind	  to	  phosphorylated	  tyrosines	  or	  to	  phosphorylated	  serines	  and	  
threonines	   that	   are	   followed	  by	  proline	   residues	   (Chen	  et	   al.,	   2011),	   this	  method	  
captures	  many	   of	   the	   phosphorylation	   changes	   stimulated	   by	   insulin.	   	  Whilst	   the	  
raw	  data	  from	  the	  screen	  is	  likely	  to	  contain	  false	  positives/negatives,	  the	  use	  of	  14-­‐
3-­‐3-­‐phosphoproteomics	   has	   been	   used	   previously	   to	   identify	   many	   proteins	   that	  
bind	   to	   14-­‐3-­‐3	   proteins	   in	   response	   to	   signalling	   pathways	   that	   are	   activated	   by	  
insulin	   (Dubois	   et	   al.,	   2009;	   Larance	   et	   al.,	   2010).	   The	   screen	   provides	   a	   good	  
starting	   point	   to	   identify	   several	   candidates,	   which	   can	   then	   be	   validated	   with	  
biochemical	  techniques	  as	  novel	  targets	  of	  the	  insulin	  PI3K/Akt	  signalling	  pathway.	  
A	  visual	  representation	  of	  the	  14-­‐3-­‐3	  binding	  proteins	  isolated	  from	  ECs	  in	  relation	  
to	   other	   published	   14-­‐3-­‐3-­‐phosphoproteomics	   screens	   best	   demonstrates	   the	  
similarities	  and	  differences	  observed	  between	  14-­‐3-­‐3	  screens	  (see	  Figure	  4.2).	  Each	  
study	   identifies	   new	   proteins,	   but	   sometimes	   also	   fails	   to	   recognise	   proteins	  
discovered	   in	   other	   studies.	   Interestingly,	   this	   even	   occurs	   when	   studies	   are	  
compared	   using	   the	   same	   experimental	   conditions	   (Johnson	   et	   al.,	   2010).	   These	  
discrepancies	  are	  to	  be	  expected	  as	  a	  consequence	  of	  all	  the	  variables	   involved	  in	  
proteomic	  methods	  and	  mass	  spectrometry.	  Therefore	  14-­‐3-­‐3	  binding	  proteins	  only	  
identified	  in	  this	  study	  and	  not	  others	  may	  not	  necessarily	  be	  unique	  to	  ECs,	  but	  the	  
screen	   provided	   interesting	   candidates	   to	   study	   functionally	   in	   ECs.	   The	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identification	  of	  seven	  known	  14-­‐3-­‐3	  ‘gold	  standard’	  proteins,	  such	  as	  Yorkie,	  Cofilin	  
and	   Myosin	   phosphatase-­‐targeting	   subunit	   1	   (MYPT1),	   in	   the	   screen	   was	  
encouraging	   and	   added	   a	   level	   of	   confidence	   to	   the	   protein	   hits	   identified.	   The	  
positioning	  of	  a	  specific	  protein	  in	  the	  VisANT	  graph	  does	  not	  increase	  its	  prediction	  
as	  a	  valid	  14-­‐3-­‐3	  binding	  protein,	  as	  ‘gold	  standard’	  proteins	  are	  distributed	  both	  in	  
the	  centre	  and	  periphery	  of	  the	  graph	  (Johnson	  et	  al.,	  2010).	  	  
	  
4.5.1 Selection	  of	  potential	  actin	  cytoskeleton	  regulators	  	  
After	   observing	   that	   insulin	  was	   able	   to	   induce	   some	   cytoskeletal	   changes	   in	   ECs	  
and	   to	   enhance	   barrier	   function	   (see	   section	   3.3.1),	   increase	   cell	   migration	   (see	  
section	   3.4)	   and	   increase	   angiogenic	   loop	   formation	   (see	   section	   3.5),	   particular	  
interest	  was	  placed	  on	  the	  Rho	  family	  small	  GTPases	  and	  their	  effectors.	   It	   is	  well	  
established	  that	  members	  of	  the	  Rho	  GTPase	  family	  are	  key	  regulators	  of	  the	  actin	  
cytoskeleton	   (reviewed	   in	   (Heasman	  and	  Ridley,	  2008)	   that	  can	  also	  contribute	  to	  
cell	   survival	   (see	   section	   1.4).	   Thus,	   these	  molecular	   switches	   could	  mediate	   the	  
anti-­‐inflammatory	   and	   protective	   effects	   of	   insulin	   on	   the	   endothelium.	  
Furthermore,	  protein	  phosphorylation	  and	  the	  subsequent	  binding	  of	  14-­‐3-­‐3s	  could	  
regulate	  the	  activity	  of	  Rho	  GTPase	  signalling	  pathways.	  
Biochemical	   validation	   of	   the	   potential	   14-­‐3-­‐3	   binding	   proteins	   identified	   in	   the	  
screen	   revealed	   that	   insulin	   signalling	  was	  more	   likely	   to	   affect	   regulators	   of	   the	  
typical	   Rho	   GTPases	   (particularly	   the	   GAPs),	   rather	   than	   the	   Rho	   GTPases	  
themselves.	  This	  does	  not	  appear	  to	  be	  the	  case	  with	  the	  atypical	  members	  of	  the	  
Rho	  GTPase	   family,	  as	   it	  was	   recently	  demonstrated	   that	  14-­‐3-­‐3	  proteins	   regulate	  
the	   activity	   of	   the	   constitutively	  GTP-­‐bound	  Rnd3	  when	  phosphorylated	   by	   ROCK	  
and	  PKC	   (Riou	  et	   al.,	   2013).	   RhoA,	  Rac3	  and	  Cdc42	  were	   identified	   in	   the	   screen,	  
however	  14-­‐3-­‐3	  binding	  was	  not	  affected	  by	   IGF-­‐I	   stimulation	  and	  PI3K	   inhibition.	  
This	  was	  particularly	  surprising	  for	  Rac3,	  which	  had	  previously	  been	  identified	  in	  a	  
high	   throughput	   14-­‐3-­‐3	   screen	   in	   HeLa	   cells	   +/-­‐	   insulin.	   Rac3	   had	   a	   high	   isotope	  
differential	   (d0/d4)	   ratio,	   suggesting	   that	   insulin	   enhanced	   Rac3	   binding	   to	   14-­‐3-­‐3	  
when	   compared	   to	   unstimulated	   cells	   (Dubois	   et	   al.,	   2009).	   However,	   this	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prediction	  was	  not	   further	   validated	   in	   that	   study,	   and	   changes	   in	   14-­‐3-­‐3	  binding	  
were	   not	   observed	   in	   Far-­‐Western	   overlays	   when	   HEK293	   cells	   were	   stimulated	  
with	   IGF-­‐I	   or	   when	   PI3K	   was	   inhibited	   in	   this	   study.	   It	   would	   be	   interesting	   to	  
investigate	   whether	   differences	   in	   14-­‐3-­‐3	   binding	   to	   Rac3	   occur	   in	   14-­‐3-­‐3	   Far-­‐
Western	  overlays	  using	  HeLa	  cells	  stimulated	  with	  insulin.	  
As	  described	  in	  Chapter	  1.4.1,	  there	  are	  two	  types	  of	  RhoGEFs,	  Dbl	  family	  and	  DOCK	  
family	   GEFs.	   It	   is	   interesting	   that	   members	   of	   both	   classes	   were	   identified	   as	  
potential	   14-­‐3-­‐3-­‐binding	  proteins	   in	   ECs.	  ARHGEF16,	   also	   known	  as	   Ephexin4,	   has	  
been	  identified	  as	  a	  Dbl	  family	  GEF	  for	  RhoG	  and	  has	  been	  shown	  to	  play	  a	  role	  in	  
cell	  migration	  in	  breast	  cancer	  (Hiramoto-­‐Yamaki	  et	  al.,	  2010).	  DOCK10,	  a	  member	  
of	  the	  other	  family	  of	  RhoGEFs,	  was	  also	  previously	  shown	  to	  play	  a	  role	  in	  cancer	  
cell	  migration	  through	  the	  activation	  of	  Cdc42	  (Gadea	  et	  al.,	  2008).	  Both	  GEFs	  were	  
selected	   to	   identify	   if	   they	   were	   involved	   in	   the	   pathways	   that	   increased	   cell	  
migration	  when	   ECs	   are	   stimulated	  with	   insulin	   (see	   section	   3.4).	   ARHGEF16	   had	  
previously	  been	  identified	  in	  other	  high	  throughput	  14-­‐3-­‐3	  affinity	  studies	  (Ewing	  et	  
al.,	   2007;	  Meek	  et	   al.,	   2004;	  Pozuelo	  Rubio	  et	   al.,	   2004)	   in	  HeLa	  and	  HEK293	   cell	  
lines	  without	   insulin	   stimulation.	   However,	   those	   studies	   did	   not	   further	   validate	  
this	  interaction.	  In	  my	  hands,	  ARHGEF16	  did	  not	  interact	  directly	  with	  14-­‐3-­‐3	  in	  14-­‐
3-­‐3	   Far	   Western	   overlays.	   In	   contrast	   to	   ARHGEF16,	   DOCK10	   directly	   interacted	  
with	  14-­‐3-­‐3;	  however	  this	  interaction	  was	  not	  regulated	  by	  insulin	  via	  the	  PI3K/Akt	  
pathway,	  and	  therefore	  neither	  protein	  was	  investigated	  further.	  
	  
4.5.2 IGF-­‐I	  responsive	  14-­‐3-­‐3	  binding	  
The	  two	  RhoGAPs	  identified	  in	  this	  study,	  RICH-­‐1	  and	  Parg1,	  have	  never	  previously	  
been	   identified	   as	   14-­‐3-­‐3	   binding	   partners.	   Although	   there	   was	   only	   a	   subtle	  
increase	   in	   14-­‐3-­‐3	   binding	   with	   IGF-­‐I	   stimulation,	   these	   changes	   could	   possibly	  
contribute	  to	  the	  cytoskeletal	  changes	  observed	   in	  Chapter	  3,	  and	  were	  therefore	  
selected	  for	  further	  functional	  analysis	  (see	  Chapter	  5).	  The	  interaction	  of	  RhoGAPs	  
with	   14-­‐3-­‐3	   proteins	   was	   previously	   shown	   to	   play	   a	   key	   role	   in	   regulating	   cell	  
motility	   (Rowland	  et	  al.,	  2011).	  RhoGAP22	  was	   identified	  as	  an	  Akt	   substrate	   that	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binds	  to	  14-­‐3-­‐3	  proteins	  when	  stimulated	  by	  insulin.	  This	  insulin-­‐responsive	  14-­‐3-­‐3-­‐
RhoGAP22	   interaction	   negatively	   regulates	   the	   GAP	   activity	   of	   RhoGAP22,	  
modulating	   the	  GTP	   loading	  of	  Rac1	  and	   thereby	  affecting	  actin	   turnover	  and	  cell	  
motility	  (Rowland	  et	  al.,	  2011).	  
Phosphorylation	  of	  Epsin2	  and	  LMO7	  by	  IGF-­‐I	  also	  resulted	  in	  an	  increase	  in	  14-­‐3-­‐3	  
binding.	  Epsin2	  had	  previously	  been	  identified	  in	  a	  14-­‐3-­‐3	  phosphoproteome	  screen	  
of	   muscle	   cells	   stimulated	   with	   insulin	   (Larance	   et	   al.,	   2010),	   as	   well	   as	   in	   a	  
proteomic	   analysis	   of	   insulin-­‐regulated	   14-­‐3-­‐3-­‐interacting	   proteins	   in	   insulin-­‐
sensitive	  tissues	  (Yip	  et	  al.,	  2008).	  Neither	  of	  these	  studies	  pursued	  the	  functional	  
role	  of	  Epsin2	  in	  insulin	  signalling.	  	  
Similarly,	  LMO7	  was	  previously	  identified	  in	  five	  high-­‐throughput	  studies	  (Benzinger	  
et	  al.,	  2005;	  Dubois	  et	  al.,	  2009;	  Johnson	  et	  al.,	  2010;	  Larance	  et	  al.,	  2010;	  Meek	  et	  
al.,	   2004).	  Moreover,	   LMO7	   had	   a	   high	   isotope	   differential	   (d0/d4)	   ratio	   between	  
HeLa	   cells	   stimulated	  with	   insulin	   and	   unstimulated	   control	   cells,	   suggesting	   that	  
insulin	   enhances	   LMO7	   binding	   to	   14-­‐3-­‐3	   (Dubois	   et	   al.,	   2009).	   Biochemical	  
validation	  confirmed	  this	  prediction	  and	  thus	  further	  analysis	  of	  the	  functional	  role	  
of	  LMO7	  in	  insulin	  signalling	  in	  ECs	  was	  investigated	  (see	  Chapter	  5.4).	  
In	   summary,	   14-­‐3-­‐3-­‐affinity	   purification	   is	   an	   effective	   method	   to	   identify	   novel	  
insulin-­‐responsive	   proteins.	   RICH-­‐1,	   Parg1,	   LMO7	   and	   Epsin2	   were	   positively	  
validated	  as	   insulin-­‐sensitive	  14-­‐3-­‐3-­‐binding	  proteins,	   and	   their	   functional	   roles	   in	  
ECs	  are	  described	   in	  Chapter	  5.	   It	  would	  be	   interesting	   to	   investigate	   the	   specific	  
roles	  of	  14-­‐3-­‐3	  proteins	  in	  these	  insulin	  signalling	  pathways,	  through	  mutagenesis	  of	  
the	  candidate	  14-­‐3-­‐3-­‐binding	  phosphosites	  identified	  by	  bioinformatic	  analysis.	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5 Investigating	  the	  roles	  of	  insulin-­‐stimulated	  14-­‐3-­‐3	  binding	  protein	  
hits	  in	  endothelial	  cells	  
5.1 Introduction	  
The	  number	  of	  proteins	  isolated	  from	  insulin-­‐stimulated	  endothelial	  cells	  in	  the	  14-­‐
3-­‐3-­‐affinity	  screen	  in	  Chapter	  4	  attests	  to	  the	  many	  proteins	  that	  insulin	  regulates.	  
Of	   the	   12	   proteins	   short-­‐listed	   for	   further	   validation,	   RICH-­‐1,	   Parg1,	   LMO7	   and	  
Epsin2	   showed	   increased	   direct	   binding	   to	   14-­‐3-­‐3	   proteins	  when	   stimulated	  with	  
IGF-­‐I,	   and	   this	   effect	   was	   PI3K	   dependent.	   This	   chapter	   describes	   a	   number	   of	  
functional	  assays	  performed	  with	  these	  proteins	  in	  order	  to	  gain	  further	  insight	  into	  
their	  roles	  in	  endothelial	  cells.	  
	  
5.2 ARHGAP17	  /	  RICH-­‐1	  
Rho	  GTPases	   are	   critical	   regulators	   of	   dynamic	   cytoskeletal	   changes	   (reviewed	   in	  
Ridley,	  2006).	  The	  ability	  of	  these	  proteins	  to	  function	  as	  molecular	  switches	  is	  due	  
to	   their	   capacity	   to	   cycle	   between	   an	   active	   GTP-­‐bound	   and	   inactive	   GDP-­‐bound	  
state.	  Three	  protein	  families	  tightly	  regulate	  this	  cycling:	  GEFs	  (guanine	  nucleotide-­‐
exchange	  factors),	  GAPs	  (GTPase-­‐activating	  proteins)	  and	  GDIs	  (guanine	  nucleotide-­‐
dissociation	   inhibitors)	   (see	   section	   1.4.1).	   The	   GAPs	   inactivate	   Rho	   GTPases	   by	  
stimulating	   their	   intrinsic	   GTPase	   activity,	   leading	   to	   the	   hydrolysis	   of	   the	   γ	   -­‐GTP	  
and	   consequently	   to	   the	   inactivation	   of	   the	   protein	   (Lamarche	   and	   Hall,	   1994;	  
Moon	  and	  Zheng,	  2003).	  It	  has	  been	  predicted	  that	  there	  are	  approximately	  2-­‐	  to	  3-­‐
fold	  more	  GAPs	  compared	  to	  the	  GTPases	  they	  regulate,	  with	  the	  human	  genome	  
encoding	   between	   59	   and	   70	   proteins	   with	   a	   RhoGAP	   domain	   (Tcherkezian	   and	  
Lamarche-­‐Vane,	  2007).	  It	  has	  been	  suggested	  that	  this	  abundance	  is	  due	  to	  several	  
reasons:	   i)	   some	   GAPs	   are	   preferentially	   expressed	   in	   specific	   tissues,	   and/or	  
localised	  at	   specific	   sites	  within	   the	  cell;	   ii)	  GAPs	  could	  act	   specifically	  on	  a	   single	  
GTPase	   or	   in	   specific	   signalling	   complexes;	   iii)	   GAPs	   could	   selectively	   regulate	  
specific	   Rho	   GTPase	   signalling	   pathways;	   or	   iv)	   GAPs	   could	   act	   as	   effectors	   or	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scaffold	  proteins	  that	  mediate	  cross-­‐talk	  between	  Rho	  GTPases	  and	  other	  signalling	  
pathways	  (Tcherkezian	  and	  Lamarche-­‐Vane,	  2007).	  
ARHGAP17	  was	  identified	  in	  a	  two-­‐hybrid	  screen	  for	  cDNAs	  encoding	  proteins	  that	  
bound	  to	  the	  Src	  homology	  3	  domain	  of	  Cdc42-­‐interacting	  protein	  4	  (CIP4)	  (Richnau	  
and	   Aspenstrom,	   2001).	   It	   was	   named	   RICH-­‐1	   (RhoGAP	   interacting	   with	   CIP4	  
homologues)	  and	  found	  to	  have	  homology	  with	  KIAA0672 (RICH-2, ARHGAP44),	  
the	  rat	  protein	  Nadrin	  (neuron-­‐associated	  developmentally	  regulated	  protein)	  and	  
mouse	   Abl-­‐binding	   protein	   3BP-­‐1	   (SH3-­‐binding	   protein	   1,	   (Cicchetti	   et	   al.,	   1992;	  
Harada	  et	  al.,	  2000;	  Richnau	  and	  Aspenstrom,	  2001)).	  All	   four	  proteins	  contain	  an	  
N-­‐terminal	   Bin/amphiphysin/Rvs	   (BAR)	   domain	   (first	   recognised	   as	   a	   conserved	  
domain	  in	  BIN1,	  amphiphysins	  and	  the	  yeast	  proteins	  Rvs167p	  and	  Rvs161p	  (David	  
et	   al.,	   1994)),	   followed	   by	   a	   RhoGAP	   domain	   and	   C-­‐terminal	   proline-­‐rich	   region	  
(Figure	  5.1).	  These	  similarities	  suggest	  that	  RICH-­‐1,	  RICH-­‐2,	  Nadrin	  and	  3BP-­‐1	  form	  a	  
closely	   related	   family	   of	   RhoGAPs	   (Richnau	   and	   Aspenstrom,	   2001).	   The	   GAP	  
domains	   of	   all	   four	   proteins	   have	   been	   shown	   to	   be	   functionally	   similar	   by	  
stimulating	   the	   GTP	   hydrolysis	   of	   Cdc42	   and	   Rac1,	   in	   vitro,	   and	   Nadrin	   also	   has	  




Figure	  5.1	  Protein	  homology	  between	  RICH-­‐1,	  RICH-­‐2,	  Nadrin	  and	  3BP-­‐1.	  
Functional	   domain	   similarities	   group	   RICH-­‐1,	   RICH-­‐2,	   Nadrin	   and	   3BP-­‐1	   into	   a	   RhoGAP	  
subfamily.	  Each	  contain	  a	  BAR	  (Bin/amphiphysin/Rvs)	  domain	  (orange),	  a	  RhoGAP	  domain	  
(green)	  and	  a	  proline-­‐rich	  region	  (p,	  blue).	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RICH-­‐1	   is	  expressed	   in	  many	   tissues,	  but	  has	  particularly	  high	  expression	   levels	   in	  
the	   heart,	   placenta	   and	   skeletal	   muscle	   (Richnau	   and	   Aspenstrom,	   2001).	   Initial	  
GTPase	   activation	   and	   nucleotide	   exchange	   assays	   revealed	   that	   the	   RhoGAP	  
domain	  of	  RICH-­‐1	  stimulated	  the	  GTP	  hydrolysis	  of	  both	  Rac1	  and	  Cdc42,	  but	  had	  
no	  effect	  on	  RhoA.	  This	  observation	  was	  confirmed	  in	  GTPase	  binding	  domain	  pull-­‐
down	  assays,	  following	  expression	  of	  the	  RhoGAP	  domain	  or	  a	  catalytically	  inactive	  
mutant	  of	  RICH-­‐1	  in	  PAE/PDGFRβ	  cells	  (Richnau	  and	  Aspenstrom,	  2001).	  However,	  
when	  RICH-­‐1	  GAP	  activity	  was	  measured	  in	  epithelial	  cells	  using	  Raichu	  FRET	  probes	  
and	  GTPase	  binding	  domain	  pull-­‐down	  assays,	  RICH-­‐1	  was	  only	  able	  to	  reduce	  the	  
levels	  of	  Cdc42-­‐GTP,	  but	  had	  no	  effect	  on	  Rac1	  or	  RhoA	   (Wells	  et	   al.,	   2006).	   This	  
observation	   suggests	   that	   RICH-­‐1	  may	   have	   cell	   specific	   functionality.	   The	   role	   of	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5.2.1 GFP-­‐RICH-­‐1	  over-­‐expression	  localises	  at	  the	  membrane	  in	  migrating	  
endothelial	  cells	  	  
Investigating	   the	   localisation	  of	  proteins	  at	   the	  sub-­‐cellular	   level	   leads	   to	  a	  better	  
understanding	   of	   protein	   function,	   interaction	   networks	   and	   cellular	   signalling	  
pathways	   (Stadler	  et	  al.,	  2013).	  The	   localisation	  of	  RICH-­‐1	   in	  endothelial	   cells	  was	  
determined	   by	   transiently	   transfecting	   HUVECs	   with	   an	   expression	   plasmid	  
encoding	   GFP-­‐tagged	   RICH-­‐1,	   then	   seeding	   onto	   fibronectin	   (FN)-­‐coated	   glass	  
coverslips.	  Cells	  were	  fixed	  and	  stained	  for	  F-­‐actin	  and	  cell-­‐cell	  junction	  proteins	  at	  
24	   h.	   GFP-­‐RICH-­‐1	   displayed	   a	   cytoplasmic	   distribution	   (Figure	   5.2,	   Figure	   5.3	   and	  
Figure	   5.4)	   with	   no	   obvious	   effect	   on	   the	   organisation	   of	   the	   actin	   cytoskeleton,	  
when	   compared	   to	   GFP-­‐transfected	   HUVECs.	   RICH-­‐1	   localised	   at	   the	   plasma	  
membrane	   in	   lamellipodia	   (indicated	   by	   the	   blue	   arrows	   in	   Figure	   5.2)	   in	   sub-­‐
confluent	   HUVECs.	   However,	   it	   did	   not	   localise	   to	   cell-­‐cell	   junctions	   in	   confluent	  
monolayers	  (Figure	  5.3	  and	  Figure	  5.4)	  suggesting	  that	  RICH-­‐1	  might	  be	  required	  at	  
the	  membrane	  to	  regulate	  lamellipodial	  protrusion.	  Over-­‐expression	  of	  GFP-­‐RICH-­‐1	  
did	   not	   disrupt	   cell-­‐cell	   adherens	   junctions	   visualised	   by	   continuous	   vascular-­‐
endothelial	   cadherin	   (VE-­‐cadherin)	   staining	   linearly	   along	   cell-­‐cell	   borders	  
(indicated	   by	   yellow	   arrow-­‐heads	   in	   Figure	   5.3).	   Tight	   junctions	   were	   also	  
maintained,	   as	   shown	   by	   linear	   ZO-­‐1	   staining	   along	   the	   cell-­‐cell	   boundaries	   (blue	  
arrows,	   Figure	  5.3).	  However,	   tight	   junctions	  were	   slightly	   disrupted	  at	   the	   apical	  
and	  basolateral	  regions	  of	  the	  unstimulated	  cells	  (red	  arrowheads,	  Figure	  5.4B).	  	  
Stimulating	   GFP-­‐RICH-­‐1-­‐expressing	   HUVECs	   with	   insulin	   increased	   the	   number	   of	  
vesicles	   in	   the	   cell	   compared	   to	  unstimulated	   cells,	  with	  GFP-­‐RICH-­‐1	   localising	  on	  
the	  vesicle	  structures	  (yellow	  arrows,	  Figure	  5.4).	  ZO-­‐1	  staining	  appeared	  to	  be	  less	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Figure	  5.2	  RICH-­‐1	  localises	  at	  the	  plasma	  membrane	  in	  subconfluent	  endothelial	  
cells	  
HUVECs	  were	  transfected	  with	  pcDNA5	  FRT/TO	  GFP	  ARHGAP17	  (GFP-­‐RICH-­‐1),	  seeded	  onto	  
FN-­‐coated	   glass	   coverslips	   and	   fixed	   after	   24	   h.	  Cells	  were	   stained	  with	  Alexa	   Fluor	   546-­‐
conjugated	  phalloidin	  for	  F-­‐actin	  (red	  in	  merge),	  and	  DAPI	  for	  nuclei	  (blue	  in	  merge).	  Blue	  
arrows	   indicate	   RICH-­‐1	   localisation	   at	   the	  membrane.	   Images	  were	   acquired	   by	   confocal	  
microscopy	  with	  a	  63x	  oil	  immersion	  objective	  and	  are	  maximum	  intensity	  projections	  of	  10	  
confocal	   z-­‐stacks,	   spanning	  4	  μm	  with	   0.4	  μm	   intervals	   between	  each	   image.	   Images	   are	  
representative	  fields	  from	  three	  independent	  experiments.	  Scale	  bars	  are	  20	  μm.	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Figure	  5.3	  Endothelial	  cell-­‐cell	  junctions	  are	  maintained	  when	  RICH-­‐1	  is	  
overexpressed	  	  
HUVECs	  were	  transfected	  with	  pcDNA5	  FRT/TO	  GFP	  ARHGAP17	  (GFP-­‐RICH-­‐1),	  seeded	  onto	  
FN-­‐coated	   glass	   coverslips	   and	   fixed	   after	   24	   h.	  Cells	  were	   stained	  with	  Alexa	   Fluor	   546-­‐
conjugated	   phalloidin	   for	   F-­‐actin	   (red	   in	   merge),	   DAPI	   for	   nuclei	   (blue	   in	   merge),	   VE-­‐
cadherin	  (A)	  or	  ZO-­‐1	  (B)	  for	  adherens	  and	  tight	  junctions,	  respectively	  (magenta	  in	  merge).	  
Yellow	   arrowheads	   indicate	   continuous	   adherens	   junctions,	   and	   blue	   arrows	   indicate	  
uninterrupted	  tight	  junctions.	  Images	  were	  acquired	  by	  confocal	  microscopy	  with	  a	  63x	  oil	  
immersion	   objective	   and	   are	   maximum	   intensity	   projections	   of	   10	   confocal	   z-­‐stacks,	  
spanning	  4	  μm	  with	  0.4	  μm	  intervals	  between	  each	  image.	  Images	  are	  representative	  from	  
three	  independent	  experiments.	  Scale	  bars	  are	  20	  μm.	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Figure	  5.4	  RICH-­‐1	  localises	  on	  vesicle	  structures	  when	  ECs	  are	  stimulated	  by	  
insulin	  
HUVECs	  were	   transfected	  with	  pcDNA5	  FRT/TO	  GFP	  ARHGAP17	   (GFP-­‐RICH-­‐1)	  and	   seeded	  
onto	  FN-­‐coated	  glass	  coverslips.	  Cells	  were	  incubated	  for	  24	  h	  and	  then	  incubated	  in	  EBM2	  
medium	   containing	   1%	   FCS	   for	   4	   h,	   stimulated	   with	   100	   nM	   insulin	   for	   1	   h	   and	   fixed.	  
Subconfluent	  cells	   (A)	  were	  stained	  with	  Alexa	  Fluor	  546-­‐conjugated	  phalloidin	  for	  F-­‐actin	  
(red	   in	   merge),	   and	   DAPI	   for	   nuclei	   (blue	   in	   merge),	   and	   confluent	   cells	   (B)	   were	   also	  
stained	  with	   ZO-­‐1	   for	   tight	   junctions	   (magenta	   in	  merge).	   Yellow	   arrows	   indicate	   RICH-­‐1	  
localisation	  on	  the	  vesicles	  in	  insulin-­‐stimulated	  cells.	  Red	  arrowheads	  indicate	  differences	  
in	  tight	  junctions.	  Yellow-­‐boxed	  areas	  are	  shown	  at	  higher	  magnification	  on	  the	  right	  of	  A	  
and	   below	   B.	   Images	   were	   acquired	   by	   confocal	   microscopy	   with	   a	   63x	   oil	   immersion	  
objective	   and	   are	  maximum	   intensity	   projections	   of	   10	   confocal	   z-­‐stacks,	   spanning	   4	   μm	  
with	   0.4	   μm	   intervals	   between	   each	   image.	   Images	   are	   representative	   fields	   from	   three	  
independent	  experiments.	  Scale	  bars	  are	  20	  μm.	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5.2.2 siRNA-­‐mediated	  knock-­‐down	  of	  RICH-­‐1	  in	  endothelial	  cells	  
In	  order	  to	  gain	  more	  insight	  into	  the	  functional	  role	  of	  RICH-­‐1	  in	  endothelial	  cells,	  
an	  RNA	  interference	  approach	  was	  chosen	  to	  knock	  down	  protein	  expression.	  Four	  
oligonucleotides	  (siRNAs)	  were	  tested	  for	  their	  ability	  to	  transiently	  decrease	  RICH-­‐
1	  expression	  in	  endothelial	  cells.	  All	  four	  siRNAs	  knocked	  down	  RICH-­‐1	  levels	  after	  
72	   h	   following	   transfection,	   compared	   to	   cells	   treated	   with	   oligofectamine	   only	  
(mock)	  and	  control	  cells	  transfected	  with	  a	  non-­‐targeting	  siRNA	  (siControl),	  with	  an	  
efficiency	  of	  between	  55	  and	  70%,	  when	  analysed	  by	  immunoblotting	  (Figure	  5.5).	  	  
Oligos	   1	   and	   2	   were	   then	   chosen	   for	   use	   in	   subsequent	   experiments,	   and	   are	  
represented	  as	  siRICH1-­‐1	  and	  siRICH1-­‐2,	  respectively.	  	  
	  
	  
Figure	  5.5	  siRNA	  mediated	  knockdown	  of	  RICH-­‐1	  in	  HUVECs	  
Representative	   immunoblot	   (A)	   of	   HUVECs	   transfected	   with	   4	   different	   siRNA	  
oligonucleotides	  targeting	  RICH-­‐1.	  Mock	  represents	  cells	  treated	  with	  oligofectamine	  only,	  
and	  Pool	  represents	  an	  equal	  mixture	  of	  oligos	  1	  –	  4.	  Cells	  were	  transfected	  with	  20	  nM	  of	  
siRNA	  using	  OligofectamineTM,	  and	  incubated	  for	  72	  h	  at	  37°C,	  5%	  CO2.	  Cells	  were	  lysed	  and	  
protein	   analysed	   by	   immunoblotting	  with	   an	   anti-­‐RICH-­‐1	   antibody.	   Blots	  were	   re-­‐probed	  
for	  GAPDH	  as	  a	  loading	  control.	  (B)	  Data	  were	  generated	  by	  densitometric	  scanning	  of	  the	  
Western	  blots,	  normalised	  to	  total	  GAPDH	  levels,	  relative	  to	  siControl.	  Data	  shown	  are	  the	  
mean	  of	  three	  independent	  experiments	  ±	  SEM.	  Statistical	  significance	  was	  assessed	  by	  an	  
unpaired	  Student’s	  t-­‐test;	  *p<0.05.	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5.2.3 RICH-­‐1	  depletion	  disrupts	  tight	  junctions	  in	  endothelial	  cells	  
	  
siControl	  treated	  HUVECs	  had	  a	  round	  cobblestone-­‐like	  morphology	  with	  bundles	  of	  
actin	  filaments	  enriched	  along	  the	  cell-­‐cell	  boundaries	  (Figure	  5.6).	  Although	  RICH-­‐
1-­‐depleted	  HUVECs	  maintained	   their	   cobblestone-­‐like	  morphology,	   cells	   exhibited	  
slightly	   more	   disorganised	   bundles	   of	   actin	   filaments,	   with	   some	   stress	   fibres	  
traversing	  the	  length	  of	  the	  cell	  (Figure	  5.6).	  At	  some	  areas,	  bright	  ‘knots’	  of	  F-­‐actin	  
were	   present	   usually	   in	   the	   area	   between	   three	   or	  more	   ECs	   (red	   arrows,	   Figure	  
5.6).	   The	   most	   noticeable	   change	   in	   cell	   morphology,	   as	   a	   result	   of	   RICH-­‐1	  
knockdown,	   was	   the	   disruption	   of	   tight	   junctions,	   visualised	   by	   altered	   ZO-­‐1	  
staining	   (highlighted	   by	   yellow	   arrowheads,	   and	   zoomed	   area	   in	   Figure	   5.6).	  
siControl	  cells	  maintained	  linear,	  continuous	  junctions	  along	  cell–cell	  borders	  (blue	  
arrow),	   whereas	   RICH-­‐1-­‐depleted	   HUVECs	   exhibited	   fragmented	   ZO-­‐1	   staining,	  
perpendicular	   to	   the	   cell-­‐cell	   borders.	   ZO-­‐1	   staining	  was	   particularly	   disjointed	  or	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Figure	  5.6	  RICH-­‐1	  depletion	  disrupts	  tight	  junctions	  in	  endothelial	  cells	  
Immunofluorescence	  micrographs	  of	  HUVECs	  transfected	  with	  siRNA	  targeting	  RICH-­‐1.	  Cells	  
were	  seeded	  on	  FN-­‐coated	  coverslips	  48	  h	  after	  transfection,	  and	  fixed	  after	  a	  further	  24	  h.	  
Cells	   were	   stained	   with	   zonula	   occludens	   protein	   1	   (ZO-­‐1)	   for	   tight	   junctions	   (green	   in	  
merge),	   Alexa	   Fluor	   546-­‐conjugated	   phalloidin	   for	   F-­‐actin	   (red	   in	   merge),	   anti	   CD31	  
(PECAM-­‐1)	  antibody	  (magenta	  in	  merge),	  and	  DAPI	  for	  nuclei	  (blue	  in	  merge).	  Yellow-­‐boxed	  
areas	   are	   shown	   at	   higher	   magnification	   below.	   Images	   were	   acquired	   by	   confocal	  
microscopy	  with	  a	  63x	  oil	  immersion	  objective	  and	  are	  maximum	  intensity	  projections	  of	  10	  
confocal	   z-­‐stacks,	   spanning	  4	  μm	  with	   0.4	  μm	   intervals	   between	  each	   image.	   Images	   are	  
representative	  from	  three	  independent	  experiments.	  Scale	  bars	  are	  20	  μm.	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5.2.4 RICH-­‐1	  knock-­‐down	  decreases	  cell	  migration	  in	  a	  wound	  healing	  assay	  
	  
Insulin	  stimulated	  EC	  migration	   in	   the	  ORISTM	  migration	  assay	   (see	  section	  3.4).	   In	  
order	  to	  investigate	  whether	  RICH-­‐1	  plays	  a	  role	  in	  migration,	  RICH-­‐1-­‐depleted	  cells	  
were	  assessed	  for	  their	  ability	  to	  migrate	  in	  this	  assay.	  	  
HUVECs	   were	   transfected	   with	   siRNAs	   targeting	   RICH-­‐1.	   After	   24	   h	   cells	   were	  
stained	  with	   CellTrackerTM	  Orange	   and	   seeded	  onto	   FN-­‐coated	  wells	   containing	   a	  
central	   stopper.	   Cells	   were	   incubated	   for	   a	   further	   24	   h	   and	   the	   central	   stopper	  
removed.	  Images	  of	  the	  wound	  were	  taken,	  and	  cells	  were	  left	  to	  migrate	  into	  the	  
central	  area	  for	  24	  h,	  and	  a	  second	  set	  of	  images	  were	  taken	  of	  the	  same	  locations.	  
RICH-­‐1	  depletion	  significantly	  reduced	  cell	  migration	  compared	  to	  cells	  treated	  with	  
oligofectamine	   only	   (mock),	   and	   non-­‐targeting	   siControl	   transfected	   cells	   at	   24	   h	  
(Figure	  5.7).	  Due	  to	  time	  limitations,	  this	  assay	  was	  only	  performed	  using	  one	  oligo,	  
and	  would	  require	  validation	  by	  another.	  When	  the	  experiment	  was	  repeated	  in	  the	  
presence	  of	   insulin,	   the	  migration	  of	  mock	  and	  siControl-­‐treated	  cells	   significantly	  
increased	   (as	   seen	   in	   section	   3.4).	   However,	   insulin	   stimulation	   had	   no	   effect	   on	  
migration	  of	  the	  RICH-­‐1-­‐depleted	  cells	  (Figure	  5.7).	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Figure	  5.7	  RICH-­‐1	  depletion	  decreases	  cell	  migration	  in	  the	  ORIS	  assay	  
HUVECs	  were	   transfected	  with	   siRNA	   targeting	   RICH-­‐1	   or	   control	   siRNA.	   After	   24	   h	   cells	  
were	  stained	  with	  Cell-­‐Tracker	  Orange	  fluorescent	  dye,	  seeded	  in	  wells	  containing	  a	  central	  
insert,	  and	  incubated	  for	  24	  h	  at	  37°C.	  	  The	  inserts	  were	  then	  removed	  to	  create	  a	  central	  
wound	  in	  the	  monolayer,	  and	  imaged	  at	  4x	  magnification	  (0	  h).	  For	  the	  insulin	  studies	  (B),	  
cells	  were	  serum	  starved	  for	  2	  h	  prior	  to	  removing	  the	  inserts,	  imaged	  and	  then	  stimulated	  
with	   100	  nM	   insulin.	   Cells	  were	   incubated	   for	   24	  hours	   at	   37°C	   and	   imaged	   again	   (24	  h)	  
using	   the	   saved	   locations	   of	   0	   h.	   The	   migratory	   capacity	   of	   the	   cells	   was	   quantified	   by	  
measuring	  the	  percentage	  area	  of	  the	  central	  wound	  that	  cells	  had	  migrated	  into	  after	  24	  h	  
using	  ImageJ	  software,	  as	  a	  percentage	  relative	  to	  siControl	  cells.	  Data	  shown	  are	  the	  mean	  
of	   four	   (A)	   and	   three	   (B)	   independent	   experiments	   ±	   SEM.	   Statistical	   significance	   was	  
assessed	  by	  an	  unpaired	  Student’s	  t-­‐test;	  *p<0.05,	  ns	  =	  not	  significant.	  Scale	  bars	  are	  200	  
μm.	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5.2.5 RICH-­‐1	  depletion	  does	  not	  affect	  loop	  formation	  in	  an	  angiogenesis	  assay	  
	  
Endothelial	  cells	  undergo	  morphogenic	  processes	  to	  form	  new	  vessels	   in	  response	  
to	   various	   stimuli	   (see	   Chapter	   1.5).	   Lumen	   and	   tube	   development	   involves	   the	  
formation	   of	   intracellular	   vacuoles,	   which	   is	   mediated	   by	   the	   establishment	   and	  
coalescence	  of	  pinocytic	   intracellular	   vacuoles	   (Bayless	  et	   al.,	   2000).	  Rho	  GTPases	  
regulate	  endothelial	  morphogenesis	  with	  Cdc42	  and	  Rac1	  specifically	  being	  shown	  
as	  critical	  regulators	  of	  endothelial	  cell	   lumen	  formation	  during	  the	  early	  stages	  of	  
angiogenesis	   (Bayless	   and	   Davis,	   2002;	   Koh	   et	   al.,	   2008).	   As	   RICH-­‐1	   is	   a	   known	  
Cdc42	   GAP,	   its	   role	   in	   angiogenesis	   was	   investigated	   by	   siRNA	   knockdown	   in	  
HUVECs.	   The	   in	   vitro	   loop	   formation	   assay	   provides	   a	   simplified	   imitation	   of	  
angiogenesis	   and	   is	   considered	   to	   mimic	   the	   cord	   formation	   step	   in	   sprouting	  
angiogenesis	  (Goodwin,	  2007).	  RICH-­‐1-­‐depleted	  HUVECs	  were	  plated	  on	  Matrigel	  to	  
investigate	   their	   ability	   to	   form	   loops	   in	   the	   in	   vitro	   angiogenesis	   assay.	   HUVECs	  
were	  transfected	  with	  siRNAs	  targeting	  RICH-­‐1,	  and	  seeded	  on	  the	  Matrigel	  after	  48	  
h.	  Cells	  were	  left	  to	  form	  loops	  for	  24	  h,	  recorded	  by	  time-­‐lapse	  movies.	  
	  
Initially,	  siRICH1-­‐1	  knockdown	  cells	  appeared	  to	  self-­‐organise	  faster	  than	  siControl	  
treated	   cells	   at	   the	   4	   h	   time-­‐point,	   elongating	   and	   forming	   the	   protrusions	   that	  
become	  the	  cords	  of	  a	   loop	   (Figure	  5.8,	  Movies	  S3	  and	  S4).	  Although	  there	  was	  a	  
slight	   increase	   in	  the	  number	  of	  angiogenic	   loops	  formed	  after	  24	  h,	  compared	  to	  
siControl	   cells,	   this	   was	   not	   statistically	   significant	   when	   repeated	   in	   three	  





Chapter	  5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Roles	  of	  insulin-­‐stimulated	  14-­‐3-­‐3	  binding	  proteins	  in	  ECs	  	  	  	  	   
	  
	   	   144	  
	  
Figure	  5.8	  RICH-­‐1	  depletion	  does	  not	  affect	  loop	  formation	  in	  the	  angiogenesis	  
assay	  
HUVECs	  were	  transfected	  with	  siRNAs	  targeting	  RICH-­‐1	  or	  control	  siRNA.	  Cells	  were	  seeded	  
onto	  polymerised	  Matrigel	   (4.5	  mg/ml)	  48	  h	  after	  transfection,	   incubated	  for	  1	  h	  at	  37	  °C	  
and	  loop	  formation	  was	  monitored	  by	  time-­‐lapse	  microscopy	  using	  a	  4x	  objective,	  acquiring	  
images	   every	   20	   min	   for	   24	   h	   (A).	   Quantification	   was	   performed	   by	   counting	   the	   total	  
number	  of	  complete	  loops	  per	  field,	  as	  a	  percentage	  relative	  to	  siControl-­‐transfected	  cells	  
(B).	  At	  least	  5	  fields	  were	  scored	  per	  condition	  in	  each	  experiment	  and	  data	  shown	  are	  the	  
mean	  of	  four	  and	  three	  independent	  experiments	  for	  siRICH1-­‐1	  and	  siRICH1-­‐2,	  respectively,	  
normalised	  to	  siControl	  ±	  SEM	  (siControl	  =	  100	  %).	  No	  significant	  differences	  were	  observed	  
between	  siRICH-­‐1	  knockdown	  and	  siControl	  cells.	  Statistical	  significance	  was	  assessed	  by	  a	  
Mann-­‐Whitney	  U	  test;	  ns	  =	  not	  significant.	  Scale	  bars	  are	  200	  μm.	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5.2.6 Effect	  of	  RICH-­‐1	  depletion	  on	  the	  permeability	  of	  endothelial	  monolayers	  
	  
Endothelial	   cell-­‐cell	   junctions	   have	   significant	   roles	   in	   mediating	   endothelial	  
permeability	  (see	  section	  1.2.3).	  Since	  the	  depletion	  of	  RICH-­‐1	  disrupted	  endothelial	  
tight	   junctions	   (see	   section	   5.2.3),	   its	   role	   on	   basal	   cell	   permeability	   was	  
investigated	   using	   the	   FITC-­‐dextran	   TranswellTM	   assay	   described	   in	   Chapter	   2.3.8	  
and	   3.3.1.	   RICH-­‐1	   depletion	   appeared	   to	   increase	   endothelial	   cell	   permeability	  
compared	  to	  siControl	   treated	  cells	   (Figure	  5.9),	  however	  this	  was	  not	  statistically	  
significant	  when	  repeated	  in	  three	  independent	  experiments,	  due	  to	  the	  variability	  
between	  repeats.	  This	  variability	  could	  be	  due	  to	  differences	  in	  RICH-­‐1	  knockdown	  
efficiency,	   or	   differences	   between	   HUVECs	   such	   as	   cell	   passage	   number.	   The	  
experiment	  would	   be	   need	   to	   be	   repeated	   to	   determine	  whether	   RICH-­‐1	   plays	   a	  
role	  in	  maintaining	  cell-­‐cell	  junctions	  in	  endothelial	  cells.	  
	  
	  
Figure	  5.9	  Effect	  of	  RICH-­‐1	  depletion	  on	  endothelial	  cell	  permeability	  
HUVECs	  were	  transfected	  with	  siRNAs	  targeting	  RICH-­‐1	  or	  control	  siRNA.	  Cells	  were	  seeded	  
onto	  Transwell™	  filters	  (0.4	  µm	  pore	  size)	  48	  h	  after	  transfection	  and	  incubated	  for	  24	  h	  at	  
37	  °C.	  FITC-­‐dextran	  (0.1	  mg/ml)	  was	  added	  to	  the	  upper	  chamber	  and	  the	  lower	  chamber	  
fluorescence	  was	  measured	  after	  60	  min.	  Fluorescence	  was	  measured	   for	  duplicate	  wells	  
and	   quantified	   as	   a	   percentage	   relative	   to	   control.	   Data	   shown	   are	   the	   mean	   of	   three	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5.3 ARHGAP29	  /	  Parg1	  	  
ARHGAP29	   was	   first	   identified	   by	   a	   yeast	   two-­‐hybrid	   screen	   in	   the	   search	   for	  
proteins	  that	  interact	  with	  protein-­‐tyrosine	  phosphatase	  PTPL1	  (Saras	  et	  al.,	  1997).	  
This	  intracellular	  protein	  has	  a	  cysteine-­‐rich	  domain,	  with	  homology	  to	  a	  regulatory	  
phorbol	  ester/diaclyglycerol-­‐binding	  domain,	  followed	  by	  a	  RhoGAP	  domain.	  It	  was	  
therefore	   named	   PTPL1-­‐associated	   RhoGAP	   1	   (Parg1)	   (Figure	   5.10)	   (Saras	   et	   al.,	  
1997;	  Tcherkezian	  and	  Lamarche-­‐Vane,	  2007).	  Parg1	  is	  expressed	  at	  higher	  levels	  in	  
skeletal	  muscle	  and	  the	  heart	  than	  in	  other	  tissues.	  The	  RhoGAP	  domain	  was	  shown	  
to	  be	  active	  with	  a	  strong	  GAP	  activity	  on	  RhoA	  (Myagmar	  et	  al.,	  2005;	  Saras	  et	  al.,	  
1997).	   Parg1	   inhibited	  Rho-­‐mediated	   stress	   fibres	   in	   in	  NIH3T3	   cells	   (Myagmar	  et	  
al.,	  2005).	  Interestingly,	  Parg1	  interacts	  with	  the	  Ras-­‐related	  protein	  Rap2	  in	  a	  GTP-­‐
dependent	   manner,	   and	   this	   interaction	   suppresses	   the	   stress	   fibre	   inhibitory	  
effects	  of	  Parg1	  (Myagmar	  et	  al.,	  2005).	  
Parg1	  was	  shown	  to	  play	  a	  critical	  role	  in	  blood	  vessel	  tubulogenesis	  in	  vitro	  (Xu	  et	  
al.,	  2011).	  Parg1	  binds	  to	  Ras	  interacting	  protein	  1	  (Rasip1),	  and	  both	  proteins	  are	  
required	   for	   blood	   vessel	   formation	   by	   endothelial	   cells.	   When	   either	   Rasip1	   or	  
Parg1	  were	  depleted,	  RhoA	  activation	  increased,	  resulting	  in	  increased	  actomyosin	  
contractility	   and	   cell	   polarity	   disruption	   that	   resulted	   in	   failed	   lumen	  
morphogenesis	  in	  vitro	  (Xu	  et	  al.,	  2011).	  	  
A	  very	   recent	   study	  provided	  a	   link	  between	  Rap1	  and	  Rasip1,	  and	  demonstrated	  
the	   importance	   of	   Parg1	   in	   regulating	   the	   endothelial	   cytoskeleton	   (Post	   et	   al.,	  
2013).	   This	   study	   showed	   that	   Rasip1	   is	   a	   Rap1	   effector,	   as	   Rap1-­‐induced	   cell	  
spreading	  and	  stabilisation	  of	  endothelial	  barrier	  function	  requires	  the	  Rasip-­‐Parg1	  
complex.	  	  
These	   studies	   demonstrate	   the	   critical	   role	   of	   Parg1	   in	   regulating	   the	   endothelial	  
actin	  cytoskeleton	  and	  barrier	  function.	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Figure	  5.10	  Domain	  structure	  of	  Parg1	  
Parg1	  has	  a	  zinc	  finger	  (612	  –	  657)	  that	  contains	  a	  cysteine-­‐rich	  phorbol	  ester	  domain	  (C),	  
followed	   by	   a	   RhoGAP	   domain	   (671	  –	  886).	   The	   last	   4	   residues	   (1258	  –	  1261)	   provide	   a	  
binding	  site	  for	  PTPL1	  (orange).	  	  
	  
	  
5.3.1 GFP-­‐Parg1	  expression	  decreases	  endothelial	  F-­‐actin	  levels	  
The	   cellular	   localisation	   of	   GFP-­‐Parg1	  was	   determined	   by	   transiently	   transfecting	  
HUVECs	  with	  an	  expression	  plasmid	  encoding	  GFP-­‐Parg1.	  Parg1	  displayed	  a	  uniform	  
diffuse	  localisation	  in	  the	  cytoplasm	  (Figure	  5.11).	  Expression	  of	  GFP-­‐Parg1	  resulted	  
in	   a	   striking	   decrease	   of	   endothelial	   F-­‐actin,	  with	   a	   complete	   loss	   of	   radial	   stress	  
fibres	   (Figure	   5.11,	   yellow	   asterisks).	   This	   finding	   was	   consistent	   with	   Parg1	  
overexpression	   in	  NIH3T3	   fibroblasts	   (Myagmar	   et	   al.,	   2005)	   and	   very	   recently	   in	  
HUVECs	   (Post	   et	   al.,	   2013).	   In	   confluent	   monolayers	   (Figure	   5.11A)	   adherens	  
junctions	  were	  well	  maintained,	  as	  visualised	  by	  the	  linear	  reticular	  distribution	  of	  
β-­‐catenin	   (reticular	   adherens	   junctions,	   yellow	   arrowhead).	   When	   β-­‐catenin	   is	  
released	   and	   stabilized	   in	   the	   cytosol,	   it	   is	   translocated	   to	   the	   nucleus	   and	  
modulates	   gene	   transcription	   (Gumbiner,	   1995).	   GFP-­‐Parg1	   expression	   cells	  
appeared	   to	   have	   less	   nuclear	   β-­‐catenin	   staining	   compared	   to	   GFP-­‐expressing	  
HUVECs.	  When	  cells	  were	  sub-­‐confluent	   (Figure	  5.11B)	  GFP-­‐Parg1	  expressing	  cells	  
were	  able	  to	  form	  junctions	  at	  the	  contact	  between	  adjacent	  cells	  (blue	  arrows).	  
Insulin	   stimulation	   of	   GFP-­‐Parg1	   expressing	   cells	   did	   not	   induce	   any	   discernable	  
morphological	   changes.	   The	   diffuse	   cytoplasmic	   distribution	   was	   still	   observed,	  
although	   GFP-­‐Parg1	   expression	   appeared	   more	   granular	   with	   less	   localisation	  
occurring	   in	  the	  perinuclear	  area	  (Figure	  5.12).	  This	   finding,	  however,	  needs	  to	  be	  
investigated	  further	  for	  greater	  confidence.	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Figure	  5.11	  GFP-­‐Parg1	  expression	  decreases	  endothelial	  F-­‐actin	  levels	  
HUVECs	  were	  transfected	  with	  pcDNA5	  FRT/TO	  GFP	  ARHGAP29	  (GFP-­‐Parg1),	  seeded	  onto	  
FN-­‐coated	   glass	   coverslips	   and	   fixed	   after	   24	   h.	  Cells	  were	   stained	  with	  Alexa	   Fluor	   546-­‐
conjugated	   phalloidin	   for	   F-­‐actin	   (red	   in	   merge),	   anti-­‐ß-­‐catenin	   for	   adherens	   junctions	  
(magenta	   in	  merge)	   and	  DAPI	   for	   nuclei	   (blue	   in	  merge).	   Yellow	  asterisk	  highlight	  overall	  
decrease	   F-­‐actin	   in	   the	   cell	   compared	   to	   untransfected	   neighbouring	   cells.	   Yellow	   arrow	  
depicts	   reticular	   adherens	   junctions;	   blue	   arrows	   show	   cell-­‐cell	   junctions	   are	   formed	   in	  
adjacent	   cells.	   Images	   were	   acquired	   by	   confocal	   microscopy	   with	   a	   63x	   oil	   immersion	  
objective	   and	   are	  maximum	   intensity	   projections	   of	   10	   confocal	   z-­‐stacks,	   spanning	   4	   μm	  
with	   0.4	   μm	   intervals	   between	   each	   image.	   Images	   are	   representative	   of	   random	   fields	  
from	  three	  independent	  experiments.	  Scale	  bars	  are	  20	  μm.	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Figure	  5.12	  Insulin	  does	  not	  affect	  Parg1	  localisation	  in	  endothelial	  cells	  
HUVECs	  were	   transfected	  with	   pcDNA5	   FRT/TO	   GFP	   ARHGAP29	   (GFP-­‐Parg1)	   and	   seeded	  
onto	  FN-­‐coated	  glass	  coverslips.	  Cells	  were	  incubated	  for	  24	  h	  and	  then	  serum	  starved	  for	  4	  
h	   in	  EBM2	  medium	  containing	  1%	  FCS.	  Cells	  were	  stimulated	  with	  100	  nM	  insulin	  for	  1	  h,	  
fixed	   and	   stained	   with	   Alexa	   Fluor	   546-­‐conjugated	   phalloidin	   for	   F-­‐actin	   (red	   in	   merge),	  
anti-­‐β-­‐catenin	   for	   adherens	   junctions	   (magenta	   in	   merge),	   and	   DAPI	   for	   nuclei	   (blue	   in	  
merge).	   Images	  were	  acquired	  by	  confocal	  microscopy	  with	  a	  63x	  oil	   immersion	  objective	  
and	  are	  maximum	  intensity	  projections	  of	  10	  confocal	  z-­‐stacks,	  spanning	  4	  μm	  with	  0.4	  μm	  
intervals	   between	   each	   image.	   Images	   are	   representative	   of	   random	   fields	   from	   three	  
independent	  experiments.	  Scale	  bars	  are	  20	  μm.	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5.3.2 siRNA	  mediated	  knock-­‐down	  of	  Parg1	  in	  endothelial	  cells	  
An	   RNA	   interference	   approach	   to	   knock	   down	   Parg1	   expression	   was	   chosen	   to	  
evaluate	   its	   functional	   role	   in	   endothelial	   cells.	   Parg1	   expression	   was	   down	  
regulated	  in	  HUVECs	  using	  four	  siRNA	  oligonucleotides	  (siRNAs),	  and	  a	  knock	  down	  
efficiency	   of	   between	   75	   to	   95%	   was	   achieved	   after	   72	   h,	   determined	   by	  
immunoblotting,	   when	   compared	   to	   a	   non-­‐targeting	   control	   siRNA	   (Figure	   5.13).	  
Oligonucleotides	  2	  and	  3	  were	  chosen	  for	  functional	  assays,	  as	  they	  provided	  good	  
knock	   down	   efficiencies	   and	   exhibited	   similar	   morphological	   phenotypes	   when	  
visualised	   by	   phase	   contrast	   microscopy	   (data	   not	   shown).	   These	   siRNAs	   are	  
referred	  to	  as	  siParg1-­‐2	  and	  siParg1-­‐3.	  
	  
	  
Figure	  5.13	  siRNA-­‐mediated	  knockdown	  of	  Parg1	  in	  HUVECs	  
Representative	  immunoblot	  (A)	  of	  lysates	  from	  HUVECs	  transfected	  with	  4	  different	  siRNA	  
oligonucleotides	   targeting	  Parg1.	  Mock	   represents	   cells	   treated	  with	  oligofectamine	  only,	  
and	  Pool	  represents	  an	  equal	  mixture	  of	  oligos	  1	  –	  4.	  Cells	  were	  transfected	  with	  20	  nM	  of	  
siRNA	  using	  OligofectamineTM,	  and	  incubated	  for	  72	  h	  at	  37°C,	  5%	  CO2.	  Cells	  were	  lysed	  and	  
protein	  analysed	  by	  immunoblotting	  with	  an	  anti-­‐Parg1	  antibody.	  Blots	  were	  re-­‐probed	  for	  
GAPDH	   as	   a	   loading	   control.	   (B)	   Data	   were	   generated	   by	   densitometric	   scanning	   of	   the	  
Western	  blots,	  normalised	  to	  total	  GAPDH	  levels,	  relative	  to	  siControl.	  Data	  shown	  are	  the	  
mean	  of	  three	  independent	  experiments	  ±	  SEM.	  Statistical	  significance	  was	  assessed	  by	  an	  
unpaired	  Student’s	  t-­‐test;	  **	  p<0.005,	  ***	  p<0.001.	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5.3.3 Parg1	  depletion	  induces	  stress	  fibres	  
	  
HUVECs	  were	  transfected	  with	  siRNAs	  targeting	  Parg1	  and	  stained	  for	  F-­‐actin	  and	  β-­‐
catenin	  (Figure	  5.14).	  Control	  cells	  maintain	  their	  cobblestone-­‐like	  morphology	  (as	  
observed	   in	   Chapter	   3),	   with	   β-­‐catenin	   localizing	   linearly	   along	   cell–cell	   borders	  
(continuous	   adherens	   junctions)	   and	   with	   a	   wider	   reticular	   distribution	   where	  
adjacent	   cells	   overlapped	   (reticular	   adherens	   junctions;	   Figure	   5.14,	   yellow	  
arrowheads)	   (Fernandez-­‐Martin	   et	   al.,	   2012).	   Depletion	   of	   Parg1	   resulted	   in	   cell	  
elongation	  and	  a	  dramatic	  increase	  in	  stress	  fibres	  that	  traversed	  the	  length	  of	  the	  
cell	  (Figure	  5.14,	  red	  arrows).	  Linear	  continuous	  adherens	  junctions	  along	  the	  cell-­‐
cell	   borders	   (parallel	   to	   the	   stress	   fibres)	   were	   maintained	   in	   Parg1	   knockdown	  
cells,	  however	  junctions	  perpendicular	  to	  the	  stress	  fibres	  were	  discontinuous	  (blue	  
arrows	  in	  Figure	  5.14),	  indicative	  of	  impaired	  barrier	  function	  (Millan	  et	  al.,	  2010).	  
	  
In	  summary,	  these	  results	  indicate	  that	  Parg1	  regulates	  stress	  fibres	  in	  endothelial	  
cells.	  
	  
Chapter	  5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Roles	  of	  insulin-­‐stimulated	  14-­‐3-­‐3	  binding	  proteins	  in	  ECs	  	  	  	  	   
	  
	   	   152	  
	  
Figure	  5.14	  Parg1	  depletion	  induces	  stress	  fibres	  
Immunofluorescence	  micrographs	  of	  HUVECs	  transfected	  with	  siRNA	  targeting	  Parg1.	  Cells	  
were	  seeded	  on	  FN-­‐coated	  coverslips	  48	  h	  after	  transfection,	  and	  fixed	  after	  a	  further	  24	  h.	  
Cells	  were	  stained	  with	  β-­‐catenin	  for	  adherens	  junctions	  (green	  in	  merge),	  Alexa	  Fluor	  546-­‐
conjugated	   phalloidin	   for	   F-­‐actin	   (red	   in	   merge),	   and	   DAPI	   for	   nuclei	   (blue	   in	   merge).	  
Images	  were	  acquired	  by	  confocal	  microscopy	  with	  a	  63x	  oil	   immersion	  objective	  and	  are	  
maximum	  intensity	  projections	  of	  10	  confocal	  z-­‐stacks,	  spanning	  4	  μm	  with	  0.4	  μm	  intervals	  
between	   each	   image.	   Images	   are	   representative	   fields	   from	   three	   independent	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5.3.4 Parg1	  knock-­‐down	  decreases	  cell	  migration	  in	  a	  wound	  healing	  assay	  
Parg1	   has	   a	   profound	   effect	   on	   the	   actin	   cytoskeleton,	   and	   therefore	   could	   be	  
involved	   in	   regulating	   cell	   migration.	   The	   ORISTM	  migration	   was	   performed	   using	  
Parg1-­‐depleted	   HUVECs	   to	   investigate	   the	   role	   of	   Parg1	   in	   endothelial	   cell	  
migration.	   The	   experiment	  was	   performed	   as	   described	   for	   RICH-­‐1-­‐depleted	   cells	  
(see	  section	  5.2.4)	  using	  siRNAs	  targeting	  Parg1.	  
Parg1-­‐depleted	  HUVECs	  had	  a	   significant	   reduction	   in	   cell	  migration	   compared	   to	  
untreated	   (mock)	   cells	   and	   siControl	   treated	   cells	   (Figure	   5.15).	   When	   the	  
experiments	  were	  repeated	  in	  the	  presence	  of	  insulin,	  untransfected	  and	  siControl-­‐
transfected	   cells	   responded	  with	   an	   increase	   in	  migration	   (as	  observed	   in	   section	  
3.4),	  however	  insulin	  stimulation	  had	  no	  effect	  on	  the	  migration	  of	  Parg1-­‐depleted	  
cells	  (Figure	  5.15).	  	  Due	  to	  time	  limitations,	  the	  effect	  of	  insulin	  on	  Parg1-­‐depleted	  
HUVECs	  was	   only	   investigated	   using	   one	   oligo	   (siParg1-­‐2),	   and	   further	   analysis	   is	  
required	  for	  siParg1-­‐3.	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Figure	  5.15	  Parg1	  knockdown	  decreases	  cell	  migration	  
HUVECs	  were	   transfected	  with	   siRNAs	   targeting	   Parg1	   or	   control	   siRNA.	   After	   24	   h	   cells	  
were	  stained	  with	  Cell-­‐Tracker	  Orange	  fluorescent	  dye,	  seeded	  in	  wells	  containing	  a	  central	  
insert,	  and	  incubated	  for	  24	  h	  at	  37°C.	  	  The	  inserts	  were	  then	  removed	  to	  create	  a	  central	  
wound	  in	  the	  monolayer,	  and	  imaged	  at	  4x	  magnification.	  For	  the	  insulin	  studies,	  cells	  were	  
serum	  starved	  for	  2	  h	  prior	  to	  removing	  the	  inserts,	  imaged	  and	  then	  stimulated	  with	  100	  
nM	   insulin.	   Cells	  were	   incubated	   for	   24	  hours	   at	   37°C	   and	   imaged	   again	  using	   the	   saved	  
locations	  of	  initial	  wounds.	  The	  migratory	  capacity	  of	  the	  cells	  was	  quantified	  by	  measuring	  
the	   percentage	   area	   of	   the	   central	   wound	   that	   cells	   had	  migrated	   into	   after	   24	   h	   using	  
ImageJ	   software,	  as	  a	  percentage	   relative	   to	   siControl	   cells.	  Data	   shown	  are	   the	  mean	  of	  
four	   and	   three	   independent	   experiments	   ±	   SEM	   of	   unstimulated	   and	   insulin	   studies,	  
respectively.	  Statistical	  significance	  was	  assessed	  by	  an	  unpaired	  Student’s	  t-­‐test;	  *p<0.05,	  
ns	  =	  not	  significant.	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5.3.5 Parg1	  depletion	  disrupts	  loop	  formation	  in	  an	  angiogenesis	  assay	  
The	   role	   of	   Parg1	   was	   investigated	   in	   an	   in	   vitro	   angiogenesis	   assay	   as	   it	   has	  
previously	   been	   shown	   to	   be	   a	   central	   regulator	   in	   developmental	   tubulogenesis	  
(Xu	   et	   al.,	   2011)	   and	   it	   affects	   endothelial	   F-­‐actin	   distribution	   (see	   Figure	   5.14).	  
HUVECs	   were	   transfected	   with	   siRNAs	   targeting	   Parg1,	   and	   seeded	   onto	  
polymerised	  Matrigel	  after	  48	  h.	  Angiogenic	  loop	  formation	  was	  monitored	  by	  time-­‐
lapse	  microscopy	  for	  24	  h.	  siControl	   treated	  cells	  elongated	  and	  extended	  cellular	  
processes	   leading	   to	   cell-­‐cell	   adhesion,	   forming	   a	  well	   organised	   network	   of	   cells	  
(Figure	   5.16).	   These	   cells	   were	   able	   to	   interact	   with	   each	   other	   and	   form	   closed	  
loops.	  Parg1-­‐depleted	  HUVECs	  were	  able	  to	  extend	  cellular	  processes,	  and	  interact	  
with	   other	   cells,	   but	   these	   connections	   were	   not	   maintained	   and	   frequently	  
collapsed	   (Figure	   5.16A,	   Movies	   S3	   and	   S5).	   There	   was	   a	   significant	   decrease	   in	  
maintained	   loop	   formation	   in	   Parg1-­‐depleted	   cells	   at	   24	   h	   (Figure	   5.16B).	  
Interestingly,	  deformation	  of	  the	  Matrigel	  was	  observed	  during	  the	  retraction	  of	  the	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Figure	  5.16	  Parg1	  depletion	  disrupts	  angiogenic	  loop	  formation	  
HUVECs	  were	  transfected	  with	  siRNAs	  targeting	  Parg1.	  Cells	  were	  seeded	  onto	  polymerised	  
Matrigel	  (4.5	  mg/ml)	  48	  h	  after	  transfection,	  incubated	  for	  1	  h	  at	  37	  °C	  and	  loop	  formation	  
was	  monitored	  by	   time-­‐lapse	  microscopy	  using	  a	  4x	  objective,	   acquiring	   images	  every	  20	  
min	  for	  24	  h	  (A).	  Quantification	  was	  performed	  by	  counting	  the	  total	  number	  of	  complete	  
loops	  per	  field,	  as	  a	  percentage	  relative	  to	  siControl	  cells	  (B).	  At	  least	  5	  fields	  were	  scored	  
per	   condition	   in	   each	   experiment	   and	   data	   shown	   are	   the	   mean	   of	   four	   and	   three	  
independent	  experiments	  for	  siParg1-­‐1	  and	  siParg1-­‐2,	  respectively,	  normalised	  to	  siControl	  
±	  SEM	  (siControl	  =	  100	  %).	  ***p<0.001,	  One-­‐way	  ANOVA	  (Holm-­‐Sidak	  method).	  Scale	  bars	  
are	  200	  μm.	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5.3.6 siRNA	  knock	  down	  of	  Parg1	  increases	  basal	  endothelial	  cell	  permeability	  
Depleting	   HUVECs	   of	   Parg1	   results	   in	   dramatic	  morphology	   changes	   (see	   section	  
5.3.3).	  Cells	  appear	  to	  elongate	  with	  stress	  fibres,	  accompanied	  by	  the	  disruption	  of	  
cell-­‐cell	  junctions.	  This	  could	  lead	  to	  leaky	  cell-­‐cell	  junctions	  and	  thus	  a	  FITC-­‐dextran	  
permeability	   assay	  was	  performed	   to	  measure	   the	  effect	  of	   Parg1	   knockdown	  on	  
endothelial	   barrier	   function.	   Parg1	   knockdown	   resulted	   in	   an	   increase	   in	   cell	  
permeability	   when	   compared	   to	   siControl	   treated	   cells	   (Figure	   5.17).	   siParg1-­‐3-­‐
treated	   HUVECs	   had	   a	   significant	   increase	   in	   cell	   permeability	   (Figure	   5.17),	  
suggesting	   that	   Parg1	   is	   essential	   for	  maintaining	   cell-­‐cell	   junctions.	   Cells	   treated	  
with	  siParg1-­‐2	  had	  a	  lot	  of	  variability	  between	  experimental	  repeats,	  and	  therefore	  
did	   not	   result	   in	   a	   statistically	   significant	   increase	   in	   permeability.	   Due	   to	   the	  
variable	   nature	   of	   this	   assay,	   further	   repeats	   are	   required	   to	   confirm	   that	   both	  
siRNA	  oligonucleotides	  produce	  similar	  phenotypes.	  	  
	  
	  
Figure	  5.17	  Parg1	  depletion	  increases	  basal	  endothelial	  cell	  permeability	  
HUVECs	  were	  transfected	  with	  siRNAs	  targeting	  Parg1.	  Cells	  were	  seeded	  onto	  Transwell™	  
filters	   (0.4	   µm	   pore	   size)	   48	   h	   after	   transfection	   and	   incubated	   for	   24	   h	   at	   37	   °C.	   FITC-­‐
dextran	  (0.1	  mg/ml)	  was	  added	  to	  the	  upper	  chamber	  and	  the	  lower	  chamber	  fluorescence	  
was	  measured	  after	  60	  min.	  Fluorescence	  was	  measured	  for	  duplicate	  wells	  and	  quantified	  
as	   a	   percentage	   relative	   to	   control.	   Data	   shown	   are	   the	   mean	   of	   three	   independent	  
experiments	   ±	   SEM.	   Statistical	   significance	   was	   assessed	   by	   a	   Mann-­‐Whitney	   U	   test;	  
*p<0.05.	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5.4 LIM	  domain	  only	  7	  (LMO7)	  
LIM	  domain	  only	  7	   (LMO7)	   is	  an	   interesting	  hit	   identified	   from	  the	  14-­‐3-­‐3-­‐binding	  
screen,	   as	   it	   had	   previously	   been	   identified	   in	   the	  MacKintosh	   laboratory	   for	   its	  
potential	  role	  in	  regulating	  insulin	  signalling	  (Dubois	  et	  al.,	  2009).	  Moreover,	  LMO7	  
was	  previously	  shown	  to	  co-­‐localise	  with	  F-­‐actin	  and	  play	  an	  important	  role	  in	  cell	  
migration,	   requiring	   Rho	   GTPases	   (Hu	   et	   al.,	   2011).	   LMO7	   is	   a	   multifunctional	  
protein	   that	  belongs	   to	   the	  PDZ	  and	  LIM	  domain-­‐containing	  protein	   family,	  which	  
function	   as	   protein-­‐protein	   recognition	  modules	   that	   are	   essential	   for	   integrating	  
diverse	  cellular	  networks	  (Kadrmas	  and	  Beckerle,	  2004).	  The	  protein	  comprises	  of	  a	  
LIM	   domain,	   Calponin	   Homology	   (CH)	   domain	   and	   a	   PDZ	   domain	   (Figure	   5.18).	  
Interestingly,	  LMO7	  shuttles	  between	  the	  cell	  surface	  and	  the	  nucleus,	  indicating	  it	  
has	  two	  different	  functions.	  	  
	  
	  
Figure	  5.18	  Domain	  structure	  of	  LMO7	  
LMO7	  consists	  of	  1683	  amino	  acids	  with	  a	  Calponin	  Homology	  (CH)	  domain,	  a	  PDZ	  domain	  
and	  an	  LIM	  domain.	  
	  
For	   its	  nuclear	   function,	  LMO7	   localises	  at	   the	  nuclear	  envelope	  binding	  a	  nuclear	  
membrane	   protein	   called	   emerin.	   Mutations	   in	   emerin	   result	   in	   X-­‐linked	   Emery-­‐
Dreifuss	  muscular	  dystrophy	  (EMED),	  and	  LMO7	  appears	  to	  also	  play	  a	  role	   in	  this	  
disease	   due	   to	   its	   ability	   to	   transcriptionally	   regulate	   emerin	   by	  mutual	   feedback	  
regulation	  (Holaska	  et	  al.,	  2006).	  LMO7	  is	  highly	  expressed	  in	  muscle	  and	  heart	  and	  
has	  been	  found	  to	  regulate	  a	  large	  number	  of	  genes,	  including	  forty-­‐six	  muscle	  and	  
heart	   genes	   (Holaska	   et	   al.,	   2006;	   Ott	   et	   al.,	   2008;	   Putilina	   et	   al.,	   1998).	   Its	  
importance	   in	   the	   heart	   was	   further	   established	   in	   zebrafish,	   where	   LMO7	  
knockdown	  resulted	  in	  severe	  defects	  in	  heart	  development	  (Ott	  et	  al.,	  2008).	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LMO7	  has	  been	  shown	  to	  localise	  at	  adherens	  junctions	  in	  epithelial	  cells	  by	  binding	  
to	  two	  F-­‐actin	  binding	  proteins,	  afadin	  and	  α-­‐actinin	  (Ooshio	  et	  al.,	  2004).	  In	  doing	  
so,	  LMO7	  acts	  as	  an	  adapter	  protein	  connecting	  the	  two	  adherens	  proteins,	  nectin	  
and	  E-­‐cadherin	  (see	  chapter	  1.2.2)	  (Ooshio	  et	  al.,	  2004).	  However,	  it	  was	  postulated	  
that	   LMO7	   is	   not	   necessary	   during	   the	   formation	   of	   cell-­‐cell	   junctions	   but	   rather	  
acts	  as	  a	  stabilizer	  of	  the	  junctional	  complexes	  after	  they	  are	  recruited.	  	  
Although	  multifunctional	  roles	  of	  LMO7	  have	  been	  identified,	  its	  role	  in	  endothelial	  
cells	  is	  yet	  to	  be	  determined.	  	  
	  
5.4.1 GFP-­‐LMO7	  localises	  in	  both	  the	  cytoplasm	  and	  the	  nucleus	  
GFP-­‐tagged	  LMO7	  localised	  diffusely	  in	  the	  nucleus	  and	  cytoplasm,	  consistent	  with	  
its	   dual	   role	   as	   a	   transcription	   factor	   and	   adaptor	   protein	   (Figure	   5.19).	   Strong	  
localisation	   at	   the	   plasma	   membrane	   was	   not	   observed,	   in	   contrast	   to	   previous	  
reports	  in	  epithelial	  cells	  (Ooshio	  et	  al.,	  2004).	  Linear	  VE-­‐cadherin	  staining	  suggests	  
that	  GFP-­‐LMO7	  expression	  does	  not	  affect	  adherens	  junctions	  (Figure	  5.19).	  LMO7	  
did	  not	  appear	   to	  affect	   F-­‐actin	   levels,	   as	  normal	  bundles	  of	   actin	   filaments	  were	  
present	  enriched	  along	  the	  cell-­‐cell	  boundaries	  (Figure	  5.19).	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Figure	  5.19	  LMO7	  localises	  in	  both	  the	  cytoplasm	  and	  nucleus	  in	  endothelial	  cells	  
HUVECs	  were	   transfected	  with	   pcDNA5	   FRT/TO	  GFP	   LMO7,	   seeded	  onto	   FN-­‐coated	   glass	  
coverslips	   and	   fixed	   after	   24	   h.	   Cells	   were	   stained	   with	   Alexa	   Fluor	   546-­‐conjugated	  
phalloidin	   for	   F-­‐actin	   (red	   in	   merge),	   VE-­‐cadherin	   for	   adherens	   junctions	   (magenta	   in	  
merge)	   and	   DAPI	   for	   nuclei	   (blue	   in	   merge).	   Yellow	   asterisks	   indicate	   transfected	   cells.	  
Images	  were	  acquired	  by	  confocal	  microscopy	  with	  a	  63x	  oil	   immersion	  objective	  and	  are	  
maximum	  intensity	  projections	  of	  10	  confocal	  z-­‐stacks,	  spanning	  4	  μm	  with	  0.4	  μm	  intervals	  
between	  each	  image.	  Images	  are	  representative	  of	  random	  fields	  from	  three	  independent	  
experiments.	  Scale	  bars	  are	  20	  μm.	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5.4.2 siRNA	  mediated	  knock-­‐down	  of	  LMO7	  in	  endothelial	  cells	  
LMO7	   protein	  was	   down	   regulated	   in	   HUVECs	   using	   four	   siRNA	   oligonucleotides,	  
and	   a	   knock-­‐down	   efficiency	   of	   between	   30	   –	   67%	   was	   achieved	   after	   72	   h,	  
determined	  by	   immunoblotting,	  when	  compared	  to	  a	  non-­‐targeting	  control	   siRNA	  
(Figure	  5.20).	  Oligonucleotides	  1	  and	  3	  were	  chosen	  for	   functional	  assays,	  as	   they	  
provided	  higher	  and	  more	  consistent	  knock	  down	  efficiencies	  with	  a	  mean	  of	  67%	  




Figure	  5.20	  siRNA	  mediated	  knock	  down	  of	  LMO7	  in	  HUVECs	  
Representative	   immunoblot	   (A)	   of	   HUVECs	   transfected	   with	   4	   different	   siRNA	  
oligonucleotides	   targeting	  LMO7.	  Mock	  represents	  cells	   treated	  with	  oligofectamine	  only.	  
Cells	  were	  transfected	  with	  20	  nM	  of	  siRNA	  using	  OligofectamineTM,	  and	  incubated	  for	  72	  h	  
at	   37°C,	   5%	  CO2.	   Cells	  were	   lysed	   and	   protein	   analysed	   by	   immunoblotting	  with	   an	   anti-­‐
LMO7	   antibody.	   Blots	   were	   re-­‐probed	   for	   GAPDH	   as	   a	   loading	   control.	   (B)	   Data	   were	  
generated	   by	   densitometric	   scanning	   of	   the	   Western	   blots,	   normalised	   to	   total	   GAPDH	  
levels,	  relative	  to	  siControl.	  Data	  shown	  are	  the	  mean	  of	  three	  independent	  experiments	  ±	  
SEM.	  Statistical	  significance	  was	  assessed	  by	  an	  unpaired	  Student’s	  t-­‐test;	  *p<0.05.	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5.4.3 LMO7	  depletion	  affects	  tight	  junctions	  in	  endothelial	  cells	  
LMO7	   binds	   two	   F-­‐actin	   binding	   proteins	   afadin	   and	   α-­‐actinin	   and	   stabilises	  
epithelial	   junctions	   by	   connecting	   the	   nectin-­‐afadin	   and	   E-­‐cadherin-­‐catenin	  
complexes	   (Ooshio	   et	   al.,	   2004).	   No	   obvious	   cell	   morphology	   changes	   were	  
observed	  in	  LMO7-­‐depleted	  HUVECs.	  β-­‐catenin	  localised	  linearly	  along	  the	  cell-­‐cell	  
boundaries	   and	   adherens	   reticular	   junctions	   were	   maintained.	   Depleting	   LMO7	  
appeared	   to	   slightly	   increase	   the	  number	  of	   stress	   fibres	  present	   in	   the	   cells	   and	  
disorganise	   F-­‐actin;	   however	   these	   did	   not	   affect	   cell	   shape	   or	   cell-­‐cell	   junctions	  
(Figure	  5.21).	  
When	  confluent	  monolayers	  of	  siLMO7-­‐depleted	  HUVECs	  were	  stained	  for	  TJs,	  the	  
localization	  of	  the	  tight	  junctional	  protein	  ZO-­‐1	  was	  altered	  (Figure	  5.22).	  siControl	  
treated	  cells	  displayed	  a	  linear	  localisation	  of	  ZO-­‐1	  along	  most	  cell-­‐cell	  boundaries,	  
however	  depleting	  LMO7	  resulted	   in	  ZO-­‐1	  proteins	  extending	  perpendicularly	   into	  
the	   neighbouring	   cells	   (yellow	   boxed	   area	   in	   Figure	   5.22).	   PECAM-­‐1	   staining	   also	  
suggested	  that	  cells	  overlapped	  less	  when	  LMO7	  was	  absent;	  with	  thinner	  areas	  of	  
PECAM-­‐1	   present	   between	   neighbouring	   cells,	   when	   compared	   to	   siControl	   cells	  
(yellow	  boxed	  area	  in	  Figure	  5.22).	  
In	  summary,	  LMO7	  depletion	  alters	  TJs,	  but	  did	  not	  appear	  to	  affect	  AJs	  in	  HUVECs.	  
Further	  quantification	  of	  the	  junctions	  is	  required	  to	  identify	  if	  any	  subtle	  changes	  
are	  occurring.	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Figure	  5.21	  LMO7	  depletion	  does	  not	  appear	  to	  affect	  adherens	  junctions	  in	  
HUVECs	  
Immunofluorescence	  micrographs	  of	  HUVECs	  transfected	  with	  siRNA	  targeting	  LMO7.	  Cells	  
were	  seeded	  on	  FN-­‐coated	  coverslips	  48	  h	  after	  transfection,	  and	  fixed	  after	  a	  further	  24	  h.	  
Cells	  were	  stained	  with	  β-­‐catenin	  for	  adherens	  junctions	  (green	  in	  merge),	  Alexa	  Fluor	  546-­‐
conjugated	   phalloidin	   for	   F-­‐actin	   (red	   in	   merge),	   and	   DAPI	   for	   nuclei	   (blue	   in	   merge).	  
Images	  were	  acquired	  by	  confocal	  microscopy	  with	  a	  63x	  oil	   immersion	  objective	  and	  are	  
maximum	  intensity	  projections	  of	  10	  confocal	  z-­‐stacks,	  spanning	  4	  μm	  with	  0.4	  μm	  intervals	  
between	  each	  image.	  Images	  are	  representative	  of	  random	  fields	  from	  three	  independent	  
experiments.	  Scale	  bars	  are	  20	  μm.	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Figure	  5.22	  LMO7	  depletion	  alters	  tight	  junctional	  proteins	  
Immunofluorescence	   micrographs	   of	   HUVECs	   transfected	   with	   siRNA	   targeting	   LMO7	   or	  
control	  siRNA.	  Cells	  were	  seeded	  on	  FN-­‐coated	  coverslips	  48	  h	  after	  transfection,	  and	  fixed	  
after	  a	  further	  24	  h.	  Cells	  were	  stained	  with	  antibodies	  to	  ZO-­‐1	  for	  tight	  junctions	  (green	  in	  
merge),	   Alexa	   Fluor	   546-­‐conjugated	   phalloidin	   for	   F-­‐actin	   (red	   in	   merge),	   anti	   CD31	  
(PECAM-­‐1)	  antibody	  (magenta	  in	  merge),	  and	  DAPI	  for	  nuclei	  (blue	  in	  merge).	  Yellow-­‐boxed	  
areas	   are	   shown	   at	   higher	  magnification	   to	   the	   right.	   Images	  were	   acquired	   by	   confocal	  
microscopy	  with	  a	  63x	  oil	  immersion	  objective	  and	  are	  maximum	  intensity	  projections	  of	  10	  
confocal	   z-­‐stacks,	   spanning	  4	  μm	  with	   0.4	  μm	   intervals	   between	  each	   image.	   Images	   are	  
representative	  from	  three	  independent	  experiments.	  Scale	  bars	  are	  20	  μm.	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5.4.4 LMO7	  knock-­‐down	  does	  not	  affect	  cell	  motility	  in	  a	  wound	  healing	  assay	  
LMO7	  was	  shown	  to	  play	  an	  important	  role	  in	  breast	  cancer	  migration	  by	  relieving	  
actin-­‐mediated	   inhibition	   through	  Rho-­‐dependent	  myocardin-­‐related	   transcription	  
factors	   (MRTFs)	   (Hu	   et	   al.,	   2011).	   	   In	   order	   to	   investigate	   the	   role	   of	   LMO7	   in	  
endothelial	   cell	  migration,	   LMO7-­‐depleted	   cells	  were	   assessed	   for	   their	   ability	   to	  
migrate	  in	  the	  ORISTM	  migration	  assay.	  The	  experiment	  was	  performed	  as	  described	  
for	  RICH-­‐1-­‐depleted	  cells	  (see	  section	  5.2.4)	  using	  siRNAs	  targeting	  LMO7.	  
Depleting	   cells	   of	   LMO7	  did	   not	   significantly	   increase	   cell	  migration	   compared	   to	  
siControl-­‐transfected	  cells	  (Figure	  5.23).	  When	  the	  experiment	  was	  repeated	  in	  the	  
presence	  of	   insulin,	   the	  migration	  of	   LMO7-­‐depleted	  cells	   slightly	   increased	  when	  
compared	  to	  unstimulated	  cells,	  however	  this	  effect	  was	  not	  statistically	  significant	  
as	   observed	   with	   mock	   and	   siControl-­‐treated	   cells	   (Figure	   5.23).	   Due	   to	   time	  
limitations,	   the	  effect	  of	   insulin	  on	   LMO7-­‐depleted	  HUVECs	  was	  only	   investigated	  
using	  one	  oligo	  (siLMO7-­‐1),	  and	  further	  analysis	  is	  required	  for	  siLMO7-­‐3.	  
	  
	  
Figure	  5.23	  LMO7	  knock-­‐down	  does	  not	  affect	  endothelial	  cell	  migration	  
HUVECs	  were	   transfected	  with	   siRNAs	   targeting	   LMO7	   or	   control	   siRNA.	   After	   24	   h	   cells	  
were	  stained	  with	  Cell-­‐Tracker	  Orange	  fluorescent	  dye,	  seeded	  in	  wells	  containing	  a	  central	  
insert,	  and	  incubated	  for	  24	  h	  at	  37°C.	  	  The	  inserts	  were	  then	  removed	  to	  create	  a	  central	  
wound	  in	  the	  monolayer,	  and	  imaged	  at	  4x	  magnification.	  For	  the	  insulin	  studies,	  cells	  were	  
serum	  starved	  for	  2	  h	  prior	  to	  removing	  the	  inserts,	  imaged	  and	  then	  stimulated	  with	  100	  
nM	   insulin.	   Cells	  were	   incubated	   for	   24	  hours	   at	   37°C	   and	   imaged	  again	  using	   the	   saved	  
locations	  of	  initial	  wounds.	  The	  migratory	  capacity	  of	  the	  cells	  was	  quantified	  by	  measuring	  
the	   percentage	   area	   of	   the	   central	   wound	   that	   cells	   had	  migrated	   into	   after	   24	   h	   using	  
ImageJ	   software,	  as	  a	  percentage	   relative	   to	   siControl	   cells.	  Data	   shown	  are	   the	  mean	  of	  
four	   and	   three	   independent	   experiments	   ±	   SEM	   of	   unstimulated	   and	   insulin	   studies,	  
respectively.	  Statistical	  significance	  was	  assessed	  by	  an	  unpaired	  Student’s	  t-­‐test;	  *p<0.05.	  
Chapter	  5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Roles	  of	  insulin-­‐stimulated	  14-­‐3-­‐3	  binding	  proteins	  in	  ECs	  	  	  	  	   
	  
	   	   166	  
5.4.5 LMO7	  depletion	  might	  increase	  loop	  formation	  in	  an	  in	  vitro	  angiogenesis	  
assay	  
	  
LMO7	   gene	   knockdown	   experiments	   in	   zebrafish	   embryos	   resulted	   in	   severe	  
defects	  in	  heart	  development	  (Ott	  et	  al.,	  2008).	  The	  role	  of	  LMO7	  in	  an	  angiogenesis	  
assay	  was	  investigated.	  Depleting	  cells	  of	  LMO7	  resulted	  in	  a	  significant	  increase	  in	  
loop	   formation	  after	  24	  h,	  when	  compared	   to	  siControl	   treated	  cells	   (Figure	  5.24,	  
Movies	  S3	  and	  S6),	  only	  with	  one	  of	  the	  two	  siRNA	  oligos.	  siLMO7-­‐1	  had	  a	  greater	  
knockdown	  efficiency	   than	  siLMO7-­‐3	   (see	  Figure	  5.20),	  and	   this	  could	  account	   for	  
the	   lack	   of	   effect	   of	   siLMO7-­‐3.	   However,	   siLMO7-­‐3	   treated	   HUVECs	   appeared	   to	  
form	   loops	   faster	   than	   siControl	   treated	   cells	   (see	   4	   h	   time-­‐point	   in	   Figure	   5.24),	  
and	  thus	  quantification	  at	  time-­‐points	  earlier	  than	  24	  h	  might	  result	   in	  a	  different	  
quantitative	  outcome.	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Figure	  5.24	  LMO7	  depletion	  might	  increase	  loop	  formation	  in	  an	  angiogenesis	  
assay	  
HUVECs	  were	  transfected	  with	  siRNAs	  targeting	  LMO7.	  Cells	  were	  seeded	  onto	  polymerised	  
Matrigel	  (4.5	  mg/ml)	  48	  h	  after	  transfection,	  incubated	  for	  1	  h	  at	  37	  °C	  and	  loop	  formation	  
was	  monitored	  by	   time-­‐lapse	  microscopy	  using	  a	  4x	  objective,	   acquiring	   images	  every	  20	  
min	  for	  24	  h	  (A).	  Quantification	  was	  performed	  by	  counting	  the	  total	  number	  of	  complete	  
loops	  per	  field	  at	  24	  h,	  as	  a	  percentage	  relative	  to	  siControl	  cells	  (B).	  At	  least	  5	  fields	  were	  
scored	  per	  condition	   in	  each	  experiment	  and	  data	  shown	  are	  the	  mean	  of	   four	  and	  three	  
independent	  experiments	  for	  siLMO7-­‐1	  and	  siLMO7-­‐3,	  respectively,	  normalised	  to	  siControl	  
±	  SEM	  (siControl	  =	  100%).	  Statistical	  significance	  was	  assessed	  by	  the	  Mann-­‐Whitney	  U	  test;	  
*p<0.05.	  Scale	  bars	  are	  200	  μm.	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5.4.6 LMO7	  depletion	  does	  not	  affect	  basal	  endothelial	  cell	  permeability	  
LMO7	   has	   been	   shown	   to	   stabilise	   epithelial	   adherens	   junctions	   by	   binding	   to	   α-­‐
actinin	   and	   afadin	   and	   linking	   the	   nectin-­‐afadin	   and	   cadherin–catenin	   complexes	  
(Ooshio	  et	  al.,	  2004).	  A	  FITC-­‐dextran	  permeability	  assay	  was	  performed	  with	  LMO7-­‐
depleted	   cells	   to	   determine	   if	   LMO7	   plays	   a	   role	   in	   endothelial	   barrier	   function.	  	  
Depleting	  HUVECs	  of	  LMO7	  did	  not	  affect	  endothelial	  permeability,	  as	  no	  significant	  
change	  was	  observed	  between	   LMO7-­‐depleted	  and	   siControl-­‐treated	   cells	   (Figure	  
5.25).	  
Together	  with	   immunostaining	   data	   (section	   5.4.3),	   this	   suggests	   that	   endothelial	  
barrier	   function	   is	  maintained	  without	   the	   presence	   of	   LMO7,	   even	   though	   ZO-­‐1	  
localisation	  was	  altered.	  	  
	  
	  
Figure	  5.25	  LMO7	  depletion	  does	  not	  affect	  endothelial	  cell	  permeability	  
HUVECs	  were	  transfected	  with	  siRNAs	  targeting	  LMO7.	  Cells	  were	  seeded	  onto	  Transwell™	  
filters	   (0.4	   µm	   pore	   size)	   48	   h	   after	   transfection	   and	   incubated	   for	   24	   h	   at	   37	   °C.	   FITC-­‐
dextran	  (0.1	  mg/ml)	  was	  added	  to	  the	  upper	  chamber	  and	  the	  lower	  chamber	  fluorescence	  
was	  measured	  after	  60	  min.	  Fluorescence	  was	  measured	  for	  duplicate	  wells	  and	  quantified	  
as	   a	   percentage	   relative	   to	   control.	   Data	   shown	   are	   the	   mean	   of	   three	   and	   four	  
independent	   experiments	   for	   siLMO7-­‐1	   and	   siLMO7-­‐3,	   respectively,	   ±	   SEM.	   Statistical	  
significance	  was	  assessed	  by	  the	  Mann-­‐Whitney	  U	  test;	  ns	  =	  not	  significant.	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5.5 Epsin2	  
Epsins	   were	   first	   discovered	   as	   interacting	   partners	   of	   the	   endocytic	   accessory	  
protein	  Eps15	  (and	  therefore	  named	  Eps15-­‐interacting	  protein,	  Epsin)	  (Chen	  et	  al.,	  
1998),	   and	  were	   found	   to	   be	   necessary	   for	   endocytosis	   (Wendland	   et	   al.,	   1999).	  
Endocytosis	  is	  an	  essential	  cellular	  process	  in	  which	  cells	  internalise	  sections	  of	  the	  
plasma	  membrane	  to	  (i)	  actively	  take	  up	  extracellular	  materials	  (such	  as	  nutrients),	  
and	  (ii)	  to	  control	  the	  composition	  of	  their	  membrane	  and	  surface	  area	  (Sen	  et	  al.,	  
2012).	   It	   is	   also	   crucial	   for	   cell	   homeostasis,	   as	   internalising	   activated	   ligand-­‐
receptor	  complexes	  from	  the	  cell	  surface	  regulates	  multiple	  signalling	  pathways	  and	  
downstream	  signal	  transduction.	  There	  are	  several	  forms	  of	  endocytosis	  (reviewed	  
in	   Conner	   and	   Schmid,	   2003);	   however	   this	   section	   will	   focus	   on	   the	   clathrin-­‐
mediated	   pathway	   as	   Epsin2	   belongs	   to	   a	   family	   of	   endocytic	   clathrin	   adapters	  
(Rosenthal	  et	  al.,	  1999).	  Clathrin	  is	  a	  self-­‐assembling	  protein	  that	  forms	  a	  coated	  pit	  
on	  the	  inner	  surface	  of	  the	  plasma	  membrane	  that	  then	  buds	  into	  the	  cell	  to	  form	  a	  
coated	  vesicle	  in	  the	  cytoplasm	  of	  the	  cell	  (Brodsky,	  2012).	  This	  highly	  coordinated	  
process	  requires	  adaptor	  proteins	  that	  bind	  to	  clathrin,	  as	  it	  cannot	  bind	  directly	  to	  
membranes	   and	   cargo.	   The	   adaptor	   proteins	   select	   transmembrane	   cargos	   that	  
have	   been	   monoubiquitinated	   at	   the	   plasma	   membrane,	   induce	   invagination,	  
scission	   and	   release	   of	   the	   newly	   formed	   endocytic	   vesicle	   into	   the	   cytosol	  
(Wendland,	   2002).	   Adaptor	   proteins	   also	   interact	   with	   accessory	   proteins,	   which	  
bind	  phospholipids	  and	  stimulate	  the	  assembly	  of	  clathrin	  into	  polymerised	  baskets	  
(Wendland,	  2002).	  	  
Mammals	  express	  three	  epsins:	  Epsin	  1,	  Epsin	  2,	  and	  Epsin	  3	  encoded	  by	  different	  
genes	  (EPN1,	  EPN2,	  and	  EPN3,	  respectively).	  EPN1	  and	  2	  are	  highly	  expressed	  in	  the	  
brain,	  but	  are	  broadly	  expressed	  in	  all	  tissues	  tested	  (Chen	  et	  al.,	  1998;	  Chen	  et	  al.,	  
2009;	   Rosenthal	   et	   al.,	   1999),	   whereas	   EPN3	   is	   highly	   expressed	   in	   the	   stomach	  
compared	   to	   other	   tissues	   (Ko	   et	   al.,	   2010).	   Epsins	   contain	   an	   epsin	   N-­‐terminal	  
homology	   (ENTH)	   domain,	   which	   directly	   interacts	   with	   PIP2	   in	   the	   plasma	  
membrane	   and	   also	   has	   membrane-­‐deforming	   properties	   (Ford	   et	   al.,	   2002),	  
followed	   by	   two	   ubiquitin-­‐interacting	   motifs	   (UIM)	   and	   an	   unstructured	   region	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containing	  motifs	   for	  clathrin	  binding,	  EPS15	  binding	  and	  adapter	  protein-­‐2	  (AP-­‐2)	  
binding	  (Chen	  et	  al.,	  1998;	  Itoh	  et	  al.,	  2001;	  Polo	  et	  al.,	  2002;	  Reider	  and	  Wendland,	  
2011;	  Rosenthal	  et	  al.,	  1999)	  (Figure	  5.26).	  Epsins	  are	  recruited	  at	  the	  early	  stages	  
of	  endocytosis	  via	  the	  binding	  of	  its	  ENTH	  domain	  to	  PIP2,	  and	  its	  interactions	  with	  





Figure	  5.26	  Representation	  of	  the	  molecular	  architecture	  of	  Epsin	  1	  and	  2	  
Epsins	   1	   and	  2	   consist	   of	   an	   epsin	  N-­‐terminal	   homology	   (ENTH)	  domain	   followed	  by	   two	  
ubiquitin	   (Ub)-­‐interacting	  motifs	   (UIM)	   and	   an	   unstructured	   region	   containing	  motifs	   for	  
clathrin	  binding	  (black	  blocks),	  EPS15	  binding	  (blue	  blocks)	  and	  AP-­‐2	  binding	  (white	  block).	  
Figure	  adapted	  from	  Reider	  and	  Wendland,	  2011.	  	  
	  
Epsin	  plays	  an	   important	   role	   in	  signalling	   regulation.	  Mice	   lacking	  either	  EPN1	  or	  
EPN2	   did	   not	   display	   any	   obvious	   phenotypic	   defects,	   suggesting	   redundant	  
functions.	   However,	   double	   knockout	   of	   EPN1	   and	   EPN2	   in	   mice	   resulted	   in	  
embryonic	   lethality	  at	   the	  beginning	  of	  organogenesis	   (embryonic	  day	  10),	  due	  to	  
the	   disruption	   of	   Notch	   signalling,	   with	   embryos	   exhibiting	   major	   angiogenesis	  
defects	   (Chen	   et	   al.,	   2009).	   However,	   in	   mouse	   models	   with	   constitutive	   or	  
inducible	  deletions	  of	  EPN1	  and	  EPN2	  specifically	  in	  endothelial	  cells,	  adult	  mice	  did	  
not	  exhibit	  any	  abnormal	  phenotypes	  (Pasula	  et	  al.,	  2012).	  This	  suggests	  that	  a	  lack	  
of	   EPN1	   and	   EPN2	   after	   the	   vasculature	   has	   developed	   has	   little	   impact	   on	  
established	  vessels	  in	  normal	  tissues.	  Interestingly,	  a	  lack	  of	  epsin	  in	  the	  vasculature	  
in	  a	  tumour	  environment	  resulted	  in	  highly	  disorganized	  vascular	  structures,	   leaky	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vessels	   and	   a	   reduction	   in	   tumour	   growth,	   due	   to	   excessive	   vascular	   endothelial	  
growth	  factor	  (VEGF)	  signalling	  (Pasula	  et	  al.,	  2012).	  VEGF	  promotes	  epsin	  binding	  
to	   ubiquitinated	   vascular	   endothelial	   growth	   factor	   receptor	   2	   (VEGFR2),	   for	  
endocytosis	   to	   occur,	   and	   subsequent	   degradation	   of	   VEGFR2.	   Endothelial	   epsins	  
therefore	   negatively	   regulate	   VEGF	   signalling	   and	   in	   their	   absence	   this	   signalling	  
cannot	  be	  attenuated,	  resulting	  in	  non-­‐productive	  leaky	  angiogenesis	  (Pasula	  et	  al.,	  
2012).	  	  
Aguilar	  et	  al.	  (2006)	  report	  that	  epsins	  are	  an	  important	  link	  between	  the	  endocytic	  
and	  cell	  polarity	  machineries	  as	  the	  ENTH	  domain	  regulates	  specific	  Cdc42	  signalling	  
pathways	   in	   yeast	   cells.	   Epsins	   bind	   to	   Cdc42	   GAPs	   and	   sequester	   their	   activity,	  
thereby	   relieving	   the	   GAP-­‐induced	   Cdc42	   inhibition	   (Aguilar	   et	   al.,	   2006).	   Epsins	  
interact	   via	   their	   ENTH	   domain	   with	   the	   Cdc42/Rac1	   GAP	   and	   Ral	   effector,	   Ral-­‐
binding	  protein	  1	   (RalBP1)	  and	   this	   interaction	  was	   shown	   to	  be	  essential	   for	   cell	  
migration	   (Coon	   et	   al.,	   2010).	   In	   mammalian	   cells	   the	   ENTH	   domain	   localises	   to	  
filopodia	  and	  lamellipodia,	  processes	  that	  require	  precise	  spatial	  and	  temporal	  fine-­‐
tuning	  of	  Cdc42	  and	  Rac1	  to	  form	  (Aguilar	  et	  al.,	  2006).	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5.5.1 GFP-­‐Epsin2	  has	  a	  punctate	  cytoplasmic	  distribution	  in	  endothelial	  cells	  
The	  role	  of	  epsins	  in	  endothelial	  cells	  has	  recently	  been	  investigated	  in	  vivo	  focusing	  
on	  the	  global	  mechanism	  of	  epsins	   in	  angiogenesis	   (Pasula	  et	  al.,	  2012).	  My	  study	  
focuses	  on	  the	  role	  of	  Epsin2	  in	  endothelial	  cells	  in	  an	  attempt	  to	  elucidate	  its	  role	  
in	  insulin	  signalling.	  	  
GFP-­‐Epsin2	   displayed	   punctate	   cytoplasmic	   distribution	   in	   HUVECs.	   This	   was	  
expected	   as	   epsin1	   was	   previously	   shown	   to	   accumulate	   in	   puncta	   in	   chinese	  
hamster	  ovary	  (CHO)	  cells	  (Chen	  et	  al.,	  1998)	  and	  COS7	  cells	  (Ford	  et	  al.,	  2002).	  GFP-­‐
Epsin2	  had	  no	  obvious	  effect	  on	   the	  organisation	  of	   the	  actin	  cytoskeleton,	  when	  
compared	   to	  GFP-­‐transfected	  HUVECs	   (Figure	  5.27).	  Adherens	   junctions	  were	  not	  
affected	   by	   GFP-­‐Epsin2	   in	   confluent	  monolayers,	   visualised	   by	   linear	   VE-­‐cadherin	  
staining	   along	   the	   cell	   boundaries	   (Figure	   5.27A).	   Sub-­‐confluent	   GFP-­‐Epsin2	  
expressing	  cells	  appeared	  to	  exhibit	  slight	  membrane	  ruffling,	  compared	  to	  control	  
GFP-­‐transfected	   HUVECS	   (Figure	   5.27B).	   Insulin	   stimulation	   of	   GFP-­‐Epsin2-­‐
expressing	  cells	   induced	   lamellipodium	  formation	  (Figure	  5.28,	   red	  arrows),	  which	  
was	  not	  observed	  in	  unstimulated	  cells	  or	  cells	  expressing	  control	  GFP.	  This	  would	  
need	   to	   be	   quantified	   to	   determine	   if	   this	   is	   a	   specific	   response	   to	   Epsin2	  
overexpression.	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Figure	  5.27	  GFP-­‐Epsin2	  is	  localised	  in	  puncta	  in	  the	  cytoplasm	  in	  endothelial	  cells	  
HUVECs	  were	   transfected	  with	   pcDNA5	   FRT/TO	  GFP	   Epsin2	   seeded	   onto	   FN-­‐coated	   glass	  
coverslips	  and	  fixed	  after	  24	  h.	  Confluent	  monolayers	  (A)	  and	  sub-­‐confluent	  (B)	  cells	  were	  
stained	  with	  Alexa	  Fluor	  546-­‐conjugated	  phalloidin	  for	  F-­‐actin	  (red	  in	  merge),	  anti-­‐β-­‐catenin	  
for	  adherens	  junctions	  in	  confluent	  monolayers	  (A,	  magenta	  in	  merge)	  and	  DAPI	  for	  nuclei	  
(blue	   in	  merge).	   Images	  were	   acquired	   by	   confocal	  microscopy	  with	   a	   63x	   oil	   immersion	  
objective	   and	   are	  maximum	   intensity	   projections	   of	   10	   confocal	   z-­‐stacks,	   spanning	   4	   μm	  
with	   0.4	   μm	   intervals	   between	   each	   image.	   Images	   are	   representative	   fields	   from	   three	  
independent	  experiments.	  Scale	  bars	  are	  20	  μm.	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Figure	  5.28	  Insulin	  stimulation	  induces	  lamellipodia	  in	  GFP-­‐Epsin2-­‐expressing	  ECs	  
HUVECs	   were	   transfected	   with	   pcDNA5	   FRT/TO	   GFP	   Epsin2	   and	   seeded	   onto	   FN-­‐coated	  
glass	   coverslips.	   Cells	   were	   incubated	   for	   24	   h	   and	   then	   serum	   starved	   for	   4	   h	   in	   EBM2	  
medium	  containing	  1%	  FCS.	  Cells	  were	   stimulated	  with	  100	  nM	   insulin	   for	  1	  h,	   fixed	  and	  
stained	  with	  Alexa	  Fluor	  546-­‐conjugated	  phalloidin	  for	  F-­‐actin	  (red	  in	  merge),	  and	  DAPI	  for	  
nuclei	  (blue	  in	  merge).	  Red	  arrows	  indicate	  lamellipodia.	  Images	  were	  acquired	  by	  confocal	  
microscopy	  with	  a	  63x	  oil	  immersion	  objective	  and	  are	  maximum	  intensity	  projections	  of	  10	  
confocal	   z-­‐stacks,	   spanning	  4	  μm	  with	   0.4	  μm	   intervals	   between	  each	   image.	   Images	   are	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5.5.2 siRNA	  mediated	  knock-­‐down	  of	  Epsin2	  in	  endothelial	  cells	  
To	   investigate	   the	   functional	   role	  of	  Epsin2	   in	  endothelial	   cells,	   Epsin2	  expression	  
was	   down	   regulated	   in	  HUVECs	   using	   four	   siRNA	  oligonucleotides.	   A	   knock-­‐down	  
efficiency	   of	   between	   78	   –	   90%	   was	   achieved	   after	   72	   h,	   determined	   by	  
immunoblotting,	  when	  compared	   to	  a	  non-­‐targeting	  control	   siRNA	   (Figure	  5.29B).	  
Oligonucleotides	  4	  and	  17	  were	  chosen	  for	  functional	  assays,	  as	  they	  provided	  good	  
knock-­‐down	   efficiencies	   and	   exhibited	   similar	   morphological	   phenotypes	   when	  
visualised	   with	   phase	   contrast	   microscopy	   (data	   not	   shown).	   These	   siRNAs	   are	  
referred	  to	  as	  siEpsin2-­‐4	  and	  siEpsin2-­‐17.	  
	  
	  
Figure	  5.29	  siRNA	  mediated	  knock	  down	  of	  Epsin2	  in	  HUVECs	  
Representative	   immunoblot	   (A)	   of	   HUVECs	   transfected	   with	   4	   different	   siRNA	  
oligonucleotides	  targeting	  Epsin2.	  Mock	  represents	  cells	  treated	  with	  oligofectamine	  only.	  
Cells	  were	  transfected	  with	  20	  nM	  of	  siRNA	  using	  OligofectamineTM,	  and	  incubated	  for	  72	  h	  
at	   37°C,	   5%	  CO2.	   Cells	  were	   lysed	   and	   protein	   analysed	   by	   immunoblotting	  with	   an	   anti-­‐
Epsin2	   antibody.	   Blots	   were	   re-­‐probed	   for	   GAPDH.	   (B)	   Data	   were	   generated	   by	  
densitometric	  scanning	  of	  the	  Western	  blots,	  normalised	  to	  total	  GAPDH	  levels,	  relative	  to	  
siControl.	  Data	   shown	  are	   the	  mean	  of	   three	   independent	  experiments	  ±	  SEM.	  Statistical	  
significance	  was	  assessed	  by	  an	  unpaired	  Student’s	  t-­‐test;	  *p<0.05,	  **	  p<0.005,	  ***p<0.001	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5.5.3 Epsin2	  depletion	  does	  not	  induce	  any	  morphological	  changes	  in	  ECs	  	  
HUVECs	  were	  transfected	  with	  siRNAs	  targeting	  Epsin2	  and	  stained	  for	  F-­‐actin	  and	  
β-­‐catenin	   (Figure	   5.30).	   Depletion	   of	   Epsin2	   had	   no	   apparent	   effect	   on	   HUVEC	  
morphology	   (Figure	   5.30).	   Nuclear	   β-­‐catenin	   appeared	   to	   increase	   in	   Epsin2-­‐
depleted	  cells,	  especially	  in	  cells	  treated	  with	  siEpsin2-­‐17.	  
	  
	  
Figure	  5.30	  Epsin2	  depletion	  does	  not	  induce	  any	  major	  morphological	  changes	  in	  
HUVECs	  
Immunofluorescence	  micrographs	   of	   HUVECs	   transfected	  with	   siRNAs	   targeting	   siControl	  
and	  Epsin2.	   Cells	  were	   seeded	  on	   FN-­‐coated	   coverslips	   48	  h	   after	   transfection,	   and	   fixed	  
after	   a	   further	   24	   h.	   Cells	   were	   stained	   with	   β-­‐catenin	   for	   adherens	   junctions	   (green	   in	  
merge),	   Alexa	   Fluor	   546-­‐conjugated	   phalloidin	   for	   F-­‐actin	   (red	   in	   merge),	   and	   DAPI	   for	  
nuclei	   (blue	   in	   merge).	   Images	   were	   acquired	   by	   confocal	   microscopy	   with	   a	   63x	   oil	  
immersion	   objective	   and	   are	   maximum	   intensity	   projections	   of	   10	   confocal	   z-­‐stacks,	  
spanning	  4	  μm	  with	  0.4	  μm	  intervals	  between	  each	  image.	  Images	  are	  representative	  fields	  
from	  three	  independent	  experiments.	  Scale	  bars	  are	  20	  μm.	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5.5.4 	  Epsin2	  depletion	  does	  not	  affect	  cell	  motility	  or	  permeability	  
It	   has	   been	   previously	   shown	   that	   epsins	   are	   required	   for	   the	   cell	   polarity-­‐
dependent	  process	  of	  cell	  migration	  and	  invasion	  in	  NIH3T3	  fibroblasts	  and	  HT1080	  
fibrosarcoma	   cells,	   through	   interaction	   with	   the	   Cdc42/Rac1	   GAP	   and	   signalling	  
molecule	   RalBP1	   (Coon	   et	   al.,	   2010).	   This	   defect	   in	   migration	   was	   observed	   in	  
epsin1-­‐	  and	  epsin2-­‐double	  knockdown	  cells.	   In	  order	  to	   investigate	   if	  Epsin2	  has	  a	  
specific	  role	   in	  endothelial	  cell	  migration,	  the	  ORIS	  wound	  healing	  migration	  assay	  
was	  performed.	  The	  experiment	  was	  performed	  as	  described	   for	  RICH-­‐1-­‐depleted	  
cells	  (see	  section	  5.2.4)	  using	  siRNAs	  targeting	  Epsin2.	  
Epsin2	  depletion	  had	  no	  significant	  on	  cell	  migration	  compared	  to	  untreated	  (mock)	  
cells,	   and	  non-­‐targeting	   siControl	   transfected	  cells	  at	  24	  h,	  either	  with	  or	  without	  
insulin	   stimulation	   (Figure	   5.31).	   Due	   to	   time	   limitations,	   the	   effect	   of	   insulin	   on	  
Epsin2-­‐depleted	   HUVECs	   was	   only	   investigated	   using	   one	   oligo	   (siEpsin2-­‐4),	   and	  
further	  analysis	  is	  required	  for	  siEpsin2-­‐17.	  
Epsins	   have	   also	  been	   shown	   to	  be	   involved	   in	   the	   regulation	  of	   Cdc42	   signalling	  
(Aguilar	  et	  al.,	  2006),	  which	  contributes	  to	  stabilising	  endothelial	  adherens	  junctions	  
(Broman	   et	   al.,	   2006).	   However,	   Epsin2	   deletion	   did	   not	   affect	   endothelial	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Figure	  5.31	  Epsin2	  knock	  down	  does	  not	  affect	  endothelial	  cell	  migration	  in	  a	  
wound-­‐healing	  assay	  
HUVECs	  were	   transfected	  with	   siRNAs	   targeting	   Epsin2	   or	   control	   siRNA.	  After	   24	   h	   cells	  
were	  stained	  with	  Cell-­‐Tracker	  Orange	  fluorescent	  dye,	  seeded	  in	  wells	  containing	  a	  central	  
insert,	  and	  incubated	  for	  24	  h	  at	  37°C.	  	  The	  inserts	  were	  then	  removed	  to	  create	  a	  central	  
wound	  in	  the	  monolayer,	  and	  imaged	  at	  4x	  magnification.	  For	  the	  insulin	  studies,	  cells	  were	  
serum	  starved	  for	  2	  h	  prior	  to	  removing	  the	  inserts,	  imaged	  and	  then	  stimulated	  with	  100	  
nM	   insulin.	   Cells	  were	   incubated	   for	   24	  hours	   at	   37°C	   and	   imaged	   again	  using	   the	   saved	  
locations	  of	  initial	  wounds.	  The	  migratory	  capacity	  of	  the	  cells	  was	  quantified	  by	  measuring	  
the	   percentage	   area	   of	   the	   central	   wound	   that	   cells	   had	  migrated	   into	   after	   24	   h	   using	  
ImageJ	   software,	  as	  a	  percentage	   relative	   to	   siControl	   cells.	  Data	   shown	  are	   the	  mean	  of	  
four	   and	   three	   independent	   experiments	   ±	   SEM	   of	   unstimulated	   and	   insulin	   studies,	  
respectively.	  Statistical	  significance	  was	  assessed	  by	  an	  unpaired	  Student’s	  t-­‐test;	  *p<0.05.	  
	  
	  
Figure	  5.32	  Epsin2	  knock	  down	  does	  not	  affect	  endothelial	  cell	  permeability	  
HUVECs	  were	  transfected	  with	  siRNAs	  targeting	  Epsin2.	  Cells	  were	  seeded	  onto	  Transwell™	  
filters	   (0.4	   µm	   pore	   size)	   48	   h	   after	   transfection	   and	   incubated	   for	   24	   h	   at	   37	   °C.	   FITC-­‐
dextran	  (0.1	  mg/ml)	  was	  added	  to	  the	  upper	  chamber	  and	  the	  lower	  chamber	  fluorescence	  
was	  measured	  after	  60	  min.	  Fluorescence	  was	  measured	  for	  duplicate	  wells	  and	  quantified	  
as	   a	   percentage	   relative	   to	   control.	   Data	   shown	   are	   the	   mean	   of	   three	   independent	  
experiments	  ±	  SEM.	  Statistical	  significance	  was	  assessed	  by	  the	  Mann-­‐Whitney	  U	  test;	  ns	  =	  
not	  significant.	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5.5.5 Epsin2	  depletion	  increases	  loop	  formation	  during	  angiogenesis	  
	  
Mice	   lacking	  both	  epsin1	  and	  2	  exhibited	  major	   angiogenesis	   defects	   and	  died	  at	  
E10	   (Chen	   et	   al.,	   2009).	   However,	   epsin1	   and	   epsin2	   deletion	   specifically	   in	  
endothelial	  cells	  did	  not	  show	  any	  obvious	  phenotypic	  defects	  in	  mice	  (Pasula	  et	  al.,	  
2012).	  In	  an	  angiogenesis	  loop	  assay	  Epsin2-­‐depleted-­‐HUVECs	  attached	  to	  Matrigel,	  
elongated,	   extended	   cellular	   processes	   and	   established	   closed	   loops	   faster	   than	  
control	   cells	   (see	   Movies	   S3	   and	   S7).	   Cells	   appeared	   to	   be	   more	   dynamic,	   and	  
formed	   islands	   of	   cells	   from	   loops	  merging	   together.	   HUVECs	   depleted	   of	   Epsin2	  
formed	  significantly	  more	  loops	  than	  siControl-­‐treated	  cells	  (Figure	  5.33,	  Movies	  S3	  
and	  S7).	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Figure	  5.33	  Epsin2	  depletion	  increases	  loop	  formation	  in	  the	  angiogenesis	  assay	  
HUVECs	   were	   transfected	   with	   siRNAs	   targeting	   Epsin2.	   Cells	   were	   seeded	   onto	  
polymerised	  Matrigel	   (4.5	  mg/ml)	  48	  h	  after	   transfection,	   incubated	   for	  1	  h	  at	  37	   °C	  and	  
loop	   formation	   was	  monitored	   by	   time-­‐lapse	  microscopy	   using	   a	   4x	   objective,	   acquiring	  
images	   every	   20	   min	   for	   24	   h	   (A).	   Quantification	   was	   performed	   by	   counting	   the	   total	  
number	  of	  complete	  loops	  per	  field	  at	  24	  h,	  as	  a	  percentage	  relative	  to	  siControl	  cells	  (B).	  
At	   least	   5	   fields	   were	   scored	   per	   condition	   in	   each	   experiment	   and	   data	   shown	   are	   the	  
mean	   of	   four	   and	   three	   independent	   experiments	   for	   siEpsin-­‐4	   and	   siEpsin2-­‐17,	  
respectively,	  normalised	  to	  siControl	  ±	  SEM	  (siControl	  =	  100	  %).	  Statistical	  significance	  was	  
assessed	  by	  the	  Mann-­‐Whitney	  U	  test;	  *p<0.05.	  Scale	  bars	  are	  200	  μm.	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5.6 Summary	  
Over-­‐expression	  and	  RNA	  interference	  analysis	  of	  RICH-­‐1,	  Parg1,	  LMO7	  and	  Epsin2	  
were	  performed	   in	  order	   to	  elucidate	   their	   role	   in	  endothelial	   insulin	  signalling.	  A	  
summary	  of	  these	  findings	  is	  presented	  in	  Table	  5.1.	  
	   	   	   RICH-­‐1	   Parg1	   LMO7	   Epsin2	  
Over-­‐expression	   	   	   	   	  
	   Localisation	  
Cytoplasm	  &	  






Effect	  on	  actin	  




knockdown	   	   	   	   	  
	   Cell-­‐cell	  junctions	   	   	   	   	  
	   	  
Adherens	  
junctions	   	   Disrupted	   	   	  
	   	  
Tight	  
junctions	   Disrupted	   	   Mislocalised	   	  
	   	  Cell	  Migration	  
ê ê è è 
	   	  Angiogenesis	  
è ê é? é	  
	   Cell	  Permeability	   é? 
é è è 
	  
Table	  5.1	  Summary	  of	  characterisation	  of	  the	  insulin-­‐stimulated	  14-­‐3-­‐3	  binding	  
protein	  hits	  in	  endothelial	  cells.	  
Functional	   assays	   were	   performed	   with	   insulin-­‐stimulated	   14-­‐3-­‐3	   binding	   proteins	   to	  
elucidate	   their	   roles	   in	  endothelial	   cells.	  All	   four	  proteins	  are	   important	   regulators	  of	   the	  
endothelial	   cytoskeleton,	   as	   over-­‐expression	   and	   RNA	   interference	   analysis	   resulted	   in	  
morphologic	  and	  functional	  changes.	  Down	  arrows	  (blue)	  indicate	  a	  decrease	  in	  the	  assay,	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5.7 Discussion	  
The	  functional	  roles	  of	  the	  selected	  insulin-­‐sensitive	  14-­‐3-­‐3	  binding	  proteins	  RICH-­‐1,	  
Parg1,	  LMO7	  and	  Epsin2	  are	  not	  well	  known	  in	  ECs.	  Overexpression	  analysis	  and	  an	  
RNAi	   approach	   were	   primarily	   used	   to	   assess	   these	   roles,	   and	   the	   analyses	  
presented	   in	   this	   chapter	   provides	   insight	   into	   their	   involvement	   in	   the	   anti-­‐
inflammatory	  effects	  of	  insulin.	  
	  
5.7.1 Possible	  roles	  of	  RICH-­‐1	  at	  the	  plasma	  membrane	  
In	  sub-­‐confluent	  HUVECs,	  GFP-­‐RICH-­‐1	  localised	  in	  the	  cytoplasm	  and	  at	  the	  plasma	  
membrane	   in	   lamellipodial	   protrusions.	   BAR	   domain	   proteins	   have	   emerged	   as	  
central	  regulators	  of	  dynamic	  membrane	  remodelling	  (reviewed	  in	  (Mim	  and	  Unger,	  
2012)).	  The	  mechanisms	  involved	  in	  membrane	  curvature	  are	  not	  fully	  elucidated,	  
however	   it	   has	   been	  proposed	   that	  BAR	  domain	  proteins	   act	   as	   scaffold	  proteins	  
that	   recruit	   different	   binding	  partners	   and	   coordinate	   the	  different	   events	   during	  
the	   endocytic	   process	   (Qualmann	   et	   al.,	   2011).	   The	   well-­‐established	   roles	   of	   the	  
endocytic	  system	  involve	  sorting,	  processing	  and	  degradation	  of	  internalized	  cargo	  
using	   a	   series	   of	   compartments	   including	   early	   and	   recycling	   endosomes,	  
multivesicular	   bodies,	   late	   endosomes	   and	   lysosomes.	   However,	   recent	   evidence	  
suggests	   that	   endosomes	   have	   key	   roles	   in	   other	   processes	   such	   as	   cellular	  
signalling,	   cytokinesis,	   cell	   polarization	   and	   migration	   (reviewed	   in	   (Gould	   and	  
Lippincott-­‐Schwartz,	   2009).	   BAR	   proteins	   bind	   to	   phospholipids	   and	   spherical	  
liposomes,	   transforming	   them	   into	   long	   tubes.	   This	   tubulating	   activity	   was	   firstly	  
observed	  with	  the	  endocytic	  proteins	  dynamin	  1,	  amphiphysin-­‐1	  (Takei	  et	  al.,	  1999),	  
endophilin	  (Farsad	  et	  al.,	  2001)	  and	  Epsin1	  (Ford	  et	  al.,	  2002).	  The	  BAR	  domain	  of	  
RICH-­‐1	   binds	   to	  membrane	   phospholipids	   and	   is	   capable	   of	   deforming	   liposomes	  
into	   tubular	   structures	   (Richnau	   et	   al.,	   2004).	   Interestingly,	   RICH-­‐1	   localised	   on	  
vesicular	   structures	   when	   cells	   were	   stimulated	   with	   insulin.	   Does	   this	   finding	  
suggest	  that	  RICH-­‐1	  could	  play	  a	  role	  in	  vesicle	  formation	  or	  membrane	  transport?	  
Aspenström	  and	  colleagues	   (Richnau	  and	  Aspenstrom,	  2001;	  Richnau	  et	  al.,	  2004)	  
have	  demonstrated	  that	  RICH-­‐1	  interacts	  with	  endophilin	  and	  amphiphysin	  through	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its	   proline-­‐rich	   motif.	   Moreover,	   a	   pulldown	   of	   RICH-­‐1	   identified	   two	   endocytic	  
adapter	   proteins	   CIN85	   (cognate	   adaptor	   cbl-­‐interacting	   protein	   of	   85	   kDa)	   and	  
CD2AP	   (CD2-­‐associated	   protein)	   (Wells	   et	   al.,	   2006),	   which	   form	   a	   complex	   with	  
endophilin	  that	  targets	  epidermal	  growth	  factor	  (EGF)	  (Dikic,	  2002;	  Kowanetz	  et	  al.,	  
2004;	   Soubeyran	  et	   al.,	   2002)	  and	  hepatocyte	  growth	   factor	   (HGF)	   (Petrelli	   et	   al.,	  
2002)	   receptors	  for	   endocytosis.	   It	   would	   be	   interesting	   to	   investigate	   whether	  
RICH-­‐1	  modulates	   insulin	   signalling	   via	   IR	   recycling,	   and	  whether	   14-­‐3-­‐3	   proteins	  
facilitate	  this	  mechanism.	  	  
	  
5.7.2 RICH-­‐1	  is	  important	  for	  tight	  junctional	  integrity	  in	  endothelial	  cells	  
The	  most	   striking	  effect	  of	  RICH-­‐1	  depletion	  by	  RNAi	   in	  ECs	  was	   the	  disruption	  of	  
tight	   junctions.	   This	  has	  previously	  been	  observed	   in	   epithelial	   cells,	   in	  which	   the	  
GAP	   activity	   of	   RICH-­‐1	   was	   required	   for	   proper	   TJ	   maintenance	   and	   long-­‐term	  
stability	   (Wells	   et	   al.,	   2006).	   Furthermore,	   that	   study	   identified	   that	  RICH-­‐1	  binds	  
through	   a	   scaffold	   protein	   angiomotin	   (Amot)	   to	   the	   polarity	   proteins	   Pals1	  
(Proteins	  Associated	  with	  Lin	  Seven	  1)	  (Straight	  et	  al.,	  2004),	  Patj	  	  (PALS1-­‐Assocated	  
Tight	   Junction	  protein)	   (or	   its	  paralogue	  Mupp1)	   (Shin	  et	   al.,	   2005)	  and	  Par3	   that	  
are	  all	  necessary	  for	  proper	  TJ	  integrity	  in	  epithelial	  cells	  (Wells	  et	  al.,	  2006).	  It	  has	  
been	   proposed	   that	   the	   association	   of	   the	   PDZ-­‐binding	   motif	   with	   scaffolding	  
proteins	   could	   be	   a	   general	   mechanism	   of	   confining	   GTPase	   activity	   to	   distinct	  
subcellular	  compartments	  (Garcia-­‐Mata	  and	  Burridge,	  2007).	  Amot	  contains	  a	  PDZ-­‐
domain	  binding	  motif	   that	   interacts	  with	  Patj	   that	  also	  binds	  TJ	  components	  ZO-­‐3	  
and	   claudin	   (Roh	   et	   al.,	   2002),	   thereby	   recruiting	   Amot	   and	   RICH-­‐1	   to	   the	   tight	  
junctions	   (Wells	   et	   al.,	   2006).	   Amot	   and	   RICH-­‐1	   interact	   through	   BAR/coiled-­‐coil	  
domains	   and	  both	   proteins	   fail	   to	   localise	   at	   the	   TJs	  without	   these	   domains	  with	  
RICH-­‐1	   shifting	   from	   the	   membrane	   to	   the	   cytoplasm	   (Wells	   et	   al.,	   2006).	  
Interestingly,	   expression	   of	   Amot	   inhibits	   RICH-­‐1	   GAP	   activity	   against	   Cdc42.	   The	  
effect	   of	   protein	   phosphorylation	   on	   this	   interaction	   is	   yet	   to	   be	   determined.	  
Further	  studies	  are	  required	  to	  investigate	  whether	  the	  phosphorylation	  of	  RICH-­‐1	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by	  insulin,	  and	  the	  subsequent	  binding	  of	  14-­‐3-­‐3	  proteins,	  affects	  the	  interaction	  of	  
Amot	  and	  RICH-­‐1.	  	  
Apical	   and	   basolateral	   polarity	   in	   epithelial	   cells	   is	   controlled	   by	   the	   precise	  
temporal	  and	  spatial	   localization	  of	  a	  conserved	  set	  of	  polarity	  proteins	   that	   form	  
complexes.	   The	   apical	   Par3/Par6/aPKC	   complex	   is	   fundamental	   for	   epithelial	  
polarity	  (recently	  reviewed	  in	  (Chen	  and	  Zhang,	  2013).	  Par3	  is	  known	  to	  interact	  at	  
epithelial	  cellular	  junctions	  (Izumi	  et	  al.,	  1998),	  while	  Par6	  and	  aPKC	  maintains	  the	  
integrity	   of	   the	   apical	   domain	  (Martin-­‐Belmonte	   et	   al.,	   2007).	   Protein	  
phosphorylation	   is	   emerging	   as	   a	   key	   mechanism	   by	   which	   polarity	   proteins	   are	  
regulated	   (Nagai-­‐Tamai	   et	   al.,	   2002).	   It	   has	   previously	   been	   shown	   that	   the	  
Par3/Par6/aPKC	   polarity	   complex	   is	   regulated	   in	   a	   phosphorylation-­‐dependent	  
mechanism	  through	  14-­‐3-­‐3	  binding	  (Hurd	  et	  al.,	  2003).	  Par3	  directly	  interacts	  with	  
14-­‐3-­‐3	  and	  this	  interaction	  requires	  the	  phosphorylation	  of	  Par3	  at	  serine	  144	  (Hurd	  
et	  al.,	  2003).	  Interestingly,	  aPKC	  and	  Par3	  have	  been	  shown	  to	  interact	  with	  RICH-­‐1	  
in	  Flag-­‐RICH-­‐1	  immunoprecipitates,	  but	  no	  interaction	  was	  observed	  between	  Par6	  
and	  RICH-­‐1	  (Wells	  et	  al.,	  2006).	  Further	  analysis	  is	  required	  to	  investigate	  if	  there	  is	  
a	  direct	  interaction	  between	  RICH-­‐1	  and	  Par3	  or	  if	  14-­‐3-­‐3	  proteins	  act	  as	  a	  scaffold	  
for	  the	  polarity	  complex	  to	  form	  upon	  protein	  phosphorylation.	  If	  the	  latter	  is	  true,	  
insulin	   stimulation	   could	   possibly	   phosphorylate	   both	   proteins,	   inducing	   14-­‐3-­‐3	  
binding	   and	   formation	   of	   a	   complex	   that	   could	   regulate	   cell	   polarity	   and	   barrier	  
control.	  
Transmembrane	   proteins	   of	   the	   tight	   junctions	   are	   delivered	   to	   the	   plasma	  
membrane	   in	  vesicles	  and	  are	  constitutively	   recycled	   into	  endosomes	   to	  maintain	  
functional	   tight	   junctions	   (Fletcher	   and	   Rappoport,	   2014).	   Further	   studies	  
investigating	  the	  involvement	  of	  RICH-­‐1	  in	  vesicle	  formation	  could	  elucidate	   if	  this	  
mechanism	  contributes	   to	   trafficking	  of	   transmembrane	  proteins	  and	  maintaining	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5.7.3 RICH-­‐1	  regulates	  endothelial	  cell	  migration	  
Amot	   was	   initially	   recognized	   for	   roles	   in	   the	   migration	   of	   ECs,	   localising	   to	  
lamellipodia	  at	  the	  leading	  edge	  of	  migrating	  cells	  (Troyanovsky	  et	  al.,	  2001).	  Amot-­‐
deficient	   ECs	   exhibited	   a	   loss	   of	   polarity,	   assessed	   by	   Golgi	   orientation,	   and	   had	  
impaired	   directional	   migration	   in	   response	   to	   chemotactic	   factors	   (Aase	   et	   al.,	  
2007).	   Furthermore,	   RICH-­‐1	   failed	   to	   localise	   to	   lamellipodia	   in	   Amot-­‐deficient	  
immortal	  ECs	  (Aase	  et	  al.,	  2007).	  It	  would	  be	  interesting	  to	  further	  investigate	  if	  the	  
decrease	   in	   cell	   migration	   was	   due	   to	   the	   mislocalisation	   of	   RICH-­‐1	   rather	   than	  
Amot	   alone,	   as	   RICH-­‐1	   depleted	   HUVECs	   also	   exhibit	   a	   significant	   defect	   in	   cell	  
migration	  in	  a	  wound-­‐healing	  assay.	  	  
The	  RICH-­‐1	  interacting	  protein	  CD2AP	  has	  also	  recently	  been	  shown	  to	  interact	  with	  
cortactin	   and	   capping	   protein	   at	   the	   cell	   periphery,	   facilitating	   lamellipodial	  
formation	  (Zhao	  et	  al.,	  2013).	  As	  an	  increase	  in	  membrane	  ruffling	  was	  observed	  in	  
GFP-­‐RICH-­‐1	   overexpressing	   HUVECs	   and	   cell	   migration	   was	   impaired	   in	   RICH-­‐1	  
depleted	  cells,	   it	  would	  be	  interesting	  to	  investigate	  whether	  RICH-­‐1	  is	   involved	  in	  
this	  complex.	  
	  
5.7.4 Parg1	  is	  an	  endothelial	  cytoskeletal	  regulator	  
Altering	   the	  expression	  of	  Parg1	   induced	   striking	   cytoskeletal	   changes	   in	  HUVECs.	  
Expression	  of	  GFP-­‐Parg1	  resulted	  in	  a	  decrease	  of	  endothelial	  F-­‐actin	   levels	  with	  a	  
noticeable	   loss	   of	   radial	   stress	   fibres.	   Moreover,	   depletion	   of	   Parg1	   produced	   a	  
distinct	  morphological	  phenotype	  in	  which	  cells	  appeared	  to	  elongate,	  induce	  stress	  
fibres	   that	   traverse	   the	   length	   of	   the	   cell	   and	   have	   disrupted	   cell-­‐cell	   junctions.	  
Multiple	   signalling	   pathways	   are	   involved	   in	   the	   formation	   of	   stress	   fibres	   in	   ECs	  
(Beckers	  et	  al.,	  2010)	  and	   the	  Rho-­‐ROCK	  signalling	  pathway	   is	   fundamental	   in	   the	  
regulation	  of	  stress	  fibres	  (Naumanen	  et	  al.,	  2008).	  Parg1	  has	  been	  shown	  to	  have	  
preferential	  GAP	   activity	   towards	   RhoA	  over	   Rac1	   and	  Cdc42	   (Saras	   et	   al.,	   1997).	  
Previous	   studies	   have	   shown	   that	   silencing	   Parg1	   in	   HUVECs	   decreased	   activated	  
Cdc42	  and	  Rac1	  levels	  and	  upregulated	  RhoA	  activation	  (Xu	  et	  al.,	  2011).	  Activation	  
of	  Rho	  results	  in	  increased	  activity	  of	  its	  effector	  ROCK,	  which	  phosphorylates	  MLC2	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and	  MYPT1,	  resulting	  in	  increased	  actomyosin	  contraction	  (Kimura	  et	  al.,	  1996)	  (see	  
Chapter	   1.4.2).	   Thus,	   overexpression	   of	   Parg1	   results	   in	   RhoA	   down	   regulation,	  
preventing	  stress	   fibre	   formation.	  HA-­‐Parg1	  expression	   in	   fibroblasts	   resulted	   in	  a	  
distinct	   morphological	   phenotype	   whereby	   cells	   rounded	   up	   and	   extended	   long	  
beaded	   dendritic	   processes	   with	   no	   actin	   stress	   fibres	   (Myagmar	   et	   al.,	   2005).	  
Conversely,	  Parg1	  depletion	  activates	  RhoA,	  resulting	  in	  MLC2	  phosphorylation	  and	  
stress	  fibre	  formation.	  	  
	  
5.7.5 Parg1	  is	  required	  to	  maintain	  endothelial	  barrier	  function	  
Perturbations	   to	   the	   actin	   cytoskeleton	   can	   affect	   the	   integrity	   of	   endothelial	  
monolayers.	  Stress	  fibres	  in	  confluent	  endothelial	  cells	  are	  predominantly	  linked	  to	  
adherens	   junctions	   (Millan	   et	   al.,	   2010)	   and	   stress	   fibre	   induction	   can	   lead	   to	   a	  
physical	   disruption	   of	   cell-­‐cell	   junctions	   as	   a	   result	   of	   an	   increase	   tensile	   force.	  
Parg1	  depletion	  resulted	  in	  an	  increase	  in	  endothelial	  permeability,	  suggesting	  that	  
cell-­‐cell	   junctions	  were	   disrupted.	   This	  was	   supported	   by	   discontinuous	   β-­‐catenin	  
staining	  of	  confluent	  HUVEC	  monolayers	  upon	  Parg1	  depletion.	  Furthermore,	  it	  has	  
recently	  been	  shown	  that	  depletion	  of	  Parg1	  decreased	  basal	  electrical	  impedance	  
in	  HUVECs,	  indicative	  of	  junction	  disruption	  (Post	  et	  al.,	  2013).	  	  
The	  small	  GTPase	  Rap1	  regulates	  endothelial	  barrier	  function	  and	  cell	  spreading	  by	  
coordinating	   both	   integrin-­‐mediated	   and	   cadherin-­‐mediated	   adhesions	   (reviewed	  
in	   (Jeyaraj	   et	   al.,	   2011).	   This	   dynamic	   modulation	   is	   regulated	   by	   the	   cAMP	  
activation	   of	   Rap1	   through	   the	   GEF	   Epac1	   (exchange	   factor	   directly	   activated	   by	  
cAMP)	   (Borland	   et	   al.,	   2009).	   In	   cultured	   HUVECs,	   activation	   of	   Epac1–Rap1	   by	  
cAMP	  enhances	  endothelial	  barrier	  function	  through	  the	  recruitment	  of	  β-­‐catenin,	  
resulting	   in	   the	   stabilization	   of	   VE-­‐cadherin	   at	   cell-­‐cell	   junctions	   (Fukuhra	   et	   al.,	  
2006),	   altering	   actin	   cytoskeleton	  organization	   and	   activating	  microtubule	   growth	  
(Jeyaraj	  et	  al.,	  2011).	  Recently,	  Parg1	  has	  been	  shown	  to	  mediate	  Rap1	  regulation	  in	  
endothelial	   barrier	   function	   by	   interacting	  with	   the	   Rap1	   effector,	   ras-­‐interacting	  
protein	   1	   (Rasip1)	   and	   the	   Rasip1	   homologue,	   Radil	   (Post	   et	   al.,	   2013).	   Parg1	   is	  
required	   as	   part	   of	   the	   effector	   complex	   for	   Rap1-­‐mediated	   cell	   spreading	   and	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endothelial	  barrier	  control.	   	  Epac1-­‐Rap1	  signalling	  disrupts	   radial	   stress	   fibres	  and	  
induces	   cortical	   actin	   bundles	   resulting	   in	   a	   switch	   from	   discontinuous,	   motile	  
junctions	   into	   linear,	   stable	   junctions	   (Cullere	   et	   al.,	   2005;	   Kooistra	   et	   al.,	   2005;	  
Pannekoek	  et	  al.,	  2011).	  Epac-­‐Rap1	  signalling	   is	   involved	  in	   insulin	  exocytosis	   in	  β-­‐
cells	   (Leech	   et	   al.,	   2010).	   As	   GFP-­‐Parg1	   expressing	   HUVECs	   exhibited	   less	   radial	  
stress	  fibres	  and	  stable	  reticular	  cell-­‐cell	  junctions,	  further	  analysis	  into	  the	  effect	  of	  
insulin	  on	   the	  Rap1	  signalling	  pathway	   in	  ECs	   is	  warranted	  to	   investigate	  whether	  
the	   enhanced	   endothelial	   barrier	   function	   induced	   by	   insulin	   occurs	   through	   this	  
signalling	  cascade.	  
	  
5.7.6 Parg1	  is	  required	  for	  EC	  migration	  and	  angiogenic	  loop	  formation	  
An	  in	  vitro	  angiogenesis	  assay	  was	  used	  to	  determine	  whether	  Parg1	  is	  involved	  in	  
regulating	  angiogenesis.	  This	  assay	  simulates	  angiogenesis	  by	  testing	  the	  capacity	  of	  
ECs	   to	   organise	   into	   stable	   networks	   that	   result	   in	   the	   formation	   of	   loop-­‐like	  
structures	  when	  plated	  onto	  polymerised	  Matrigel.	  Although	  this	  assay	  represents	  
only	   a	   part	   of	   the	   angiogenic	   process,	   it	   provides	   insight	   into	   the	   mechanisms	  
involved	   for	   the	   initial	   stages	   of	   cord	   sprouting	   angiogenesis	   (Goodwin,	   2007).	  
HUVECs	  initially	  extended	  cellular	  processes	  within	  the	  first	  8	  h,	  however	  in	  Parg1-­‐
depleted	   cells	   there	   were	   fewer	   extensions	   made	   and	   those	   that	   were	   able	   to	  
connect	   with	   other	   cells	   eventually	   collapsed.	   A	   decrease	   in	   loop	   formation	   was	  
observed	   in	   Parg1-­‐depleted	   HUVECs,	   as	   cells	   were	   unable	   to	   maintain	   these	  
connections.	   Previous	   in	   vitro	   studies	   have	   shown	   that	   Cdc42	   and	   Rac1	  mediate	  
endothelial	   lumen	   formation,	   while	   RhoA	   activation	   suppresses	   it	   (Bayless	   and	  
Davis,	  2002,	  2004;	  Koh	  et	  al.,	  2009).	  	  Silencing	  Parg1	  in	  HUVECs	  decreased	  levels	  of	  
activated	   Cdc42	   and	   Rac1,	   and	   upregulated	   RhoA	   levels	   (Xu	   et	   al.,	   2011),	   which	  
could	   contribute	   to	   the	   defect	   in	   angiogenesis	   observed.	   Furthermore,	   depleting	  
HUVECs	  of	  Parg1	  significantly	  reduced	  their	  ability	  to	  migrate	  in	  the	  wound-­‐healing	  
assay.	   For	   effective	   angiogenic	   sprout	   formation,	   ECs	   need	   to	   migrate	   and	   this	  
defect	  could	  result	  in	  the	  limited	  ability	  of	  Parg1-­‐depleted	  HUVECs	  to	  sprout.	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5.7.7 LMO7	  and	  endothelial	  tight	  junction	  regulation	  	  
LMO7	  localises	  diffusely	   in	  the	  nucleus	  and	  cytoplasm	  of	  ECs	  as	  observed	  in	  other	  
cell	   types,	   MDCK	   (Yamada	   et	   al.,	   2004),	   MTD-­‐1A	   (Ooshio	   et	   al.,	   2004),	   C2C12	  
myoblasts	  (Dedeic	  et	  al.,	  2011)	  and	  HeLa	  cells	  (Holaska	  et	  al.,	  2006).	  Although	  GFP-­‐
LMO7	  did	  not	   localise	  at	  endothelial	  AJs	  as	  previously	  described	   in	  epithelial	   cells	  
(Ooshio	   et	   al.,	   2004),	   the	   importance	   of	   LMO7	   in	   TJ	   regulation	   appears	   to	   be	  
consistent	  across	   cell	   types.	   LMO7	   transduces	   signals	   from	   the	  cell	   surface	   to	   the	  
nucleus	   and	   it	   has	   been	   previously	   proposed	   that	   specific	   signals	   could	   release	  
LMO7	   from	   its	   sequestered	   position	   at	   the	   plasma	   membrane,	   allowing	   it	   to	  
translocate	   to	   the	  nucleus	   to	  enhance	  the	  expression	  of	  emerin	  and	  other	  LMO7-­‐
dependent	   genes	   (Holaska	   et	   al.,	   2006).	   Could	   insulin	   trigger	   this	   shift	   by	  
phosphorylating	   LMO7	   and	   inducing	   14-­‐3-­‐3	   binding?	   This	   is	   plausible,	   as	   14-­‐3-­‐3-­‐
mediated	   conformational	   changes	   can	   facilitate	   subcellular	   relocalization	   by	  
deforming	  and/or	  masking	  a	  nuclear	  localization	  signal	  (Muslin	  and	  Xing,	  2000).	  	  
Many	   reports	   have	   suggested	   that	   AJs	   and	   TJs	   are	   functionally	   and	   structurally	  
linked	  and	  while	  EC	  AJs	  were	  not	  visibly	  affected	  by	  the	  overexpression	  or	  depletion	  
of	  LMO7,	  AJs	  could	   influence	  TJ	  organization	  (Ikenouchi	  et	  al.,	  2007;	  Taddei	  et	  al.,	  
2008).	  Similar	  to	  LMO7,	  the	  AJ	  protein	  β-­‐catenin	  is	  also	  a	  transcription	  factor	  that	  is	  
tethered	  to	  the	  plasma	  membrane	  by	  cadherins	  and	  α-­‐catenin	  (Liebner	  et	  al.,	  2006;	  
Wheelock	  and	  Johnson,	  2003)	  (see	  Chapter	  1.2.2.1).	  When	  β-­‐catenin	  translocates	  to	  
the	   nucleus	   it	   modulates	   cell	   transcription.	   Not	  much	   is	   known	   about	   the	   genes	  
modulated	   by	   β-­‐catenin	   specifically	   in	   ECs;	   however,	   β-­‐catenin	   can	   stabilize	  
Forkhead-­‐box	   protein-­‐O1	   (FoxO1)	   at	   the	   promoter	   of	   the	   TJ	   protein	   claudin-­‐5	  
(Taddei	  et	  al.,	  2008).	  β-­‐catenin	  forms	  a	  complex	  with	  the	  T-­‐cell	  factor	  (TCF),	  which	  is	  
constitutively	   associated	   with	   the	   claudin-­‐5	   promoter,	   and	   with	   FoxO1,	   this	  
complex	   represses	   the	   expression	   of	   claudin-­‐5	   (Gavard	   and	   Gutkind,	   2008).	  
Interestingly,	   Akt	   phosphorylation	   of	   FoxO	   induces	   14-­‐3-­‐3	   binding,	   reducing	   its	  
transcriptional	   activity	   (Brunet	   et	   al.,	   1999;	   Cahill	   et	   al.,	   2001).	   Binding	   of	   14-­‐3-­‐3	  
masks	   the	   DNA	   binding	   domain	   of	   FoxO,	   as	   well	   as	   increasing	   nuclear	   export	  
sequestering	  it	  in	  the	  cytoplasm	  (reviewed	  in	  (Tzivion	  et	  al.,	  2011).	  Previous	  studies	  
have	  demonstrated	  that	  insulin	  is	  able	  to	  inhibit	  the	  transcriptional	  activity	  of	  FoxO	  
(Perrot	   and	  Rechler,	   2003;	   Tsai	   et	   al.,	   2003).	   If	   the	  phosphorylation	  of	   LMO7	  and	  
concomitant	  binding	  of	  14-­‐3-­‐3	   resulted	   in	  nuclear	   importation,	  emerin	  expression	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would	   increase,	   because	   LMO7	  positively	   regulates	   emerin	   (Holaska	   et	   al.,	   2006).	  
Emerin	  binds	  directly	  to	  β-­‐catenin	  and	  attenuates	  β-­‐catenin	  activity	  by	  restricting	  its	  
accumulation	   in	   the	  nucleus	   (Markiewicz	   et	   al.,	   2006).	  Moreover,	   14-­‐3-­‐3	   proteins	  
have	   also	   been	   shown	   to	   sequester	   β-­‐catenin	   in	   the	   cytoplasm	   when	  
phosphorylated	  by	  Akt	  (Tian	  et	  al.,	  2004).	  	  
In	  summary,	  further	  studies	  are	  required	  to	  test	  if	  insulin	  enhances	  emerin	  levels	  by	  
nuclear	   importation	  of	   LMO7.	  Hypothetically,	   insulin	   stimulation	  could	  upregulate	  
claudin-­‐5	   indirectly,	   by	   releasing	   the	   inhibitory	   effect	   of	   FoxO1	   and	   β-­‐catenin	  
through	  the	  induction	  of	  Akt	  and	  14-­‐3-­‐3	  binding.	  
	  
5.7.8 Insulin	  stimulation	  of	  GFP-­‐Epsin2-­‐expressing	  HUVECs	  induces	  
lamellipodium	  formation	  
Epsins	  were	  initially	  discovered	  as	  a	  result	  of	  their	  ability	  to	  bind	  components	  of	  the	  
endocytic	   machinery	   and	   were	   identified	   as	   key	   adaptor	   proteins	   required	   for	  
endocytosis	  (Chen	  et	  al.,	  1998;	  Wendland	  et	  al.,	  1999).	  However,	  recent	  studies	  are	  
beginning	   to	   elucidate	   the	   critical	   roles	   that	   epsins	   play	   in	   signalling	   (reviewed	   in	  
(Sen	   et	   al.,	   2012).	   Epsins	   are	   able	   to	   regulate	   Cdc42	   by	   interacting	   with	   and	  
sequestering	   Cdc42	   GAPs	   in	   yeast	   (Aguilar	   et	   al.,	   2006),	   similar	   to	   the	   epsin-­‐
interacting	   protein,	   intersectin	   (Hussain	   et	   al.,	   2001;	   Jenna	   et	   al.,	   2002).	  
Interestingly,	  epsins	  are	  also	  able	  to	  regulate	  Rac	  signalling	  through	  its	   interaction	  
with	  RalBP1	  (Coon	  et	  al.,	  2010).	  Epsin	  depletion	  led	  to	  decreased	  levels	  of	  activated	  
Rac1,	  resulting	  in	  cell	  migration	  defects	  (Coon	  et	  al.,	  2010).	  	  
HUVECs	   expressing	   GFP-­‐Epsin2	   displayed	   a	   punctate	   cytoplasmic	   distribution	   as	  
previously	   observed	   in	   other	   cell	   types,	   such	   as	   fibrosarcoma	   cells	   (Coon	   et	   al.,	  
2010).	   Insulin	   stimulation	   appeared	   to	   increase	   lamellipodia	   in	   GFP-­‐Epsin2-­‐
expressing	  cells.	  These	  extensions	  were	  not	  observed	  in	  unstimulated	  cells	  and	  thus	  
it	  would	  be	   interesting	  to	   investigate	  whether	   insulin	  stimulation	  activates	  RalBP1	  
signalling,	   increasing	   localised	   active	   Rac1	   that	   could	   induce	   these	   protrusions	   at	  
the	  plasma	  membrane.	  	  
Espin2-­‐depletion	  did	  not	  affect	  migration	  of	  unstimulated	  ECs,	   in	  contrast	  to	  what	  
was	  observed	  in	  fibrosarcoma	  cells	  (Coon	  et	  al.,	  2010).	  Interestingly,	  insulin	  did	  not	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increase	  cell	  migration	   in	  Epsin2-­‐depleted	  HUVECs.	  This	  suggests	  that	  primary	  ECs	  
require	   an	   external	   stimulus	   to	   recruit	   epsins	   to	   drive	   the	   migratory	   machinery,	  
whilst	  cancer	  cells	  may	  secrete	  autocrine	  factors	  that	  act	  via	  epsins	  to	  promote	  cell	  
migration.	  
	  
5.7.9 Epsin2	  is	  required	  to	  regulate	  angiogenesis	  
Epsin2	   depletion	   in	   ECs	   resulted	   in	   an	   increase	   of	   loop	   formation	   in	   an	   in	   vitro	  
angiogenesis	   assay.	   It	   has	   previously	   been	   demonstrated	   that	   silencing	   of	   Epsin1	  
and	   Epsin2	   in	   HUVECs	   results	   in	   elevated	   VEGFR2	   signalling	   (Pasula	   et	   al.,	   2012).	  
VEGF	  signalling	  is	  crucial	  for	  angiogenesis,	  initiating	  signal	  cascades	  required	  for	  EC	  
migration	   and	   proliferation	   (reviewed	   in	   (Olsson	   et	   al.,	   2006);	   see	   Chapter	   1.5).	  
VEGF	   induces	   epsin	   binding	   to	   ubiquitinated	  VEGFR2,	   promoting	   endocytosis	   and	  
degradation	   of	   the	   receptor	   (Pasula	   et	   al.,	   2012).	   In	   the	   absence	   of	   epsin,	   VEGF	  
signalling	  is	  constitutively	  active	  leading	  to	  increased	  proliferation	  of	  ECs.	  	  
Interestingly,	   an	   increase	   in	   cell	   migration	   was	   observed	   in	   HUVECs	   depleted	   of	  
both	  Epsin1	  and	  Epsin2	  (Pasula	  et	  al.,	  2012),	  whereas	  no	  significant	  change	   in	  cell	  
migration	  was	  observed	  with	  Epsin2-­‐depleted	  HUVECs	   in	   the	  ORIS	  wound-­‐healing	  
assay.	  Mice	  lacking	  either	  epsin	  grew	  normally	  and	  did	  not	  exhibit	  any	  phenotypic	  
defects,	  whereas	  double	  knockout	  mice	  died	  at	  E10	  (Chen	  et	  al.,	  2009).	  The	  authors	  
suggest	   that	   Epsin1	   and	   Epsin2	   function	   redundantly,	   and	   that	   isoform-­‐specific	  
functions	  are	  not	  essential	  for	  life.	  However,	  these	  findings	  do	  not	  exclude	  specific	  
and	   unique	   roles	   of	   either	   isoform,	   for	   example	   specifically	   in	   ECs.	   So	   although	  
Epsin2-­‐depletion	  increases	  angiogenic	  loop	  formation,	  it	  may	  be	  that	  Epsin1	  is	  able	  
to	   compensate	   for	   Epsin2	   depletion	   during	   cell	  migration.	   This	   suggests	   that	   the	  
increase	   in	   loop	   formation	   could	   be	   due	   to	   an	   increase	   in	   proliferation	   due	   to	  
excessive	  VEGF	  signalling,	  however	  further	  studies	  are	  required	  to	  confirm	  this.	  
As	   insulin	   stimulates	   angiogenic	   loop	   formation	   (see	   Chapter	   3.5),	   it	   would	   be	  
interesting	  to	  investigate	  whether	  the	  insulin-­‐stimulated	  phosphorylation	  of	  Epsin2,	  
and	   subsequent	   binding	   of	   14-­‐3-­‐3,	   sequesters	   the	   ability	   Epsin2	   to	   bind	   to	  
ubiquitylated	   VEGFR2	   thus	   enhancing	   VEGF/VEGFR2	   signalling.
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6 Concluding	  Remarks	  
Insulin	   elicits	   metabolism-­‐independent,	   anti-­‐inflammatory	   protection	   against	  
myocardial	   ischaemic	   injury	   and	   the	   development	   of	   atherosclerosis	   (Yu	   et	   al.,	  
2011).	  However,	   the	  mechanisms	   through	  which	   insulin	  exerts	   this	  protection	  are	  
not	   fully	  understood.	  Although	  a	   loss	  of	  endothelial	  barrier	   function	   is	  one	  of	   the	  
earliest	  indications	  of	  inflammation	  (Libby,	  2012),	  the	  roles	  of	  insulin	  in	  endothelial	  
barrier	  regulation	  are	  not	  well	  described.	  This	  thesis	  provides	  some	  insight	  into	  the	  
effect	  of	  insulin	  on	  the	  endothelial	  cytoskeleton	  and	  cell-­‐cell	  junctions.	  	  
Results	   presented	   in	   this	   thesis	   suggest	   that	   insulin	   could	   possibly	   mediate	   its	  
protective	   action	   by	   activating	   proteins	   that	   stabilise	   the	   cell-­‐cell	   junctions.	   This	  
study	  was	  performed	  in	  a	  non-­‐diseased	  cell	  model	  with	  functional	  insulin	  signalling	  
pathways.	   However,	   these	   findings	   may	   not	   be	   evident	   or	   beneficial	   in	   certain	  
pathological	  states,	  such	  as	   insulin	  resistance	  or	  cancer.	  This	  study	  focused	  on	  the	  
role	  of	  insulin	  as	  a	  cardioprotective	  agent	  in	  the	  context	  of	  CVD.	  
Insulin	   was	   shown	   to	   decrease	   basal	   HUVEC	   permeability,	   increase	   angiogenesis	  
loop	   formation	   and	   increase	   cell	   migration	   in	   a	   wound-­‐healing	   model	   in	   vitro,	  
compared	   to	   untreated	   cells.	   EC	   morphology	   and	   responses	   to	   cytokines	   vary	  
substantially	   between	   different	   vascular	   beds	   (Aird,	   2012),	   and	   it	   is	   therefore	  
possible	  that	  ECs	  from	  different	  parts	  of	  the	  vasculature	  might	  respond	  differently	  
to	   insulin	   (Woth	   et	   al.,	   2013).	   It	   would	   be	   interesting	   to	   compare	   the	   effects	   of	  
insulin	  on	  ECs	  from	  different	  vascular	  beds.	  
Using	   phospho-­‐specific	   14-­‐3-­‐3	   proteins	   as	   bait,	   4	   insulin-­‐sensitive	   proteins	   were	  
identified	   in	  a	  proteomic	   screen.	  Although	  14-­‐3-­‐3	  proteins	  were	  used	  as	  a	   tool	   in	  
this	  study	  to	  identify	  protein	  phosphorylation	  changes	  stimulated	  by	  insulin	  in	  ECs,	  
it	   would	   be	   important	   to	   investigate	   the	   specific	   roles	   of	   the	   14-­‐3-­‐3	   proteins	   in	  
these	   signalling	   cascades.	   These	   roles	   could	   be	   elucidated	   by	  mutagenesis	   of	   the	  
candidate	  14-­‐3-­‐3-­‐binding	  phosphosites	  identified	  by	  bioinformatic	  analysis.	  Further	  
analysis	  is	  required	  to	  confirm	  that	  insulin	  stimulates	  the	  phosphorylation	  of	  these	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proteins	  and	  to	  elucidate	  the	  specific	  kinase	  responsible	  for	  phosphorylating	  the	  14-­‐
3-­‐3	  phosphosites.	  	  
All	   four	   insulin-­‐sensitive	   14-­‐3-­‐3-­‐binding	   proteins	   identified	   in	   this	   study	   are	  
important	   for	   the	  normal	   function	  of	   ECs.	  As	  described	   in	  Chapter	   5,	   altering	   the	  
expression	   of	   these	   proteins	   in	   ECs	   induced	   major	   cytoskeletal	   and/or	   cell-­‐cell	  
junctional	   changes,	   indicating	   that	   they	   participate	   in	   EC	   signalling	   pathways.	  
Further	   experiments	   are	   required	   to	   elucidate	   the	   exact	   mechanisms	   of	   their	  
actions.	  Firstly,	  Rho	  GTPase	  activity	  assays	  would	  determine	   if	   the	   target	  proteins	  
induce	   the	   observed	   changes	   via	   these	   molecular	   switches.	   The	   hypothesized	  
working	  model	   suggests	   that	   insulin	   stimulation	   results	   in	   phosphorylation	  of	   the	  
target	  proteins,	  creating	  a	  docking	  site	  for	  14-­‐3-­‐3	  protein	  family	  members	  (Johnson	  
et	  al.,	  2010).	  For	  RICH-­‐1,	  this	  interaction	  could	  induce	  a	  conformational	  change	  that	  
disrupts	   the	   association	  with	  Amot,	   alleviating	   its	   inhibitory	   action	   on	   the	   RICH-­‐1	  
GAP	  activity	  (Wells	  et	  al.,	  2006),	  resulting	  in	  decreased	  Rac	  activity	  at	  the	  TJs	  (Figure	  
6.1).	  Active	  Rac1	  has	  previously	  been	  shown	  to	  disrupt	  EC	  TJs	  (Wojciak-­‐Stothard	  et	  
al.,	   2001),	   and	   thus	   RICH-­‐1	   could	   act	   to	   stabilise	   EC	   TJs	   via	   Rac1	   regulation.	   For	  
Parg1,	   it	   would	   be	   necessary	   to	   investigate	   if	   insulin	   stimulation	   activates	   Parg1,	  
resulting	   in	   a	   decrease	   in	   RhoA	   activity.	   A	   decrease	   in	   RhoA	   activation	   would	  
prevent	   MLC	   phosphorylation	   required	   for	   stress	   fibre	   formation	   (Amano	   et	   al.,	  
1996;	   Kimura	   et	   al.,	   1996)	   and	   thus	   ensure	   AJs	   are	   not	   subjected	   to	   centripetal	  
tension	  (Dejana	  and	  Orsenigo,	  2013),	  resulting	  in	  more	  stable	  AJs	  (Figure	  6.1).	  	  
One	  possible	  way	  LMO7	  could	  affect	  endothelial	  cell-­‐cell	   junctions	  is	  by	  regulating	  
the	   expression	   of	   TJ	   proteins.	   LMO7	   has	   previously	   been	   shown	   to	   exert	   signal-­‐
dependent	  transcription	  by	  regulating	  actin	  dynamics	  via	  the	  Rho-­‐dependent	  MRTF-­‐
SRF	  signalling	  pathway	  (Hu	  et	  al.,	  2011).	  Further	  studies	  are	  required	  to	  investigate	  
whether	  insulin	  is	  able	  to	  act	  as	  a	  stimulus	  that	  releases	  LMO7	  from	  its	  association	  
with	   cell-­‐cell	   junctional	   proteins	   (Ooshio	   et	   al.,	   2004).	   These	   studies	   should	   also	  
include	  constructs	  of	  LMO7	  with	  mutated	  14-­‐3-­‐3	  binding	  sites,	  in	  order	  to	  establish	  
if	  14-­‐3-­‐3	  proteins	  are	  required	  to	  shuttle	  LMO7	  into	  the	  nucleus	  (Figure	  6.1).	  LMO7	  
is	  a	  transcription	  factor	  that	  regulates	  the	  transcription	  of	  emerin,	  as	  well	  as	  many	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other	  genes	  (Holaska	  et	  al.,	  2006)	  and	  has	  been	  shown	  to	  bind	  directly	  to	  β-­‐catenin	  
and	  attenuate	  β-­‐catenin	  activity	  in	  the	  nucleus	  (Markiewicz	  et	  al.,	  2006).	  β-­‐catenin	  
stabilises	   FoxO1	   at	   the	   promoter	   of	   the	   TJ	   protein	   claudin-­‐5	   (Taddei	   et	   al.,	   2008)	  
and	  together	  with	  TCF,	  this	  complex	  represses	  the	  expression	  of	  claudin-­‐5	  (Gavard	  
and	   Gutkind,	   2008).	   Thus,	   further	   studies	   are	   required	   to	   elucidate	   if	   insulin	  
stimulation	   results	   in	   an	   increase	  of	   claudin-­‐5	  expression	   required	   for	  TJ	   stability,	  
via	  LMO7/emerin	  sequestering	  of	  β-­‐catenin.	  
Apart	   from	   the	   possibility	   that	   insulin	   induces	   changes	   to	   EC	   junctions	   via	   Rho	  
GTPases,	  insulin	  signalling	  could	  also	  be	  regulated	  by	  endocytosis	  (Figure	  6.2).	  RICH-­‐
1	   has	   been	   previously	   shown	   to	   associate	   with	   two	   endocytic	   adapter	   proteins,	  
CIN85	  and	  CD2AP	  (Wells	  et	  al.,	  2006),	  which	  form	  a	  complex	  with	  endophilin	  that	  
targets	   receptors	  for	   endocytosis	   (Petrelli	   et	   al.,	   2002).	  Moreover,	   an	   increase	   in	  
vesicle-­‐like	   structures	   was	   observed	   when	   GFP-­‐RICH-­‐1-­‐expressing	   HUVECs	   were	  
stimulated	  with	  insulin.	  Further	  studies	  are	  required	  to	  investigate	  whether	  RICH-­‐1	  
modulates	  insulin	  signalling	  via	  IR	  recycling.	  	  
The	   epsin	   family	   of	   proteins	   are	   essential	   for	   clathrin-­‐mediated	   endocytosis,	  
however	   they	   have	   also	   be	   described	   to	   play	   roles	   in	   cell	  migration	   (Coon	   et	   al.,	  
2010)	  and	  angiogenesis	  (Pasula	  et	  al.,	  2012).	  IGF-­‐I	  stimulation	  of	  Epsin2	  induced	  14-­‐
3-­‐3-­‐binding,	  however	  bioinformatic	  prediction	  only	  indicates	  one	  candidate	  14-­‐3-­‐3	  
binding	  site	  on	  Epsin2	  (Chapter	  4.4).	  It	  has	  previously	  been	  shown	  than	  Epsin	  binds	  
and	   inhibits	   the	  Rac1	  and	  Cdc42	  GAP	  activity	  of	  RalBP1	   (Coon	  et	  al.,	  2010).	  Could	  
the	  14-­‐3-­‐3-­‐dimer	  act	  as	  a	  scaffold	  protein	  to	  facilitate	  this	  interaction	  (Figure	  6.2)?	  
Further	   analyses	   are	   required	   to	   establish	  whether	   Epsin2	   contributes	   to	   insulin-­‐
stimulated	  cell	  migration	  by	  driving	  lamellipodium	  extension	  and	  whether	  this	  is	  via	  
an	  increase	  in	  Rac1	  activity.	  
The	  following	  hypothetical	  models	  present	  the	  proposed	  functions	  of	  RICH-­‐1,	  Parg1,	  
LMO7	  and	  Epsin2	  in	  ECs	  and	  summarises	  results	  presented	  in	  this	  thesis.	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Figure	  6.1	  Schematic	  of	  proposed	  roles	  of	  RICH-­‐1,	  Parg1	  and	  LMO7	  on	  endothelial	  
cell-­‐cell	  junctions	  
Insulin	  stimulation	  of	  ECs	  results	  in	  the	  activation	  of	  Akt	  and	  other	  AGC	  kinases	  that	  
phosphorylate	  many	  down-­‐stream	  substrates.	  Phosphorylation	  of	  RICH-­‐1	  by	  one	  of	  
these	  kinases	  induces	  14-­‐3-­‐3	  binding,	  which	  could	  disrupt	  the	  association	  of	  RICH-­‐1	  
from	   Amot,	   alleviating	   its	   inhibitory	   action	   on	   the	   RICH-­‐1	   GAP	   activity	   and	   thus	  
possibly	  reduce	  Rac1	   levels.	  Reduced	  Rac1	  activity	  could	  stabilize	  TJs.	  LMO7	  could	  
also	   contribute	   to	   TJ	   stabilization	   by	   regulating	   the	   expression	   of	   the	   TJ	   protein	  
Claudin-­‐5.	  14-­‐3-­‐3-­‐binding	  could	  induce	  nuclear	  import	  of	  LMO7,	  enhancing	  levels	  of	  
emerin	   in	   the	   nucleus.	   Emerin	   inhibits	   β-­‐catenin,	   which	   is	   required	   to	   stabilize	  
FoxO1	  on	   the	  Claudin-­‐5	   promoter	  with	   TCF.	   14-­‐3-­‐3	  proteins	   export	   FoxO1	  and	  β-­‐
catenin	   out	   of	   the	   nucleus,	   relieving	   the	   inhibition	   of	   Claudin-­‐5	   gene	   expression.	  
Phosphorylation	   of	   Parg1	   and	   subsequent	   14-­‐3-­‐3	   binding	   could	   enhance	   its	   Rho	  
GAP	   activity	   for	   RhoA,	   reducing	   the	   levels	   of	   active	   RhoA	   at	   AJs	   and	   preventing	  
stress	  fibre	  formation.	  	  The	  resulting	  decrease	  in	  centripetal	  tension	  could	  result	  in	  
stable	   AJs.	   Solid	   lines	   indicate	   direct	   known	   signalling	   mechanisms	   and	   direct	  
protein-­‐protein	   interactions,	   broken	   lines	   indicate	   proposed	   mechanisms	   that	  
require	  further	  analysis	  to	  be	  fully	  characterised.	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Figure	  6.2	  Schematic	  model	  of	  the	  roles	  of	  Epsin2	  in	  insulin	  signalling	  in	  ECs	  
Epsins	   are	   essential	   for	   clathrin-­‐mediated	   endocytosis.	   Further	   analyses	   are	  
required	   to	   investigate	   if	   Epsin2	   and	   RICH-­‐1	   are	   involved	   in	   the	   recycling	   of	   the	  
insulin	   receptor	   (IR).	   Insulin-­‐stimulated	   phosphorylation	   of	   Epsin2	   is	   proposed	   to	  
increase	   lamellipodium	   formation.	   The	   interaction	  of	   Epsins	   and	  RalBP1	  has	  been	  
shown	   to	   alleviate	   the	   Rac1/Cdc42	   GAP	   activity	   inhibition	   of	   RalBP1,	   resulting	   in	  
increased	  levels	  of	  active	  Rac1.	  Further	  studies	  are	  required	  to	  investigate	  whether	  
14-­‐3-­‐3	   proteins	   facilitate	   this	   interaction	   upon	   insulin-­‐stimulated	   Epsin2	  
phosphorylation.	  Solid	  lines	  indicate	  direct	  known	  signalling	  mechanisms	  and	  direct	  
protein-­‐protein	   interactions,	   broken	   lines	   indicate	   proposed	   mechanisms	   that	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6.1 Study	  limitations	  
This	  study	  encountered	  a	  number	  of	  limitations,	  which	  need	  to	  be	  considered.	  	  
Due	   to	   the	   scale	   required	   to	   perform	   the	   proteomic	   screen,	   the	   study	   used	  
immortalised	   ECs	   from	   human	   bone	   marrow	   (HBMECs),	   whereas	   all	   functional	  
analyses	   were	   performed	   with	   primary	   ECs	   isolated	   from	   human	   umbilical	   veins	  
(HUVECs).	   Similarities	   between	   HBMECs	   and	   HUVECs	   have	   previously	   been	  
demonstrated	   (Hillyer	   et	   al.,	   2003),	   and	   proteins	   identified	   in	   the	   HBMEC	   screen	  
were	   expressed	   in	   HUVECs,	   as	   demonstrated	   in	   Chapter	   5.	   However,	   differences	  
may	   exist	   between	   ECs	   from	   difference	   vascular	   beds	   as	   well	   as	   between	  
immortalised	  and	  primary	  cells,	  and	  it	  is	  worth	  noting	  that	  performing	  the	  screen	  in	  
another	  cell	  model	  could	  have	  identified	  other	  insulin-­‐stimulated	  14-­‐3-­‐3-­‐proteins.	  
The	   insulin	   concentrations	   investigated	   in	   the	   study	  were	  widely	  used	   in	  other	   in	  
vitro	   studies	   (Hermann	   et	   al.,	   2000;	   Zeng	   et	   al.,	   2000).	   However,	   it	   must	   be	  
acknowledged	   that	   these	   levels	   are	   unphysiologically	   high	   and	   at	   these	  
concentrations	   other	   receptors,	   such	   as	   IGF-­‐IR	   and	   insulin/IGF-­‐I	   hybrid	   receptors,	  
may	  also	  be	  activated	  (Nitert	  et	  al.,	  2005).	  Further	  studies	  could	  incorporate	  the	  use	  
of	   inhibitors	   to	   identify	   the	   exact	   receptors	   and	   signalling	   pathways	   required	   for	  
insulin	   to	   stimulate	   14-­‐3-­‐3-­‐binding	   to	   RICH-­‐1,	   Parg1,	   LMO7	   and	   Epsin2.	   These	  
studies	   would	   also	   provide	   evidence	   that	   these	   proteins	   mediate	   the	   effects	   of	  
insulin.	  
GFP-­‐fusion	   proteins	   were	   utilised	   in	   this	   study	   to	   investigate	   temporal	   protein	  
localisation	  in	  HUVECs.	  This	  common	  technique	  is	  useful	  to	  study	  the	  distribution	  of	  
the	  protein	   in	   its	  natural	   environment,	  however	  any	   such	  engineering	  of	   a	  native	  
protein	   carries	   the	   risk	   of	   affecting	   its	   localization.	   Moreover,	   as	   the	   HUVECs	  
continue	   to	   express	   endogenous	   levels	   of	   these	   proteins,	   effects	   arising	   from	  
overexpression	   also	   need	   to	   be	   taken	   into	   consideration.	   Analysing	   endogenous	  
proteins,	  by	  the	  use	  of	  specific	  antibodies	  and	  immunofluorescence	  in	  fixed	  cells,	  is	  
an	  alternative	  method	  that	  could	  be	  utilised.	  However,	  this	  method	  also	  comes	  with	  
limitations,	   such	   as	   artefacts	   generated	   from	   cell	   fixation	   and	   permeabilization	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methods	  or	  off-­‐target	  binding	  due	  to	  antibody	  cross-­‐reactivity	  with	  other	  proteins	  
(Stadler	   et	   al.,	   2013).	   Ideally,	   both	   methods	   should	   be	   incorporated	   and	   the	  
complementary	  data	  used	  to	  determine	  the	  subcellular	  protein	  localisation.	  
	  
In	   conclusion,	   this	   thesis	   has	   described	   a	   14-­‐3-­‐3-­‐based	   proteomic	   screen	   that	  
identified	   novel	   insulin-­‐stimulated	   regulators	   of	   endothelial	   function.	  
Understanding	  the	  molecular	  basis	  for	  insulin	  signalling	  on	  endothelial	  functions	  is	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Supplementary	  
Table	  S1	  List	  of	  proteins	  identified	  from	  14-­‐3-­‐3-­‐affinity	  purification	  of	  HBMEC	  
lysates	  ±	  insulin	  
	  
HBMECs	   were	   stimulated	   with	   insulin	   (100	   nM)	   for	   10	   min,	   or	   left	   unstimulated	   after	  
incubation	  in	  DMEM	  containing	  1%	  FCS	  for	  16	  h.	  Proteins	  in	  cell	   lysates	  were	  captured	  on	  
14-­‐3-­‐3-­‐Sepharose	  and	  eluted	  with	  2	  mM	  of	  the	  competitive	  phosphopeptide	  ARAApSAPA.	  
Following	  concentration	  in	  Vivaspin	  concentrators	  (10	  000	  MW	  cut-­‐off),	  the	  eluted	  samples	  
were	   separated	   on	   a	   4–12%	   Bis-­‐Tris	   SDS-­‐polyacryamide	   gel	   and	   proteins	  were	   visualised	  
using	  colloidal	  Coomassie	  blue	  (see	  Figure	  4.1).	  The	  separated	  proteins	  were	  excised	  from	  
the	  gel	   in	   six	   segments	   (unstimulated	   labelled	   segment	  1-­‐6,	   insulin	   stimulated	   labelled	  7-­‐
12)	  for	  tryptic	  digestion	  and	  mass	  spectral	  analysis.	  Proteins	  ranked	   in	  alphabetical	  order.	  
Proteins	  highlighted	  in	  red	  are	  Gold	  standard	  proteins,	  for	  which	  14-­‐3-­‐3-­‐binding	  sites	  have	  
been	  established.	  Proteins	  highlighted	  in	  blue	  are	  known	  insulin	  signalling	  mediators.	  
Accession	  





Q04446	   1,4-­‐alpha-­‐glucan-­‐branching	  enzyme	   GLGB_HUMAN	   80879	   2	  &	  8	  
P61604	   10	  kDa	  heat	  shock	  protein,	  mitochondrial	   CH10_HUMAN	   10925	   6	  &	  12	  
Q9NRX4	   14	  kDa	  phosphohistidine	  phosphatase	   PHP14_HUMAN	   13995	   12	  
P31946	   14-­‐3-­‐3	  protein	  beta/alpha	   1433B_HUMAN	   28179	   5	  &	  11	  
P62258	   14-­‐3-­‐3	  protein	  epsilon	   1433E_HUMAN	   29326	   5	  &	  11	  
Q04917	   14-­‐3-­‐3	  protein	  eta	   1433F_HUMAN	   28372	   5	  
P61981	   14-­‐3-­‐3	  protein	  gamma	   1433G_HUMAN	   28456	   5	  &	  11	  
P27348	   14-­‐3-­‐3	  protein	  theta	   1433T_HUMAN	   28032	   5	  &	  11	  
P63104	   14-­‐3-­‐3	  protein	  zeta/delta	   1433Z_HUMAN	   27899	   5	  &	  11	  
P62191	   26S	  protease	  regulatory	  subunit	  4	  	   PRS4_HUMAN	   49325	   9	  
P51665	   26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  7	  	   PSD7_HUMAN	   37060	   10	  
P49189	   4-­‐trimethylaminobutyraldehyde	  dehydrogenase	   AL9A1_HUMAN	   54679	   3	  &	  9	  
P63220	   40S	  ribosomal	  protein	  S21	   RS21_HUMAN	   9220	   6	  &	  12	  
P08865	   40S	  ribosomal	  protein	  SA	   RSSA_HUMAN	   32947	   5	  &	  11	  
P52209	   6-­‐phosphogluconate	  dehydrogenase,	  decarboxylating	   6PGD_HUMAN	   53619	   4	  &	  10	  
P10809	   60	  kDa	  heat	  shock	  protein,	  mitochondrial	   CH60_HUMAN	   61187	   3	  &	  9	  
P11021	   78	  kDa	  glucose-­‐regulated	  protein	   GRP78_HUMAN	   72402	   2	  &	  8	  
Q9BWD1	   Acetyl-­‐CoA	  acetyltransferase,	  cytosolic	   THIC_HUMAN	   41838	   4	  &	  10	  
P24752	   Acetyl-­‐CoA	  acetyltransferase,	  mitochondrial	   THIL_HUMAN	   45456	   4	  &	  10	  
Q99798	   Aconitate	  hydratase,	  mitochondrial	   ACON_HUMAN	   86113	   7	  
O14639	   Actin-­‐binding	  LIM	  protein	  1	   ABLM1_HUMAN	   89513	   5	  
O96019	   Actin-­‐like	  protein	  6A	   ACL6A_HUMAN	   47944	   4	  
P61160	   Actin-­‐related	  protein	  2	   ARP2_HUMAN	   45017	   4	  &	  10	  
O15143	   Actin-­‐related	  protein	  2/3	  complex	  subunit	  1B	   ARC1B_HUMAN	   41722	   4	  &	  10	  
O15145	   Actin-­‐related	  protein	  2/3	  complex	  subunit	  3	   ARPC3_HUMAN	   20761	   6	  &	  12	  
P59998	   Actin-­‐related	  protein	  2/3	  complex	  subunit	  4	   ARPC4_HUMAN	   19768	   6	  &	  12	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O15511	   Actin-­‐related	  protein	  2/3	  complex	  subunit	  5	   ARPC5_HUMAN	   16367	   6	  &	  12	  
Q9BPX5	   Actin-­‐related	  protein	  2/3	  complex	  subunit	  5-­‐like	  protein	   ARP5L_HUMAN	   16931	   6	  &	  12	  
P61158	   Actin-­‐related	  protein	  3	   ARP3_HUMAN	   47797	   4	  &	  10	  
P68032	   Actin,	  alpha	  cardiac	  muscle	  1	   ACTC_HUMAN	   42334	   4	  &	  10	  
P62736	   Actin,	  aortic	  smooth	  muscle	   ACTA_HUMAN	   42381	   11	  
P60709	   Actin,	  cytoplasmic	  1	   ACTB_HUMAN	   42052	   4	  &	  10	  
O95433	   Activator	  of	  90	  kDa	  heat	  shock	  protein	  ATPase	  homolog	  1	  	   AHSA1_HUMAN	   38421	   10	  
P07741	   Adenine	  phosphoribosyltransferase	   APT_HUMAN	   19766	   6	  &	  12	  
P23526	   Adenosylhomocysteinase	   SAHH_HUMAN	   48255	   4	  &	  10	  
P54819	   Adenylate	  kinase	  2,	  mitochondrial	   KAD2_HUMAN	   26689	   5	  &	  11	  
P00568	   Adenylate	  kinase	  isoenzyme	  1	   KAD1_HUMAN	   21735	   6	  &	  12	  
P30520	   Adenylosuccinate	  synthetase	  isozyme	  2	  	   PURA2_HUMAN	   50465	   10	  
Q01518	   Adenylyl	  cyclase-­‐associated	  protein	  1	   CAP1_HUMAN	   52325	   3	  &	  9	  
P36405	   ADP-­‐ribosylation	  factor-­‐like	  protein	  3	   ARL3_HUMAN	   20614	   12	  
P49588	   Alanine-­‐-­‐tRNA	  ligase,	  cytoplasmic	  	   SYAC_HUMAN	   107484	   1	  &	  7	  
P14550	   Alcohol	  dehydrogenase	  [NADP(+)]	   AK1A1_HUMAN	   36892	   5	  &	  11	  
P15121	   Aldose	  reductase	   ALDR_HUMAN	   36230	   5	  &	  11	  
P12814	   Alpha-­‐actinin-­‐1	  	   ACTN1_HUMAN	   103563	   1	  &	  7	  
O43707	   Alpha-­‐actinin-­‐4	   ACTN4_HUMAN	   105245	   1	  &	  7	  
P49419	   Alpha-­‐aminoadipic	  semialdehyde	  dehydrogenase	   AL7A1_HUMAN	   59020	   3	  &	  9	  
P06733	   Alpha-­‐enolase	   ENOA_HUMAN	   47481	   4	  &	  10	  
P04083	   Annexin	  A1	   ANXA1_HUMAN	   38918	   5	  &	  11	  
P07355	   Annexin	  A2	   ANXA2_HUMAN	   38808	   5	  &	  11	  
P12429	   Annexin	  A3	   ANXA3_HUMAN	   36524	   5	  &	  11	  
P09525	   Annexin	  A4	   ANXA4_HUMAN	   36088	   5	  &	  11	  
P08758	   Annexin	  A5	   ANXA5_HUMAN	   35971	   5	  &	  11	  
P08133	   Annexin	  A6	   ANXA6_HUMAN	   76168	   2	  &	  8	  
Q9NQ90	   Anoctamin-­‐2	  	   ANO2_HUMAN	   114695	   9	  
Q9BZZ5	   Apoptosis	  inhibitor	  5	  	   API5_HUMAN	   59310	   9	  
O95831	   Apoptosis-­‐inducing	  factor	  1,	  mitochondrial	   AIFM1_HUMAN	   67144	   3	  &	  9	  
O43776	   Asparagine-­‐-­‐tRNA	  ligase,	  cytoplasmic	   SYNC_HUMAN	   63758	   9	  
P17174	   Aspartate	  aminotransferase,	  cytoplasmic	   AATC_HUMAN	   46447	   4	  &	  10	  
P00505	   Aspartate	  aminotransferase,	  mitochondrial	   AATM_HUMAN	   47886	   4	  &	  10	  
Q15121	   Astrocytic	  phosphoprotein	  PEA-­‐15	   PEA15_HUMAN	   15088	   6	  
P06576	   ATP	  synthase	  subunit	  beta,	  mitochondrial	   ATPB_HUMAN	   56525	   3	  &	  9	  
O00148	   ATP-­‐dependent	  RNA	  helicase	  DDX39A	   DDX39_HUMAN	   49611	   4	  &	  10	  
Q8NHQ9	   ATP-­‐dependent	  RNA	  helicase	  DDX55	   DDX55_HUMAN	   69073	   2	  
P51572	   B-­‐cell	  receptor-­‐associated	  protein	  31	   BAP31_HUMAN	   28031	   5	  
Q9Y2J2	   Band	  4.1-­‐like	  protein	  3	   E41L3_HUMAN	   121458	   5	  &	  12	  
Q562R1	   Beta-­‐actin-­‐like	  protein	  2	   ACTBL_HUMAN	   42318	   10	  
P06865	   Beta-­‐hexosaminidase	  subunit	  alpha	  	   HEXA_HUMAN	   61120	   9	  
P07686	   Beta-­‐hexosaminidase	  subunit	  beta	   HEXB_HUMAN	   63527	   11	  
P31939	   Bifunctional	  purine	  biosynthesis	  protein	  PURH	   PUR9_HUMAN	   65089	   2	  &	  8	  
Q13867	   Bleomycin	  hydrolase	   BLMH_HUMAN	   53155	   9	  
O60885	   Bromodomain-­‐containing	  protein	  4	   BRD4_HUMAN	   152580	   5	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P62158	   Calmodulin	   CALM_HUMAN	   16827	   6	  &	  12	  
P27797	   Calreticulin	   CALR_HUMAN	   48283	   3	  &	  9	  
P10644	   cAMP-­‐dependent	  protein	  kinase	  type	  I-­‐alpha	  regulatory	  subunit	   KAP0_HUMAN	   43183	   10	  
P16152	   Carbonyl	  reductase	  [NADPH]	  1	   CBR1_HUMAN	   30641	   5	  &	  11	  
O75828	   Carbonyl	  reductase	  [NADPH]	  3	   CBR3_HUMAN	   31230	   5	  
P07339	   Cathepsin	  D	   CATD_HUMAN	   45037	   5	  &	  11	  
P60953	   Cell	  division	  control	  protein	  42	  homolog	   CDC42_HUMAN	   21587	   12	  
Q99741	   Cell	  division	  control	  protein	  6	  homolog	   CDC6_HUMAN	   63650	   5	  
P49454	   Centromere	  protein	  F	  	   CENPF_HUMAN	   370844	   8	  
Q5SW79	   Centrosomal	  protein	  of	  170	  kDa	   CE170_HUMAN	   175586	   6	  &	  12	  
O00299	   Chloride	  intracellular	  channel	  protein	  1	   CLIC1_HUMAN	   27248	   5	  &	  11	  
Q9Y696	   Chloride	  intracellular	  channel	  protein	  4	   CLIC4_HUMAN	   28982	   5	  &	  11	  
Q13185	   Chromobox	  protein	  homolog	  3	   CBX3_HUMAN	   20969	   6	  &	  12	  
O75390	   Citrate	  synthase,	  mitochondrial	   CISY_HUMAN	   51908	   10	  
Q00610	   Clathrin	  heavy	  chain	  1	   CLH1_HUMAN	   193260	   1	  	  &	  7	  
Q14019	   Coactosin-­‐like	  protein	   COTL1_HUMAN	   16049	   6	  &	  12	  
P53618	   Coatomer	  subunit	  beta	   COPB_HUMAN	   108214	   4	  
P23528	   Cofilin-­‐1	   COF1_HUMAN	   18719	   6	  &	  12	  
Q9Y281	   Cofilin-­‐2	   COF2_HUMAN	   18839	   12	  
Q99829	   Copine-­‐1	  	   CPNE1_HUMAN	   59649	   9	  
Q8IYJ1	   Copine-­‐9	  	   CPNE9_HUMAN	   62281	   9	  
Q13951	   Core-­‐binding	  factor	  subunit	  beta	  	   PEBB_HUMAN	   21723	   12	  
Q9ULV4	   Coronin-­‐1C	   COR1C_HUMAN	   53899	   4	  &	  10	  
P42771	   Cyclin-­‐dependent	  kinase	  inhibitor	  2A,	  isoforms	  1/2/3	   CD2A1_HUMAN	   16579	   6	  &	  12	  
P21291	   Cysteine	  and	  glycine-­‐rich	  protein	  1	  	   CSRP1_HUMAN	   21409	   12	  
P99999	   Cytochrome	  c	   CYC_HUMAN	   11855	   6	  
P28838	   Cytosol	  aminopeptidase	   AMPL_HUMAN	   56530	   3	  &	  9	  
O00154	   Cytosolic	  acyl	  coenzyme	  A	  thioester	  hydrolase	   BACH_HUMAN	   42454	   4	  &	  10	  
Q96KP4	   Cytosolic	  non-­‐specific	  dipeptidase	   CNDP2_HUMAN	   53187	   3	  &	  9	  
Q96BY6	   Dedicator	  of	  cytokinesis	  protein	  10	   DOC10_HUMAN	   251825	   2	  &	  8	  
P30038	   Delta-­‐1-­‐pyrroline-­‐5-­‐carboxylate	  dehydrogenase,	  mitochondrial	   AL4A1_HUMAN	   62137	   9	  
Q13011	   Delta(3,5)-­‐Delta(2,4)-­‐dienoyl-­‐CoA	  isomerase,	  mitochondrial	   ECH1_HUMAN	   36136	   5	  
P33316	   Deoxyuridine	  5~-­‐triphosphate	  nucleotidohydrolase,	  mitochondrial	   DUT_HUMAN	   26832	   6	  &	  12	  
P60981	   Destrin	   DEST_HUMAN	   18950	   6	  &	  12	  
Q9NR28	   Diablo	  homolog,	  mitochondrial	   DBLOH_HUMAN	   27342	   6	  &	  12	  
P09622	   Dihydrolipoyl	  dehydrogenase,	  mitochondrial	   DLDH_HUMAN	   54713	   3	  &	  9	  
P36957	  
Dihydrolipoyllysine-­‐residue	  succinyltransferase	  
component	  of	  2-­‐oxoglutarate	  dehydrogenase	  
complex	  
ODO2_HUMAN	   49067	   9	  
Q16555	   Dihydropyrimidinase-­‐related	  protein	  2	   DPYL2_HUMAN	   62711	   9	  
Q14195	   Dihydropyrimidinase-­‐related	  protein	  3	   DPYL3_HUMAN	   62323	   3	  &	  9	  
Q9NY33	   Dipeptidyl	  peptidase	  3	   DPP3_HUMAN	   82880	   7	  
Q9UKJ8	   Disintegrin	  and	  metalloproteinase	  domain-­‐containing	  protein	  21	   ADA21_HUMAN	   83403	   1	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O14490	   Disks	  large-­‐associated	  protein	  1	   DLGP1_HUMAN	   110117	   6	  
Q16531	   DNA	  damage-­‐binding	  protein	  1	   DDB1_HUMAN	   128142	   1	  &	  7	  
P49736	   DNA	  replication	  licensing	  factor	  MCM2	  	   MCM2_HUMAN	   102516	   7	  
Q14566	   DNA	  replication	  licensing	  factor	  MCM6	  	   MCM6_HUMAN	   93801	   7	  
P27695	   DNA-­‐(apurinic	  or	  apyrimidinic	  site)	  lyase	   APEX1_HUMAN	   35931	   5	  &	  11	  
Q9UBS4	   DnaJ	  homolog	  subfamily	  B	  member	  11	   DJB11_HUMAN	   40774	   4	  &	  10	  
Q96FJ2	   Dynein	  light	  chain	  2,	  cytoplasmic	  	   DYL2_HUMAN	   10457	   6	  
Q32P44	   Echinoderm	  microtubule-­‐associated	  protein-­‐like	  3	  	   EMAL3_HUMAN	   96221	   7	  
P29692	   Elongation	  factor	  1-­‐delta	  	   EF1D_HUMAN	   31217	   12	  
P26641	   Elongation	  factor	  1-­‐gamma	   EF1G_HUMAN	   50429	   4	  &	  10	  
P13639	   Elongation	  factor	  2	   EF2_HUMAN	   96246	   1	  &	  7	  
P30040	   Endoplasmic	  reticulum	  resident	  protein	  29	   ERP29_HUMAN	   29032	   5	  &	  11	  
P14625	   Endoplasmin	  OS=Homo	  sapiens	  	   ENPL_HUMAN	   92696	   1	  &	  7	  
P84090	   Enhancer	  of	  rudimentary	  homolog	   ERH_HUMAN	   12422	   6	  &	  12	  
P30084	   Enoyl-­‐CoA	  hydratase,	  mitochondrial	   ECHM_HUMAN	   31823	   11	  
O95208	   Epsin-­‐2	  	   EPN2_HUMAN	   68667	   5	  &	  12	  
P60842	   Eukaryotic	  initiation	  factor	  4A-­‐I	   IF4A1_HUMAN	   46353	   4	  &	  10	  
P62495	   Eukaryotic	  peptide	  chain	  release	  factor	  subunit	  1	   ERF1_HUMAN	   49228	   9	  
P05198	   Eukaryotic	  translation	  initiation	  factor	  2	  subunit	  1	   IF2A_HUMAN	   36374	   11	  
P06730	   Eukaryotic	  translation	  initiation	  factor	  4E	   IF4E_HUMAN	   25310	   5	  
A6NMX2	   Eukaryotic	  translation	  initiation	  factor	  4E	  type	  1B	   I4E1B_HUMAN	   27750	   11	  
P55010	   Eukaryotic	  translation	  initiation	  factor	  5	   IF5_HUMAN	   49648	   3	  &	  9	  
Q6IS14	   Eukaryotic	  translation	  initiation	  factor	  5A-­‐1-­‐like	   IF5AL_HUMAN	   16990	   6	  &	  12	  
P15311	   Ezrin	   EZRI_HUMAN	   69484	   2	  &	  8	  
P47755	   F-­‐actin-­‐capping	  protein	  subunit	  alpha-­‐2	   CAZA2_HUMAN	   33157	   5	  
P14324	   Farnesyl	  pyrophosphate	  synthase	   FPPS_HUMAN	   48758	   5	  &	  11	  
Q16658	   Fascin	   FSCN1_HUMAN	   55123	   3	  &	  9	  
Q01469	   Fatty	  acid-­‐binding	  protein,	  epidermal	  	   FABP5_HUMAN	   15497	   12	  
Q53RD9	   Fibulin-­‐7	   FBLN7_HUMAN	   49055	   4	  &	  10	  
P21333	   Filamin-­‐A	  	   FLNA_HUMAN	   283301	   1	  &	  7	  
O75369	   Filamin-­‐B	  	   FLNB_HUMAN	   280157	   1	  &	  7	  
Q14315	   Filamin-­‐C	  	   FLNC_HUMAN	   293407	   1	  &	  7	  
P30043	   Flavin	  reductase	  (NADPH)	  	   BLVRB_HUMAN	   22219	   6	  
P04075	   Fructose-­‐bisphosphate	  aldolase	  A	   ALDOA_HUMAN	   39851	   4	  &	  10	  
P09972	   Fructose-­‐bisphosphate	  aldolase	  C	   ALDOC_HUMAN	   39830	   4	  
P07954	   Fumarate	  hydratase,	  mitochondrial	   FUMH_HUMAN	   54773	   4	  &	  10	  
P09382	   Galectin-­‐1	   LEG1_HUMAN	   15048	   6	  &	  12	  
P17931	   Galectin-­‐3	   LEG3_HUMAN	   26193	   5	  &	  11	  
P09104	   Gamma-­‐enolase	   ENOG_HUMAN	   47581	   10	  
P11413	   Glucose-­‐6-­‐phosphate	  1-­‐dehydrogenase	   G6PD_HUMAN	   59675	   3	  &	  9	  
P06744	   Glucose-­‐6-­‐phosphate	  isomerase	   G6PI_HUMAN	   63335	   3	  &	  9	  
P14314	   Glucosidase	  2	  subunit	  beta	   GLU2B_HUMAN	   60357	   11	  
P00390	   Glutathione	  reductase,	  mitochondrial	  	   GSHR_HUMAN	   56791	   3	  &	  9	  
P78417	   Glutathione	  S-­‐transferase	  omega-­‐1	   GSTO1_HUMAN	   27833	   5	  &	  11	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P09211	   Glutathione	  S-­‐transferase	  P	   GSTP1_HUMAN	   23569	   6	  &	  12	  
P48637	   Glutathione	  synthetase	   GSHB_HUMAN	   52523	   3	  &	  9	  
P04406	   Glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	   G3P_HUMAN	   36201	   5	  &	  11	  
Q8WTR4	   Glycerophosphodiester	  phosphodiesterase	  domain-­‐containing	  protein	  5	   GDPD5_HUMAN	   69112	   6	  &	  12	  
P30419	   Glycylpeptide	  N-­‐tetradecanoyltransferase	  1	   NMT1_HUMAN	   57112	   3	  &	  9	  
Q9HC38	   Glyoxalase	  domain-­‐containing	  protein	  4	   GLOD4_HUMAN	   35170	   5	  &	  11	  
Q9HAV7	   GrpE	  protein	  homolog	  1,	  mitochondrial	   GRPE1_HUMAN	   24492	   11	  
P62826	   GTP-­‐binding	  nuclear	  protein	  Ran	   RAN_HUMAN	   24579	   5	  &	  11	  
P47224	   Guanine	  nucleotide	  exchange	  factor	  MSS4	   MSS4_HUMAN	   14115	   6	  &	  12	  
P63244	   Guanine	  nucleotide-­‐binding	  protein	  subunit	  beta-­‐2-­‐like	  1	   GBLP_HUMAN	   35511	   5	  &	  11	  
P08107	   Heat	  shock	  70	  kDa	  protein	  1A/1B	   HSP71_HUMAN	   70294	   2	  &	  8	  
P34932	   Heat	  shock	  70	  kDa	  protein	  4	  	   HSP74_HUMAN	   95127	   1	  &	  7	  
P11142	   Heat	  shock	  cognate	  71	  kDa	  protein	   HSP7C_HUMAN	   71082	   2	  &	  8	  
Q92598	   Heat	  shock	  protein	  105	  kDa	   HS105_HUMAN	   97716	   7	  
P04792	   Heat	  shock	  protein	  beta-­‐1	   HSPB1_HUMAN	   22826	   5	  
P07900	   Heat	  shock	  protein	  HSP	  90-­‐alpha	  	   HS90A_HUMAN	   85006	   1	  &	  7	  
P08238	   Heat	  shock	  protein	  HSP	  90-­‐beta	  	   HS90B_HUMAN	   83554	   1	  &	  7	  
Q9UK76	   Hematological	  and	  neurological	  expressed	  1	  protein	   HN1_HUMAN	   16005	   6	  &	  12	  
P52597	   Heterogeneous	  nuclear	  ribonucleoprotein	  F	   HNRPF_HUMAN	   45985	   12	  
P61978	   Heterogeneous	  nuclear	  ribonucleoprotein	  K	   HNRPK_HUMAN	   51230	   9	  
P19367	   Hexokinase-­‐1	   HXK1_HUMAN	   103561	   1	  
P09429	   High	  mobility	  group	  protein	  B1	   HMGB1_HUMAN	   25049	   5	  &	  11	  
P26583	   High	  mobility	  group	  protein	  B2	   HMGB2_HUMAN	   24190	   5	  &	  11	  
P49773	   Histidine	  triad	  nucleotide-­‐binding	  protein	  1	   HINT1_HUMAN	   13907	   6	  &	  12	  
Q9BX68	   Histidine	  triad	  nucleotide-­‐binding	  protein	  2,	  mitochondrial	   HINT2_HUMAN	   17208	   6	  &	  12	  
P12081	   Histidine-­‐-­‐tRNA	  ligase,	  cytoplasmic	   SYHC_HUMAN	   57944	   3	  &	  9	  
O15047	   Histone-­‐lysine	  N-­‐methyltransferase	  SETD1A	   SET1A_HUMAN	   186718	   2	  
Q16543	   Hsp90	  co-­‐chaperone	  Cdc37	   CDC37_HUMAN	   44953	   4	  &	  10	  
Q16836	   Hydroxyacyl-­‐coenzyme	  A	  dehydrogenase,	  mitochondrial	   HCDH_HUMAN	   34329	   11	  
P52292	   Importin	  subunit	  alpha-­‐2	  	   IMA2_HUMAN	   58168	   9	  
Q15181	   Inorganic	  pyrophosphatase	   IPYR_HUMAN	   33095	   5	  &	  11	  
P14735	   Insulin-­‐degrading	  enzyme	   IDE_HUMAN	   118692	   7	  
O75874	   Isocitrate	  dehydrogenase	  [NADP]	  cytoplasmic	   IDHC_HUMAN	   46915	   4	  
P48735	   Isocitrate	  dehydrogenase	  [NADP],	  mitochondrial	   IDHP_HUMAN	   51333	   4	  &	  10	  
Q13907	   Isopentenyl-­‐diphosphate	  Delta-­‐isomerase	  1	   IDI1_HUMAN	   26645	   5	  
Q12840	   Kinesin	  heavy	  chain	  isoform	  5A	   KIF5A_HUMAN	   118161	   1	  &	  7	  
P00338	   L-­‐lactate	  dehydrogenase	  A	  chain	   LDHA_HUMAN	   36950	   5	  &	  11	  
P07195	   L-­‐lactate	  dehydrogenase	  B	  chain	   LDHB_HUMAN	   36900	   5	  &	  11	  
Q04760	   Lactoylglutathione	  lyase	   LGUL_HUMAN	   20992	   6	  &	  12	  
P09960	   Leukotriene	  A-­‐4	  hydrolase	   LKHA4_HUMAN	   69868	   2	  &	  8	  
Q14847	   LIM	  and	  SH3	  domain	  protein	  1	   LASP1_HUMAN	   30097	   6	  &	  12	  
Q8WWI1	   LIM	  domain	  only	  protein	  7	   LMO7_HUMAN	   194002	   12	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P31025	   Lipocalin-­‐1	   LCN1_HUMAN	   19409	   6	  &	  12	  
P24666	   Low	  molecular	  weight	  phosphotyrosine	  protein	  phosphatase	   PPAC_HUMAN	   18487	   6	  &	  12	  
Q12912	   Lymphoid-­‐restricted	  membrane	  protein	  	   LRMP_HUMAN	   62767	   8	  
Q15046	   Lysine-­‐-­‐tRNA	  ligase	   SYK_HUMAN	   68461	   3	  &	  9	  
P42785	   Lysosomal	  Pro-­‐X	  carboxypeptidase	  	   PCP_HUMAN	   56277	   9	  
P14174	   Macrophage	  migration	  inhibitory	  factor	   MIF_HUMAN	   12639	   6	  &	  12	  
P40121	   Macrophage-­‐capping	  protein	   CAPG_HUMAN	   38760	   4	  &	  10	  
Q14764	   Major	  vault	  protein	   MVP_HUMAN	   99551	   1	  &	  7	  
P40925	   Malate	  dehydrogenase,	  cytoplasmic	   MDHC_HUMAN	   36631	   5	  &	  11	  
P40926	   Malate	  dehydrogenase,	  mitochondrial	   MDHM_HUMAN	   35937	   5	  &	  11	  
Q9Y5P6	   Mannose-­‐1-­‐phosphate	  guanyltransferase	  beta	   GMPPB_HUMAN	   40379	   4	  &	  10	  
P11310	   Medium-­‐chain	  specific	  acyl-­‐CoA	  dehydrogenase,	  mitochondrial	   ACADM_HUMAN	   47015	   4	  &	  10	  
Q9NZL9	   Methionine	  adenosyltransferase	  2	  subunit	  beta	   MAT2B_HUMAN	   37870	   5	  
P50579	   Methionine	  aminopeptidase	  2	  	   AMPM2_HUMAN	   53713	   9	  
Q15691	   Microtubule-­‐associated	  protein	  RP/EB	  family	  member	  1	   MARE1_HUMAN	   30151	   5	  &	  11	  
Q10713	   Mitochondrial-­‐processing	  peptidase	  subunit	  alpha	   MPPA_HUMAN	   58729	   3	  &	  9	  
P28482	   Mitogen-­‐activated	  protein	  kinase	  1	   MK01_HUMAN	   41762	   10	  
P26038	   Moesin	   MOES_HUMAN	   67892	   2	  &	  8	  
Q9UKD2	   mRNA	  turnover	  protein	  4	  homolog	   MRT4_HUMAN	   27657	   2	  &	  8	  
P14649	   Myosin	  light	  chain	  6B	   MYL6B_HUMAN	   22864	   6	  &	  12	  
P58546	   Myotrophin	   MTPN_HUMAN	   13058	   6	  &	  12	  
Q9NXD2	   Myotubularin-­‐related	  protein	  10	  	   MTMRA_HUMAN	   89186	   7	  
P15586	   N-­‐acetylglucosamine-­‐6-­‐sulfatase	   GNS_HUMAN	   62840	   3	  &	  7	  
O95865	   N(G),N(G)-­‐dimethylarginine	  dimethylaminohydrolase	  2	   DDAH2_HUMAN	   29911	   5	  &	  11	  
Q9Y6E7	   NAD-­‐dependent	  ADP-­‐ribosyltransferase	  sirtuin-­‐4	  	   SIRT4_HUMAN	   35678	   8	  
Q13765	   Nascent	  polypeptide-­‐associated	  complex	  subunit	  alpha	  	   NACA_HUMAN	   23370	   5	  &	  12	  
Q8NF91	   Nesprin-­‐1	  	   SYNE1_HUMAN	   1017069	   6	  &	  12	  
Q14697	   Neutral	  alpha-­‐glucosidase	  AB	   GANAB_HUMAN	   107263	   1	  &	  7	  
P55769	   NHP2-­‐like	  protein	  1	   NH2L1_HUMAN	   14393	   12	  
P22307	   Non-­‐specific	  lipid-­‐transfer	  protein	   NLTP_HUMAN	   59640	   12	  
P61970	   Nuclear	  transport	  factor	  2	   NTF2_HUMAN	   14640	   6	  &	  12	  
P15531	   Nucleoside	  diphosphate	  kinase	  A	   NDKA_HUMAN	   17309	   6	  
P22392	   Nucleoside	  diphosphate	  kinase	  B	   NDKB_HUMAN	   17401	   12	  
Q9NTK5	   Obg-­‐like	  ATPase	  1	   OLA1_HUMAN	   44943	   10	  
P04181	   Ornithine	  aminotransferase,	  mitochondrial	   OAT_HUMAN	   48846	   4	  &	  10	  
Q9BZ23	   Pantothenate	  kinase	  2,	  mitochondrial	   PANK2_HUMAN	   63268	   4	  &	  10	  
P20962	   Parathymosin	   PTMS_HUMAN	   11523	   6	  &	  12	  
O00151	   PDZ	  and	  LIM	  domain	  protein	  1	   PDLI1_HUMAN	   36505	   12	  
Q9NR12	   PDZ	  and	  LIM	  domain	  protein	  7	   PDLI7_HUMAN	   50896	   12	  
P62937	   Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  A	   PPIA_HUMAN	   18229	   6	  &	  12	  
P23284	   Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  B	   PPIB_HUMAN	   23785	   6	  &	  12	  
Q96AY3	   Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP10	   FKB10_HUMAN	   64717	   3	  &	  9	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P62942	   Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP1A	   FKB1A_HUMAN	   12000	   6	  &	  12	  
P26885	   Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP2	   FKBP2_HUMAN	   15810	   6	  &	  12	  
Q00688	   Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP3	   FKBP3_HUMAN	   25218	   5	  
Q02790	   Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP4	   FKBP4_HUMAN	   52057	   3	  &	  9	  
O43447	   Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  H	   PPIH_HUMAN	   19481	   6	  &	  12	  
Q13526	   Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  NIMA-­‐interacting	  1	   PIN1_HUMAN	   18346	   12	  
O60437	   Periplakin	   PEPL_HUMAN	   205193	   11	  
Q06830	   Peroxiredoxin-­‐1	   PRDX1_HUMAN	   22324	   6	  &	  12	  
P32119	   Peroxiredoxin-­‐2	   PRDX2_HUMAN	   22049	   6	  &	  12	  
P30044	   Peroxiredoxin-­‐5,	  mitochondrial	   PRDX5_HUMAN	   22301	   12	  
P30041	   Peroxiredoxin-­‐6	   PRDX6_HUMAN	   25133	   12	  
P30086	   Phosphatidylethanolamine-­‐binding	  protein	  1	   PEBP1_HUMAN	   21158	   6	  &	  12	  
P00558	   Phosphoglycerate	  kinase	  1	   PGK1_HUMAN	   44985	   4	  &	  10	  
P07205	   Phosphoglycerate	  kinase	  2	   PGK2_HUMAN	   45166	   4	  
P18669	   Phosphoglycerate	  mutase	  1	   PGAM1_HUMAN	   28900	   5	  &	  11	  
Q8IV08	   Phospholipase	  D3	  	   PLD3_HUMAN	   55127	   9	  
Q9Y617	   Phosphoserine	  aminotransferase	   SERC_HUMAN	   40796	   10	  
P13797	   Plastin-­‐3	   PLST_HUMAN	   71279	   3	  &	  9	  
P07359	   Platelet	  glycoprotein	  Ib	  alpha	  chain	   GP1BA_HUMAN	   69425	   5	  &	  11	  
P68402	   Platelet-­‐activating	  factor	  acetylhydrolase	  IB	  subunit	  beta	   PA1B2_HUMAN	   25724	   5	  &	  11	  
Q15102	   Platelet-­‐activating	  factor	  acetylhydrolase	  IB	  subunit	  gamma	   PA1B3_HUMAN	   25832	   5	  &	  11	  
Q15149	   Plectin	   PLEC_HUMAN	   533462	   9	  
Q9UHX1	   Poly(U)-­‐binding-­‐splicing	  factor	  PUF60	   PUF60_HUMAN	   60009	   11	  
Q9Y2S7	   Polymerase	  delta-­‐interacting	  protein	  2	  	   PDIP2_HUMAN	   42235	   5	  &	  11	  
P26599	   Polypyrimidine	  tract-­‐binding	  protein	  1	   PTBP1_HUMAN	   57357	   12	  
P02545	   Prelamin-­‐A/C	   LMNA_HUMAN	   74380	   2	  &	  8	  
A2PYH4	   Probable	  ATP-­‐dependent	  DNA	  helicase	  HFM1	  	   HFM1_HUMAN	   163705	   8	  
Q13206	   Probable	  ATP-­‐dependent	  RNA	  helicase	  DDX10	   DDX10_HUMAN	   101168	   10	  
Q6PRD1	   Probable	  G-­‐protein	  coupled	  receptor	  179	   GP179_HUMAN	   260623	   11	  
O00469	   Procollagen-­‐lysine,2-­‐oxoglutarate	  5-­‐dioxygenase	  2	   PLOD2_HUMAN	   85373	   1	  &	  7	  
P07737	   Profilin-­‐1	   PROF1_HUMAN	   15216	   6	  &	  12	  
P35080	   Profilin-­‐2	   PROF2_HUMAN	   15378	   12	  
O14737	   Programmed	  cell	  death	  protein	  5	  	   PDCD5_HUMAN	   14276	   6	  
P12004	   Proliferating	  cell	  nuclear	  antigen	   PCNA_HUMAN	   29092	   5	  &	  11	  
Q9UQ80	   Proliferation-­‐associated	  protein	  2G4	   PA2G4_HUMAN	   44101	   4	  &	  10	  
Q15185	   Prostaglandin	  E	  synthase	  3	   TEBP_HUMAN	   18971	   6	  &	  12	  
Q14914	   Prostaglandin	  reductase	  1	   PTGR1_HUMAN	   36075	   5	  
P25786	   Proteasome	  subunit	  alpha	  type-­‐1	   PSA1_HUMAN	   29822	   5	  &	  11	  
P25787	   Proteasome	  subunit	  alpha	  type-­‐2	   PSA2_HUMAN	   25996	   6	  &	  12	  
P25788	   Proteasome	  subunit	  alpha	  type-­‐3	   PSA3_HUMAN	   28643	   5	  &	  11	  
P25789	   Proteasome	  subunit	  alpha	  type-­‐4	   PSA4_HUMAN	   29750	   5	  &	  11	  
P28066	   Proteasome	  subunit	  alpha	  type-­‐5	   PSA5_HUMAN	   26565	   11	  
P60900	   Proteasome	  subunit	  alpha	  type-­‐6	   PSA6_HUMAN	   27838	   5	  &	  11	  
Q8TAA3	   Proteasome	  subunit	  alpha	  type-­‐7-­‐like	   PSA7L_HUMAN	   28683	   5	  &	  11	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P49721	   Proteasome	  subunit	  beta	  type-­‐2	   PSB2_HUMAN	   22993	   6	  &	  12	  
P28070	   Proteasome	  subunit	  beta	  type-­‐4	   PSB4_HUMAN	   29242	   6	  &	  12	  
P28072	   Proteasome	  subunit	  beta	  type-­‐6	   PSB6_HUMAN	   25570	   6	  &	  12	  
Q99622	   Protein	  C10	   C10_HUMAN	   13284	   12	  
Q9Y2B0	   Protein	  canopy	  homolog	  2	   CNPY2_HUMAN	   20981	   6	  &	  12	  
O60888	   Protein	  CutA	   CUTA_HUMAN	   19218	   12	  
P07237	   Protein	  disulfide-­‐isomerase	   PDIA1_HUMAN	   57480	   3	  &	  9	  
P30101	   Protein	  disulfide-­‐isomerase	  A3	   PDIA3_HUMAN	   57146	   3	  &	  9	  
P13667	   Protein	  disulfide-­‐isomerase	  A4	  	   PDIA4_HUMAN	   73229	   2	  &	  8	  
Q15084	   Protein	  disulfide-­‐isomerase	  A6	   PDIA6_HUMAN	   48490	   4	  &	  10	  
Q99497	   Protein	  DJ-­‐1	  	   PARK7_HUMAN	   20050	   6	  &	  12	  
O95571	   Protein	  ETHE1,	  mitochondrial	   ETHE1_HUMAN	   28368	   5	  
Q8N485	   Protein	  limb	  expression	  1	  homolog	   LIX1_HUMAN	   32213	   4	  
O14974	   Protein	  phosphatase	  1	  regulatory	  subunit	  12A	   MYPT1_HUMAN	   115610	   6	  &	  12	  
P49593	   Protein	  phosphatase	  1F	   PPM1F_HUMAN	   49971	   3	  
P31949	   Protein	  S100-­‐A11	   S10AB_HUMAN	   11847	   12	  
P06703	   Protein	  S100-­‐A6	  	   S10A6_HUMAN	   10230	   6	  &	  12	  
P55735	   Protein	  SEC13	  homolog	   SEC13_HUMAN	   36031	   11	  
Q92734	   Protein	  TFG	   TFG_HUMAN	   43478	   6	  &	  12	  
Q15436	   Protein	  transport	  protein	  Sec23A	  	   SC23A_HUMAN	   87018	   7	  
P53992	   Protein	  transport	  protein	  Sec24C	  	   SC24C_HUMAN	   119789	   7	  
O94979	   Protein	  transport	  protein	  Sec31A	   SC31A_HUMAN	   133900	   12	  
P21980	   Protein-­‐glutamine	  gamma-­‐glutamyltransferase	  2	   TGM2_HUMAN	   78420	   7	  
P06454	   Prothymosin	  alpha	   PTMA_HUMAN	   12196	   6	  &	  12	  
P61457	   Pterin-­‐4-­‐alpha-­‐carbinolamine	  dehydratase	   PHS_HUMAN	   12049	   6	  &	  12	  
P00491	   Purine	  nucleoside	  phosphorylase	   PNPH_HUMAN	   32325	   5	  &	  11	  
A6NMY6	   Putative	  annexin	  A2-­‐like	  protein	   AXA2L_HUMAN	   38806	   10	  
Q5VTE0	   Putative	  elongation	  factor	  1-­‐alpha-­‐like	  3	   EF1A3_HUMAN	   50495	   5	  &	  10	  
Q8IZP2	   Putative	  protein	  FAM10A4	   F10A4_HUMAN	   27561	   10	  
Q2M238	   Putative	  RRN3-­‐like	  protein	  FLJ77916	  	   RRN3L_HUMAN	   17529	   10	  
Q5JXB2	   Putative	  ubiquitin-­‐conjugating	  enzyme	  E2	  N-­‐like	   UE2NL_HUMAN	   17366	   12	  
P11177	   Pyruvate	  dehydrogenase	  E1	  component	  subunit	  beta,	  mitochondrial	   ODPB_HUMAN	   39550	   11	  
P14618	   Pyruvate	  kinase	  isozymes	  M1/M2	   KPYM_HUMAN	   58470	   3	  &	  9	  
Q9BXR0	   Queuine	  tRNA-­‐ribosyltransferase	   TGT_HUMAN	   44703	   10	  
Q53FA7	   Quinone	  oxidoreductase	  PIG3	   QORX_HUMAN	   35685	   11	  
P31150	   Rab	  GDP	  dissociation	  inhibitor	  alpha	   GDIA_HUMAN	   51177	   3	  &	  9	  
P50395	   Rab	  GDP	  dissociation	  inhibitor	  beta	   GDIB_HUMAN	   51087	   4	  &	  10	  
Q15404	   Ras	  suppressor	  protein	  1	   RSU1_HUMAN	   31521	   5	  
P15153	   Ras-­‐related	  C3	  botulinum	  toxin	  substrate	  2	   RAC2_HUMAN	   21814	   6	  
P60763	   Ras-­‐related	  C3	  botulinum	  toxin	  substrate	  3	   RAC3_HUMAN	   21764	   12	  
P62491	   Ras-­‐related	  protein	  Rab-­‐11A	   RB11A_HUMAN	   24492	   12	  
O43353	   Receptor-­‐interacting	  serine/threonine-­‐protein	  kinase	  2	   RIPK2_HUMAN	   61726	   2	  
P18754	   Regulator	  of	  chromosome	  condensation	   RCC1_HUMAN	   45397	   4	  &	  10	  
P52565	   Rho	  GDP-­‐dissociation	  inhibitor	  1	   GDIR1_HUMAN	   23250	   5	  &	  11	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P52566	   Rho	  GDP-­‐dissociation	  inhibitor	  2	   GDIR2_HUMAN	   23031	   5	  &	  12	  
Q68EM7	   Rho	  GTPase-­‐activating	  protein	  17	   RHG17_HUMAN	   95776	   9	  
Q52LW3	   Rho	  GTPase-­‐activating	  protein	  29	   RHG29_HUMAN	   143514	   7	  
Q5VV41	   Rho	  guanine	  nucleotide	  exchange	  factor	  16	  	   ARHGG_HUMAN	   80340	   9	  
Q96AT9	   Ribulose-­‐phosphate	  3-­‐epimerase	  	   RPE_HUMAN	   25139	   6	  
Q9Y5S9	   RNA-­‐binding	  protein	  8A	   RBM8A_HUMAN	   19934	   6	  &	  12	  
P10768	   S-­‐formylglutathione	  hydrolase	   ESTD_HUMAN	   31956	   11	  
Q8WVM8	   Sec1	  family	  domain-­‐containing	  protein	  1	   SCFD1_HUMAN	   72676	   9	  
Q12765	   Secernin-­‐1	   SCRN1_HUMAN	   46980	   3	  &	  9	  
Q9NVA2	   Septin-­‐11	   SEP11_HUMAN	   49652	   9	  
Q15019	   Septin-­‐2	   SEPT2_HUMAN	   41689	   4	  &	  10	  
Q16181	   Septin-­‐7	   SEPT7_HUMAN	   50933	   4	  &	  10	  
P34897	   Serine	  hydroxymethyltransferase,	  mitochondrial	   GLYM_HUMAN	   56414	   3	  &	  9	  
O43464	   Serine	  protease	  HTRA2,	  mitochondrial	   HTRA2_HUMAN	   48868	   5	  &	  11	  
P49591	   Serine-­‐-­‐tRNA	  ligase,	  cytoplasmic	   SYSC_HUMAN	   59253	   9	  
Q9BXM7	   Serine/threonine-­‐protein	  kinase	  PINK1,	  mitochondrial	  	   PINK1_HUMAN	   63641	   1	  
Q9H0K1	   Serine/threonine-­‐protein	  kinase	  SIK2	   SIK2_HUMAN	   104705	   12	  
P30153	   Serine/threonine-­‐protein	  phosphatase	  2A	  65	  kDa	  regulatory	  subunit	  A	  alpha	  isoform	   2AAA_HUMAN	   66065	   3	  &	  9	  
P62714	   Serine/threonine-­‐protein	  phosphatase	  2A	  catalytic	  subunit	  beta	  isoform	   PP2AB_HUMAN	   36123	   5	  &	  11	  
P62140	   Serine/threonine-­‐protein	  phosphatase	  PP1-­‐beta	  catalytic	  subunit	   PP1B_HUMAN	   37961	   11	  
P35237	   Serpin	  B6	   SPB6_HUMAN	   42936	   9	  
P02768	   Serum	  albumin	   ALBU_HUMAN	   71317	   2	  &	  8	  
O75368	   SH3	  domain-­‐binding	  glutamic	  acid-­‐rich-­‐like	  protein	   SH3L1_HUMAN	   12766	   12	  
Q9H299	   SH3	  domain-­‐binding	  glutamic	  acid-­‐rich-­‐like	  protein	  3	   SH3L3_HUMAN	   10488	   6	  &	  12	  
Q7L8J4	   SH3	  domain-­‐binding	  protein	  5-­‐like	  	   3BP5L_HUMAN	   43701	   9	  
Q9NR45	   Sialic	  acid	  synthase	   SIAS_HUMAN	   40738	   4	  &	  10	  
Q8IUH8	   Signal	  peptide	  peptidase-­‐like	  2C	   IMP5_HUMAN	   75538	   10	  
Q96FS4	   Signal-­‐induced	  proliferation-­‐associated	  protein	  1	  	   SIPA1_HUMAN	   112821	   6	  
Q04837	   Single-­‐stranded	  DNA-­‐binding	  protein,	  mitochondrial	   SSBP_HUMAN	   17249	   6	  &	  12	  
Q6EEV6	   Small	  ubiquitin-­‐related	  modifier	  4	   SUMO4_HUMAN	   10735	   6	  &	  12	  
Q86UG4	   Solute	  carrier	  organic	  anion	  transporter	  family	  member	  6A1	   SO6A1_HUMAN	   81176	   12	  
Q13813	   Spectrin	  alpha	  chain,	  brain	  	   SPTA2_HUMAN	   285163	   7	  
Q01082	   Spectrin	  beta	  chain,	  brain	  1	  	   SPTB2_HUMAN	   275237	   7	  
Q7KZF4	   Staphylococcal	  nuclease	  domain-­‐containing	  protein	  1	   SND1_HUMAN	   102618	   1	  &	  7	  
P16949	   Stathmin	   STMN1_HUMAN	   17292	   6	  &	  12	  
P38646	   Stress-­‐70	  protein,	  mitochondrial	   GRP75_HUMAN	   73920	   2	  &	  8	  
P31948	   Stress-­‐induced-­‐phosphoprotein	  1	   STIP1_HUMAN	   63227	   2	  &	  8	  
Q9HCN8	   Stromal	  cell-­‐derived	  factor	  2-­‐like	  protein	  1	  	   SDF2L_HUMAN	   23812	   6	  
Q96I99	   Succinyl-­‐CoA	  ligase	  [GDP-­‐forming]	  subunit	  beta,	   SUCB2_HUMAN	   46824	   10	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mitochondrial	  
Q8NBJ7	   Sulfatase-­‐modifying	  factor	  2	   SUMF2_HUMAN	   33936	   11	  
Q9UBE0	   SUMO-­‐activating	  enzyme	  subunit	  1	   SAE1_HUMAN	   38882	   10	  
Q9UBT2	   SUMO-­‐activating	  enzyme	  subunit	  2	   SAE2_HUMAN	   71749	   7	  
P00441	   Superoxide	  dismutase	  [Cu-­‐Zn]	   SODC_HUMAN	   16154	   6	  &	  12	  
O60264	  
SWI/SNF-­‐related	  matrix-­‐associated	  actin-­‐
dependent	  regulator	  of	  chromatin	  subfamily	  A	  
member	  5	  	  
SMCA5_HUMAN	   122513	   3	  
Q96C24	   Synaptotagmin-­‐like	  protein	  4	   SYTL4_HUMAN	   76603	   10	  
P17987	   T-­‐complex	  protein	  1	  subunit	  alpha	   TCPA_HUMAN	   60819	   9	  
P50991	   T-­‐complex	  protein	  1	  subunit	  delta	  	   TCPD_HUMAN	   58401	   9	  
P48643	   T-­‐complex	  protein	  1	  subunit	  epsilon	  	   TCPE_HUMAN	   60089	   9	  
P49368	   T-­‐complex	  protein	  1	  subunit	  gamma	   TCPG_HUMAN	   61066	   3	  &	  9	  
P50990	   T-­‐complex	  protein	  1	  subunit	  theta	   TCPQ_HUMAN	   60153	   3	  &	  9	  
P40227	   T-­‐complex	  protein	  1	  subunit	  zeta	   TCPZ_HUMAN	   58444	   9	  
Q9Y490	   Talin-­‐1	   TLN1_HUMAN	   271766	   1	  &	  7	  
P10599	   Thioredoxin	   THIO_HUMAN	   12015	   12	  
O95881	   Thioredoxin	  domain-­‐containing	  protein	  12	   TXD12_HUMAN	   19365	   6	  &	  12	  
Q9BRA2	   Thioredoxin	  domain-­‐containing	  protein	  17	   TXD17_HUMAN	   14217	   6	  &	  12	  
Q8NBS9	   Thioredoxin	  domain-­‐containing	  protein	  5	   TXND5_HUMAN	   48283	   4	  &	  10	  
Q16881	   Thioredoxin	  reductase	  1,	  cytoplasmic	   TRXR1_HUMAN	   71832	   9	  
P30048	   Thioredoxin-­‐dependent	  peroxide	  reductase,	  mitochondrial	   PRDX3_HUMAN	   28017	   6	  &	  12	  
O43396	   Thioredoxin-­‐like	  protein	  1	   TXNL1_HUMAN	   32630	   5	  &	  11	  
P26639	   Threonine-­‐-­‐tRNA	  ligase,	  cytoplasmic	  	   SYTC_HUMAN	   84294	   7	  
P04818	   Thymidylate	  synthase	   TYSY_HUMAN	   35978	   11	  
Q9UDY2	   Tight	  junction	  protein	  ZO-­‐2	   ZO2_HUMAN	   134104	   12	  
P37837	   Transaldolase	   TALDO_HUMAN	   37688	   5	  &	  11	  
P20290	   Transcription	  factor	  BTF3	   BTF3_HUMAN	   22211	   12	  
Q13263	   Transcription	  intermediary	  factor	  1-­‐beta	   TIF1B_HUMAN	   90261	   11	  
P61586	   Transforming	  protein	  RhoA	   RHOA_HUMAN	   22096	   6	  &	  12	  
Q01995	   Transgelin	   TAGL_HUMAN	   22653	   6	  &	  12	  
P37802	   Transgelin-­‐2	   TAGL2_HUMAN	   22548	   6	  &	  12	  
P55072	   Transitional	  endoplasmic	  reticulum	  ATPase	   TERA_HUMAN	   89950	   1	  &	  7	  
P29401	   Transketolase	   TKT_HUMAN	   68519	   2	  &	  8	  
P13693	   Translationally-­‐controlled	  tumor	  protein	   TCTP_HUMAN	   19697	   6	  &	  12	  
P60174	   Triosephosphate	  isomerase	   TPIS_HUMAN	   31057	   5	  &	  11	  
P67936	   Tropomyosin	  alpha-­‐4	  chain	   TPM4_HUMAN	   28619	   5	  &	  11	  
P07951	   Tropomyosin	  beta	  chain	   TPM2_HUMAN	   32945	   5	  &	  11	  
P23381	   Tryptophan-­‐-­‐tRNA	  ligase,	  cytoplasmic	   SYWC_HUMAN	   53474	   3	  &	  9	  
O75347	   Tubulin-­‐specific	  chaperone	  A	   TBCA_HUMAN	   12904	   6	  &	  12	  
P62310	   U6	  snRNA-­‐associated	  Sm-­‐like	  protein	  LSm3	   LSM3_HUMAN	   11838	   12	  
P54578	   Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  14	   UBP14_HUMAN	   56489	   3	  &	  9	  
P40818	   Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  8	   UBP8_HUMAN	   128413	   9	  
P09936	   Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  isozyme	  L1	   UCHL1_HUMAN	   25151	   6	  &	  12	  
P62979	   Ubiquitin-­‐40S	  ribosomal	  protein	  S27a	   RS27A_HUMAN	   18296	   6	  &	  12	  
Q13404	   Ubiquitin-­‐conjugating	  enzyme	  E2	  variant	  1	   UB2V1_HUMAN	   16598	   6	  &	  12	  
Supplementary	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P22314	   Ubiquitin-­‐like	  modifier-­‐activating	  enzyme	  1	  	   UBA1_HUMAN	   118858	   1	  &	  7	  
O60701	   UDP-­‐glucose	  6-­‐dehydrogenase	   UGDH_HUMAN	   55674	   9	  
Q16222	   UDP-­‐N-­‐acetylhexosamine	  pyrophosphorylase	   UAP1_HUMAN	   59131	   3	  &	  9	  
P30085	   UMP-­‐CMP	  kinase	   KCY_HUMAN	   22436	   6	  &	  12	  
Q5NDL2	   Uncharacterized	  glycosyltransferase	  AER61	   AER61_HUMAN	   62826	   9	  
Q8TDB4	   Uncharacterized	  protein	  C4orf49	   CD049_HUMAN	   25431	   11	  
Q9BY89	   Uncharacterized	  protein	  KIAA1671	   K1671_HUMAN	   197617	   11	  
Q9HB07	   UPF0160	  protein	  MYG1,	  mitochondrial	   MYG1_HUMAN	   42765	   10	  
Q9H7C9	   UPF0366	  protein	  C11orf67	   CK067_HUMAN	   13438	   6	  &	  12	  
Q969H8	   UPF0556	  protein	  C19orf10	  	   CS010_HUMAN	   18897	   6	  
P06132	   Uroporphyrinogen	  decarboxylase	   DCUP_HUMAN	   41103	   4	  
Q16851	   UTP-­‐-­‐glucose-­‐1-­‐phosphate	  uridylyltransferase	   UGPA_HUMAN	   57076	   3	  &	  9	  
P21281	   V-­‐type	  proton	  ATPase	  subunit	  B,	  brain	  isoform	  	   VATB2_HUMAN	   56807	   9	  
Q96QK1	   Vacuolar	  protein	  sorting-­‐associated	  protein	  35	  	   VPS35_HUMAN	   92447	   7	  
P50552	   Vasodilator-­‐stimulated	  phosphoprotein	   VASP_HUMAN	   39976	   5	  &	  12	  
P13611	   Versican	  core	  protein	   CSPG2_HUMAN	   374585	   12	  
P18206	   Vinculin	   VINC_HUMAN	   124292	   1	  &	  7	  
O75083	   WD	  repeat-­‐containing	  protein	  1	   WDR1_HUMAN	   66836	   2	  &	  8	  
P12955	   Xaa-­‐Pro	  dipeptidase	  	   PEPD_HUMAN	   55311	   9	  
P46937	   Yorkie	  homolog	   YAP1_HUMAN	   54484	   6	  &	  12	  
Q5T200	   Zinc	  finger	  CCCH	  domain-­‐containing	  protein	  13	   ZC3HD_HUMAN	   197203	   4	  
Q5BKZ1	   Zinc	  finger	  protein	  326	   ZN326_HUMAN	   65955	   11	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